category,datetime,headline,id,image,related,source,summary,url
company,2022-09-24 09:00:44,"Institutional owners may take dramatic actions as Gilead Sciences, Inc.'s (NASDAQ:GILD) recent 4.2% drop adds to one-year losses",116233189,https://s.yimg.com/uu/api/res/1.2/toOHA4B9c_p415zczXd3bQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. We can...",https://finnhub.io/api/news?id=7a0879fef75fa12e0a1f1bebc6fdf590102ff73e583be05801faecd6a725cf8c
company,2022-09-23 12:55:00,Gilead Sciences Inc. stock outperforms market despite losses on the day,116241762,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 1.43% to $62.86 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=13386472c6f4b1b240173a53aabab6c86506ce74607c363f2acf1eaf288d8f8d
company,2022-09-23 10:10:00,4 Questions With Dr. Javier Cortes: The Importance of Scientific Exchange To Advance Breast Cancer,116214592,https://s.yimg.com/uu/api/res/1.2/IBuzIy7ab2f1szZyc54C1g--~B/aD0zNjY7dz02NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/d3655912e7d70700f1b1e01f4133b3eb,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / September 23, 2022 / Gilead Sciences For Dr. Javier Cortes, being a breast cancer researcher isn't just a profession - it's a calling. As the head of the International Breast Cancer Center (IBCC) in Madrid and Barcelona, ...",https://finnhub.io/api/news?id=0d0ea354cb0a44b5b0ec158e81675c323c7b518a2df045d076331a3d8d196641
company,2022-09-23 09:45:00,"Got $1,000? 2 Stocks That Could Be Bargain Buys For 2022 and Beyond",116214593,https://s.yimg.com/ny/api/res/1.2/qYKxEgjNEge2.jCrPgCK6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/78af640f00e795e705d37336919e5bc1,GILD,Yahoo,"Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD).  AbbVie is one of the largest pharmaceutical companies around.  Like other drugmakers, AbbVie benefits from the fact that doctors do not stop prescribing lifesaving drugs even during challenging economic times, nor do patients stop taking them.",https://finnhub.io/api/news?id=ff765c070a626888a82ba77d3375efe305e0806bf714aeda55c4986bcc315bb6
company,2022-09-28 13:00:00,Gilead Sciences: WHO Expands Recommendation for Veklury(R) (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline,116311678,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"Gilead Sciences, Inc. (Nasdaq:GILD) today announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury® (remdesivir) for the treatment of patients with severe COVID-19 and continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization.",https://finnhub.io/api/news?id=9a75933aeef411b9a402a8e5f293d9d4ecfadbeddaac09edc5f71bb69a76f695
company,2022-09-28 12:55:00,Gilead Sciences Inc. stock outperforms market on strong trading day,116374173,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. advanced 2.08% to $63.93 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the...",https://finnhub.io/api/news?id=103b8e1a309cdeef6fbd8a57468217a82126de2805cf62b43595216b26faa5e5
company,2022-09-28 09:04:03,Gilead Sciences: WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline,116306829,,GILD,Finnhub,"Veklury is Now Recommended by the WHO for Use in Both Non-Severe COVID-19 Patients at the Highest Risk of Hospitalization and Patients with Severe COVID-19FOSTER CITY, Calif. - Gilead Sciences, Inc.... | September 28, 2022",https://finnhub.io/api/news?id=19b3b3dc571e7f3f21ecd2f23a8439eebebafb74c389afe83405d284290a7c8e
company,2022-09-28 09:02:08,"In the wake of Gilead Sciences, Inc.'s (NASDAQ:GILD) latest US$2.4b market cap drop, institutional owners may be forced to take severe actions",116311680,https://s.yimg.com/uu/api/res/1.2/toOHA4B9c_p415zczXd3bQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the...",https://finnhub.io/api/news?id=cf2701ed22bc64b91549e4c3a00f4133329557a704a0fe929c032d24791afe7d
company,2022-09-28 07:15:00,Cantor Fitzgerald healthcare analysts to hold KOL luncheon panel,116308315,https://thefly.com/images/meta/converenceevents.jpg,GILD,Thefly.com,"In conjunction with Canto... AZN, AMGN, MRTX, GILD, IMAB, NVS, SURF, PFE, ALXO, RHHBY, MRK",https://finnhub.io/api/news?id=1926d0e59864f56ab4cb7342c8c43478564671697ad81ed28a5aeef8646795e6
company,2022-09-28 02:22:00,Blue Star Capital shares rise on conclusion of portfolio review,116312363,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f0288afd1226852cdee9421e14ef677006c2c6ea251f88da7ab92324656cb203
company,2022-09-27 23:28:00,Gilead Sciences (GILD) Shares Cross Above 200 DMA,116334850,,GILD,Dividend Channel,"dividend channel,GILD,",https://finnhub.io/api/news?id=0c8abbf82df69621abad12a3a0bd2eaeb6c2188a6ef21b53fe0e1ab6e07230c8
company,2022-09-27 17:50:09,Gilead Sciences (GILD) Gains As Market Dips: What You Should Know,116290017,https://s.yimg.com/uu/api/res/1.2/wbCMwMtKIoXj_iQA0ego4g--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295,GILD,Yahoo,"Gilead Sciences (GILD) closed the most recent trading day at $62.63, moving +0.47% from the previous trading session.",https://finnhub.io/api/news?id=a2a5719ee7286d3ef55487de2cca21b16c1803c9c24456d48484c09b6d76d360
company,2022-09-27 12:55:00,"Gilead Sciences Inc. stock rises Tuesday, outperforms market",116374174,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.47% higher to $62.63 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=e8e8066754e75658b14af880976645263e07f6ca8133f9af0e38a84baf396da7
company,2022-09-27 10:30:33,I-Mab: Another CD47 Inhibitor Biotech With Great Potential,116285094,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1426761198/image_1426761198.jpg?io=getty-c-w750,GILD,SeekingAlpha,I-Mab expects to have three BLAs file in China over the next few years. Read why IMAB is a great speculative biotech play.,https://finnhub.io/api/news?id=a7a8e8b64ab8ce73d38b9c5e4aaae0c3c8097fc7cdee5ebba3b446ea530f6cfe
company,2022-09-27 04:09:00,IN BRIEF: Guild Esports renegotiates agreement with David Beckham,116312365,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f33614331e64f200d787dabd62f79d008f2f71024941802669db16004c1e3171
company,2022-09-27 02:20:00,The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market,116283880,https://investorplace.com/wp-content/uploads/2022/08/hidden-bull-market.png,GILD,InvestorPlace,"Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market.",https://finnhub.io/api/news?id=ccc1b727bde4a72205d89981df541b60c99d71a5b442550ed973da6cf3feb072
company,2022-09-26 12:55:00,Gilead Sciences Inc. stock underperforms Monday when compared to competitors,116374175,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 0.83% to $62.34 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=874704729191f8a2a718a5db9af27105daec1686867de9c39b4c0bfbc6817b9b
company,2022-09-26 03:32:00,Guild Esports shares rocket on global sponsorship deal with Sky,116260431,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9cf4f8489a8f4f7618c4eaf9fadf9a5983ec225a157d2070c12aef14f4fcbceb
company,2022-09-24 20:55:10,"Dividend Champion, Contender, And Challenger Highlights: Week Of September 25",116239457,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w750,GILD,SeekingAlpha,"Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Click here to see companies with upcoming ex-dividend dates and pay dates.",https://finnhub.io/api/news?id=ed079c68aa87337b42b4c7ce59fafa66ac60a64393e5e163cb73b5994dae73a7
company,2022-10-02 10:00:00,2 Top Biotech Stocks to Buy for the Long Haul,116382871,,GILD,Yahoo,The healthcare industry is a great place to start.  Let's examine two biotechs that seem to be able to do that: Gilead Sciences (NASDAQ: GILD) and CRISPR Therapeutics (NASDAQ: CRSP).  Gilead Sciences is a leader in the market for HIV drugs although the company has recently faced some headwinds in this space.,https://finnhub.io/api/news?id=21d948ffc91031b71bcc3e2a70406698dbdab51767ed4ec334814baaeda7d1de
company,2022-10-02 07:00:48,"Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst institutional investors who own 81%",116383009,https://s.yimg.com/uu/api/res/1.2/toOHA4B9c_p415zczXd3bQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. And the...",https://finnhub.io/api/news?id=d0916e014bd29406c79bb97ceb79812f94c10f2bccb559da34ecc674fdff8826
company,2022-09-30 12:55:00,Gilead Sciences Inc. stock underperforms Friday when compared to competitors,116374171,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 2.19% to $61.69 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=60a10d4b5ba119b46503eac20e45fdbab17d9f515aae3216fb955795ca271539
company,2022-09-30 09:55:00,Gilead Sciences: Mother of Three Shares Her CAR T-Cell Therapy Journey: Kelly's Story,116383010,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"Kelly was getting ready to leave on a trip to celebrate her 25th wedding anniversary when she started experiencing pain in her abdomen and discovered a lump on her neck. When the pain progressed to the point where it got worse when she laid down, she asked her husband, an emergency room doctor, what he thought.",https://finnhub.io/api/news?id=fadf7c2446e7b2ea347bcc5dbd11fc25aa1a3a25ced57a4a8a738e663dacfb3a
company,2022-09-30 04:40:00,Unusually active option classes on open September 30th,116360003,https://thefly.com/images/meta/options.jpg,GILD,Thefly.com,"Unusual total active opti... QUAD, WSM, INDA, AMLX, AVCT, NCLH, GILD, LULU, LI, APRN",https://finnhub.io/api/news?id=f263a415e244c1ec65691b11a3bb6c2f657948236c2db36e450d8d509542f501
company,2022-09-29 12:55:00,Gilead Sciences Inc. stock underperforms Thursday when compared to competitors,116374172,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.35% to $63.07 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=b10cd5aec44e8aef1c4596ecd9bcb64184a2de5c631dad440431bf9da85fecc3
company,2022-09-29 07:10:54,Gilead's Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme,116383011,https://s.yimg.com/uu/api/res/1.2/1frQNhFVuEwrW7uHyQZn6A--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/dcfd7f93b70a9c89a3b17f5a9fb6d520,GILD,Yahoo,"U.S. District Judge Ann Donnelly has ordered to freeze several assets related to people and entities accused of operating a U.S. supply chain that distributes counterfeit bottles of Gilead Sciences Inc's (NASDAQ: GILD) HIV drugs. In a statement, Gilead has identified and named as defendants two individuals responsible for leading and orchestrating the counterfeit scheme. The company initiated this litigation in July 2021 to halt the distribution of counterfeits. A court filing uncovered an opera",https://finnhub.io/api/news?id=9702368dd95912ece2958647a66030bb43ebf048edb0b35789cc96305dcd5a70
company,2022-09-29 06:45:34,7 Monthly Dividend Stocks to Buy for Safety,116383012,https://s.yimg.com/uu/api/res/1.2/FIP5dHnL0cS314TCJXP0ow--~B/aD00MDA7dz03Mjg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/investorplace_417/411d2afd1c09862ee985bb4a88be632b,GILD,Yahoo,"The best safe monthly dividend stocks are remarkably compelling during the current market downturn. However, many top dividend stocks have also taken a sizeable hit in value over the past several months. The pull-back presents an incredible opportunity to load up on dividend stocks and generate regular income. Dividend stocks usually belong to companies with stable businesses with robust earnings that can be reinvested for the benefit of their shareholders. During the current bear run, it can he",https://finnhub.io/api/news?id=2b71ea834dea7c238ab4d50dfe39cc859dad43cce47bc44dc44f972079fdad96
company,2022-09-28 23:03:00,3 Biotech Stocks to Sell in October,116344157,https://investorplace.com/wp-content/uploads/2022/04/penny-stocks-sell-bad1600.png,GILD,InvestorPlace,These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market.,https://finnhub.io/api/news?id=ad67aa49d4b60c95de82e50260571f943a99602e2240e76208fd6b0a90bcefec
company,2022-09-28 23:01:00,,116334849,,GILD,TipRanks,,https://finnhub.io/api/news?id=d3e083f67946d5b85025997c4288af37c6011901f5c24b2f419a13c2095a92b2
company,2022-09-28 20:27:23,Gilead widens battle against alleged counterfeit HIV drug ring,116316442,https://static.reuters.com/resources/r/?m=02&d=20220929&t=2&i=1610083716&r=LYNXMPEI8S00B,GILD,Reuters,"A federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc HIV drugs, including two alleged ""kingpins.""",https://finnhub.io/api/news?id=8f3f3b689f2f87da9fce15764858b63d7526a7c44c424bda61e0b09e41ea120d
company,2022-10-06 12:55:00,Gilead Sciences Inc. stock outperforms competitors despite losses on the day,116557388,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 0.76% to $64.95 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=b75681d2d07109faec230726a823ce52dd20b43b9d21402f34d58e55045a1e0e
company,2022-10-06 10:59:07,Top 20 Drug Companies in the World in 2022,116513014,https://s.yimg.com/uu/api/res/1.2/1.x_TmbebC4DnO9AYZ8ypw--~B/aD00NzQ7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d13bc0eacb984711f97f75d4d5fa774a,GILD,Yahoo,"In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […]",https://finnhub.io/api/news?id=c81b8dbe469c244a136597169eba47b170d040fd5916d13b17395fee01a31e6f
company,2022-10-06 09:45:00,Kingmakers of Oakland Aims to Improve the Lives of Young Black Men,116517965,https://s.yimg.com/uu/api/res/1.2/fs0wmj4cxyQP0THEkEXTRQ--~B/aD0zNjY7dz02NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/fc6c7a1c05e7ac2aea1dee59f31c11fd,GILD,Yahoo,"Growing up in Oakland, Alonzo Henderson didn't have a lot of teachers that looked like him. As a young Black man, he says he felt isolated and thought the educators around him didn't understand his experiences or interests.",https://finnhub.io/api/news?id=d7f04104587d4625de6c6cddd427fa16fdddcf74b621a2060e79085286276a84
company,2022-10-06 08:01:17,"Gilead Sciences, Inc. (NASDAQ:GILD) Looks Just Right",116517967,https://s.yimg.com/uu/api/res/1.2/toOHA4B9c_p415zczXd3bQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"With a price-to-earnings (or ""P/E"") ratio of 19.8x Gilead Sciences, Inc. ( NASDAQ:GILD ) may be sending bearish signals...",https://finnhub.io/api/news?id=24b031a653a8a734439c63fae5f5c0b46540ecd25a0236542d58333f8a3c7550
company,2022-10-05 12:55:00,"Gilead Sciences Inc. stock rises Wednesday, outperforms market",116557390,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.21% higher to $65.45 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=a8b8bf557ad6da6f0da49f4aa2196e464a65204d5571dc8a2078d7922b63e05b
company,2022-10-05 12:16:00,"Assembly Biosciences CEO John McHutchison to Retire, Succeeded by Jason Okazaki",116557391,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,"By Kathryn Hardison Assembly Biosciences Inc. said Chief Executive Officer John McHutchison is retiring and will be succeeded by Jason Okazaki, the company's...",https://finnhub.io/api/news?id=f1c3fa1b78a9eb9b2c7d8dcea5cdabe0462dbdf2e27a64c55c491b20af60a71b
company,2022-10-05 09:12:16,10 Healthcare Stocks to Watch in Light of Biden’s ‘60 Minutes’ Interview,116465273,https://s.yimg.com/uu/api/res/1.2/BwZ6ltH8fATW46ejWybaHg--~B/aD01MDA7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3370590db737e59fb2f15f745fd120ab,GILD,Yahoo,"In this article, we will be taking a look at the 10 healthcare stocks to watch in light of Biden’s 60 Minutes interview. To skip our detailed analysis of these stocks and Biden’s insights, you can go directly to see the 5 Healthcare Stocks to Watch in Light of Biden’s 60 Minutes Interview. On September […]",https://finnhub.io/api/news?id=0c3da75beb95b55568689a6ca72f34cc2980b2c77574db7ff2831af9f30d197f
company,2022-10-04 23:09:00,"Assembly Biosciences CEO John McHutchison to retire, Jason Okazaki to succeed",116477464,https://thefly.com/images/meta/hotstocks.jpg,GILD,Thefly.com,"Assembly Biosciences (ASM... ASMB, GILD",https://finnhub.io/api/news?id=f85d0a2a3800284beea77d6632fc6c064aabccfec8c87811f686ff0f1ac98920
company,2022-10-04 13:28:00,How to Trade Gilead Sciences as Charts Get More Positive,116440141,https://s.yimg.com/uu/api/res/1.2/LgMN5VQyrhc_IY3d4ARNhg--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet.com/0e680c545da0d7933f3d4adddef9afe9,GILD,Yahoo,"Biopharmaceutical company Gilead Sciences  was raised to an ""overweight (buy)"" rating by a sell-side firm Tuesday.  In the daily bar chart of GILD, below, we can see that the shares have been working on a bottom pattern since February.  Trading volume has been improving since June.",https://finnhub.io/api/news?id=84b83584ae995b31a93ed5ac6c896faeb7450d3ee4ad4dfaacac522b06720a89
company,2022-10-04 12:55:00,"Gilead Sciences Inc. stock rises Tuesday, outperforms market",116557392,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 4.80% to $65.31 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=57f4d32c861e78920fa032b36965e2d41a8e8159d42247fc4d5bac49ebd2dd90
company,2022-10-04 08:44:21,"Stocks making the biggest moves midday: Twitter, Poshmark, Rivian and more",116431921,https://image.cnbcfm.com/api/v1/image/106824689-1610646841088-gettyimages-1230585737-POSHMARK_IPO.jpeg?v=1664901861&w=1920&h=1080,GILD,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=d1e88b09517d209ca21a0b696c511e6601de521cdc1b51d6df1ccb01ce103d65
company,2022-10-04 07:28:50,"Gilead stock rallies after J.P. Morgan turns bullish, citing HIV and undervalued oncology businesses",116440142,https://s.yimg.com/uu/api/res/1.2/S8SCotpO9m2XQyQUIGU5dw--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,GILD,Yahoo,"Shares of Gilead Sciences Inc. rallied 3.2% in premarket trading Tuesday, after the biopharmaceutical company was upgraded at J.P. Morgan, which cited greater clarity on the human immunodeficiency virus (HIV) IV franchise and an emerging and undervalued oncology, or cancer treatment franchise. Analyst Christopher Schott raised his rating to overweight, after being at neutral for at least the past 2 1/2 years, while raising his stock price target to $80 from $72. ""At current levels, we see GILD's",https://finnhub.io/api/news?id=17ee9d70c2b43f86517b48a4031c57488209a1d305750d49eb87298add6574e9
company,2022-10-04 07:23:00,What You Missed On Wall Street This Morning,116430302,https://image.thefly.com/catalog/201904/img_457.jpg,GILD,Thefly.com,"Five top five lists with the news and calls moving stocks, powered by The Fly. TWTR, TSLA, POSH, MU, BA, F, PARA, DPZ, GILD, AMZN, UBER, COMM, HNHPF, AAPL, BABA, TCEHY, BBBY, INBX, RIVN, CORZ, KALV, MRVI, HAS, AXTI, AYI, REBN, AEP",https://finnhub.io/api/news?id=74efd3edad46eb7336c0c4c2fb68ece8f6fe05bce260f087c0972aee48c6c130
company,2022-10-04 05:00:00,"Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations",116428783,https://image.thefly.com/catalog/201811/img_112.jpg,GILD,Thefly.com,"Domino's Pizza upgrade, Paramount downgrade and TD Synnex initiation among today's top calls on Wall Street GILD, DPZ, ILMN, COMM, BK, PARA, SRAD, MCG, MTB, WLK, AGTC, SNX, GKOS, DHX, LFG",https://finnhub.io/api/news?id=41526dd4d2a9f149a47686edf6e8c7b00a41a0899dd54b38cf05b300e908bd7e
company,2022-10-04 04:49:00,"Gilead Has Growth Potential in HIV and Oncology Franchises, Analyst Says",116557393,https://images.barrons.com/im-248896/social,GILD,MarketWatch,A JPMorgan analyst upgraded shares of Gilead to Overweight from Neutral.,https://finnhub.io/api/news?id=104be94126923975f6cdca863311392c87770cd7daeba04f539370a57df21f65
company,2022-10-04 03:45:20,"Stocks making the biggest moves premarket: Rivian, Credit Suisse, Poshmark and more",116434207,https://image.cnbcfm.com/api/v1/image/106975024-1636745549862-riv2.jpg?v=1664883920&w=1920&h=1080,GILD,CNBC,These are the stocks posting the largest moves in premarket trading. ,https://finnhub.io/api/news?id=fdc730d3110ee329037d1c66e4a56853c5c7efaf98a48c22660f373a30fa5f13
company,2022-10-04 03:38:53,Gilead Company - Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product,116421463,,GILD,Finnhub,"SANTA MONICA - Kite, a Gilead Company , today announced the U.S. Food and Drug Administration has approved the company's retroviral vector manufacturing facility in Oceanside, California, for... | October 4, 2022",https://finnhub.io/api/news?id=821cd02382323d4825b5e7c12d84bde8475e1a6ed8f382334ac6ec0b1ea2e62e
company,2022-10-04 03:21:02,"Rivian, Poshmark, Tesla Rise Premarket; Kalvista Pharmceuticals Falls",116440144,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,By Peter Nurse,https://finnhub.io/api/news?id=9ec74788757e178854ea66d902083d1793796793b597e7c3da1ba5189804c39d
company,2022-10-04 02:50:00,GLOBAL BROKER RATINGS: RBC raises Severn Trent; BofA likes B&M,116428792,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b76ee098e3d2a97b8963f7f5bdf6981bd9034d7c4158248380899143e9467f33
company,2022-10-04 01:36:00,Gilead upgraded to Overweight from Neutral at JPMorgan,116430305,https://thefly.com/images/meta/streetresearch_upgrade.jpg,GILD,Thefly.com,JPMorgan analyst Chris Sc... GILD,https://finnhub.io/api/news?id=60263b41585f29ccb7b2e0f05603b61e4a0e696e7d83d2b8db896abd1c972cb5
company,2022-10-04 01:20:00,Home - The Fly,116430306,https://thefly.com/images/meta/metatags.jpg,GILD,Thefly.com,The Fly is a leading digital publisher of real-time financial news. The Fly team scours all sources of company news and delivers short-form stories consisting of only market moving content.,https://finnhub.io/api/news?id=af5ffb8416d7c85f9daae2028753e2afb1f135d0f04ef403650cdfdb21cbe064
company,2022-10-03 23:45:00,What You Missed On Wall Street On Tuesday,116434673,https://image.thefly.com/catalog/201810/img_66.png,GILD,Thefly.com,"Five top five lists with the news and calls moving stocks, powered by The Fly. TSLA, TWTR, POSH, MU, F, DXC, PARA, PARAA, DPZ, GILD, AMZN, UBER, COMM, SSNLF, TCEHY, BABA, BA, AAPL, INBX, RIVN, CORZ, KALV, MRVI, HAS, AXTI, AYI, REBN, AEP",https://finnhub.io/api/news?id=65402afd409adffd4707b40f933c57858f3708da4da682c5fb446453ab925a52
company,2022-10-03 17:50:09,Gilead Sciences (GILD) Gains But Lags Market: What You Should Know,116413711,https://s.yimg.com/uu/api/res/1.2/M2z0wFqvnPw7eaLU0tPuyQ--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85,GILD,Yahoo,"Gilead Sciences (GILD) closed at $62.32 in the latest trading session, marking a +1.02% move from the prior day.",https://finnhub.io/api/news?id=b9cec79bcaa731ebdb67acf7b9c566d9e2b8b4e5d51a169eabeea3ad01628383
company,2022-10-03 12:55:00,"Gilead Sciences Inc. stock rises Monday, still underperforms market",116557395,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 1.02% to $62.32 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=b9217c8d805b4f5f06b578b86d53301ced49cba822b368cc07f43899dc4fc852
company,2022-10-03 09:00:00,Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product,116413712,https://s.yimg.com/uu/api/res/1.2/za7xerL6ce0y2u2ymFE_7A--~B/aD0xNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c3ee5814e89c3183ac8d004df317aa8d,GILD,Yahoo,"SANTA MONICA, Calif., October 03, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production. Viral vectors are key components needed to manufacture Kite’s cell therapies to treat certain blood cancers. Kite is the only cell therapy company with in-house commercial and clinical trial viral vector manufacturing capabilities, au",https://finnhub.io/api/news?id=1988ee2d31d20457147baf9098d7bc277ed15cad6d3cc9f62ba5acbe6e3dec86
company,2022-10-03 04:05:00,Kite announces FDA approval of RVV manufacturing facility in California,116430308,https://thefly.com/images/meta/hotstocks.jpg,GILD,Thefly.com,"Kite, a Gilead company, a... GILD",https://finnhub.io/api/news?id=460a6627db4972f063dc18f4ecabf54c1f44e736b40834482210aabcce1fa7d8
company,2022-10-03 03:49:55,Gilead Sciences: Becoming A Cure,116395010,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w750,GILD,SeekingAlpha,Gilead Sciences remains a solid Covid-19 hedge and some bolt-on deal making adds to the potential. Click here for a full investment analysis of GILD stock.,https://finnhub.io/api/news?id=ed3f55f1927d87eab5bc1f68fecab383a8d9d445b668c0371ce765367950fae3
company,2022-10-03 00:36:00,Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio ,116429088,https://cdn.pixabay.com/photo/2018/07/15/10/44/dna-3539309_960_720.jpg,GILD,TalkMarkets,Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio.,https://finnhub.io/api/news?id=e586d7b067baa4caedf4f0bf0873b3145abd9657570bee9335d39e0401f9311e
company,2022-10-10 18:00:10,Gilead Sciences (GILD) Gains As Market Dips: What You Should Know,116584840,https://s.yimg.com/uu/api/res/1.2/hYDVEF34jJNULlluFRTwjg--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4,GILD,Yahoo,"Gilead Sciences (GILD) closed at $64.46 in the latest trading session, marking a +0.26% move from the prior day.",https://finnhub.io/api/news?id=c5566a069d78fbdc1cdccc9b1fd74f3e4a2e30485e388f08ae31d6a4812e9931
company,2022-10-10 11:52:03,Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?,116579557,https://s.yimg.com/uu/api/res/1.2/2Uxrul9Xalj9HwUZqlOfZA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,Gilead (GILD) is having a good run despite the volatility on a string of positive updates.,https://finnhub.io/api/news?id=2e8afa8093c85150c3b1f8e9eea7171d0dd87b82bf786790c2649e16c701d2a9
company,2022-10-10 08:36:00,How to Find Stocks That Rise 10x,116587577,https://investorplace.com/wp-content/uploads/2022/04/growth-confidence.png,GILD,InvestorPlace,Investors looking for 10X stocks should prioritize companies in high-growth areas that demonstrate high earnings quality.,https://finnhub.io/api/news?id=f1cbc57e14ef3952445ed115504cb3453c74df494e3be2f03c23a088c27e7830
company,2022-10-10 08:00:58,"Great week for Gilead Sciences, Inc. (NASDAQ:GILD) institutional investors after losing 1.0% over the previous year",116572208,https://s.yimg.com/uu/api/res/1.2/toOHA4B9c_p415zczXd3bQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the...",https://finnhub.io/api/news?id=578b2fc88af3f5744d35a2986d460aa39366f8991a02a65727cc3119eb278ae1
company,2022-10-07 21:03:00,Chipotle Stock Could Heat Up. Here Comes a Speedy Robo Burrito Maker.,116541220,,GILD,Yahoo,"Analysts also report on Gilead Sciences, Airbnb, CME Group, L3Harris Technologies, and Petco Health.",https://finnhub.io/api/news?id=53e97efc583bfec0ff01d309fe97debfdc10b0d410dd3591ab7834420691d932
company,2022-10-07 12:55:00,"Gilead Sciences Inc. stock falls Friday, still outperforms market",116557387,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.02% to $64.29 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=691bd3c0300fc555d866aca79362e14faed32c7f1c687cbe4d343d3096361f73
company,2022-10-14 12:56:00,"Gilead Sciences Inc. stock falls Friday, still outperforms market",116715543,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 0.44% to $66.17 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=36c886c56d14143e52920299dbe72d211f02a1d0843f73acd02fad58e3b406de
company,2022-10-14 06:41:00,Why Cash-Rich Companies And #ETFs Are Beating The Market?,116665536,https://talkmarkets.com/contributor/mirjana-mishevska/user_content/ckimages/orig_etfs.jpg,GILD,TalkMarkets,"Investors believe that “cash is king” in the current environment of surging inflation, rising rates, and a potential economic downturn. ETFs that hold cash-rich companies have seen a lot of interest from investors lately.",https://finnhub.io/api/news?id=4880d597dff16d9861b8c95b928523c9800ed87159d8ea7f2e4c1c98422aa982
company,2022-10-14 05:33:19,My Dividend Stock Portfolio: New September Record,116636555,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w750,GILD,SeekingAlpha,September has been one of the worst months for stocks with all 3 major indices dropping at least 5%. Check out how my dividend stock portfolio performed in Sept.,https://finnhub.io/api/news?id=540137948ad52ecf9e401f4775176c4f6178410091728fb0f1a331ed1176d85e
company,2022-10-14 05:19:35,Gilead's Quality And Growth Potential Are Underappreciated,116636435,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w750,GILD,SeekingAlpha,Gilead Sciences is a high-quality pharma company with a protected market position. Read why we think that GILD is an attractive investment.,https://finnhub.io/api/news?id=3ebbcebea805327a143fe30784b60624089914d89640f4cb1c29b3a28ec202b5
company,2022-10-14 05:01:00,Top 5 3rd Quarter Trades of GR - GuruFocus.com,116640875,https://static.gurufocus.com/images/logo_global.png,GILD,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=f072cf7ae3a1b4e09422f2b3314a4215653bbdd931cc2c685718c468ff221bb8
company,2022-10-13 17:50:09,Gilead Sciences (GILD) Gains But Lags Market: What You Should Know,116629092,https://s.yimg.com/uu/api/res/1.2/7h8ntzJXcDOdVmDKQ08gRg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a,GILD,Yahoo,"In the latest trading session, Gilead Sciences (GILD) closed at $66.46, marking a +1.64% move from the previous day.",https://finnhub.io/api/news?id=b6799ece3a998d3b34312ce286bfb843b39d08c4c8012dab90398acf460a7545
company,2022-10-13 17:49:10,"Gilead looks to shift 250,000 square feet in Peninsula campus master plan from office to lab",116629093,,GILD,Yahoo,"The change represents Gilead's focus on research, now concentrated on the south section of its 72-acre Foster City campus.",https://finnhub.io/api/news?id=1423579d21a1ec7a8e1ace521a3c0be11a2915c2d8dfb41f697857fcae4999a6
company,2022-10-13 16:05:00,"Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022",116629094,https://s.yimg.com/uu/api/res/1.2/0pI1rb9X0D7RG_wFI51AWg--~B/aD0xNjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5e811150d0de41dd5b4594e126d91a54,GILD,Yahoo,"FOSTER CITY, Calif., October 13, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2022 financial results will be released on Thursday, October 27 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2022 financial results and will provide a business update.",https://finnhub.io/api/news?id=15ab532f40c15671666a435cf85f6ed7ce4ff1e3f9297411618e70df64cf3297
company,2022-10-13 12:56:00,"Gilead Sciences Inc. stock rises Thursday, still underperforms market",116715544,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rallied 1.64% to $66.46 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=08cc3041f0ddfd1601bcc63e5228e67fe165976ee325a6d894a35e9493f32278
company,2022-10-13 09:00:01,"Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know",116629095,https://s.yimg.com/uu/api/res/1.2/ksLAzii1aL14haHFbPC1Rg--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f,GILD,Yahoo,"Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",https://finnhub.io/api/news?id=05cae05876e83bf292f82446a80c9af9404d00fc8b7801728acc33cf14fc5fad
company,2022-10-13 06:44:00,Cornell Pochily Investment Adv - GuruFocus.com,116641197,https://static.gurufocus.com/images/logo_global.png,GILD,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=2a5ab83b4bb8fe147aa56b13a1f8d7e863c106e947604e5bae1b0f22beabc5ee
company,2022-10-13 00:22:00,Dividend Income Update September 2022,116623404,https://images.unsplash.com/photo-1565514021506-1dc81b752c5e?ixid=MXwxMjA3fDB8MHxwaG90by1wYWdlfHx8fGVufDB8fHw%3D&ixlib=rb-1.2.1&auto=format&fit=crop&w=1000&q=80,GILD,TalkMarkets,"With the start of the final quarter of 2022, it’s time to take a look back at my previous month of dividend income.",https://finnhub.io/api/news?id=cf1f85761f9bb3ef694a9ab19d5a83ccbe978a9552487559a8a247b2bec49d07
company,2022-10-12 13:29:17,Gilead Stock Delivers Stable Dividend In Hot Biotech Sector,116616005,https://s.yimg.com/uu/api/res/1.2/fyTFfDMNOI9J9heDPJvTtw--~B/aD01NzI7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/7ce26b4b87cc5cc7683c1900afb4c75b,GILD,Yahoo,"The established nature of Gilead's business allows the company to pay out a strong dividend, currently yielding 4.2%.",https://finnhub.io/api/news?id=c116d27d5406c314ac08e43e32b406e97a7cb241fa4c238cfe863442ef4f69ed
company,2022-10-12 12:56:00,"Gilead Sciences Inc. stock falls Wednesday, underperforms market",116715545,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 0.43% to $65.39 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=dd81a7df6f188a2ea9879046749d9dba85dae330d966024442882ef100cddd5e
company,2022-10-12 10:30:00,These 2 Growth Stocks Have Potential Catalysts on the Way,116606931,https://s.yimg.com/ny/api/res/1.2/oNWj4CPl57qLW6qkHKzwKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/a4bccf55bee8ed614b79ad97eecffa8a,GILD,Yahoo,Both drugmakers have been outperforming the market -- which may continue if they earn important regulatory approvals soon.,https://finnhub.io/api/news?id=a61f36f771679e4aeea8714e66b98a8bf77477a37d481673329c53259e665fee
company,2022-10-12 09:47:01,Gilead (GILD) Trodelvy Label Expansion sBLA Gets Priority Review,116609215,https://s.yimg.com/uu/api/res/1.2/2Uxrul9Xalj9HwUZqlOfZA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,"Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.",https://finnhub.io/api/news?id=aae7191cbf92f4a04adc63adc9dbfd9f7aea70741386b2450f458e120007224e
company,2022-10-12 08:55:00,Gilead Sciences: Gilead's Rashad Burgess Is Advancing Health and Equity in LGBTQ Communities of Color (The Reckoning),116616008,https://s.yimg.com/uu/api/res/1.2/rrPGIyGT1CbSsRP2ejy7eg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/f0a9dff1f9ab33b45525f0bbf223e76d,GILD,Yahoo,"Before Rashad Burgess held the professional title of Vice President of Advancing Health and Equity at Gilead Sciences or the personal identification of husband and father, he witnessed the devastating effects of HIV in the early nineties as a gay teenager growing up on the south side of Chicago.",https://finnhub.io/api/news?id=0e1e3c5284f3f898779e783642d10499395c6ce9b1aac4db63287848c50781ce
company,2022-10-12 08:48:00,Want to Collect 4% in Dividends Every Month? Buy These 3 Stocks,116610614,https://s.yimg.com/ny/api/res/1.2/nh8hjUuVZa_1kSfCF8FKcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/1d897ca1789c6e929549b5995817482c,GILD,Yahoo,These stocks pay at different intervals and collectively can ensure you're collecting a dividend payment each month.,https://finnhub.io/api/news?id=35c01aa43f3b54fd8e117d41e0c785cbc213e8722ce7ad14b669a5882e095fb0
company,2022-10-12 05:29:00,4 Biotech Stocks With Huge Incoming Catalysts,116603290,https://s.yimg.com/ny/api/res/1.2/rjDJOTgYlzJo2PN_Ho0Kdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/640849c7b0ed3c19e85370846f2e6dd8,GILD,Yahoo,All four of these drugmakers are expecting important FDA approval decisions over the next few months.,https://finnhub.io/api/news?id=9ab433458952f1b87ff198115f881b1211858704683817bc92a1e8962f59e1a4
company,2022-10-12 00:20:00,Gilead price target raised to $60 from $56 at Barclays,116611375,https://thefly.com/images/meta/streetresearch_recommendations.jpg,GILD,Thefly.com,Barclays analyst Carter G... GILD,https://finnhub.io/api/news?id=0ae5ac73ec9a9c995cd8147e15a72d35fb4300b0b4c71dad6b441381c6b52760
company,2022-10-11 14:37:37,Gilead's Trodelvy Under FDA Review For Pre-Treated HR+/HER2- Metastatic Breast Cancer,116600502,https://s.yimg.com/uu/api/res/1.2/NDtzoiTLpcTLQ2DDRdqfng--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/5e4a65b7bf5a46bc8e0fd9603e750365,GILD,Yahoo,"The FDA has accepted for review Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for unresectable locally advanced or metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. The supplemental application covers patients who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The target action date of the Prescription Drug User Fee Act (PDUFA) is February",https://finnhub.io/api/news?id=ee65346a4fd3b7ad211b1b6bd6cd5c691316b07f2db458a0f9d4ed98d18793ae
company,2022-10-11 09:00:21,12 Best Ethical Stocks To Buy Now,116584092,https://s.yimg.com/uu/api/res/1.2/xlrbY_hL8gKYJR0hBfnZzA--~B/aD0yNjc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/76cab0686691ff14bc2c440f0df574d7,GILD,Yahoo,"In this article, we will take a look at 12 best ethical stocks to buy now. If you want to see some more of the best ethical stocks to buy, go directly to 5 Best Ethical Stocks To Buy Now. Sometimes investing is more than about just making money. Investing can also be used to […]",https://finnhub.io/api/news?id=365d42203164526b78739dcf9e4634aee00a178a8c4bd2f0e452bdba4fd49531
company,2022-10-11 08:30:00,U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer,116584839,https://s.yimg.com/uu/api/res/1.2/WMxMdCj3rCza3yJ5kcMI2Q--~B/aD0xNjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0fbd0c80d349f044cfcf392bc3db48ed,GILD,Yahoo,"FOSTER CITY, Calif., October 11, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have receiv",https://finnhub.io/api/news?id=f705a597357cd0c5a70835ee2888d6a4901f5405affe7c0118148d7cb187dd2a
company,2022-10-11 04:46:00,Gilead Gets FDA Priority Review for Trodelvy in HR+/HER2- Metastatic Breast Cancer,116715546,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Colin Kellaher Gilead Sciences Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review to its application for expanded use of...,https://finnhub.io/api/news?id=c05e6c0ec0ac00d91a31ac39391d4f7ad0388d662e3d3824f20404cb94b91334
company,2022-10-11 04:45:00,"Gilead's Trodelvy granted priority review by FDA, says Piper Sandler",116596362,https://thefly.com/images/meta/streetresearch_recommendations.jpg,GILD,Thefly.com,Piper Sandler analyst Do ... GILD,https://finnhub.io/api/news?id=748b7dd3b2033cb2aefe166b4b085f8fe4212bd7d7751ca3a00210566777fc57
company,2022-10-11 03:37:00,FDA gives Gilead priority review for Trodelvy sBLA  for breast cancer treatment,116596364,https://thefly.com/images/meta/hotstocks.jpg,GILD,Thefly.com,"Gilead Sciences, announce... GILD",https://finnhub.io/api/news?id=c7cdfbb5d7b5fec159030711811703d3b7ab45c7d6a520054b15de958e3942fa
company,2022-10-11 01:46:00,Arcus Biosciences initiated with an Overweight at Morgan Stanley,116586681,https://thefly.com/images/meta/streetresearch_initiate.jpg,GILD,Thefly.com,"Morgan Stanley analyst Te... RCUS, GILD, RHHBY",https://finnhub.io/api/news?id=33efdc704c15e957cd8cd9c68ea9707f321ce27956d0d939f85f48bc9f743160
company,2022-10-18 12:56:00,"Gilead Sciences Inc. stock rises Tuesday, still underperforms market",116715540,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.74% higher to $66.87 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with...",https://finnhub.io/api/news?id=d836bfe78b4eb7243382bc4ab598a30d097dffa737345caecf82e0c6be838739
company,2022-10-18 12:44:04,Gilead's (GILD) Yescarta Gets EC Nod for New Cancer Indication,116710195,https://s.yimg.com/uu/api/res/1.2/2Uxrul9Xalj9HwUZqlOfZA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,"The European Commission approves Gilead's (GILD) CAR T-cell therapy, Yescarta, for treating adult patients with second-line diffuse large b-cell lymphoma and high-grade b-cell lymphoma.",https://finnhub.io/api/news?id=53dba8c9a7b69309cea157e71806e980722a40c5dfbc6dbd16bfba9bfa1ab059
company,2022-10-18 09:26:07,Europe Approves First CAR T-Cell Therapy For B-Cell Lymphoma In 30 Years to Improve Upon Standard of Care,116710467,https://s.yimg.com/uu/api/res/1.2/G56emgXDlMCWT1eZHh6kFw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/30b23c87b939676499f039f955cc9df1,GILD,Yahoo,"The European Commission approved Kite Pharma's, a Gilead Sciences Inc (NASDAQ: GILD) Yescarta (axicabtagene ciloleucel) for diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). The approval covers patients who relapse within 12 months of completion or are refractory to first-line chemoimmunotherapy. The approval is based on results from the pivotal Phase 3 ZUMA-7 study, the largest and longest trial of a CAR T-cell therapy versus SOC in this patient population. Also Read:",https://finnhub.io/api/news?id=5b45ee044416733d942bb943749100e1354e07a906965c0d3e16317e8cad5b8f
company,2022-10-18 08:30:00,Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022,116699654,https://s.yimg.com/uu/api/res/1.2/CgsFqiuLBGC8jUv4NlO4jA--~B/aD0xNjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5df19853ec31d86d8191d056dd17170f,GILD,Yahoo,"FOSTER CITY, Calif., October 18, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company’s upcoming new data from its HIV research and development programs to be presented at the 30th International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2022) in Glasgow, Scotland and virtually from October 23-26, 2022. Gilead will present data supporting its current and pipeline innovations in HIV treatment and the latest research from its ongoing cure development program, reflecti",https://finnhub.io/api/news?id=2ba0b463bc784ee44b7db70661cfb01f59669f0c0bc01b58b56e75bb252adadc
company,2022-10-18 05:01:00,RNC CAPITAL MANAGEMENT LLC Buy - GuruFocus.com,116721452,https://static.gurufocus.com/images/logo_global.png,GILD,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=6c7fa033d085cb0077717be25de63170b06598f5e220f528e997835e3fb4c165
company,2022-10-18 03:45:00,Gilead gives new data from HIV R&D programs at at HIV Glasgow 2022,116721454,https://thefly.com/images/meta/hotstocks.jpg,GILD,Thefly.com,Gilead Sciences announced... GILD,https://finnhub.io/api/news?id=bf24afa035ba1ac4b40dad161a5ddfef88eab33cfdeef4c50a5b084d9a4523d7
company,2022-10-17 16:30:00,Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma,116689808,https://s.yimg.com/uu/api/res/1.2/qkU6INhUDD7p97To34vaeQ--~B/aD0xNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c6eee866c5cc9159a2794ecc82cabced,GILD,Yahoo,"SANTA MONICA, Calif., October 17, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission (EC) has granted approval for the use of Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. The approval is based on results from the pivotal Phase 3 ZUMA-7 study, the larg",https://finnhub.io/api/news?id=4d274f2ecb579ab209b5b9a5384dc8833d26f1329155d068a38136fe57f88bc5
company,2022-10-17 13:07:00,IN BRIEF: Gilead Sciences gets EU marketing authorisation for Yescarta,116721455,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e4482d999b51500b8f7dbdee7c1e465388473a19b10625e289286ba772a04663
company,2022-10-17 13:04:32,MacroGenics strikes deal with Gilead potentially worth more than $1.7B,116689042,https://s.yimg.com/ny/api/res/1.2/EUf_MsTTv0phOkYoiOlejQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bizjournals.com/c5fd9ace88cef908c11fb654d59d9e9b,GILD,Yahoo,"Rockville’s MacroGenics Inc. just struck a deal with a major U.S. pharmaceutical company that could mean more than $1.7 billion for the local biotech.  MacroGenics (NASDAQ: MGNX) said Monday it has formed a collaboration agreement with Foster City, California-based Gilead Sciences Inc. (NASDAQ: GILD) — giving Gilead the green light to develop and exclusively license MacroGenics’ blood cancer treatment candidate, called MGD024.",https://finnhub.io/api/news?id=a115b85453225be44c59b7be2654d4aaa5dad8f70b3fa0b5a0a24999760af3ef
company,2022-10-17 12:56:00,"Gilead Sciences Inc. stock rises Monday, still underperforms market",116715541,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.32% higher to $66.38 Monday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=a09fd00dd1469d0cc6c0ad69cc43017ee62dcf7b1b0866f502416e7877ec581a
company,2022-10-17 09:15:03,MacroGenics Shares Jump On Gilead Licensing Pact For Blood Cancer Candidates,116689043,https://s.yimg.com/uu/api/res/1.2/LsXd_jztgeJYLIX_.g1eLg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/9ff0c855360a3a31cf80c7873fecceac,GILD,Yahoo,"Gilead Sciences Inc (NASDAQ: GILD) and MacroGenics Inc (NASDAQ: MGNX) announced an exclusive option and collaboration agreement to develop MGD024 and two additional bispecific research programs. MGD024 is an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics' DART platform. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia and myelodysplastic syndromes. Also Read:",https://finnhub.io/api/news?id=c0ddc98534832c98b21bbeaa9590d3e70a5932d8419f4335eeba0e80f5f6e8be
company,2022-10-17 07:30:00,Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies,116689044,https://s.yimg.com/uu/api/res/1.2/I_lVYlWhzJ4kQRU.M9kuWA--~B/aD0xNjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a629b483ed0846700e61e0145253a400,GILD,Yahoo,"FOSTER CITY, Calif. & ROCKVILLE, Md., October 17, 2022--Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid",https://finnhub.io/api/news?id=0547f5217ec6f5368829a653825baf3c1c1634efb3715c44719acc7c6060f4e5
company,2022-10-17 04:43:00,MacroGenics Teams up with Gilead,116716894,https://blog.tipranks.com/wp-content/uploads/2022/10/shutterstock_2180186725-750x406.jpg,GILD,TipRanks,Biopharmaceutical company MacroGenics’ (NASDAQ:MGNX) stock is soaring today after it announced a collaboration with Gilead Sciences (NASDAQ:GILD) for the developmen...,https://finnhub.io/api/news?id=b33744a9b7bcb1cfa360b4274b48cd9a0b40229bdd89be680e84e97eb328e24c
company,2022-10-17 03:55:00,MacroGenics in Collaboration Agreement With Gilead Sciences for MGD024,116715542,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,"By Chris Wack Gilead Sciences Inc. and MacroGenics Inc. have entered into an exclusive option and collaboration agreement to develop MGD024, a potential...",https://finnhub.io/api/news?id=670123757b2afcb5c941d6a208e7ea69cf23b19af2ef49dc610f48ce73e9bcc5
company,2022-10-17 02:40:00,"Gilead, MacroGenics announce MGD024 option and collaboration agreement",116716897,https://thefly.com/images/meta/hotstocks.jpg,GILD,Thefly.com,"Gilead (GILD) and MacroGe... GILD, MGNX",https://finnhub.io/api/news?id=c53bfa435a55aabaef02b57383ef6e1184f0e70c01109b24b214940b243f2f8e
company,2022-10-16 23:31:00,Kite says EC granted approval for use of Yescarta,116721462,https://thefly.com/images/meta/hotstocks.jpg,GILD,Thefly.com,"Kite, a Gilead Company, a... GILD",https://finnhub.io/api/news?id=61370e5b626f1175e2c1750663d1d3c565cb12ce21e614d26b385880a7b361d5
company,2022-10-16 06:41:00,3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off,116673575,https://s.yimg.com/ny/api/res/1.2/xNtn811uWjtjD1omXFtQrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/e47f0fdcadc34a8f96df955ef93a97cb,GILD,Yahoo,"Medical stocks don't generally have high dividends, but Abbvie (NYSE: ABBV), Pfizer (NYSE: PFE), and Gilead Sciences (NASDAQ: GILD) all have dividends with yields of 3.5% or more, and these pharmaceuticals stocks serve as a great hedge against inflation because their business models are largely resistant to recessions.  A high-yielding dividend without sound fundamentals can easily become a dividend trap, but all three of these companies have pipelines with great potential and a strong history of increasing revenue -- and none appear to be overpriced yet.  AbbVie is a new Dividend King.",https://finnhub.io/api/news?id=333ff49398e3c10f40bc498253ea7aa2c734212a572bca3557da14b7b89cc4df
company,2022-10-15 07:01:04,"Why We're Not Concerned About Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price",116668293,https://s.yimg.com/uu/api/res/1.2/toOHA4B9c_p415zczXd3bQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Gilead Sciences, Inc.'s ( NASDAQ:GILD ) price-to-earnings (or ""P/E"") ratio of 20x might make it look like a sell right...",https://finnhub.io/api/news?id=7898cdd21222d3e42a563cb7ddfa3ff5cc8f885a48e421d43c6cbc31b580b48e
company,2022-10-21 12:27:04,Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers,116778304,https://s.yimg.com/uu/api/res/1.2/2Uxrul9Xalj9HwUZqlOfZA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.,https://finnhub.io/api/news?id=3d1923d36550c39312acdd5c9bbf7fd05977b6b0c447a33ca1135031ed7ca74b
company,2022-10-20 12:56:00,"Gilead Sciences Inc. stock falls Thursday, still outperforms market",116779991,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 0.05% to $66.16 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=833cb5c1e48fc916ad922d50d844bdcef71d8ed0ef84b954cdc38b1dbd09fb78
company,2022-10-20 10:02:02,Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for,116752902,https://s.yimg.com/uu/api/res/1.2/6Ex_CnpNXcMseRWMhPXBow--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94,GILD,Yahoo,Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=9f557686fbc9bf2082c2d8dda86bdaccf266afb594aec06adc77a2c1743880e9
company,2022-10-20 09:00:00,Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers,116752904,https://s.yimg.com/uu/api/res/1.2/59_3.D8pjzv5aEPGel402A--~B/aD0xNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e66e6832aa4c0c63294c7ea1241e94fa,GILD,Yahoo,"SANTA MONICA, Calif. & MENLO PARK, Calif., October 20, 2022--Kite, a Gilead Company (Nasdaq: GILD) and Refuge Biotechnologies, Inc. (""Refuge""), today announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for cancer immunotherapy, for exclusive rights to utilize Refuge’s proprietary gene expression platform to develop potential treatments for blood cancers.",https://finnhub.io/api/news?id=fc56b72e20809028e1417400a75c5f4994176436274b10ef9211ee8ca1788766
company,2022-10-20 04:08:00,"Kite, Refuge announce exclusive cancer immunotherapy license agreement",116752474,https://thefly.com/images/meta/hotstocks.jpg,GILD,Thefly.com,"Kite, a Gilead (GILD) com... GILD",https://finnhub.io/api/news?id=51adc5b2dba315626c129358fd970775a336c1a9c0b3bff94d1521cb87b097b3
company,2022-10-20 00:31:33,HQH: A Dividend Paymaster That Fails To Register Price Growth,116736568,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363842522/image_1363842522.jpg?io=getty-c-w750,GILD,SeekingAlpha,Tekla Healthcare Investors is able to generate steady yield and currently trades at a good discount to its NAV. Read more to see why HQH is a Buy.,https://finnhub.io/api/news?id=44e3ceaa6735a44d2ae48e01c7a49530361cf5019b93c83838fca7214c20dbc4
company,2022-10-19 21:01:00,Boston Common Asset Management - GuruFocus.com,116748198,https://static.gurufocus.com/images/logo_global.png,GILD,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=540320a1ef9ae9e551022a9922339b6276b2f261528d74bf3039551ce3ffe900
company,2022-10-19 18:00:10,Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know,116731067,https://s.yimg.com/uu/api/res/1.2/aMCT_Lh5K9xNn9.QUdX03w--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a,GILD,Yahoo,"Gilead Sciences (GILD) closed the most recent trading day at $66.19, moving -1.02% from the previous trading session.",https://finnhub.io/api/news?id=0911e1ae41eb3c25008bfff7851571db88c91633a0b75bc16b247245f8b62878
company,2022-10-19 12:56:00,"Gilead Sciences Inc. stock falls Wednesday, underperforms market",116779993,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 1.02% to $66.19 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=40b5ab6e577132073514c5cac0e18545bc6514aef69588efc53bb7362def6d23
company,2022-10-19 11:05:00,Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity,116731068,https://s.yimg.com/uu/api/res/1.2/rrPGIyGT1CbSsRP2ejy7eg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/f0a9dff1f9ab33b45525f0bbf223e76d,GILD,Yahoo,"Gilead Sciences, Inc. (Nasdaq:GILD) recently announced that the Gilead Foundation's Creating Possible Fund™ will provide a total of $20 million to 13 inaugural grantees. The Creating Possible Fund was launched to support creative and high-impact strategies that advance health through education equity, with a main focus on building a pipeline of Black health leaders.",https://finnhub.io/api/news?id=c3e12d4aa645846db1be1670ffd2b1a183a8a5b207ce2f359d3decf68e8821ab
company,2022-10-19 09:11:14,15 Best Drug Stocks to Buy Now,116714405,https://s.yimg.com/uu/api/res/1.2/5pauLosoN1w4T3nTn6aJWQ--~B/aD01MTI7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d7b54ab6c172424f8eb29273c1277201,GILD,Yahoo,"In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […]",https://finnhub.io/api/news?id=535617df1d1e377855a29827c2ac087d4bc17c9f9d9e2e59c0e0268518a28be2
company,2022-10-19 09:02:27,"A Note On Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE and Debt To Equity",116714923,https://s.yimg.com/uu/api/res/1.2/toOHA4B9c_p415zczXd3bQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",https://finnhub.io/api/news?id=def4d2acf85ab8fd5caceab97b3b7cf8380dfb1142be21a0256b14c6cb8dea19
company,2022-10-19 08:14:00,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), UnitedHealth (UNH) and MacroGenics (MGNX)",116716888,,GILD,TipRanks,Companies in the  Healthcare sector have received a lot of coverage today as analysts  weigh in on Gilead Sciences (<span class='tr-stock-ticker' style='color:blue;...,https://finnhub.io/api/news?id=b7c26306379e4bfec7b8f1c30b14af35e533e44cc145ca8348ab59a912c5dc05
company,2022-10-26 12:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,116889849,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rallied 1.75% to $70.82 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",https://finnhub.io/api/news?id=ad2c06d383730333b7a181c767d8c3e53d64ac86972b248380e21f0247014acc
company,2022-10-26 06:00:00,Bristol Myers Squibb: Looking Down A Patent Cliff,116836407,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/158759380/image_158759380.jpg?io=getty-c-w750,GILD,SeekingAlpha,Bristol Myers Squibb stock looks cheap and the dividends will likely be increased when the company reduces its debt leverage. Click here to see why BMY is a Hold.,https://finnhub.io/api/news?id=ddc89029931840176c19c3fd4f76cc0c643308be902d9abcaea966af5cfdae28
company,2022-10-25 12:56:00,"Gilead Sciences Inc. stock rises Tuesday, still underperforms market",116828328,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.87% higher to $69.60 Tuesday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=136df2fc5cca8913c74882157685823e70560941664c086d01c732def39a01f2
company,2022-10-25 10:01:02,Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release,116820996,https://s.yimg.com/uu/api/res/1.2/auhFPLcthJM50UYepXcODg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926,GILD,Yahoo,Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=40f278bda88e109d66b621c04e33998e3d6c8d531fcf5e71074566eb773ab1bb
company,2022-10-24 05:01:00,Top 5 3rd Quarter Trades of Tw - GuruFocus.com,116804282,https://static.gurufocus.com/images/logo_global.png,GILD,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=5927db94d85b89719f8efc493a56a0162f726d67f2a2c81cc2183043d60bde97
company,2022-10-24 02:00:00,Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities,116807434,https://s.yimg.com/uu/api/res/1.2/4ql1G1QT4TJyYjb8eXg05Q--~B/aD0xNjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c8e056880e5cb8af5c8588dc73cf7840,GILD,Yahoo,"FOSTER CITY, Calif., October 24, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of real-world results from the BICSTaR study, highlighting Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a generally well tolerated and efficacious regimen regardless of prior treatment and comorbidity status in people with HIV. The latest five-year data from two Phase 3 studies (Study 1489 and Study 1490) provide evidence of the long-t",https://finnhub.io/api/news?id=26d8a5df4f24ffe8b932ebd41b36183263e16e1924c63889c9b01ddaa4292caf
company,2022-10-24 01:01:00,MATRIX ASSET ADVISORS INC/NY B - GuruFocus.com,116818845,https://static.gurufocus.com/images/logo_global.png,GILD,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=79bce0d4a99ea386b072710d18d8c79248b9837d4c3db04c7240e8b7997fe0c0
company,2022-10-23 09:00:49,"Investors Interested In Gilead Sciences, Inc.'s (NASDAQ:GILD) Earnings",116807435,https://s.yimg.com/uu/api/res/1.2/toOHA4B9c_p415zczXd3bQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"When close to half the companies in the United States have price-to-earnings ratios (or ""P/E's"") below 14x, you may...",https://finnhub.io/api/news?id=94edc166bb6edf28b6f9b68ae50281db059c97021c8a8ac30da3d4e604becf4d
company,2022-10-23 04:39:54,Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV,116794447,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397335462/image_1397335462.jpg?io=getty-c-w750,GILD,SeekingAlpha,Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV. Read why investors are getting HQL at an attractive valuation.,https://finnhub.io/api/news?id=39f2b2da6ea132f39340c41a4d82c407e545c5a52652e5ce189b8614ec2d043a
company,2022-10-30 07:33:00,SVB Securities Reaffirms Their Hold Rating on Gilead Sciences (GILD),116909021,,GILD,TipRanks,SVB Securities analyst David Risinger maintained a Hold rating on Gilead Sciences (GILD &#8211; Research Report) on October 27 and set a price target of $112.00. Th...,https://finnhub.io/api/news?id=9af672a6827940f7128b5c97af889ecade86c29233f4ac1b2e4e9919304a3476
company,2022-10-30 07:23:00,"Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Gilead Sciences (GILD) and InMode (INMD)",116882588,,GILD,TipRanks,Companies in the  Healthcare sector have received a lot of coverage today as analysts  weigh in on Argenx Se (<span class='tr-stock-ticker' style='color:blue; font-...,https://finnhub.io/api/news?id=d7cdde87f42c3e6c1a0ca137e3400b215a30d298ba80ea1741988acd6731311d
company,2022-10-30 07:00:01,Under-the-radar trend shows tech investors remain loyal despite major losses this year,116870487,https://image.cnbcfm.com/api/v1/image/106871431-1618995206523-gettyimages-1230188826-AFP_8XC7VA.jpeg?v=1667230150&w=1920&h=1080,GILD,CNBC,The widely held ARK Innovation ETF and the Technology Select Sector SPDR Fund aren't showing meaningful outflows so far this year.,https://finnhub.io/api/news?id=b0a9338ced4b907e31daafef5128dd729578700594cc118cfdc2f5754fbce404
company,2022-10-29 01:21:00,$10K to $100K in 10 Years? Build Your Own ETF with Undervalued Dividend Stocks,116857386,https://blog.tipranks.com/wp-content/uploads/2022/10/ETF-750x406.png,GILD,TipRanks,"Exchange-traded funds, or ETFs, are a fast and convenient way to own a group of stocks with something in common. There&#8217;s nothing inherently wrong with taking ...",https://finnhub.io/api/news?id=fade8c074505df3236492480f2aea6881c7419080640a402c122d9b8c2942e50
company,2022-10-28 17:35:00,These 2 Stock Winners Topped Apple's Big Gains Friday,116944751,https://s.yimg.com/ny/api/res/1.2/LbGj0l7Eyez4k9NXxRD57w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/ee62811a174eeb46cb32d7657af56add,GILD,Yahoo,"The stock market soared on Friday, ignoring one high-profile earnings miss among the largest companies in the market and instead focusing on the relatively solid performance from Apple (NASDAQ: AAPL).",https://finnhub.io/api/news?id=ffc6afbbf3db9b18f3c0fa67c9535395c9202b8823b85a42e7c2bc62fa683c3e
company,2022-10-28 16:48:47,FDA rejects Gilead hepatitis delta virus drug already greenlighted in Europe,116944752,https://s.yimg.com/ny/api/res/1.2/1pk1Af5Vc8qJi9G3vw_wLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03OTg-/https://media.zenfs.com/en/bizjournals.com/51b38094d90c4762c0f21ed0ada46a3b,GILD,Yahoo,"The company said it will resubmit the drug to the FDA for approval. There are no FDA-approved therapies for hepatitis D, or HDV.",https://finnhub.io/api/news?id=8ba9491e9321c0c591bed0fb9430e9f8d1f5467dedab39f7be762e69a62ff421
company,2022-10-28 16:04:13,Gilead Breaks Out In Bullish Volume As Its Cancer Drug Sales Nearly Double,116944753,https://media.zenfs.com/en/ibd.com/42ec1eee4c32ef9fd681c92c689f33f4,GILD,Yahoo,"Gilead Sciences reported 79% growth for its cancer drugs, helping beat expectations. On Friday, GILD stock broke out.",https://finnhub.io/api/news?id=e53c75987fdcd69797e59ce68fd08795e01a2d94a38f1e9a8d7c1895cb934b73
company,2022-10-28 15:42:45,Gilead Sciences stock surges amid earnings beat and analyst upgrades,116926301,https://s.yimg.com/ny/api/res/1.2/Hn_.EtVUDfAmI5biIl3PMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2022-10/b007c210-56f8-11ed-bddd-5a68502fd579,GILD,Yahoo,Shares of Gilead Sciences are getting a boost thanks to strong earnings for its third quarter.,https://finnhub.io/api/news?id=be2857187aeeb64369b48a702286c9cf048517c64eb7ff5b3c65dd107423bece
company,2022-10-28 15:00:24,Top 10 Gainers on Friday,116873608,https://media.zenfs.com/en/insidermonkey.com/c5a299131495043dc9951e0d351ca092,GILD,Yahoo,"In this article, we will take a look at the top 10 gainers on Friday. If you want to see some more stocks rallying today, go directly to Top 5 Gainers on Friday. All three key U.S. indices jumped this morning, thanks to better-than-expected earnings of giants like Apple Inc. (NASDAQ:AAPL), Intel Corporation (NASDAQ:INTC) and […]",https://finnhub.io/api/news?id=59d8bdd1a4f8419da26e520424d15e0af17718d548a77e28237467a15a2c7ea2
company,2022-10-28 13:06:05,"Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised",116869020,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.,https://finnhub.io/api/news?id=92e1e026dfd48dcabf9ca1831c6a048d88c2e1abf8a9dfd3c5f8c05c95d0b3ab
company,2022-10-28 12:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,116889843,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. jumped 12.92% to $79.27 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=ef6766bc91e545f4ed25ad1936903f45d5fd8d96ab5dfc2c99830ef8f9edea12
company,2022-10-28 12:21:00,How major US stock indexes fared Friday 10/28/2022,116909024,,GILD,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7969bf730f599610805960aa41030120a42c03d4acc021d8c47f7650288b12f9
company,2022-10-28 12:13:00,"Intel, Gilead Sciences rise; Amazon, DaVita fall",116857352,,GILD,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c4931ff3650085fc1d89fc5f72477f27091c581cb2c4905f3aaeb6e29e3d45c6
company,2022-10-28 08:57:33,"Stocks making the biggest moves midday: Apple, Amazon, Intel and more",116871440,https://image.cnbcfm.com/api/v1/image/107126928-16644887532022-09-16t144907z_450453849_rc2diw9oby2u_rtrmadp_0_apple-iphone-usa.jpeg?v=1666976253&w=1920&h=1080,GILD,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=b9d32fbf87774f702a7f57f954dacbad62427ab061513f29711b7069c66e48c0
company,2022-10-28 08:23:00,"Notable Friday Option Activity: GILD, DVA, ALGN",116909026,,GILD,Stock Options Channel,"Staff article entitled Notable Friday Option Activity: GILD, DVA, ALGN, about stock options, from Stock Options Channel.",https://finnhub.io/api/news?id=bd2ef3fec2fc87fda29d61063b487fb306c25955680d104ee322d352bb6d5adf
company,2022-10-28 08:11:00,Gilead Stock Jumps as 2 Analysts Turn Upbeat,116889845,https://images.barrons.com/im-182548/social,GILD,MarketWatch,"Truist's Robyn Karnauskas and Piper Sandler's Do Kim lifted their ratings to Buy and Overweight, respectively, from the equivalent of Hold.",https://finnhub.io/api/news?id=588516cd7f3362a57dabe620a023663a411cacb49b862d8c4cf418eb9ea8d835
company,2022-10-28 07:42:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Dexcom (DXCM), Gilead Sciences (GILD) and Laboratory (LH)",116885609,,GILD,TipRanks,Companies in the  Healthcare sector have received a lot of coverage today as analysts  weigh in on Dexcom (<span class='tr-stock-ticker' style='color:blue; font-wei...,https://finnhub.io/api/news?id=af3ff818574c80f1cead5b98fe107cbcd0f10f0437aaab9dfaa5ec900a0d8c1c
company,2022-10-28 06:44:00,WHO panel says no evidence yet that new omicron subvariants are more dangerous than others that are circulating,116889844,https://images.mktw.net/im-538365/social,GILD,MarketWatch,The omicron sublineages named BQ.1 and XBB do not appear to have immune escape mutations that warrant their being designated as variants of concern,https://finnhub.io/api/news?id=cdfd871261f6990180631a80321fa45f60451aaf29ce477faa90620c2dc1e156
company,2022-10-28 04:55:00,Early notable gainers among liquid option names on October 28th,116857354,https://thefly.com/images/meta/options.jpg,GILD,Thefly.com,"Notable gainers among liq... DXCM, INTC, VRSN, GILD, TMUS",https://finnhub.io/api/news?id=0699eeed47ca67c77418616a315c12783c2d8e0ee6dcfb9bd80dbef91221a845
company,2022-10-28 04:30:00,Bristol-Myers Squibb And Gilead - Still A Buy After Strong Q3?,116854523,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341512128/image_1341512128.jpg?io=getty-c-w750,GILD,SeekingAlpha,Both Bristol-Myers Squibb (BMY) and Gilead (GILD) reported solid Q3 results. Check out whether I am still a buyer despite the outperformance of both stocks.,https://finnhub.io/api/news?id=69410f7955dddd923cb26bb92d32450dc8a767c94445ae618127f12041f268bb
company,2022-10-28 04:19:00,Gilead price target raised to $72 from $63 at BMO Capital,116909029,https://thefly.com/images/meta/streetresearch_recommendations.jpg,GILD,Thefly.com,BMO Capital analyst Evan ... GILD,https://finnhub.io/api/news?id=4a1073151f4628c4ebccc4d36dcb2b6c7efe6926604d7847648b6f8db74e5fcd
company,2022-10-28 03:38:00,Wells Fargo Keeps Their Hold Rating on Gilead Sciences (GILD),116909030,,GILD,TipRanks,"In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Gilead Sciences (GILD &#8211; Research Report), with a price target of $75.00....",https://finnhub.io/api/news?id=a333b47cc6dd6867c506522624437bcc499e675519fef0d546ec40451d230a50
company,2022-10-28 03:34:00,Gilead price target raised to $80 from $75 at Cowen,116909031,https://thefly.com/images/meta/streetresearch_recommendations.jpg,GILD,Thefly.com,Cowen analyst Tyler Van B... GILD,https://finnhub.io/api/news?id=0f37273ae569f6241197ed06d514eb3b6a3be8c4c6f3a49ece22627e560c11a3
company,2022-10-28 02:11:00,Gilead upgraded to Buy at Truist on oncology assets and COVID drugs,116909033,https://thefly.com/images/meta/streetresearch_upgrade.jpg,GILD,Thefly.com,Truist analyst Robyn Karn... GILD,https://finnhub.io/api/news?id=590da3c7cfbac8a3e6429ccb64e262575ed6b971d5550d5af3c03461d7b6527d
company,2022-10-28 01:43:00,Needham Reaffirms Their Hold Rating on Gilead Sciences (GILD),116909034,,GILD,TipRanks,"In a report released today, Joseph Stringer from Needham maintained a Hold rating on Gilead Sciences (GILD &#8211; Research Report). The company&#8217;s shares clos...",https://finnhub.io/api/news?id=9853d0dcaf84ef9cf06d6105b6973f1d184e58852d3f16c9d28e9fc55414b3e4
company,2022-10-28 00:23:00,Gilead upgraded to Buy from Hold at Truist,116909036,https://thefly.com/images/meta/streetresearch_upgrade.jpg,GILD,Thefly.com,Truist analyst Robyn Karn... GILD,https://finnhub.io/api/news?id=6f16b6358e303c4f985f4d196408408a6d9d8571317e0b7002a077cb84bc7f84
company,2022-10-27 23:55:00,American Association for Cancer Research to hold a symposium,116871303,https://thefly.com/images/meta/converenceevents.jpg,GILD,Thefly.com,"EORTC-NCI-AACR Molecular ... CYCC, OLMA, MRUS, VERU, GILD, NVCT, CYT, KRON, CLLS, MAIA, AADI, TYRA",https://finnhub.io/api/news?id=b0a072390d2ecd46f602bf7feddd6d3a20dae1646f0d3b67aeaad6e08459f563
company,2022-10-27 16:33:05,"Gilead Sciences, Inc. (GILD) Q3 2022 Earnings Call Transcript",116850827,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q3 2022 Results Conference Call October 27, 2022 04:30 PM ET Company Participants Jacquie Ross - VP, IR Daniel OâDay - Chairman and CEO Johanna...",https://finnhub.io/api/news?id=bc9cc6409637de5d280e91c4763bc4bb05829a87bd941724f591341029b30b3e
company,2022-10-27 13:26:00,Gilead Science sees revenue and profit drop on lower Veklury sales,116909039,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=53800917ab9bebd1bb8583c06672e6b301d395da53d8992d7466b6e279fa13bb
company,2022-10-27 12:56:00,Gilead Sciences Inc. stock underperforms Thursday when compared to competitors,116889847,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 0.88% to $70.20 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",https://finnhub.io/api/news?id=1d8587899ee5bf02a73a56f5566c0d6517d3bc966a9f782db3adbba97e36a3dc
company,2022-10-27 12:26:00,"Gilead stock rises on more upbeat forecasts, while COVID drug sales slide",116889846,https://images.mktw.net/im-653318/social,GILD,MarketWatch,Shares of Gilead Sciences Inc. rose after the drugmaker reported third-quarter results that topped expectations and boosted its full-year profit and sales...,https://finnhub.io/api/news?id=6a7a7749bef9f1d62dfa1263710cab6291100e4c18905cd2ad81034a38915353
company,2022-10-27 12:20:00,Gilead Sciences 3Q Profit Fell as Sales of Covid-19 Drug Declined,116889848,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,"By Jeffrey T. Lewis Gilead Sciences Inc.'s profit fell in the third quarter after sales of antiviral medicine Veklury declined. The Foster City, Calif.-based...",https://finnhub.io/api/news?id=a397f759c1cadd52e25899de09f9f9143223bb1b17374d2b21b84790ba187b2d
company,2022-10-27 12:01:00,Gilead Sciences Announces Third Quarter 2022 Financial Results,116909041,,GILD,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ef26a1b92d65c3eab46ae2b999f3b6233871d37277c9c79e7867ef4d31e5b89b
company,2022-10-27 08:34:00,Notable companies reporting after market close,116849481,https://thefly.com/images/meta/earnings.jpg,GILD,Thefly.com,"Notable companies reporti... AAPL, AMZN, TMUS, INTC, GILD, VRTX, EW, DXCM, COF, PINS, ZEN, FSLR, TXRH",https://finnhub.io/api/news?id=fbe9d51c9407a7a50ebed9c268a74f8926ee4bc237f766c627041b89329ebd68
company,2022-10-27 00:07:00,Gilead Sciences (GILD) Receives a Buy from Mizuho Securities,116909043,,GILD,TipRanks,Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD &#8211; Research Report) today and set a price target of $75.00. The company&#...,https://finnhub.io/api/news?id=7b9e312d682cf85b35a0da1131dbf760fcdf941d0413e064d9fa2efe98ec458b
company,2022-10-26 23:04:00,Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75,116909045,https://thefly.com/images/meta/earnings.jpg,GILD,Thefly.com,Consensus $6.54. Sees Tot... GILD,https://finnhub.io/api/news?id=ee38d7b86c3f1ed5d4e721266798b61609685232de0cb2966dc04adb200a15bd
company,2022-11-03 13:29:05,"Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook",116942348,https://media.zenfs.com/en/zacks.com/9e8d93e17a792e7de990e3344e61fa6a,GILD,Yahoo,"Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.",https://finnhub.io/api/news?id=4fab0f40dbc050880192c3365e385a4b63ecdcb11c7210fd356ce2ee3fd775c0
company,2022-11-03 13:25:05,"Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates",116942524,https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0,GILD,Yahoo,Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement.,https://finnhub.io/api/news?id=30fa78e48a2af4840c1d2d800001825cb380a3e4d166727797174d540e295ee3
company,2022-11-03 13:16:05,Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3,116942349,https://media.zenfs.com/en/zacks.com/c0c563b233f28a1874a33c46aadaa70e,GILD,Yahoo,"Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates.",https://finnhub.io/api/news?id=f869a47fc84a8a7853fc8a833bd480253f99f86bbdf8e88b3e81a348b21f1b34
company,2022-11-03 12:56:00,"Gilead Sciences Inc. stock rises Thursday, outperforms market",116941247,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 2.03% to $79.46 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=dd85bf2038095c53755eaeddf85d9740f7de252b2fb0d5e2196bf949bd4d4421
company,2022-11-03 09:15:00,Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022,116944740,https://media.zenfs.com/en/business-wire.com/eaddd858a3bd95bb95691e0b37cab9ac,GILD,Yahoo,"FOSTER CITY, Calif. & SANTA MONICA, Calif., November 03, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will support 30 data presentations, including seven oral presentations in large B-cell lymphoma (LBCL), and two oral presentations on investigator-sponsored studies in acute myeloid leukemia (AML) during the 64th Annual American Society of Hematology (ASH) Annual Meeting (December 10-13).",https://finnhub.io/api/news?id=e8895893f911af3e2a344ddbd6ba09c3617228dd5cd909d02c50559aa0f02d3f
company,2022-11-02 12:56:04,"Esperion (ESPR) Q3 Earnings Beat Estimates, Revenues Miss",116925875,https://media.zenfs.com/en/zacks.com/c0c563b233f28a1874a33c46aadaa70e,GILD,Yahoo,"Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.",https://finnhub.io/api/news?id=d2ab122e37052f51430977c97debd45f3e24660f1af1e2cfdb740e7e9b0d5613
company,2022-11-02 12:56:00,Gilead Sciences Inc. stock outperforms market despite losses on the day,116922623,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.84% to $77.88 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=2f53aea8194b12baf6153a9d32e3efe76ce6abe26dc91f3cd9a36c215f06929c
company,2022-11-02 10:19:02,G1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer Drug,116920965,https://media.zenfs.com/en/Benzinga/c683fd3ba4ec8bfc0c3bab86030e01c8,GILD,Yahoo,"G1 Therapeutics Inc (NASDAQ: GTHX) described safety data from the first 18 patients enrolled in its ongoing Phase 2 study of trilaciclib administered before sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Sacituzumab govitecan is marketed as trodelvy by Gilead Sciences Inc (NASDAQ: GILD). ""We believe we are seeing on-target effects of trilaciclib in the expected reduction in the rate of myelosuppression and the rates o",https://finnhub.io/api/news?id=4680364c719b64e5a1a3f9ff00cca65a04f387b6077a8ec5514409bf47e8dd36
company,2022-11-02 08:55:00,Gilead's Path to Equitable Global COVID-19 Treatment Access,116926297,https://media.zenfs.com/en/accesswire.ca/f0a9dff1f9ab33b45525f0bbf223e76d,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences Since the beginning of the COVID-19 pandemic, Gilead's first-in-class antiviral was made available to more than 11 million patients globally- over 65% of whom live in low-and lower-middle-income ...",https://finnhub.io/api/news?id=8e524be20765357db0a5b4ed9dd9d2d072531d7475f5c9058d37e8c7d3130ca6
company,2022-11-02 08:00:00,"Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.",116909305,https://media.zenfs.com/en/globenewswire.com/b843762a094f7b7be78232509fc10b60,GILD,Yahoo,"CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today earning a $15.0 million clinical milestone payment from Gilead Sciences, Inc. (NASDAQ: GILD) under the exclusive license agreement for GS-1811, an anti-CCR8 antibody for which Gilead has exclusive rights to develop and commercialize. GS-1811 (formerly JTX-1811) is",https://finnhub.io/api/news?id=3d082df7d0205795f1324bee1f3712f10d37d996092e636e80df52df353283bc
company,2022-11-02 07:01:00,U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients,116926299,https://media.zenfs.com/en/business-wire.com/801fef70837f799ffef914ed928fce39,GILD,Yahoo,"FOSTER CITY, Calif., November 02, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients 12 years of age and older with compensated liver disease.",https://finnhub.io/api/news?id=d97c4e487cb1b7d4d90bf5e0b628014dff4123e3bd2edcb6fda2778d9d25e281
company,2022-11-02 05:01:00,Top 5 3rd Quarter Trades of HO - GuruFocus.com,116923925,https://static.gurufocus.com/images/logo_global.png,GILD,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=598994a384565fbceeb9864faf4f2832cfb4325d378b02606764e191490b1657
company,2022-11-02 04:40:00,Unusually active option classes on open November 2nd,116909000,https://thefly.com/images/meta/options.jpg,GILD,Thefly.com,"Unusual total active opti... THO, GOOS, BEKE, GSK, CVS, UNG, UAL, GILD, HYG, FUBO",https://finnhub.io/api/news?id=09cc316b9feffa9c28972357433ba250b821ce4f19f429f53c51ad445877b473
company,2022-11-02 03:18:00,Jounce earns clinical milestone payment under agreement with Gilead,116909003,https://thefly.com/images/meta/hotstocks.jpg,GILD,Thefly.com,"Jounce Therapeutics (JNCE... JNCE, GILD",https://finnhub.io/api/news?id=dd4a065464658766af6d710a74266e5685c119555132341774a5237193b3bdcf
company,2022-11-02 02:50:00,FDA approves Gilead sNDA  for Vemlidy to treat pediatric hepatitis B virus,116909006,https://thefly.com/images/meta/hotstocks.jpg,GILD,Thefly.com,"Gilead Sciences, announce... GILD",https://finnhub.io/api/news?id=837c95c218af1feb267c1826dde810cc9d82574ac4d0c5978b9dde8bc2cc1674
company,2022-11-01 23:30:00,6 Stocks With Healthy Dividends and Solid Returns,116919415,https://images.barrons.com/im-655658/social,GILD,MarketWatch,"AbbVie, Gilead Sciences, Cardinal Health, Merck, Bristol Myers, and Amgen are large-cap healthcare companies that have the capacity to grow their dividends.",https://finnhub.io/api/news?id=324fda67d96abfa43831840cc453f00278422b6b33b20aa6c062e472ae15b03d
company,2022-11-01 12:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,116889841,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 1.12% to $79.34 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=c6d7e3149896df0800480273ca7ae7260ad3d731e1e190560eb2bbc8f28cbf98
company,2022-11-01 12:44:04,"Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View",116908910,https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707,GILD,Yahoo,Eli Lilly's (LLY) earnings and sales surpass third-quarter estimates. The company lowers 2022 financial view for the third time this year. The stock falls in pre-market trading.,https://finnhub.io/api/news?id=06eea8d77c1284caad3255fd47be1e47c6aa657413a7a761f0574947c17426c9
company,2022-11-01 09:03:15,15 Best NASDAQ Dividend Stocks To Buy,116892935,https://media.zenfs.com/en/insidermonkey.com/7ed25828648f7da3a7f6f16ffb97117d,GILD,Yahoo,"In this article we present the list of 15 Best NASDAQ Dividend Stocks To Buy. Click to skip ahead and see the 5 Best NASDAQ Dividend Stocks To Buy. Starbucks Corporation (NASDAQ:SBUX), Gilead Sciences, Inc. (NASDAQ:GILD), and Intel Corporation (NASDAQ:INTC) are just a handful of the best NASDAQ dividend stocks to buy, which we’ll examine in […]",https://finnhub.io/api/news?id=06836b5de778b25849c807d552ee12cd5b4c947c184a4df87f01dd064303fca5
company,2022-11-01 09:00:00,"Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease",116926300,https://media.zenfs.com/en/business-wire.com/4eb29d7e17dad80283e8c6618835d250,GILD,Yahoo,"FOSTER CITY, Calif., November 01, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that clinical and real-world data from more than 70 abstracts will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place from Nov. 4-8, 2022. Key presentations include Week 48 integrated efficacy and safety analyses from Phase 2 and Phase 3 studies of Hepcludex® (bulevirtide), Gilead’s first-in-class investigational treatment for chronic hepatit",https://finnhub.io/api/news?id=1b706c298a51ed99c415c9ebabe1c8f8805099a8d9ca73793779fd19b0fe3192
company,2022-11-01 03:42:00,SVB Securities Keeps Their Hold Rating on Gilead Sciences (GILD),116909010,,GILD,TipRanks,SVB Securities analyst David Risinger maintained a Hold rating on Gilead Sciences (GILD &#8211; Research Report) today and set a price target of $81.00. The company...,https://finnhub.io/api/news?id=1530cb3a2702f43b1474577b96ea6e26fdb420b8e19e8980c2c980ea8145b4e6
company,2022-11-01 01:55:00,AnaptysBio upgraded to Buy at Guggenheim on checkpoint agonist opportunity,116904864,https://thefly.com/images/meta/streetresearch_upgrade.jpg,GILD,Thefly.com,"Guggenheim analyst Yatin ... ANAB, GILD",https://finnhub.io/api/news?id=12b339d1bc1f8cf89033a7727a95d0529e9c04d104fb0881a7bb8c2a0b9c76f0
company,2022-10-31 12:56:00,Gilead Sciences Inc. stock underperforms Monday when compared to competitors,116889842,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 1.02% to $78.46 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=5b61e221a41622edabe76733b47f6eb4a344164a49ba90efd148ac4c7de084e0
company,2022-10-31 10:51:27,Biogen: Super-Strong Momentum In A Defensive Sector,116872770,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/164478117/image_164478117.jpg?io=getty-c-w750,GILD,SeekingAlpha,"Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. See why I would reenter a position in BIIB stock.",https://finnhub.io/api/news?id=02cc49fce4d5cfc67af2c78349a703259b473657c3c0dfc24fa85d4c927866f4
company,2022-10-31 09:00:17,"Institutional investors are Gilead Sciences, Inc.'s (NASDAQ:GILD) biggest bettors and were rewarded after last week's US$14b market cap gain",116944749,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the...",https://finnhub.io/api/news?id=25f708e27dd3c960fee66690ad556d173f07fb1e7e843fa2c1398ab1b6e5f714
company,2022-10-31 09:00:01,"Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It",116944750,https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2,GILD,Yahoo,"Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.",https://finnhub.io/api/news?id=ae2621e0a404b1b4394591cad1cb7290d68e322db0ee2086f6ce8275f05670b1
company,2022-10-31 07:58:00,Can Biotech Stocks Continue Rallying In This Bear Market? ,116889218,https://i0.wp.com/raygent.com/wp-content/uploads/2022/10/image-6.png,GILD,TalkMarkets,Despite a vicious bear market in 2022 biotech stocks have come back in October recovering with the XBI up 3.72% to $83.76 on Friday.,https://finnhub.io/api/news?id=de4754ef0cfa2e044c44cbdf23ed92cf8121534a863046e1b1cc3941dcabc8e4
company,2022-10-31 04:02:00,GLOBAL BROKER RATINGS: Jefferies raises Reckitt; DB likes BASF,116871745,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a81e1d69a1a36af689e4edf5d1d52014616120acac3adb0b3539ae8a17b5343f
company,2022-10-31 04:01:43,Peak Gilead,116864851,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411442615/image_1411442615.jpg?io=getty-c-w750,GILD,SeekingAlpha,Gilead's future will be sprinkled with important new revenue drivers. Click here to see why GILD stock can well afford to pay a nice dividend and keep its debt in check.,https://finnhub.io/api/news?id=d10c02fb62ffddf9c85f76254941eea0c216d75a7f2054680fcc2658aea62821
company,2022-10-31 03:27:00,Gilead price target raised to $92 from $84 at Maxim,116909017,https://thefly.com/images/meta/streetresearch_recommendations.jpg,GILD,Thefly.com,Maxim analyst Jason McCar... GILD,https://finnhub.io/api/news?id=09180008525d0319ea6fd3efae6e105af1da7a23d8223519f0eb43328accc602
company,2022-10-31 02:45:00,Gilead Sciences Reaches Analyst Target Price,116909019,,GILD,ETF Channel,"Staff article entitled Gilead Sciences Reaches Analyst Target Price, about ETFs, from ETF Channel.",https://finnhub.io/api/news?id=0e7cae7bf6153a01cb73b20e5f29815524a158947650227d0b68abcf6a4efee3
company,2022-10-30 20:09:00,"Stocks slip, but still end up with big gains for October",116884733,,GILD,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=aa3fdc412dec26341d2c9e17793fa9e85cc44e5c5d17911d29a530a14517bb8e
company,2022-11-07 13:20:24,US Supreme Court Throws Out Bristol Myers Appeal On Cancer-Drug Related Patent With Gilead,116992371,https://media.zenfs.com/en/Benzinga/1c78fff066913193899988b2def72eae,GILD,Yahoo,"The U.S. Supreme Court turned away an appeal made by rebuffed efforts made by Bristol Myers Squibb Co's (NYSE: BMY) Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc's (NASDAQ: GILD) Kite Pharma Inc over Yescarts, a lymphoma drug. Juno and Sloan Kettering Institute for Cancer Research sued Kite in 2017 in a federal court in Los Angeles, accusing it of copying technology the institute licenses to Juno. A jury awarded the plaintiffs $778 mi",https://finnhub.io/api/news?id=8190793c03cc55792ac1bd1f22eb3e38c717282d9c7a19d03bf30166e83cedc2
company,2022-11-07 12:14:45,"UPDATE 1-Gilead, Kite in process of pausing Twitter advertising",116987519,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"Gilead Sciences Inc said on Monday the company and its unit Kite were in the ""process of pausing advertising"" on Twitter, after Elon Musk completed his takeover of the social media company.  In a statement to Reuters, Gilead said it was monitoring its advertising spend and waiting to better understand how community standards and content moderation will be handled on Twitter now.  Gilead joins a growing list of U.S. companies, including General Motors and General Mills, who have either paused or are in the process of re-evaluating advertising on the social media platform.",https://finnhub.io/api/news?id=cc34cc68fba3d1df5161502866a9111c738b630f59fb238bf8dab03ea17c69d8
company,2022-11-07 11:57:16,"Gilead, Kite in process of pausing Twitter advertising",116987167,https://static.reuters.com/resources/r/?m=02&d=20221107&t=2&i=1613617250&r=LYNXMPEIA60P8,GILD,Reuters,"Gilead Sciences Inc said on Monday the company and its unit Kite were in the ""process of pausing advertising"" on Twitter, after Elon Musk completed his takeover of the social media company.",https://finnhub.io/api/news?id=7d9f2c7476bb13172037d801fcf85c1bf4f9d8eec8a1c9a26a7bf52a77631a17
company,2022-11-07 11:55:00,"Gilead Sciences Inc. stock rises Monday, outperforms market",117038672,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 1.39% to $81.46 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=4e4ad921b283db165530f6e7b6582f1348c6a62bcb82f5494b758d499ec73eab
company,2022-11-07 09:37:56,U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead,116987146,,GILD,Reuters,The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc subsidiary Kite Pharma Inc over a lymphoma drug.,https://finnhub.io/api/news?id=5034574085690c4a081ade4b66bb878dda297e49d38d8a97fa68f4992e5ed6e6
company,2022-11-05 09:31:00,3 No-Brainer Dividend Stocks to Buy in November,116969002,https://s.yimg.com/ny/api/res/1.2/_CM82AewtvGbfN6XVf9yFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NDI-/https://media.zenfs.com/en/motleyfool.com/5d72722c96e18d33d3954f2e80f6a924,GILD,Yahoo,"Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ).  This FUD relates to concerns about how the impending loss of exclusivity (LOE) in the U.S. for Humira will impact AbbVie.  The blockbuster drug generated more than 37% of the company's total sales in the third quarter.",https://finnhub.io/api/news?id=70bcb40601222b52f9d612900daaf780a3c1606afd0ff210530d7ec4fe1f47cb
company,2022-11-04 12:56:00,"Gilead Sciences Inc. stock rises Friday, still underperforms market",116973803,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. advanced 1.11% to $80.34 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=bb250fabe620e6027ef7b0c364e5aa7e15eae801a02a170971b508d24e48cf98
company,2022-11-04 12:35:04,Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates,116956086,https://media.zenfs.com/en/zacks.com/c0c563b233f28a1874a33c46aadaa70e,GILD,Yahoo,Nektar (NKTR) reports encouraging third-quarter 2022 results. The narrower-than-expected loss is on account of lower operating expenses incurred during the quarter.,https://finnhub.io/api/news?id=8d97f74ec73246947c83616e3daa73be8f9308feb19e10df694de1e9305a2e2c
company,2022-11-04 12:15:04,Karuna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 Loss,116956146,https://media.zenfs.com/en/zacks.com/c0c563b233f28a1874a33c46aadaa70e,GILD,Yahoo,Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.,https://finnhub.io/api/news?id=4ab2e00df9638084e2994584585fbfddee7969dda562f6d7defad25f8496556c
company,2022-11-04 11:18:03,"Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up",116953960,https://media.zenfs.com/en/zacks.com/cb4b690d325dd8102d704a07d05bf229,GILD,Yahoo,Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States.,https://finnhub.io/api/news?id=d1656de85ee2ba92a3c6dcdee946c73df873bda1fefb97842cd8b51cb38034b7
company,2022-11-04 10:45:02,"TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down",116953961,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,GILD,Yahoo,"TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.",https://finnhub.io/api/news?id=c49e769f86c50153680aa85be369f81c8289005ab709398320920a4ca72f83b9
company,2022-11-04 09:00:42,"Is There An Opportunity With Gilead Sciences, Inc.'s (NASDAQ:GILD) 46% Undervaluation?",116969887,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Gilead Sciences, Inc...",https://finnhub.io/api/news?id=043727ae992db2c605bae2d41f80f700125983d107fd407c84a07dd4f7618455
company,2022-11-11 09:00:02,"Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",117124628,https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177,GILD,Yahoo,"Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",https://finnhub.io/api/news?id=d40ca8025823ec879d21132c4508d10ef65a334b157d583c4844d254e5e097d8
company,2022-11-10 21:30:00,Big Pharma Stocks Are Breaking Out. Here Are Some Winners.,117126747,https://images.barrons.com/im-388513/social,GILD,MarketWatch,Drug stocks have been outperforming the market all year since their sales are unaffected by changes in economic demand.,https://finnhub.io/api/news?id=7856ba8047bb74afe88eb540226562e82c93a134f69c2d41cde4c4adaf298850
company,2022-11-10 11:40:04,"Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales",117073470,https://media.zenfs.com/en/zacks.com/c0c563b233f28a1874a33c46aadaa70e,GILD,Yahoo,Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance.,https://finnhub.io/api/news?id=07e222bea6c06b6adb2142086539eeef11ef0502ab96da15d0744b4f3a180904
company,2022-11-10 10:05:00,Gilead Sciences: A Career Rooted in Championing Diversity and Inclusion: Jesse's Story,117069100,https://media.zenfs.com/en/accesswire.ca/f0a9dff1f9ab33b45525f0bbf223e76d,GILD,Yahoo,"NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences While Jesse Garcia was growing up in Chicago's inner city, his parents didn't immediately turn to a doctor when someone in the family got sick. ""We relied on traditional Latino ...",https://finnhub.io/api/news?id=4c9722458e0e719e867075492e5a6acc234e6169dcf1c0394d3267182b21eb0b
company,2022-11-10 09:30:00,Has This Hot Stock Run Out of Steam?,117073577,https://s.yimg.com/ny/api/res/1.2/UmN87ovM.jSq3N2Tu.iVQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/motleyfool.com/fe54783b8cd6739760424e38408489be,GILD,Yahoo,"One of the hottest healthcare stocks on the markets of late has been HIV-focused drugmaker Gilead Sciences (NASDAQ: GILD).  Shares of Gilead are up a whopping 33% over just the past three months, dwarfing the S&P 500 and its 8% losses during that stretch.  Here's a closer look at what's been behind Gilead's recent rally and whether or not its shares could still go higher.",https://finnhub.io/api/news?id=b7f84931e7c6ec97e25a26c334f8262838469c7b56a80e21eef616f89f9f5153
company,2022-11-10 08:27:05,"AlloVir: Solid Data, But Market Isn't Paying Attention",117072404,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1366654397/image_1366654397.jpg?io=getty-c-w750,GILD,SeekingAlpha,AlloVir has some solid data in an area of unmet need. The company is well-capitalized. Read why this could be a buying opportunity for ALVR stock.,https://finnhub.io/api/news?id=4a6201a68bda2f4a524c8256d3386ee3840a61dfabda817edf7fe0ebd9b0b0fd
company,2022-11-09 11:55:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,117038667,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.11% higher to $82.32 Wednesday, on what proved to be an all-around grim trading session for the stock market, with...",https://finnhub.io/api/news?id=f3b761026fccf71f772cf8c475259241737f39c858b5bc811983a76c2f51c018
company,2022-11-09 05:23:01,My Dividend Stock Portfolio: New October Record - 103 Holdings With 27 Buys,117022517,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w750,GILD,SeekingAlpha,"My dividend income amounted to a new October record of $566, which is up 63% Y/Y. Read more to know the details of my dividend stock portfolio for October.",https://finnhub.io/api/news?id=7eb61ecc246e780314529141e72500399b45b036d1d881210b941d61bbe4e492
company,2022-11-09 03:48:00,See Which Of The Latest 13F Filers Holds Gilead Sciences,117033703,,GILD,Preferred Stock Channel,"Staff article entitled See Which Of The Latest 13F Filers Holds Gilead Sciences, about stock options, from Holdings Channel.",https://finnhub.io/api/news?id=822af490693a147e758efd2d7fca2a47046a26a20b37b9fa27c698d09fe0d2ea
company,2022-11-08 14:29:00,Here's My Formula for Investing in Gilead Sciences,117011101,,GILD,Yahoo,"We reviewed the charts of Gilead Sciences on Oct. 4 and wrote that we ""like the current look of the charts and indicators. Traders could go long GILD on strength above $68 and above $72. Our price target is $81 for now.",https://finnhub.io/api/news?id=e34fb48bdb85f1de04bc85f6306c1c7d87db06779aed3d883a9ae1dddfc46286
company,2022-11-08 12:01:27,Goldman Sachs’ Cheap Dividend Stocks,117002097,https://media.zenfs.com/en/insidermonkey.com/c1c2933a5655260bed1ddbb26d54adda,GILD,Yahoo,"In this article, we will discuss Goldman Sachs’ cheap dividend stocks. You can skip our detailed analysis of dividend investing and the firm’s outlook on dividend stocks, and go directly to read Goldman Sachs’ 5 Cheap Dividend Stocks. Growth tech stocks have dominated the market for years due to their innovative products and services. However, […]",https://finnhub.io/api/news?id=1f3bb1b79c8b58ab1d84a24529e3dc1a52552b9b51de9ef89128aaacdf433c84
company,2022-11-08 11:55:00,Gilead Sciences Inc. stock outperforms market on strong trading day,117038669,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.95% higher to $82.23 Tuesday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=4449304546caddb0b752e1b215f25dccfcfc164a53f9ba9d395ff4f6ddbfb152
company,2022-11-08 11:22:04,"Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '22 EPS View",117004177,https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0,GILD,Yahoo,Perrigo (PRGO) reports dismal third-quarter 2022 results. Unfavorable currency movements force management to lower earnings outlook for 2022. Shares down.,https://finnhub.io/api/news?id=ba3ac04d8f0cb3f1fc225730b1f631e1e20f3aed2fa96a4f12aac06fc6dd8146
company,2022-11-08 11:00:43,Why Shares of Gilead Sciences Rose 27.20% in October,117011104,,GILD,Yahoo,"Gilead Sciences (NASDAQ: GILD) saw its shares rise 27.20% in October, according to data from S&P Global Intelligence.  The biotech stock ended September at $61.69.  Gilead, a biopharmaceutical company that focuses on oncology and HIV therapies, showed it has a strong future even as sales of its COVID-19 therapy, Veklury (remdesivir), have begun to ebb.",https://finnhub.io/api/news?id=ab63c7f694ecd71837511196b55747195cc7d819335d0f450af7157fc87a13af
company,2022-11-08 05:43:20,Gilead Sciences Third Quarter 2022 Earnings: Beats Expectations,117011105,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,Gilead Sciences ( NASDAQ:GILD ) Third Quarter 2022 Results Key Financial Results Revenue: US$7.04b (down 5.1% from 3Q...,https://finnhub.io/api/news?id=eb8bd2440112682c20e5566e03333b5799c8c777306150b7c628578fc08a0f9f
company,2022-11-08 00:39:00,Gilead price target raised to $88 from $75 at Mizuho,116997716,https://thefly.com/images/meta/streetresearch_recommendations.jpg,GILD,Thefly.com,Mizuho analyst Salim Syed... GILD,https://finnhub.io/api/news?id=322d507314038cfd783fda7e86b693f4637cb17fea64c31d5a64d23b684652a8
company,2022-11-07 22:55:00,American Association for Study of Liver Diseases to hold a meeting,116994713,https://thefly.com/images/meta/converenceevents.jpg,GILD,Thefly.com,"AASLD 2022: The Liver Mee... WXXWY, VIR, SRZN, LGND, LLY, EXEL, EXAS, BAYRY, BD, BMRN, BMY, CALT, ALBO, ALGS, ALIM, ALNY, ALT, ALXN, ASMB, AXLA, JNJ, KMDA, IPSEY, IVA, SLP, SMMNY, SIEGY, RARE, PKI, NVO, GSK, GLTO, GILD",https://finnhub.io/api/news?id=caff596946cc91df1b78b757678e3f339c98074832968606677e2cc36533228d
company,2022-11-15 16:05:00,Gilead Sciences to Present at Upcoming Investor Conferences,117166857,https://media.zenfs.com/en/business-wire.com/b3bc72d532d424755f5223fcad8516b7,GILD,Yahoo,"FOSTER CITY, Calif., November 15, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",https://finnhub.io/api/news?id=590e416dd273359fd2d35fa0c332cbba44c06968610641aa1ff49552faf3dc73
company,2022-11-15 11:56:00,"Gilead Sciences Inc. stock rises Tuesday, still underperforms market",117204398,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.18% higher to $83.00 Tuesday, on what proved to be an all-around positive trading session for the stock market, with...",https://finnhub.io/api/news?id=c32e2ac5d37a3f351d54291649c017b609e5201e7bcfcac069f1fb8a8f8f9d18
company,2022-11-15 03:01:00,Weaver C. Barksdale & Associat - GuruFocus.com,117160810,https://static.gurufocus.com/images/logo_global.png,GILD,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=ffb66e5543312c5847c64c0b4d2f80ac1836b53dbaa68ce0d209f7dab12d0534
company,2022-11-14 23:01:00,"GLOBEFLEX CAPITAL L P Buys 4,  - GuruFocus.com",117171826,https://static.gurufocus.com/images/logo_global.png,GILD,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=837a72623b9e49985151b4e6d781ee22caefadec38c0a98c9dd635397483add7
company,2022-11-14 21:01:00,SHELTON CAPITAL MANAGEMENT Buy - GuruFocus.com,117166384,https://static.gurufocus.com/images/logo_global.png,GILD,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=28c6b549af6ddda0bb77e6b7512dd6633359e81962190c3e9aa1283313f0445f
company,2022-11-14 11:55:00,"Gilead Sciences Inc. stock rises Monday, outperforms market",117204399,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rallied 1.26% to $82.85 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=659acbd8812d75a27e0dd7814265d9d2f9cae82621fde4fcdc6f75345d44ae0a
company,2022-11-14 11:23:59,Gilead Sciences: A Range Trader's Dream Stock (Technical Analysis),117147304,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1340690117/image_1340690117.jpg?io=getty-c-w750,GILD,SeekingAlpha,Gilead has been range bound for several years and is now testing the upper range that has been established. A sell or short at the current price around $80 could net positive returns.,https://finnhub.io/api/news?id=dac2efcd7a1cb9fe0e2eaf1b1f4aea2dd4622a2c7779eb26699f931334df5ddc
company,2022-11-14 11:11:01,Tango Therapeutics: Behind The Recent Momentum,117147274,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368429013/image_1368429013.jpg?io=getty-c-w750,GILD,SeekingAlpha,"Shares of early clinical-stage biotech Tango Therapeutics, Inc. (TNGX) are down ~50% since going public in August 2021 â primarily victimized by a lack of catalysts and a tough market.",https://finnhub.io/api/news?id=8e5ec39fd7e2b600273692d674f128b18cff2be03fd32e01d591e59098aca31c
company,2022-11-13 13:28:25,Vertex: High Growth For Years Ahead,117138953,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326625612/image_1326625612.jpg?io=getty-c-w750,GILD,SeekingAlpha,Vertex is the market leader company for Cystic Fibrosis disease. The company reports unexpected sales and earnings growth in recent quarters Q3.,https://finnhub.io/api/news?id=dd7b258b859f483ba7892042f817363216b6d69ae6da141055e9c4c0b7fa6eac
company,2022-11-13 08:00:28,Those who invested in Gilead Sciences (NASDAQ:GILD) three years ago are up 43%,117137522,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,You can receive the average market return by buying a low-cost index fund. But you can make superior returns by picking...,https://finnhub.io/api/news?id=1897512c1f91b8f7d7dbb84f7bc88657520a613ba3e3e6b98f9400a9886cd746
company,2022-11-12 10:15:00,2 Top Biotech Stocks to Buy in November,117130485,,GILD,Yahoo,Biotech giants Regeneron Pharmaceuticals (NASDAQ: REGN) and Gilead Sciences (NASDAQ: GILD) are among them.  Eylea could lose patent protection as early as next year.  Why is Regeneron beating the market this year despite these issues?,https://finnhub.io/api/news?id=91a5a2027ae547ca7199eda1e67fd989781bca4f561ae1b8d06678539d1c3e5c
company,2022-11-18 14:54:30,Rockville’s MacroGenics scores $60M from Provention Bio’s FDA approval,117200260,https://s.yimg.com/ny/api/res/1.2/EUf_MsTTv0phOkYoiOlejQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bizjournals.com/c5fd9ace88cef908c11fb654d59d9e9b,GILD,Yahoo,"Rockville’s MacroGenics Inc. (NASDAQ: MGNX) just had its second big win within a month, after inking a major deal with a U.S. pharmaceutical company in October.  MacroGenics said late Thursday the Food and Drug Administration has approved teplizumab, a Type 1 diabetes treatment candidate that Provention Bio Inc. bought from MacroGenics in 2018.  As part of that deal, Red Bank, New Jersey's Provention agreed to pay $60 million to Macrogenics upon receiving the agency’s green light to take the drug to market.",https://finnhub.io/api/news?id=060ba38a574ee93315ec006cb4e6f28fefcf862e06669c3891e4e974b7ec30a1
company,2022-11-18 14:52:22,Billionaire Cliff Asness’ Top 10 Dividend Stocks,117199327,https://media.zenfs.com/en/insidermonkey.com/6744cfcdef603b6db1c84d05b5410924,GILD,Yahoo,"In this article, we will take a look at billionaire Cliff Asness’ top 10 dividend stocks. If you want to see more of billionaire Cliff Asness’ dividend stocks, go directly to Billionaire Cliff Asness’ Top 5 Dividend Stocks. Billionaire Cliff Asness is the founder of AQR Capital Management, one of the largest hedge funds in […]",https://finnhub.io/api/news?id=97c0b74971fbc40511753381c91f7655523f4b4d0d6650cceaee8425140328d9
company,2022-11-18 14:02:07,"Top Analyst Reports for Lowe's, Gilead Sciences & Intuitive Surgical",117199987,https://media.zenfs.com/en/zacks.com/069d34e886cd22f5346dcf8ffcffd2af,GILD,Yahoo,"Today's Research Daily features new research reports on 16 major stocks, including Lowe's Companies, Inc. (LOW), Gilead Sciences, Inc. (GILD) and Intuitive Surgical, Inc. (ISRG).",https://finnhub.io/api/news?id=ae550caa532bade1c5259cffc7a011d4048288bba3557a7aa961b0c2a29e3b67
company,2022-11-18 13:45:06,Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?,117200270,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.,https://finnhub.io/api/news?id=9b70e9faab0028f63db872a73b50e7047bfdd4091ffd1a4b1c154f04f9164a2f
company,2022-11-18 11:55:00,"Gilead Sciences Inc. stock remains steady Friday, underperforms market",117204395,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. were unchanged Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=8a7a689534a1c9a33e679ec8681e1bd7c0f6c1fe9c91da83040a628c621a80f1
company,2022-11-17 11:55:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,117204396,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.89% higher to $83.62 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=bef2bd6e87cf8c3e7a22857ae5c2b89aecc6f3f19acd056b4ad11981ca0ab648
company,2022-11-17 09:40:02,Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?,117188946,https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9,GILD,Yahoo,Here is how Gilead Sciences (GILD) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.,https://finnhub.io/api/news?id=6ccb1306c7c59dd83ed6321a2f90ef43ed549c17c02cb810a11ef2f935bf1961
company,2022-11-17 09:02:08,"Is There An Opportunity With Gilead Sciences, Inc.'s (NASDAQ:GILD) 44% Undervaluation?",117193413,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Does the November share price for Gilead Sciences, Inc. ( NASDAQ:GILD ) reflect what it's really worth? Today, we will...",https://finnhub.io/api/news?id=e9e99ba5b5fbbed1e01404462200afefdc54ba3f0bc0a9df85f1d74d1bba562f
company,2022-11-17 09:00:00,Gilead Sciences: Dr. Amelie Ramirez Seeks To End Disparities in Latino Cancer Care,117193414,https://media.zenfs.com/en/accesswire.ca/f0a9dff1f9ab33b45525f0bbf223e76d,GILD,Yahoo,"For nearly 30 years, Dr. Amelie Ramirez has sought to move the needle on health disparities in the Latino community through a mix of education, research and community-based care.",https://finnhub.io/api/news?id=9565b60404708c08ac2b0b20669134f152c99f02c9314ddfb783d85646eb3d4e
company,2022-11-16 11:55:00,"Gilead Sciences Inc. stock falls Wednesday, still outperforms market",117204397,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 0.14% to $82.88 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=fee004789d1eff5887f867224c381a0ff58fe3f86bdae05f30cef1c795ba3fd2
company,2022-11-16 07:26:02,IDNA: Healthcare Dashboard For November,117172493,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1224202684/image_1224202684.jpg?io=getty-c-w750,GILD,SeekingAlpha,The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Read how this ties into the IDNA healthcare ETF.,https://finnhub.io/api/news?id=22c548708b2e201e0de533d4b94edc94de36d3b03561215c71ce42d37870ff59
company,2022-11-23 11:56:00,"Gilead Sciences Inc. stock rises Wednesday, still underperforms market",117339204,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.22% higher to $85.42 Wednesday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=05d7d5fdcca5b3d1a0f60f1ac62f87e20df858fdc63409ed2282593a3da24f52
company,2022-11-23 09:00:02,"Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?",117274395,https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4,GILD,Yahoo,"Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",https://finnhub.io/api/news?id=82fad67cf1fe991ecdf4897182f300c2f73925ab4b50d86165e75f7b23646e5c
company,2022-11-23 09:00:00,Gilead Sciences: Staying Positive While Facing Metastatic Triple-Negative Breast Cancer: Jacquie's Story,117264360,https://media.zenfs.com/en/accesswire.ca/f0a9dff1f9ab33b45525f0bbf223e76d,GILD,Yahoo,Jacquie's journey with cancer began with non-Hodgkin lymphoma when she was just 15 years old.,https://finnhub.io/api/news?id=23c6cbaa4f8c4ba341adf05f3a7c90d2b28c5f2c5ba5261fbcefadc233ab1e9a
company,2022-11-23 07:45:02,See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch,117264361,,GILD,Yahoo,Gilead Sciences' first-in-class cancer drug and GILD stock are finally hitting their stride. The oncology business is growing bullishly.,https://finnhub.io/api/news?id=cb542b0f12513abe534ec6b627c221ca874239d6d29d81c4aa1facbd00a7d81a
company,2022-11-22 21:30:59,Gilead Sciences: Best Near-Term Biopharma Cap Gain Bet Say Market-Makers,117261179,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w750,GILD,SeekingAlpha,"This articleâs focus is on earning capital gain from stock investment in Gilead Sciences, Inc. Read more to see what makes GILD stock a buy at this time.",https://finnhub.io/api/news?id=5502c340fc54afbbd0f107a42032db9a8c5bbd17ac67038242178c3c66844b92
company,2022-11-22 11:53:04,Buy this Medical Sector Pioneer Stock,117253985,https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071,GILD,Yahoo,"Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.",https://finnhub.io/api/news?id=b17f396254800c5d133f9c3d6ea9bb109a3ace5c782408082d1bedd1a871e57c
company,2022-11-22 11:40:04,GILD vs. HALO: Which Stock Is the Better Value Option?,117253986,https://media.zenfs.com/en/zacks.com/670d1917693293f70179651625deb88f,GILD,Yahoo,GILD vs. HALO: Which Stock Is the Better Value Option?,https://finnhub.io/api/news?id=492a4322d6c1868aa1bc042a79846c39a702f588ae1cf602b656788aaafb6529
company,2022-11-22 10:00:15,"We still think there's more room for biotech to go higher, says Jefferies' Yee",117256583,https://image.cnbcfm.com/api/v1/image/107155846-16691460531669146051-26734515867-1080pnbcnews.jpg?v=1669147215&w=1920&h=1080,GILD,CNBC,"Michael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and if it's too late to 'nibble' on stocks in the sector.",https://finnhub.io/api/news?id=7e21fa18916b8fe72f13b787205058eb3ead11af4c663d86fb3db5f7728da2f5
company,2022-11-22 09:15:02,"Puma Biotechnology, Inc. (PBYI) Hits Fresh High: Is There Still Room to Run?",117251831,https://media.zenfs.com/en/zacks.com/670d1917693293f70179651625deb88f,GILD,Yahoo,"Puma Biotech (PBYI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",https://finnhub.io/api/news?id=93c93ef9916cf0a6733a12aace9828dc449de5887fd96b5d643d47c8482b20a2
company,2022-11-21 20:39:27,Investing In Minimum Volatility Stocks Can Backfire,117247513,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346996582/image_1346996582.jpg?io=getty-c-w750,GILD,SeekingAlpha,The minimum volatility factor outperformed last week and is also outperforming for the year. See why low-volatility trade often turns into a higher-risk trade.,https://finnhub.io/api/news?id=06962e9d87795dec1d32e48dce188bf0cde937645fbeaa7b5aedadf74ac890f6
company,2022-11-21 18:31:31,SDOG: Dividend ETF Not To Be Confused With 'Dogs Of The Dow',117246393,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/585054838/image_585054838.jpg?io=getty-c-w750,GILD,SeekingAlpha,SDOG ETF applies the Dogs of the Dow theory on a sector-by-sector basis using the S&P 500 as the starting point. Read if it is a good dividend income opportunity.,https://finnhub.io/api/news?id=204e9179907fed0282f76bb537e64751cecf64f25bb3516250a6aa6633e30a88
company,2022-11-21 09:23:02,"The Zacks Analyst Blog Highlights Lowe's, Gilead Sciences, Intuitive Surgical, Valero Energy and MercadoLibre",117242653,https://media.zenfs.com/en/zacks.com/061202f5f20cdac455f44c0d23d1d1de,GILD,Yahoo,"Lowe's, Gilead Sciences, Intuitive Surgical, Valero Energy and MercadoLibre are part of the Zacks top Analyst Blog.",https://finnhub.io/api/news?id=fac6241eab6049c4edbc5e0b9416e2498fbe5ef3b0cf0947219d6b065aaeef5a
company,2022-11-21 09:00:30,"Is There An Opportunity With Gilead Sciences, Inc.'s (NASDAQ:GILD) 44% Undervaluation?",117243376,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Gilead Sciences, Inc...",https://finnhub.io/api/news?id=73c88529e33b41aaa291cae59c7ad7029e32497d2d51c37e3cacb179abe4d368
company,2022-11-25 09:00:49,Investing in Gilead Sciences (NASDAQ:GILD) three years ago would have delivered you a 45% gain,117285987,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Thanks in no small measure to Vanguard founder Jack Bogle, it's easy buy a low cost index fund, which should provide...",https://finnhub.io/api/news?id=f000c01f8b1f5cead58276edd2ce070754ab852f0d9c4f7cef1acd493c56716d
company,2022-12-01 11:31:04,Why Is Exelixis (EXEL) Up 0.4% Since Last Earnings Report?,117367558,https://media.zenfs.com/en/zacks.com/670d1917693293f70179651625deb88f,GILD,Yahoo,Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=be6a3291e261e98adc318b9fff30b9f2a404bc5bce7fe5b69938dcc265558078
company,2022-12-01 09:35:00,Gilead Sciences: All Stars Project Empowers Youth Through Performance,117360833,https://media.zenfs.com/en/accesswire.ca/f0a9dff1f9ab33b45525f0bbf223e76d,GILD,Yahoo,Dancing has always been a part of Shadae McDaniel's life.,https://finnhub.io/api/news?id=ba2cb96ae76ef87d3de39f8c5a3c399121e8468ddc8a2afb73349883bad854e8
company,2022-12-01 09:05:00,The Top Healthcare Stocks to Buy With $100,117360835,,GILD,Yahoo,"Although hard, it's not impossible, there are healthcare companies with solid earnings and dividend growth that can be had for less than a bill with Ben Franklin's picture on it.  Gilead Sciences (NASDAQ: GILD) and Bristol Myers Squibb (NYSE: BMY) have posted triple-digit percentage gains over the past 10 years in revenue, earnings per share (EPS), and total return price.  On top of that, shares of Gilead and Bristol can both be bought for less than $90 a share, at least for the time being.",https://finnhub.io/api/news?id=0ff3399fea99892ee349f13a71214d95b6eef61117ac4846ec1e0533046b4cb8
company,2022-11-30 09:45:28,"Gilead Sciences, Inc. (GILD) Management presents at Piper Sandler Healthcare Conference (Transcript)",117348255,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Piper Sandler Healthcare Conference November 30, 2022 11:30 AM Company Participants Merdad Parsey - Chief Medical Officer Conference Call...",https://finnhub.io/api/news?id=50f8b82ec467d1ef5b3ad7deaf48b69424564faa464197a18b0b33a2939a4d38
company,2022-11-30 08:37:00,2 Reasons This Stock Could Outperform in 2023,117348307,,GILD,Yahoo,"Biotech giant Gilead Sciences (NASDAQ: GILD) is a member of this elite club, having seen its shares rise by 15% year to date.  Let's consider two reasons why Gilead Sciences is worth serious consideration heading into the new year.  Gilead Sciences' most important unit by some margin remains its HIV business.",https://finnhub.io/api/news?id=cc251a6679e3fb6dd99eb8a4f70e71f38ea17d8137eafa9d7d6c8d7263f861be
company,2022-11-30 07:35:12,Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion,117348308,https://media.zenfs.com/en/zacks.com/7de283b2224f57ff914c609b38092b2c,GILD,Yahoo,Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations.,https://finnhub.io/api/news?id=16b59f04bee4a7e7dab54bfc558b86ea90f87786b98509b607ceabe929e1502b
company,2022-11-30 05:12:00,These 3 Stocks Are Rallying While the Rest of the Market Plunges,117341958,https://s.yimg.com/ny/api/res/1.2/.dxfQsyaChwq5Pup9T0FIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03Nzc-/https://media.zenfs.com/en/motleyfool.com/b0d70c3dcccfd1d7f1675d67b8101611,GILD,Yahoo,Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.,https://finnhub.io/api/news?id=7736ada1cc965aecfe8bb8350d4919bfbb39d5688907cf9ba1fc63f4d9e0ee17
company,2022-11-29 15:58:01,"Gilead Sciences, Inc. (GILD) 2022 5th Annual Evercore ISI HealthCONx Conference(Transcript)",117335995,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) 2022 5th Annual Evercore ISI HealthCONx Conference Call November 29, 2022 13:00 ET Company Participants Andrew Dickinson - Executive Vice...",https://finnhub.io/api/news?id=7074a5a4330851d6f1b9642c94e8b1fce8dc73923229d936b9acb227e88715d9
company,2022-11-29 12:03:00,"Gilead Sciences Inc. stock rises Tuesday, outperforms market",117339202,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.65% higher to $85.76 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the...",https://finnhub.io/api/news?id=9d2ec454ef6090af8081230cb0edf15c6c0566736e31d1325512c126f425af1a
company,2022-11-29 10:14:03,"Gilead (GILD), RCUS Announce Positive Data From NSCLC Study",117328876,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).,https://finnhub.io/api/news?id=542f4d2dda650c6214e17bff5021c1c84eb3e1711c93622a31e4ab10cc9e10c4
company,2022-11-29 09:00:27,Investors in Gilead Sciences (NASDAQ:GILD) have made a notable return of 46% over the past three years,117328877,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Thanks in no small measure to Vanguard founder Jack Bogle, it's easy buy a low cost index fund, which should provide...",https://finnhub.io/api/news?id=5f36913950f5f81fe560aa02096e960e258fb36c26f76c3534829770628570c9
company,2022-11-29 08:30:00,European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations,117327363,https://media.zenfs.com/en/business-wire.com/c67a6e71962607d55ea84621b157bf43,GILD,Yahoo,"FOSTER CITY, Calif., November 29, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) and an extension of the indication for Biktarvy to treat HIV infection in virologically suppressed children who are at least two years of age and weigh at least 14 kg. The European Marketing Authorization is the first pediatric approv",https://finnhub.io/api/news?id=a054dcaafedc9683c959c1714cbd8bfb064f6c0322f71b933dcf00695492306c
company,2022-11-29 07:43:00,"Overdone Selloff? Fed Talking Heads, Trading Gilead, Iger's Magic Disney Words",117323201,https://media.zenfs.com/en/thestreet.com/e687de5636872845c344d91b3693bb79,GILD,Yahoo,"What happened on Monday, was largely profit-taking, pin action related to a couple of large names, and defensive selling.",https://finnhub.io/api/news?id=781860d66fba4e4785f7e3fdda8ec4e22ffc4604787dbf09469b766f743e3bf9
company,2022-11-28 12:27:21,"Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges",117313794,,GILD,Yahoo,"Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.",https://finnhub.io/api/news?id=edbff66bc916b4de6438e5d6eb688e74310812b863e1802d09793bee883780d8
company,2022-11-28 12:02:00,"Gilead Sciences Inc. stock falls Monday, still outperforms market",117339203,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 1.22% to $85.21 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=6eb1c1fbee70978e3b4bac10f140fc08946f05659228894c2b508e0a39475a9e
company,2022-11-28 11:18:04,Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures,117316856,https://media.zenfs.com/en/Benzinga/bd1694009bf8f52ee53ca8a6c8cd60ee,GILD,Yahoo,Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences (NASDAQ: RCUS) announced an update from the fourth interim analysis of Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is evaluating the combinations of anti-TIGIT antibody domvanalimab plus zimberelimab (doublet) and domvanalimab plus zimberelimab and,https://finnhub.io/api/news?id=4cddecdb51413a2f9d3b5a63aa81d690fc40449a6b216dce2aabdb178c1cf1ab
company,2022-11-28 08:30:00,Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer,117309780,https://media.zenfs.com/en/business-wire.com/80dea94eb5bde01b0278a03b0cf7d09b,GILD,Yahoo,"FOSTER CITY, Calif. & HAYWARD, Calif., November 28, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is evaluating the combinations of a",https://finnhub.io/api/news?id=b0dc3cb801a3bf7b3a953f138e3b0804423821c5061c107f465696115697e641
company,2022-11-28 08:02:01,Retirement Stock Portfolio: 11 Safe Tech Stocks to Consider,117309781,https://media.zenfs.com/en/insidermonkey.com/98c0c7d011f7e68747c68035233f9ade,GILD,Yahoo,"In this article, we discuss the 11 safe tech stocks for a retirement stock portfolio. If you want to read about some more tech stocks, go directly to Retirement Stock Portfolio: 5 Safe Tech Stocks to Consider. There is broad-based consensus among finance professionals that the traditional definitions of growth and value stocks do hold-up […]",https://finnhub.io/api/news?id=621189f0a056f03af2cacf99b28ac305455b21a5ccd17a4bff51a3c9640fbac8
company,2022-11-28 07:49:37,Retirement Stock Portfolio: 11 Safe Dividend Stocks to Consider,117309782,https://media.zenfs.com/en/insidermonkey.com/c807f94b40f28c99d63c0527ec3bdc1a,GILD,Yahoo,"In this article, we discuss the 11 safe dividend stocks for a retirement stock portfolio. If you want to read about some more dividend stocks, go directly to Retirement Stock Portfolio: 5 Safe Dividend Stocks to Consider. Across the world, investors have been scrambling to find ways to strengthen their portfolios and reduce risk as […]",https://finnhub.io/api/news?id=c7708bcc962e5b566b586a2956be2185143e8ba7fc4c6f82dc166dcfea1302b8
company,2022-12-05 10:26:27,Adaptive Biotechnologies Isn't Quite Your Portfolio's Immune Booster,117405414,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1355849088/image_1355849088.jpg?io=getty-c-w750,GILD,SeekingAlpha,"Adaptive is, in my opinion, still too early in its development cycle to warrant a buy recommendation. Click here to read my analysis of ADPT stock.",https://finnhub.io/api/news?id=9f5e79b3ab6e8a034868f73f6e6a5ffd7a82719751d3360a14d68c14ae3e3d2b
company,2022-12-05 09:40:02,Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?,117403692,https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39,GILD,Yahoo,Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.,https://finnhub.io/api/news?id=b810e805f258313eb20073503b9ee6eb4ba63ee0651aaa7448c191c384503ebb
company,2022-12-03 09:00:22,"Gilead Sciences, Inc. (NASDAQ:GILD) Delivered A Weaker ROE Than Its Industry",117390447,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",https://finnhub.io/api/news?id=dab3abb4572dedf31db6d9d58fd103700769262d2a8700e15544d054ff827cc7
company,2022-12-03 01:34:43,"Finally, We're Less Fed Up With The Fed",117387031,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398812620/image_1398812620.jpg?io=getty-c-w750,GILD,SeekingAlpha,It feels like markets are moving in the investorsâ favor. Check out what's working and what's not this week.,https://finnhub.io/api/news?id=6dd8a7d3927c7e322556f1561efc94cc6270b665dd29fca12ebdf9e150e3d934
company,2022-12-02 11:31:04,Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?,117379688,https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619,GILD,Yahoo,Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=1ea4f47b3e7c5edebe2eacf7f6675245d27e6484a6eb10d113a3828a831be0de
company,2022-12-02 09:45:08,BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns,117378542,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358625679/image_1358625679.jpg?io=getty-c-w750,GILD,SeekingAlpha,"BBH has an asset base of $520 million, posted strong growth over the past 6 months, and is trading much higher than its pre-pandemic price range. Click here to learn more.",https://finnhub.io/api/news?id=5e5f3f8e58df8e06fb2eb5be86c731e7de3eec7229b466a5c6ffc5c13a637f5a
company,2022-12-02 02:32:00,Here's how one hedge fund is going aginst the grain and beating the markets,117407866,https://images.mktw.net/im-677726/social,GILD,MarketWatch,This fund is crushing it. Here are its top 5 stock picks,https://finnhub.io/api/news?id=57d3daa6f54c6f2bdfc3ed1259a35987bb8e50f349e71d2063136d28c51c79ae
company,2022-12-09 11:30:04,Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue?,117463005,https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462,GILD,Yahoo,Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=dbf97bc6da8b70c949a85290e3dd4268dcd733b6464e7edbd5d56790a4381d7f
company,2022-12-09 10:32:08,Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences,117455151,,GILD,Yahoo,"Recent initial public offering Arcellx forged a $325 million cancer deal with Gilead Sciences on Friday, and the IPO stock broke out.",https://finnhub.io/api/news?id=9c608ab618a1626b8ef5e4a7711c19e9a7b76fb83b611ea9aebe3a97deb815dc
company,2022-12-09 08:46:08,Gilead to co-develop Arcellx's multiple myeloma drug,117455154,,GILD,Yahoo,"Gilead Sciences Inc. said Friday that it will co-develop and co-commercialize Arcellx Inc.'s multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcellx $225 million upfront, plus make a $100 million equity investment in the company. The deal, which will reduce Gilead's GAAP and non-GAAP earnings per share next year by 16 cents, is expected to close in the first quarter. Gilead's stock is up 37.0% over the past three months, while Arcellx shares h",https://finnhub.io/api/news?id=065b6d42cb31b76a8b4c897a2f16dda3c6671767cfd474cf520ed6c8ee8010f8
company,2022-12-09 08:17:00,Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma,117455157,https://media.zenfs.com/en/business-wire.com/e06802ed1e3114c22373013cc0f91f25,GILD,Yahoo,"SANTA MONICA, Calif. & REDWOOD CITY, Calif., December 09, 2022--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.",https://finnhub.io/api/news?id=e737ba7ea176516c25ebd8c1d7250e0e12da7482426f3f67b5af90134e1d1e85
company,2022-12-09 08:15:00,Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma,117455158,https://media.zenfs.com/en/prnewswire.com/e84ca3714fbb4ee480e7f4979f52d7f9,GILD,Yahoo,"Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.",https://finnhub.io/api/news?id=190235d690543803036afb4e3262b5060e356e8c1575407af2369550c4cff4c5
company,2022-12-09 06:23:26,"Don't Race Out To Buy Gilead Sciences, Inc. (NASDAQ:GILD) Just Because It's Going Ex-Dividend",117456204,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"It looks like Gilead Sciences, Inc. ( NASDAQ:GILD ) is about to go ex-dividend in the next four days. The ex-dividend...",https://finnhub.io/api/news?id=57de51afa9e7e4887b1b1acb708361470de83b103c43d59574f39987243a8dbe
company,2022-12-09 05:27:00,Arcellx Shares Reach New Heights on Gilead Collaboration >ACLX,117484176,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Colin Kellaher Shares of Arcellx Inc. hit an all-time high on Friday after the clinical-stage biotechnology inked a lucrative agreement with Gilead...,https://finnhub.io/api/news?id=cabc2e507e29247527cc43902fe440432277980a3cb994573a5e4ad8e5c6729d
company,2022-12-09 04:54:00,Arcellx Stock Surges on Multiple Myeloma Treatment Collaboration With Gilead,117484177,https://images.barrons.com/im-478158/social,GILD,MarketWatch,The deal involves an upfront cash payment of $225 million to Arcellx and a $100 million equity investment from Gilead's Kite Pharma.,https://finnhub.io/api/news?id=848d12db1c8dc1b6505b0dae7b1a832b2f210b6552a58bf63d74cee538fd855d
company,2022-12-09 03:34:00,"Arcellx, Gilead Ink Multiple Myeloma Collaboration >ACLX GILD",117484179,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Colin Kellaher Arcellx Inc. and Gilead Sciences Inc. on Friday said they agreed to co-develop and co-commercialize Arcellx's lead late-stage product...,https://finnhub.io/api/news?id=7633a8cdb95d10347723ce01526d7598599fec02463406d84d6bc0500c0c55d2
company,2022-12-08 10:00:00,Is Gilead Sciences a Buy?,117444754,https://s.yimg.com/ny/api/res/1.2/m4zEXmZdVeluSPvlVkxEiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/e4f33e43ccd1f8a8b03659aaca3b3015,GILD,Yahoo,Gilead Sciences (NASDAQ: GILD) is a top healthcare company that generates the bulk of its revenue from medicine that treats HIV.  Lenacapavir is an HIV treatment that would require patients to receive an injection just twice a year.  It's a significant change from the daily pills many HIV patients are accustomed to taking today.,https://finnhub.io/api/news?id=14141fadd5cb6f8e9cfa88c87b50b59c57aad3d74f9cf2229399a0ffd2a4ff46
company,2022-12-08 09:40:00,Gilead Sciences: U.S. Military Veteran Battles Lymphoma With Car T-Cell Therapy: Marcus' Story,117444755,https://media.zenfs.com/en/accesswire.ca/f0a9dff1f9ab33b45525f0bbf223e76d,GILD,Yahoo,"Marcus arrived home to Mississippi from his military assignment overseas, excited to see his 20-month-old son, when he realized something was wrong.",https://finnhub.io/api/news?id=ab64be2cdda867a9c8b9cc38f5e4530279dbc0e149bf02a1dd34ce49862439ff
company,2022-12-08 05:52:00,Is Gilead Sciences Stock Still a Buy After Soaring in 2022?,117440983,https://s.yimg.com/ny/api/res/1.2/fGeKwcCs8G3nPEqlGWVP3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/1180e644e3c1a0d670363bfece0c538d,GILD,Yahoo,Gilead faces some challenges. But there are several reasons to think the stock could keep the momentum going.,https://finnhub.io/api/news?id=0c6b5d16599b364f988bf038259ea45e201bd69fd0217b96badf2ff7982709d6
company,2022-12-08 04:50:55,"Will Big Pharma Stocks Stronghold Endure In 2023, Or Is It Time To Sell?",117441717,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/616106906/image_616106906.jpg?io=getty-c-w750,GILD,SeekingAlpha,"Most Big Pharma stocks have performed very well in 2022, which is hardly surprising given the late stage of the cycle we are in. See is it time to sell them.",https://finnhub.io/api/news?id=5ce889d4c44f2b519a3573a9c8af634966828266a2eb17da193154727e22e7b5
company,2022-12-07 19:53:00,Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan,117436780,https://media.zenfs.com/en/business-wire.com/58092559238da1121c2f68a45b505bca,GILD,Yahoo,"SANTA MONICA, Calif. & TOKYO, December 08, 2022--Kite Pharma, Inc., a Gilead Company, (hereafter Kite) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) today jointly announced the revision of their 2017 partnership agreement, which gave Daiichi Sankyo exclusive rights to develop, manufacture and commercialize Yescarta (axicabtagene ciloleucel) in Japan. Kite was acquired by Gilead Sciences, Inc. later in 2017 after the Daiichi Sankyo partnership agreement. Daiichi Sankyo and Kite have no",https://finnhub.io/api/news?id=eb71557cae2257b7eed3159520a16e6f3fa910a6e127bb5875d69affb9ebe537
company,2022-12-07 09:55:02,Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?,117433130,https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af,GILD,Yahoo,"The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",https://finnhub.io/api/news?id=f7561cc6da3d4589bd7d09a714fad4a78982142008c01e2c2a55a0a71fed8f06
company,2022-12-07 08:40:04,"Gilead Sciences, Inc. (GILD) Presents at NASDAQ 47th Investor Conference (Transcript)",117432365,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) NASDAQ 47th Investor Conference December 07, 2022, 08:00 AM ET Company Participants Dan O'Day - Chairman and CEO Conference Call Participants...",https://finnhub.io/api/news?id=0bbebf2d7d8273ee421c37c5303fd59ddf9fc16094b332a9094bd0795ad8be5a
company,2022-12-07 08:00:22,"Should Gilead Sciences, Inc. (NASDAQ:GILD) Focus On Improving This Fundamental Metric?",117429112,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...,https://finnhub.io/api/news?id=32bea191df20c1facb6dd1a8fda49fb373c0346c00fd12199f9ae3aaaf319b4a
company,2022-12-07 06:13:11,"The Zacks Analyst Blog Highlights Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands",117428562,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,"Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands are included in this Analyst Blog.",https://finnhub.io/api/news?id=658d29140264805ad25b831c3647122cc7bbefaeaef8aa997a3e2350fc9366d5
company,2022-12-06 15:00:00,New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer,117422030,https://media.zenfs.com/en/business-wire.com/434fd2d74a7bcb4af6600464ce44ae2a,GILD,Yahoo,"FOSTER CITY, Calif., December 06, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies. In the analysis, Trodelvy improved progression-free survival (PFS), overall surviva",https://finnhub.io/api/news?id=6773a3932967fa850c0925e7454beb67eca8681707c80fc5f496648b9dc34008
company,2022-12-06 08:12:01,5 Dividend Stocks to Allay Fears of a More-Aggressive Fed,117416385,https://media.zenfs.com/en/zacks.com/24c76eed34fbfe9e7e6769aff76cc9be,GILD,Yahoo,"As U.S. stocks stumble on concerns of further rate hikes, investing in dividend players like Exxon Mobil (XOM), Gilead Sciences (GILD) and Conagra Brands (CAG) for a steady stream of income seems prudent.",https://finnhub.io/api/news?id=28676cda9c8985525a35f069b3abefa060b78f0a5ca971b72829c13560ab3814
company,2022-12-06 08:05:58,Should You Consider Adding Gilead Sciences (GILD) to Your Portfolio?,117416386,https://media.zenfs.com/en/insidermonkey.com/03a6e5ed068a6575327e23896182338c,GILD,Yahoo,"Ariel Investments, an investment management company, released its “Ariel Global Fund” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined -10.05%, underperforming the MSCI ACWI Index and the MSCI ACWI Value Index, which returned -6.82% and -7.66%, respectively. Multiple headwinds from all over the world affected […]",https://finnhub.io/api/news?id=2ecd6ccac7417e96156f7f6ec382f22174ca419652895c40f1104183d8846dbc
company,2022-12-13 11:56:00,"Gilead Sciences Inc. stock rises Tuesday, still underperforms market",117561860,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.24% higher to $88.75 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with...",https://finnhub.io/api/news?id=d20a9da747d72bc824e62908634581649825e65283e97da773d604c210ec5887
company,2022-12-13 11:39:53,22 Most Charitable Companies in 2022,117498478,https://s.yimg.com/ny/api/res/1.2/KbcE7uF5_62TWbNx9lMbNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/074ccb26a92e97a4fa369c5c396e5973,GILD,Yahoo,"In this article, we discuss the 22 most charitable companies in 2022. If you want to skip the details about corporate and individual charitable practices and global charity statistics, go directly to the 5 Most Charitable Companies in 2022. According to the Charities Aid Foundation World Giving Index 2022, 40% of the global population took […]",https://finnhub.io/api/news?id=1b7fdefb38eb4b2458cb0c954594bf8429979fd0aa005d6dfa0385afaf505f3b
company,2022-12-13 06:27:15,"My Dividend Stock Portfolio: New November Record - 100 Holdings With 24 Buys, 1 Sale",117498053,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w750,GILD,SeekingAlpha,Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Check out my dividend income for November.,https://finnhub.io/api/news?id=d8e53fcd3d87126db448494b6f9ab550d715da63ea0d6f078f0929eb99a475d6
company,2022-12-13 06:01:30,"With 83% ownership, Gilead Sciences, Inc. (NASDAQ:GILD) boasts of strong institutional backing",117504492,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. With 83...",https://finnhub.io/api/news?id=1f3b915e4da10e922f024535c496135005663234fc972710f1aa5475ae4c9af0
company,2022-12-12 11:56:00,"Gilead Sciences Inc. stock rises Monday, still underperforms market",117561861,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.65% higher to $88.54 Monday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=8207e67feca2167651ff8626b7739b42f93e7bb7c6731c9e1c8f65fb55361a6f
company,2022-12-12 11:00:00,Gilead Sciences Again Named to Dow Jones Sustainability World Index,117487569,https://media.zenfs.com/en/business-wire.com/b357b7e2c72e4cef2b52910dee11267b,GILD,Yahoo,"FOSTER CITY, Calif., December 12, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World). This ranking is based on an in-depth analysis of Gilead’s sustainability performance and highlights the company’s longstanding sustainable business practices and transparency on environmental, social and governance (ESG) issues.",https://finnhub.io/api/news?id=42b837fe286c2e969011bf4137ede5aaf0180e08519ca6c55598695557c4ee4b
company,2022-12-12 10:53:34,Beat the Dow Jones With This Unstoppable Dividend Stock,117487570,https://s.yimg.com/ny/api/res/1.2/qIJXpB44MilBP5Tpa2N1Xw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/8c6e6a1ca8e84d445f279c390081d1a0,GILD,Yahoo,"The Dow Jones Industrial Average is an index of 30 of the largest companies in the U.S. and it serves as a popular (if somewhat flawed) indicator of how the broader stock market is doing, and it has averaged an annual return of 8% since the 1980s.  Pharmaceutical company Gilead Sciences (NASDAQ: GILD) is one possible answer.  The company pays a solid dividend and could have the growth prospects to deliver market-beating returns over the next several years.",https://finnhub.io/api/news?id=da60fbe4a9ea6349ae8f1afdc88defef7e9d6d8e721a739af0918cf80808b551
company,2022-12-12 10:00:00,New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response,117487572,https://media.zenfs.com/en/business-wire.com/5af6c263a7c6e6e0fc29c21890a1f7ec,GILD,Yahoo,"SANTA MONICA, Calif., December 12, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from follow-up analyses of two pivotal studies (ZUMA-2 and ZUMA-3) of the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel). A comparison of two-year follow-up from ZUMA-3 and SCHOLAR-3, a retrospective historical control study, evaluating Tecartus versus standard of care (SOC) in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), was presented i",https://finnhub.io/api/news?id=01897b9bf7a5a87e9e43ab3fb43bca655bede5091dbbbca1ef88ac2ebfcdc825
company,2022-12-12 10:00:00,Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months,117487571,https://media.zenfs.com/en/business-wire.com/52162325314d4373a5219169c0151917,GILD,Yahoo,"SANTA MONICA, Calif., December 12, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced three-year follow-up data from the pivotal ZUMA-5 study for Yescarta® (axicabtagene ciloleucel) in relapsed or refractory (r/r) indolent non-Hodgkin lymphoma (iNHL), showing continued response in 52% of all enrolled patients, and prolonged duration of progression-free survival (PFS) in the Phase 2 study, presented at the 2022 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract #",https://finnhub.io/api/news?id=bd9af872b788325bf422cdacc5ab6989d4d5334eb0f1a16808b753a9bd019e52
company,2022-12-12 09:11:02,4 Stocks With Impressive Interest Coverage Ratio to Snap Up,117483146,https://media.zenfs.com/en/zacks.com/d3e6082245f05efd98282f79c39d114d,GILD,Yahoo,"A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Sprouts Farmers (SFM), Fortinet (FTNT), O'Reilly Automotive (ORLY) and Gilead Sciences (GILD) are strong enough to meet financial obligations.",https://finnhub.io/api/news?id=dc3a32422b39ebaf00711c75d926e0b11c54a5ec49379bae6457304936c9ad50
company,2022-12-12 06:54:37,"SPYD, SPHD: Dividend Gives S&P 500 Wings",117483757,https://media.gettyimages.com/id/689955616/photo/the-flying-bulls-aerobatic-team-air-show-siaf-2016-international-air-fest-sliac-airport.jpg?b=1&s=170667a&w=0&k=20&c=QoVb7bmxYZO0QCTlCTRHwBttgnzZfcIbXD3sKy-n4yI=,GILD,SeekingAlpha,"The S&P 500 nearly moved from bear-market to bull-market in a matter of weeks. However, read why we aren't backing off from our defensive approach.",https://finnhub.io/api/news?id=eda789e66f970563cd6144b72dcddabd8cd2d4fc60a4903477a472b3fb847c4e
company,2022-12-12 06:22:35,Pfizer: The Best Long-Term Investment Setup Since 2009,117483239,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344323367/image_1344323367.jpg?io=getty-c-w750,GILD,SeekingAlpha,Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high. Read more on PFE stock here.,https://finnhub.io/api/news?id=0e74d2cf86a7d6ee6bf5b3f5638c57c73af098e1f08b0737c71762970272a841
company,2022-12-11 17:30:00,Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma,117479056,https://media.zenfs.com/en/business-wire.com/35d4bc90bec68a79c26b83b9acca329d,GILD,Yahoo,"SANTA MONICA, Calif., December 11, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from two new analyses of the landmark ZUMA-7 trial of Yescarta® (axicabtagene ciloleucel), the largest and longest follow-up of a CAR T-cell therapy versus standard of care (SOC) in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). These results include an analysis of outcomes for patients who received subsequent treatment for their lymphoma following second-line Yescarta",https://finnhub.io/api/news?id=999df91d88acc840c401496e2062baf2dd0531437d57781d06609c24f44a756c
company,2022-12-11 10:00:00,Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis,117475068,https://media.zenfs.com/en/business-wire.com/3c39ab2ef17069b3835ffaba022c0640,GILD,Yahoo,"SANTA MONICA, Calif., December 11, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced results from one of the largest real-world analyses of patients who received CAR T-cell therapy assessing the impact of time from leukapheresis to infusion (""vein-to-vein"" time) for Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). The analysis reported shorter vein-to-vein times associated with improved outcomes in patients treated w",https://finnhub.io/api/news?id=79a75b578c64b1a15be79e0b042d7ee69c7513e0b057bab52d489c24216ccc65
company,2022-12-10 19:29:01,"Dividend Champion, Contender, And Challenger Highlights: Week Of December 11",117472713,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w750,GILD,SeekingAlpha,"Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more to see companies with upcoming ex-dividend dates and pay dates.",https://finnhub.io/api/news?id=02660665f6eff4f3e9ceec1ebb2d3f8462877a4fb133810681b7a96a46c91c8c
company,2022-12-17 07:00:15,"With 82% ownership, Gilead Sciences, Inc. (NASDAQ:GILD) boasts of strong institutional backing",117556650,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Every investor in Gilead Sciences, Inc. ( NASDAQ:GILD ) should be aware of the most powerful shareholder groups. The...",https://finnhub.io/api/news?id=c759d25830ad290954a20d6771988cd6cc8a5d249284ada80332f9cece3f8035
company,2022-12-16 11:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,117561857,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.21% higher to $86.76 Friday, on what proved to be an all-around rough trading session for the stock market, with the...",https://finnhub.io/api/news?id=e6d99ae0b601d189c8fde30342805e35c6f28b807095ebd1437dcbd0a91b62e4
company,2022-12-15 23:29:04,Gilead: Downgrade To Hold,117534157,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1221879709/image_1221879709.jpg?io=getty-c-w750,GILD,SeekingAlpha,Gilead's return profile has weakened substantially given the valuation risks and fundamental uncertainties. Read why GILD is a Hold.,https://finnhub.io/api/news?id=304b71afbbe8a1f0e3adf617d87d7397f3d115cbdc2a3ef6fb7e13bfccde7843
company,2022-12-15 18:58:27,Shionogi's Xocova Potentially Better Than Pfizer And Merck's Antivirals,117530221,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/876505358/image_876505358.jpg?io=getty-c-w750,GILD,SeekingAlpha,Shionogi's Xocava is set to outcompete far less effective COVID antivirals by Pfizer and Merck. Read why I think an investment in Shionogi is worth consideration.,https://finnhub.io/api/news?id=821c1b2737785e26e256553959850a280c7f8c2e0ee66a462f9c4619b87af42b
company,2022-12-15 11:56:00,Gilead Sciences Inc. stock outperforms market despite losses on the day,117561858,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 2.06% to $86.58 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=3e3ce5f744343263d23fb43a1cce801acdc99865a01008c3792a8c688c87a9b3
company,2022-12-15 08:15:00,Gilead Sciences: Latinas Contra Cancer Empowers Patients To Advocate for Change,117527743,https://media.zenfs.com/en/accesswire.ca/f0a9dff1f9ab33b45525f0bbf223e76d,GILD,Yahoo,"When Darcie Green's dad got sick, she thought she was prepared to help him navigate the healthcare system. She'd spent her entire career in healthcare policy.",https://finnhub.io/api/news?id=be4644197b0b834558c2862ed724f946289731584189b27f305be4b56e539307
company,2022-12-14 17:45:10,Gilead Sciences (GILD) Stock Moves -0.39%: What You Should Know,117527744,https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85,GILD,Yahoo,"Gilead Sciences (GILD) closed at $88.40 in the latest trading session, marking a -0.39% move from the prior day.",https://finnhub.io/api/news?id=5811fc5f55683a4af8ef266815fe0329fe3ab4fae95dc2da5e109a24891009ed
company,2022-12-14 11:56:00,"Gilead Sciences Inc. stock rises Wednesday, outperforms market",117561859,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.43% higher to $88.40 Wednesday, on what proved to be an all-around grim trading session for the stock market, with...",https://finnhub.io/api/news?id=8f6d10238436659cbdb46d2801d081c7439964bfa0e5b389f84ebb7fa0b3870f
company,2022-12-14 10:24:03,"Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More",117517043,https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96,GILD,Yahoo,Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=c6308dab59c4c06cad07e8fc5bec17f5999fb31b39ef9b85ca5ced5ca08a4065
company,2022-12-21 11:56:00,"Gilead Sciences Inc. stock rises Wednesday, still underperforms market",117765444,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.59% higher to $85.27 Wednesday, on what proved to be an all-around great trading session for the stock market, with...",https://finnhub.io/api/news?id=69c22ced7cec48c62fbbf1fcc3128cdcc8096747b74c15ee7cd975a2e5983965
company,2022-12-21 09:40:02,Are Medical Stocks Lagging  Gilead Sciences (GILD) This Year?,117604908,https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926,GILD,Yahoo,Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.,https://finnhub.io/api/news?id=3610ede1194f01d182ba89619ac7f878f75f223aa697a667639a04d34876b93d
company,2022-12-21 09:30:00,Gilead Sciences: Tatiana Williams Leads the Way With the Transinclusive Group,117604909,https://media.zenfs.com/en/accesswire.ca/f0a9dff1f9ab33b45525f0bbf223e76d,GILD,Yahoo,"When Tatiana Williams was growing up as a young Trans woman in Florida, she faced many challenges and hardships - but she didn't find many resources available to her.",https://finnhub.io/api/news?id=6d655faf7dafe25e8d0e738fc3905d2cbedbe4f81fc5d331d9535cb9cbed4064
company,2022-12-21 07:00:19,"Is Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE Of 16% Concerning?",117604910,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...",https://finnhub.io/api/news?id=28c8ff05320a4db21bab3a6338dbd3d8372b92f6e97177149c6ca99c8d32300a
company,2022-12-21 06:16:46,XBI: Attractive Value In Diversified Biotech Growth,117601011,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1395657542/image_1395657542.jpg?io=getty-c-w750,GILD,SeekingAlpha,Valuations on biotechnology stocks have moderated substantially since the pandemic peak in 2021. Click to read my analysis of the SPDR S&P Biotech ETF (XBI).,https://finnhub.io/api/news?id=58c417a94bece7fd134bf3fa546f31167f009d6ce8721ed13a50843061b8a486
company,2022-12-21 06:03:32,Madrigal: Next Steps After 'Wow' Data In NASH,117600556,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352674281/image_1352674281.jpg?io=getty-c-w750,GILD,SeekingAlpha,"On Monday, Madrigal Pharmaceuticals announced a best-case dataset from its phase 3 trial in NASH. Click here to read why I think his opens up a Huge market for MDGL.",https://finnhub.io/api/news?id=8dc6d4b12215639df0bb85512ae1a47feb692a3c2e29ab800356197db3c3e8b9
company,2022-12-21 05:08:00,Madrigal: Next Steps After `Wow` Data In NASH,117663116,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0d0f38a4ffeb80582feccceb018858e324eea88bcd6a3a9f6b36e47893dc67be
company,2022-12-20 17:45:10,Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know,117596225,https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1,GILD,Yahoo,"Gilead Sciences (GILD) closed at $84.77 in the latest trading session, marking a -1.91% move from the prior day.",https://finnhub.io/api/news?id=da648da26de59a929743bffa8a96cce383ef55a7b476c1de58110dcb15ae1034
company,2022-12-20 11:56:00,"Gilead Sciences Inc. stock falls Tuesday, underperforms market",117604698,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.91% to $84.77 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=c73e7f6560431ed02fd5655fd35965ec24541fa3e1608d924296c3900806b6b1
company,2022-12-20 11:14:00,"FuelCell, Wells Fargo fall; Steelcase, Blucora rise",117648124,,GILD,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b247567034d70690450ccac46fb314e85057fb7b23bf8e17f4ef52e4c546145d
company,2022-12-20 10:27:00,Gilead unit to buy Carl June-founded Penn cell therapy spinout,117586134,,GILD,Yahoo,The Philadelphia cell therapy developer suffered a major setback last year when two patients died in a clinical trial testing the company's prostate cancer cell therapy.,https://finnhub.io/api/news?id=76ef32a242fb5041cab26518d6a61bf667947dc4eaa5c09838b89b4d62c37d19
company,2022-12-20 10:17:15,"Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche",117586135,,GILD,Yahoo,Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%.,https://finnhub.io/api/news?id=087cca3a000c3936913158b2a998eb93d68af9e92131a4c5080ae402dcb297d4
company,2022-12-20 09:56:30,Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients,117592513,https://media.zenfs.com/en/Benzinga/4ee3806967b637d665c024be59768cdc,GILD,Yahoo,Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NASDAQ: RCUS) announced results from the fourth interim analysis of the ARC-7 Phase 2 study for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations. The study evaluates the combinations of domvanalimab + zimberelimab (doublet) and domvanalimab + zimberelimab + etrumadenant (triplet) versus zimberelimab monotherapy. Related: Gilead,https://finnhub.io/api/news?id=706311b981a0b7e1c8a6e4af4442010642c6b4c05d56738478fdb791fb6018af
company,2022-12-20 09:06:02,bluebird's (BLUE) SCD Studies Clinical Hold Lifted by the FDA,117586058,https://media.zenfs.com/en/zacks.com/2db9674ed3dae8b5017b58b4e4b808c0,GILD,Yahoo,bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted.,https://finnhub.io/api/news?id=0072d14b38efe8f80450890e5aa7c5e39bbd7d14806b721a2760c7627fc47386
company,2022-12-20 08:47:43,"Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug",117586137,,GILD,Yahoo,"Shares of Arcus Biosciences Inc. were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that it's developing with Gilead Sciences Inc. improved progression-free survival and overall response rate [ORR] in a Phase 2 clinical study. ""The data clearly show that the program is viable, keeping hope alive for active building blocks within the large lung cancer space, but numerical ORR may be disappointing to",https://finnhub.io/api/news?id=dbcd6e3f639854bdb72969decb130a960a435fcc7c17617f4bce99a840607fe3
company,2022-12-20 08:10:00,Gilead Data Raise New Questions About Cancer Therapy,117604144,https://images.barrons.com/im-689147/social,GILD,MarketWatch,New data on a cancer drug trial from Gilead Sciences and Arcus Biosciences are resurfacing debate around the class of cancer drugs known as anti-TIGITs.,https://finnhub.io/api/news?id=d5b9807ea02fd6239bec27354cd4cf78b9a63f2b6cbf670870e0ce065bb7bf6f
company,2022-12-20 08:00:00,Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer,117586138,https://media.zenfs.com/en/business-wire.com/c1898a7bbbb6a853db78d9f3a47dc870,GILD,Yahoo,"SANTA MONICA, Calif. & PHILADELPHIA, December 20, 2022--Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. The acquisition of Tmunity complements Kite’s existing in-house cell therapy research capabilities by adding additional pipeline assets, platform capabilities, and a stra",https://finnhub.io/api/news?id=fe82179d3443f58841bc9a02f9ce6adc1f00076d9762cf11c238216c29d068b6
company,2022-12-20 07:36:31,"Stocks making the biggest moves midday: Gilead Sciences, Moderna, Tesla and more",117588167,https://image.cnbcfm.com/api/v1/image/106512621-1588190065431gettyimages-1221879709.jpeg?v=1671557791&w=1920&h=1080,GILD,CNBC,These are the stocks posting the largest moves midday.,https://finnhub.io/api/news?id=26c4078961026cfe1672cd18835447fccc09991d18fb24a29bf9df51e5ab5844
company,2022-12-20 06:11:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amicus (FOLD), Gilead Sciences (GILD) and Staar Surgical (STAA)",117631630,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d854ab13abbb4cd7a3bbacb04d0310292374b2c7d9e0b89db0f9fa78b25f5bb1
company,2022-12-20 06:04:00,What You Missed On Wall Street This Morning,117637860,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a02865061d458eb93f1a626099b26a83f63260781cbc6c7c0b2615fb2bd7e331
company,2022-12-20 05:56:00,"Video: Nasdaq 100 Movers: GILD, LCID",117960896,,GILD,Market News Video,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f0c12e6f3874999cdbeeaa9b9bf662667c87310e8f26ff874c658401e0d7dc59
company,2022-12-20 05:54:00,"Video: S&P 500 Movers: GILD, NEM",117960897,,GILD,Market News Video,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=df380ee00a15f3888537b4e936448c5a56085d62fb87fc22a65f62ba3f64e3c2
company,2022-12-20 03:33:00,Gilead's Kite Unit to Buy Tmunity Therapeutics,117604703,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,"By Dean Seal The Gilead Sciences Inc. subsidiary Kite has signed a deal to acquire the biotech company Tmunity Therapeutics. Kite said Tuesday that Tmunity,...",https://finnhub.io/api/news?id=814bbb89f01a6e2b6aeabac20514e518482c0c3a22105e109264e76db2b31b65
company,2022-12-20 03:11:00,Gilead`s Kite unit to acquire CAR T therapy developer Tmunity Therapeutics,117960898,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6aa83c1dad5a3a498c17c05bf190549cbd2d2123ea0a833071501edffb0f527f
company,2022-12-20 02:41:00,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Staar Surgical (STAA) and Cocrystal Pharma (COCP)",117631632,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6b06b23a90d8205252d86f2b757b4cbd5ff3e0c96a5dc2860c4e8387c116bc2f
company,2022-12-20 02:12:00,Gilead expects Tmunity acquisition to reduce FY23 EPS by 18c-22c,117960901,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=094553c39c8ca603cfcfc6c813d5303e31a8116003eb0b252c45202b99734103
company,2022-12-20 02:10:00,"Kite to acquire Tmunity, terms undisclosed",117960902,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fd00f5f3d8738a44e9c69baf5f922b082b7e9f1173425eea896c7e61bedb3789
company,2022-12-19 23:23:39,Gilead: A Phoenix Has Risen From Its Ashes,117582681,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1187806357/image_1187806357.jpg?io=getty-c-w750,GILD,SeekingAlpha,"Gilead Sciences is committed to growing its dividend and repurchasing its own shares, to at least make sure the stock is not diluted. Read why I am not selling GILD stock.",https://finnhub.io/api/news?id=184815ebe9299367bd2a1271dd9dd889e37517cf91d3faea00e6a99dc2070aa8
company,2022-12-19 23:22:00,Tuesday Talk: Where is Santa?,117662151,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9b7e4d67a3e28c03d35b7b106245c73c1edb99f517a48112219c9c13cd89c1c7
company,2022-12-19 18:17:07,"Unusual Options Activity in Apple, Home Depot and 8 Other Stocks",117578150,,GILD,Fintel,,https://finnhub.io/api/news?id=4c070c7e4a5ef1672a874d323b04ab9f5d2b6a04f3f77b996bc009806bb310bf
company,2022-12-19 17:00:00,Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study,117580056,https://media.zenfs.com/en/business-wire.com/82fb291aecfc84ee2cafb8992a0f2c8d,GILD,Yahoo,"FOSTER CITY, Calif. & HAYWARD, Calif., December 19, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is a Phase 2, multicenter, three-arm, randomized, open-label",https://finnhub.io/api/news?id=0e4e23fb0b207c9dd857ef2ce822fa77cb5931907372a1983a638c7261824d6f
company,2022-12-19 11:56:00,Gilead Sciences Inc. stock underperforms Monday when compared to competitors,117604705,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 0.39% to $86.42 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=eeb662bf333b7810a68a1714de0d8dc5544567b2ff9dd5beaf85179a6a1b5428
company,2022-12-19 03:15:00,Schrodinger: Upgrading My Rating Post The Recent Nimbus Deal,117572307,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345903441/image_1345903441.jpg?io=getty-c-w750,GILD,SeekingAlpha,Schrodinger shares have rallied ~25% since the Nimbus Takeda deal announcement. See why I believe SDGR stock is a good buy for long-term investors.,https://finnhub.io/api/news?id=c81fdf34be4845ec2ef3335e38cff3dfe835c5b25b5644b19f12cd179f3b4d41
company,2022-12-18 00:00:17,IBBQ: Healthcare Dashboard For December,117565452,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310024666/image_1310024666.jpg?io=getty-c-w750,GILD,SeekingAlpha,The pharmaceuticals/biotechnology subsector has good value and quality scores. Click here to read more about IBBQ ETF.,https://finnhub.io/api/news?id=e5bf97def27912b4a2d83c6964251e037ef37a2457f0e776d37832fcc5e3cfcb
company,2022-12-25 07:45:00,3 Stocks That Could Soar in a Santa Claus Rally,117739314,,GILD,Yahoo,"Years ago, investors observed that a phenomenon dubbed the Santa Claus rally often occurred during the year-end holidays.  Three Motley Fool contributors identified stocks they think could soar in a Santa Claus rally.  Here's why they picked Gilead Sciences (NASDAQ: GILD), NovoCure (NASDAQ: NVCR), and Pfizer (NYSE: PFE).",https://finnhub.io/api/news?id=0cc8d629b5322232efc12e01e44f29385132ef6db0d55712a9f054e711b9e60c
company,2022-12-25 07:11:00,"Dividend Champion, Contender, And Challenger Highlights: Week Of December 25",117721936,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d4b074bf94dec3846e62a21ee0978e4f78d80e65670fa2276edccbf7cd97589d
company,2022-12-25 06:00:43,"Gilead Sciences, Inc. (NASDAQ:GILD) Shares Could Be 40% Below Their Intrinsic Value Estimate",117735817,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Today we will run through one way of estimating the intrinsic value of Gilead Sciences, Inc. ( NASDAQ:GILD ) by taking...",https://finnhub.io/api/news?id=90c6f1e64f0c0c863fdd24e045202af435ff3b49efe1df622159b7497169b73a
company,2022-12-24 04:00:00,"HQH: 50 Big-Yield Healthcare Stocks, These 3 Worth Considering",117670966,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1426076413/image_1426076413.jpg?io=getty-c-w750,GILD,SeekingAlpha,"We share data on over 50 big-yield healthcare investments, including individual stocks, REITs, closed-end funds (CEFs) and bonds. Learn about our 3 top picks here.",https://finnhub.io/api/news?id=90a31bbb4df25c0d58e1bf3fc1dcb54df8cc83ab76b41dcd03bb1ebb3a4dd5ef
company,2022-12-23 16:05:00,Gilead Sciences to Present at Upcoming Investor Conference,117646643,https://media.zenfs.com/en/business-wire.com/cac796d497291b62777352590927ee9b,GILD,Yahoo,"FOSTER CITY, Calif., December 23, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:",https://finnhub.io/api/news?id=ea1231eee363ac572169e651ba752eef491ead7d10d88953a56b00fe4243d6c7
company,2022-12-23 12:27:05,Gilead (GILD) Gets FDA Nod for Twice-Yearly HIV Treatment,117635837,https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071,GILD,Yahoo,Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistance.,https://finnhub.io/api/news?id=caee725dbfff9dea027a32e8e0ea6231a5cda4e5975f6e8a9a3515d275d0630b
company,2022-12-23 11:56:00,Gilead Sciences Inc. stock underperforms Friday when compared to competitors,117765438,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 0.62% to $84.75 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=660ed33a233f6cfa7e116273b438c50eb498b97ff7a9bfb59e429387a8d603ac
company,2022-12-23 09:53:00,3 Nasdaq Stocks That Are Up 25% in 3 Months,117627760,,GILD,Yahoo,"The Nasdaq Composite has plummeted 33% this year, but there are signs that for at least some stocks, brighter days could be on the horizon.  Entering this week, three Nasdaq stocks were up 25% in just the past three months.  Among the hottest buys of late are chipmaker Nvidia (NASDAQ: NVDA), and healthcare companies Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD).",https://finnhub.io/api/news?id=ddb1abccb6b1a5a82ba7ccf653217376494e1974573f024c0ddd6c3b1c892373
company,2022-12-22 22:21:00,Gilead's treatment for large B-cell lymphoma gets approval in Japan,117960870,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c7815d1d861a61ae0773e844a0c275abb5743628374a8b0b0dc4d1e61b104081
company,2022-12-22 16:30:00,Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma,117621252,https://media.zenfs.com/en/business-wire.com/a23fefb820499ab4e7239641443d1498,GILD,Yahoo,"SANTA MONICA, Calif. & TOKYO, December 22, 2022--Kite Pharma, Inc., a Gilead Company, (hereafter, Kite) (NASDAQ: GILD) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) (TSE: 4568) today jointly announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma ( R/R LBCL): diffuse large B-cell lymphoma,",https://finnhub.io/api/news?id=c3ae6ce4d0cd059051f9f33829a61d1c756ef37c7c4b5dbc3f251b8901f4a632
company,2022-12-22 16:09:58,Gilead Sciences Snags FDA Approval For Twice-Yearly HIV Shot,117621253,,GILD,Yahoo,Gilead won Food and Drug Administration approval for a twice-a-year HIV treatment called Sunlenca on Thursday.,https://finnhub.io/api/news?id=bd2dfcfeeae4286ef230e4a9c5d28c54a067fbe7fc5b1e7e45fe994384d816c3
company,2022-12-22 14:25:44,Gilead's twice-a-year HIV drug Sunlenca approved by FDA,117621254,,GILD,Yahoo,"The drug will cost $42,250 as therapy is initiated — a combination of tablets, an injection just under the skin and antiretroviral drugs — and $39,000 a year for maintenance therapy.",https://finnhub.io/api/news?id=4f53ee20963fdea55a92d5597c16871416ebb870de855498f160b0615c80b9e9
company,2022-12-22 14:01:34,FDA Approves Gilead's New HIV Treatment For Heavily Treated With Multi-Drug Resistant Patients,117621255,https://media.zenfs.com/en/Benzinga/512159d6cdad158960764f62886716e3,GILD,Yahoo,"The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) Sunlenca (lenacapavir), in combination with another antiretroviral (s) (ARV), for HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection. The approval comes almost a week before the PDUFA date of December 27. The company says that Sunlenca offers a new, twice-yearly treatment option for adults with HIV that is not adequately controlled by their current treatment regimen. In August, th",https://finnhub.io/api/news?id=9475c9151eed635abc048498d7ee552585ae423150e8c81ea9d07f25fe1a1d86
company,2022-12-22 11:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,117765440,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.01% higher to $85.28 Thursday, on what proved to be an all-around grim trading session for the stock market, with the...",https://finnhub.io/api/news?id=80c4129e47c9eedf932bc5d4b8834d1b27b762ea5dabda77ddbd9a66b4fedf51
company,2022-12-22 11:40:06,U.S. FDA approves Gilead's long-acting HIV drug Sunlenca,117617700,https://static.reuters.com/resources/r/?m=02&d=20221222&t=2&i=1617943029&r=LYNXMPEIBL0J1,GILD,Reuters,"The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments.",https://finnhub.io/api/news?id=89134555e1e452dd02cf5952699d3b2cb90bd558ea1c88a272654d4d2f09b72e
company,2022-12-22 10:44:44,UPDATE 2-U.S. FDA approves Gilead's long-acting HIV drug Sunlenca,117621256,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments.  Treatment of HIV infections typically involves daily administration of a combination of drugs - such as Gilead's Biktarvy and ViiV Healthcare's Triumeq - that suppress replication of the virus.  The initial doses of Sunlenca, whose chemical name is lenacapavir, are given as oral tablets and injections to get the drug up to therapeutic levels quickly, followed by injections every six months to sustain the treatment.",https://finnhub.io/api/news?id=d8795cacae2152bfe67f4d14aede5e34b2d9f290f1aeeabd62290b3c2e415491
company,2022-12-22 10:27:00,"Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV",117621257,https://media.zenfs.com/en/business-wire.com/6169b01585cb6c97aa57326070c57517,GILD,Yahoo,"FOSTER CITY, Calif., December 22, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Sunlenca® (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection. Sunlenca has a multi-stage mechanism of action distinguishable from other currently approved classes of antiviral agents",https://finnhub.io/api/news?id=b2982095a367a1af7e066197ef782570cf2f0474c8193445185575ecfde2e0b3
company,2022-12-22 07:16:00,Gilead says Sunlenca treatment for HIV-1 patients gets US FDA approval,117960873,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ce231fe9286f3cc337f0a56fb72068ef2875fc0a76c041b3b0aee5b6852f228f
company,2022-12-22 06:46:00,"Gilead`s Sunlenca could expand into broader HIV, says Piper Sandler",117960874,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=df17408dfe3730b0860a8ebba6d1b6823c1461b13f71f6b5299d83308f502288
company,2022-12-22 05:43:00,Gilead Sciences Gets FDA Approval for Sunlenca to Treat HIV-1,117765442,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,"By Chris Wack Gilead Sciences Inc. said Thursday that Sunlenca lenacapavir, in combination with other antiretrovirals, has been granted approval by the U.S....",https://finnhub.io/api/news?id=d975794e0f51b032cc72539b4faed4a7832dcf3df075cfafe5ee62e54c6497cb
company,2022-12-22 05:15:00,Gilead wins U.S. approval for twice yearly HIV med lenacapavir,117960876,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0a36ca70bf64bd083f893f8651e5e412f5d57e8d1e58079760f7846200ddf907
company,2022-12-22 05:10:00,Gilead wins U.S. approval for twice yearly HIV med,117960877,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2390fbe039a41aa77fd07b4e5db32b9933f8422e89c4709c3cba0e386631d06e
company,2022-12-22 04:29:00,Gilead announces Sunlenca granted FDA approval in multidrug resistant HIV,117960879,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=302b0d78360873f7de3e8f066dab54b4b7dddacdaf6c5e1629aa758e4c1d32f9
company,2022-12-21 23:02:00,Gilead`s Yescarta approved in Japan for initial treatment of B-cell lymphomas,117960881,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=61d231874ec6f4c467454c1c891cb11c7da8f7d3d8f92aed83fc4b669b2738a7
company,2022-12-21 22:32:00,Kite says Yescarta now approved in Japan for initial treatment,117960885,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3be506797d9907004a35cf0ef5d96d038e6624f7ecf8f81315790b0b6c8f0eac
company,2022-12-29 17:45:10,Gilead Sciences (GILD) Gains But Lags Market: What You Should Know,117916375,https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295,GILD,Yahoo,"In the latest trading session, Gilead Sciences (GILD) closed at $85.26, marking a +0.82% move from the previous day.",https://finnhub.io/api/news?id=eef5dc0becf3a1750e65a626b9884ec0438b60d948980943fba3ae7de0a477ae
company,2022-12-29 15:25:58,A promising new Covid pill shows key advantages over Paxlovid in trial,118083448,https://image.cnbcfm.com/api/v1/image/107172461-1672362772077-gettyimages-1245528150-Medicine_Supply.jpeg?v=1672363558&w=1920&h=1080,GILD,CNBC,"A Chinese antiviral pill was found to be as effective as Paxlovid in a Phase 3 trial, and it appeared to cause fewer side effects, NBC News reports.",https://finnhub.io/api/news?id=e0dd357df7530e5f2fc4a3d1fc958f52c99716cab53abb016858e4423c9268ef
company,2022-12-29 11:56:00,"Gilead Sciences Inc. stock rises Thursday, still underperforms market",118001912,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.82% higher to $85.26 Thursday, on what proved to be an all-around positive trading session for the stock market, with...",https://finnhub.io/api/news?id=573f41dd85c04863949af1584569ebfe86954c12e2069826c928cd918b2eabe9
company,2022-12-29 11:36:04,"Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More",117867161,https://media.zenfs.com/en/zacks.com/ea60c5d3630e17d44f311d6ac6395c89,GILD,Yahoo,Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=adcdf59b3ba423ddafa7d1e8b25a8a1988db1a96b20776249870a8fe1f4ec9be
company,2022-12-29 09:20:00,This New Drug Could Be Gilead Sciences' Growth Catalyst,117855284,https://s.yimg.com/ny/api/res/1.2/tMwb06OHrl_YtgPnZTc92w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/8d608f86729134f8eb9bbf1e73f31c7c,GILD,Yahoo,"Gilead Sciences (NASDAQ: GILD) has been a top stock to own this year, with its shares rising 17% and dwarfing the S&P 500 and its 21% loss over the same stretch.  Health officials have given the green light on another one of its HIV treatments, which promises to improve lives and potentially generate billions in revenue for the business.  Is now the time to load up on Gilead's stock?",https://finnhub.io/api/news?id=c17b5899352910e044119a43e2c2cbc1b2868dc9417ef18bf20ec1e625175560
company,2022-12-29 09:00:00,3 High-Yielding Dividend Stocks That Could See Hikes in January,117855285,https://s.yimg.com/ny/api/res/1.2/073M5PINK6ovHHZ5r._NMw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/e84c96b3f99676990a0348303460a7c6,GILD,Yahoo,"As long as a company is doing well and an increase to the dividend looks probable, the timing of the announcement often will come at around the same time as it did in the previous year.  Three stocks that I expect will announce increases to their dividend payments in January are Gilead Sciences (NASDAQ: GILD), Viatris (NASDAQ: VTRS), and Kimberly-Clark (NYSE: KMB).  Gilead Sciences is a healthcare company that makes a wide range of medicines focused on treating HIV, hepatitis, and cancer.",https://finnhub.io/api/news?id=1d17a1663418776cbcb998c72c91ada7db7e6297697d5865e2bdcfb1747fa2c9
company,2022-12-29 06:00:32,"Are Investors Undervaluing Gilead Sciences, Inc. (NASDAQ:GILD) By 40%?",117855286,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Does the December share price for Gilead Sciences, Inc. ( NASDAQ:GILD ) reflect what it's really worth? Today, we will...",https://finnhub.io/api/news?id=43a889b597e0064eaf948161e3b672a8074bb8d043c950cf5c57e22376053ba8
company,2022-12-28 14:19:07,Biotech: 3 Profitable Bios Worth Owning,117826417,https://media.zenfs.com/en/zacks.com/7de283b2224f57ff914c609b38092b2c,GILD,Yahoo,The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval. Today we will look at three top biotech stocks that are very profitable and have attractive future prospects.,https://finnhub.io/api/news?id=c829fbe2345fc3b966fa71dbe38c60b6ef2aa2e17756230195fd0d47d2dcc9e7
company,2022-12-28 11:56:00,Gilead Sciences Inc. stock outperforms market despite losses on the day,118001913,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. sank 0.52% to $84.57 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=68979a82f4761a6f4b873b0a0982c45ce722277a7a01f0ba68fdd59c03a36bec
company,2022-12-28 10:59:03,Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy,117820178,,GILD,Yahoo,Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.,https://finnhub.io/api/news?id=75f9a8cb8df78af8ed216baa26a7b537c2306fdfac9550f83b6fe1d79fa267e1
company,2022-12-28 09:14:12,Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program,117820179,,GILD,Yahoo,"Gilead Sciences Inc (NASDAQ: GILD) and Jounce Therapeutics Inc (NASDAQ: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under the license agreement executed in August 2020. GS-1811, an immunotherapy, is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in the tumor microenvironment. It is currently in Phase 1 development for solid tumors. Jounce will recei",https://finnhub.io/api/news?id=0ec1978dceb936289473a15373dd863ae3d371e682d657985a46ab128a4168e5
company,2022-12-28 07:15:12,"Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals",117817747,,GILD,Yahoo,"Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article.",https://finnhub.io/api/news?id=4a96afd64d2e7a23dea0ab63a04bb7f92598bbdcbed88123c8fff7f047217430
company,2022-12-28 06:03:00,What You Missed On Wall Street This Morning,117821016,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4c56c7d50a1f83dc119ac6252cb0b3fecfd80fbf29316e88f6038cde56797e28
company,2022-12-28 03:21:00,Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?,117902434,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c7dd7beee441e64d91eec0713850948bddb90693aecd0e10d1102485254c5a1a
company,2022-12-28 03:21:00,Fly Intel: Pre-market Movers,117819230,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8a3538fbd10ed787a98b67d543d04faaaf8a4e24595b6664f82b6e0ef6a23079
company,2022-12-28 00:43:00,Gilead Sciences buys sole rights to cancer therapy for USD67 million,117902435,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2523c0d98a6f6667e9befed4a7fb45d9750bcb6920a599d9fcc8e2daaf0d7d00
company,2022-12-27 22:32:00,What You Missed On Wall Street On Wednesday,117830710,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b6f9316c97a4b894aa388baa10d9065c61b6f58f32be33491db70bdcefa0f7c3
company,2022-12-27 21:42:29,Gilead buys out rights to cancer therapy from Jounce for $67 million,117813522,https://static.reuters.com/resources/r/?m=02&d=20221228&t=2&i=1618375058&r=LYNXMPEIBR01G,GILD,Reuters,"Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.",https://finnhub.io/api/news?id=0d27bd8ae93e7dba730972bc4c1c9d22f22948e12c258a776849cf0c536ecce0
company,2022-12-27 17:50:10,Gilead Sciences (GILD) Gains As Market Dips: What You Should Know,117810809,https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af,GILD,Yahoo,"In the latest trading session, Gilead Sciences (GILD) closed at $85.01, marking a +0.31% move from the previous day.",https://finnhub.io/api/news?id=2c938b751c31514ada423bb7cdbe4360fffcabf515016d0f562587538d0faca4
company,2022-12-27 17:44:13,Tracking John Rogers' Ariel Investments Portfolio - Q3 2022 Update,117810776,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/477618545/image_477618545.jpg?io=getty-c-w750,GILD,SeekingAlpha,Ariel Investmentsâ 13F portfolio value decreased from $10.02B to $9.11B this quarter. Read more to for an update on the portfolio's trades for Q3 2022.,https://finnhub.io/api/news?id=1bd27341a9b611d27672bed7953f2d24d6e17117774c8bbb8bc29ce120cc15cb
company,2022-12-27 17:44:00,Gilead buys remaining rights to cancer immunotherapy drug from East Coast partner,117810810,https://s.yimg.com/ny/api/res/1.2/14FLvRm16gqUVHZbW.BRVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/bizjournals.com/78ec55a864fc1a65266f947ae169dfcb,GILD,Yahoo,"Gilead Sciences Inc. will pay $67 million for the remaining rights to a cancer immunotherapy drug from partner Jounce Therapeutics Inc., a move to strengthen the Foster City-based drug maker's pipeline of potential cancer drugs.  Gilead (NASDAQ: GILD) said Tuesday that it and Cambridge, Massachusetts-based Jounce (NASDAQ: JNCE) amended a licensing agreement for a drug named JTX-1811 — now GS-1811 — that enables Gilead to buy out all remaining contingent payments.  The deal comes more than two years after Gilead and Jounce disclosed a potential $805 million deal — including a $35 million equity investment in Jounce — that was part of a push by Gilead to beef up the number of potential cancer drugs.",https://finnhub.io/api/news?id=a5fc5d54563dae818010cb47e2289ab397ce2230945545c8bc79b216b602eb70
company,2022-12-27 17:31:18,UPDATE 1-Gilead buys out rights to cancer therapy from Jounce for $67 mln,117810811,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.  The amended licensing deal will bolster Jounce's cash resources in a challenging market for biotech companies.  Shares of Jounce more than doubled to $1.68, while Gilead's shares fell marginally in after market trading.",https://finnhub.io/api/news?id=a32773609b36df9d465cc7aa6c0f22f57f454b68290a634f642f0979b498de48
company,2022-12-27 16:49:00,Jounce stock bounces more than 70% after Gilead acquires immunotherapy drug,117810812,https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,GILD,Yahoo,"Jounce Therapeutics Inc.  (JNCE)  shares jumped more than 70% in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc.  (GILD)  would completely acquire rights to an immunotherapy drug from Jounce.  Gilead said it would buy out its remaining obligations under a licensing agreement executed in 2020 between the two companies and acquire intellectual property and rights to the cancer treatment, known as GS-1811.  “It was important for Jounce at this time to bolster our cash resources, given challenges in capital markets for biotech companies,” Jounce Chief Executive Richard Murray said in a statement.",https://finnhub.io/api/news?id=16864272913576998105a789a74a1b92bf661d58da8906cd450d79b3bfd67076
company,2022-12-27 16:30:00,Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics,117810813,https://media.zenfs.com/en/business-wire.com/addf528bdcab925584c4427b907aa0f5,GILD,Yahoo,"FOSTER CITY, Calif. & CAMBRIDGE, Mass., December 27, 2022--Gilead Acquires All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 from Jounce Therapeutics",https://finnhub.io/api/news?id=7c45187f70f1c9707c62e1a7642f3580c3b91ac1e612d0cd8087b0e7558059e4
company,2022-12-27 13:15:00,"Stocks to Watch: Kala Pharmaceuticals, Clene, Jounce Therapeutics",117837225,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Denny Jacob Kala Pharmaceuticals Inc. said the Food and Drug Administration accepted its investigational new drug application for the treatment of an eye...,https://finnhub.io/api/news?id=fd4d8daca0dd590019f6667d917236112fe5bc9696a5c3789a6eb214a18bb760
company,2022-12-27 11:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,118001915,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.31% higher to $85.01 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the...",https://finnhub.io/api/news?id=66ce3378a3dd0d6fb225e1acd84f914d5764f370ae245b34d22e82820dbe08b6
company,2022-12-27 11:54:00,Gilead Sciences to Acquire Remaining Rights to GS-1811 from Jounce Therapeutics,117840888,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Denny Jacob Gilead Sciences Inc. on Tuesday said it will acquire all outstanding rights of Jounce Therapeutics Inc. to GS-1811 following an amended...,https://finnhub.io/api/news?id=9b8e432c416454665548cc17289eef8621133e7f7dc5cd48cfeae612c245297d
company,2022-12-27 11:51:00,Gilead buys out remaining rights for oncology asset GS-1811,117902437,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9af9b42ffee474952a90613237eae0b930368c61decef339558c303f3aceef76
company,2022-12-27 11:30:00,Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics,117902438,,GILD,GlobeNewswire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a556a0b5680bbec483105a8202a5882466f4135e1d89f667946a1c40b3c07e99
company,2022-12-27 04:46:00,Tracking John Rogers` Ariel Investments Portfolio - Q3 2022 Update,117815429,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bc9b005d2978580b3b7d44999c6fe4505f2787a91a6fb8ce4b97e0b6a27790b9
company,2022-12-26 22:34:00,Gilead to buy remaining rights for GS-1811 from Jounce Therapeutics for $67M,117902444,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=099424e3ac07eb5b314ad466b7d07db23aa69b4e61faffb173d7899d203a3a40
company,2023-01-02 09:00:00,Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?,118089739,https://s.yimg.com/ny/api/res/1.2/dUhV_drp.HKdjo5MMWfPlg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04OTk-/https://media.zenfs.com/en/motleyfool.com/053590d43d3efcb086ec07cd026404bc,GILD,Yahoo,"Roche Holding (OTC: RHHBY) and Gilead Sciences (NASDAQ: GILD) both saw increased sales during the pandemic, due in part to their COVID-19 products.  For Gilead, it was its COVD-19 antiviral, Veklury, and for Roche, its revenue was boosted mostly by coronavirus tests.  Gilead's shares have glittered in 2022, with the stock up more than 16%, while Roche's have fallen more than 23% so far this year.",https://finnhub.io/api/news?id=3d5f35d996356686ada88e58daf5d68b451ee466036926ee8946eeb92ee69fc4
company,2023-01-02 06:00:09,"Why Investors Shouldn't Be Surprised By Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E",118089740,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"With a price-to-earnings (or ""P/E"") ratio of 32.3x Gilead Sciences, Inc. ( NASDAQ:GILD ) may be sending very bearish...",https://finnhub.io/api/news?id=022e7bda19d541b0ba36f686a4b79d12d5f9f295fd02fb4338c8e6cdb5ddda39
company,2023-01-02 00:50:00,"Piper Sandler keeps Overweight on Jounce Therapeutics, lowers price target to $5",118099579,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=848f19ed4c998ebfcf6a23403d99e2e349e290416c81723b5b564892a7198dda
company,2022-12-31 17:52:13,Jim Simons Stock Portfolio: 10 Biggest Healthcare Stocks,118034914,https://media.zenfs.com/en/insidermonkey.com/00d514a054884081553dae19073f6d33,GILD,Yahoo,"In this article we take a look at Jim Simons Stock Portfolio: 10 Biggest Healthcare Stocks. Click to skip ahead and see Jim Simons Stock Portfolio: 5 Biggest Healthcare Stocks. Gilead Sciences, Inc. (NASDAQ:GILD), Novo Nordisk A/S (NYSE:NVO), and Molina Healthcare, Inc. (NYSE:MOH) are three of the healthcare companies that Jim Simons’ quant fund has identified as […]",https://finnhub.io/api/news?id=f9b4731747f162f815cfd5f58bfa8b1a1e52c06f56cf786ae4c10e0f771715ca
company,2022-12-30 19:54:12,"Galapagos: Slow Transformation, But Led By An Expert",117975950,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1370514197/image_1370514197.jpg?io=getty-c-w750,GILD,SeekingAlpha,Galapagos is setting up to transform its business after a slew of failures. Read more to see why I think GLPG will be successful in its transformation plans.,https://finnhub.io/api/news?id=ef6e25281f6c4adcdb888cbcdcb3790cc61a6fc5802a9cf119389a8d0b0cb2d2
company,2022-12-30 11:56:00,Gilead Sciences Inc. stock outperforms market on strong trading day,118001911,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.69% higher to $85.85 Friday, on what proved to be an all-around rough trading session for the stock market, with the...",https://finnhub.io/api/news?id=1bba9d8f965b9085218922b66096bed0a5eae8850db33c48f8c87c5d9b5615f2
company,2022-12-30 06:12:00,What You Missed On Wall Street This Morning,117923825,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=567ebe15151cb6f530f1e68bb3860edef0865909adc587d5398a91e23d2891b9
company,2022-12-30 05:30:00,Biotech Alert: Searches spiking for these stocks today,117960837,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=13101d32985a3408cee83312a26fb730a1d3b29bca82cc939bf9e3d1b0969bc9
company,2022-12-30 02:02:00,Opco reveals three biotech stocks that will outperform in 2023,117923828,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f4c27c66a2e6ca0ce8b0745fd25e94d0f73977a46b1fb157d66ee343d29006eb
company,2023-01-06 11:57:00,Gilead Sciences Inc. stock outperforms market on strong trading day,118218386,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 2.60% to $88.08 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=037c8b38bb47230640f369155262343c7da400e9771bbf370cd0854f0f6d8b3b
company,2023-01-06 08:00:00,Economic Forecast 2023: New challenges in biotech's 'valley of death',118169580,,GILD,Yahoo,The disappearance of investors and their cash is giving biotechs with drugs in development a vexing problem.,https://finnhub.io/api/news?id=61c6daffd31317aa65b9bf3f3b5959cab6b7543a7fdbe618947ef34611ab9a47
company,2023-01-06 06:01:12,Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?,118169582,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...",https://finnhub.io/api/news?id=9c25c0bcb22417041ce820c9846f9e4ffd12dc5d26c2049cb195c8df98795a53
company,2023-01-06 05:11:03,AstraZeneca And Daiichi Sankyo's Zauberkugel (Magic Bullet),118162148,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/139978748/image_139978748.jpg?io=getty-c-w750,GILD,SeekingAlpha,"AstraZeneca, Daiichi Sankyo to market HER-2 cancer domain targeting therapy Enhertu. See why I consider accumulating DSKYF stock for Enhertu momentum play.",https://finnhub.io/api/news?id=8ccd333990eb55a6645377839ea5da15a0573b04871785958b410c34387f6013
company,2023-01-06 02:15:00,Johnson & Johnson Vs. AbbVie: The Better Dividend Aristocrat Buy Might Shock You,118159624,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520885672/image_520885672.jpg?io=getty-c-w750,GILD,SeekingAlpha,Johnson & Johnson and AbbVie Inc. historically fall 70% to 80% less than the S&P 500 Index during bear markets since 1985. Click here to find out which is the better dividend aristocrat.,https://finnhub.io/api/news?id=e29082f4ff059ae31ed6183eb38b9b1e5c9d44585df93f46ed65408146ccaa95
company,2023-01-05 13:50:00,Gilead Sciences Again Named to Dow Jones Sustainability World Index,118154525,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"Gilead Sciences, Inc. (Nasdaq:GILD) announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World).",https://finnhub.io/api/news?id=b0d0b1abdeaa3ec3bf99603546108d624ca951a5f06e116e217cbb73ddda3644
company,2023-01-05 11:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,118155114,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.41% higher to $85.85 Thursday, on what proved to be an all-around poor trading session for the stock market, with the...",https://finnhub.io/api/news?id=99620ca5ff4e66b83e2f040299ccb578f9d9ed52b21e9f0b41d95fe2cd1190fe
company,2023-01-05 03:20:00,"My Dividend Stock Portfolio: New December Record - 96 Holdings With 24 Buys, 6 Sales",118139432,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w750,GILD,SeekingAlpha,Inflation and (expected) actions by the Fed continue to dominate market movements. Learn more about the holdings for December in my dividend income portfolio.,https://finnhub.io/api/news?id=ea960feec83c570adc2dde318c4f30d42b16e2fa50f93061c11c689c2e88203c
company,2023-01-04 17:50:10,Gilead Sciences (GILD) Gains But Lags Market: What You Should Know,118142597,https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9,GILD,Yahoo,"Gilead Sciences (GILD) closed at $85.50 in the latest trading session, marking a +0.13% move from the prior day.",https://finnhub.io/api/news?id=51671c218122f1b9c982105d22d1acc8fd46dcff292b452b84d343068b0320cc
company,2023-01-04 11:56:00,"Gilead Sciences Inc. stock rises Wednesday, still underperforms market",118127723,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.13% higher to $85.50 Wednesday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=7911c2d470bd459019d6cbc64f883be9633ba39ee4ed4fe0fafd9fce9c90da3c
company,2023-01-04 11:45:04,Gilead's (GILD) Application for Trodelvy Gets EMA Validation,118124373,https://media.zenfs.com/en/zacks.com/7a54c1205dce82fe019c16047a3cf20a,GILD,Yahoo,Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.,https://finnhub.io/api/news?id=ad40d3caf6b036c7d485142d75cf367692397243d33df8a11339665ffe841d06
company,2023-01-04 10:00:00,Gilead Sciences: Connecting Breast Cancer Education to Community: Equal Hope,118113095,https://s.yimg.com/ny/api/res/1.2/ouMeNkLnfnZ5Loy_k_GuAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://media.zenfs.com/en/accesswire.ca/dd2a87f0fdb4bf2c2db34ce900719e8e,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / January 4, 2023 / Gilead Sciences On any given day on the west side of Chicago, you might encounter something unexpected. Outside a retail store or hair salon, there may be a table providing breast cancer education ...",https://finnhub.io/api/news?id=6d47b247819bdbb7e114f3cfa9e549fe0ce98c1a99aca583e2d93ea513156bf5
company,2023-01-04 07:13:00,HOOKIPA Pharma achieves $5M milestone payment under collaboration with Gilead,118125365,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2803e64b75b1d8d681d4151bd1d4e3eba487af5ba779c793202c711ad5d22a78
company,2023-01-04 04:48:00,First Week of GILD August 18th Options Trading,118125368,,GILD,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b91bb81cf79bb0260641a9ae2d41b28142dc1096195ac2450bda51c11f39be4a
company,2023-01-04 02:23:00,Hookipa Pharma Gets $5M Milestone Payment From Gilead Sciences,118127725,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Chris Wack Hookipa Pharma Inc. said Wednesday that it has achieved a $5 million non-dilutive milestone payment under its collaboration agreement with...,https://finnhub.io/api/news?id=0464de24522f7436372d063040d77f60130a3765271b5af5c2a615789fd8fbd4
company,2023-01-04 01:16:00,Hookipa Pharma achieves $5M milestone payment from Gilead,118125370,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=10b06d8e77f28284b4a5109c94913ff44b217e8ab126f226af65ff13ea590c02
company,2023-01-03 11:56:00,Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors,118127727,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 0.54% to $85.39 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=9aaed3d11c27fa016c797441f2c86194e640ba8e2db07720eb631e453c5568fc
company,2023-01-03 08:30:00,European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer,118098341,https://media.zenfs.com/en/business-wire.com/58c1464d0d8f5ca77644b9542c1eb3c7,GILD,Yahoo,"FOSTER CITY, Calif., January 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated a Type II variation Marketing Authorization Application (MAA) for Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and",https://finnhub.io/api/news?id=c8a6c183dcfa7f83cfa06051380bc93ec62d7d3fd0db5d5bf220f6798b0913f7
company,2023-01-03 08:30:00,Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies,118098339,https://media.zenfs.com/en/business-wire.com/90d721cbe24aee724ea633d4059cd574,GILD,Yahoo,"FOSTER CITY, Calif. & ANN ARBOR, Mich., January 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and EVOQ Therapeutics, Inc. (EVOQ) today announced a collaboration and licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ’s NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases. Under the agreement, Gilea",https://finnhub.io/api/news?id=0658c9cb647ee805d337885436e189c6faa18973541473af1ac1bc0f5807cb11
company,2023-01-03 07:46:00,Truist biotech analyst to hold an industry dinner meeting,118099244,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0b151e89d0da8436eea43399c7eaab9625a128d8c73d04d662a7cdd089fdaf38
company,2023-01-03 07:18:00,Gilead to collaborate with EVOQ on autoimmune treatments,118100378,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9995bbedfa4275d400d6b5ee9d013943d1d66185712f5aec0ae30e0d3963af8c
company,2023-01-03 06:06:00,Allogene ends winning streak as R&D chief departs,118097325,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fc8e696a812dae91c64cfddfb7f6c3b9e6e35851837920996458c08d475e2ba0
company,2023-01-03 04:41:00,EMA approves change to marketing authorization for Gilead`s breast cancer drug Trodelvy,118100380,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cd9d9ae88d4c25a441eba00e0c17784391bfcc92a6676a5480fa71fb66ebc497
company,2023-01-03 03:52:00,"Gilead Teams with EVOQ on Lupus, Rheumatoid Arthritis Treatment",118127728,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Dean Seal Gilead Sciences Inc. and EVOQ Therapeutics Inc. said Tuesday that they are teaming up to advance the latter company's proprietary technology for...,https://finnhub.io/api/news?id=061d1d046ec1909935ca9e349d2b15a592fd0e40b3d7d0c760fb9f1e5384f4d2
company,2023-01-03 03:31:00,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Intra-Cellular Therapies (ITCI),118100381,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=26b53bb81ca5b9dee7ae4787d5d8846ba7cd1e7f2046ed4f9e74af8dadcd81ed
company,2023-01-03 02:50:00,"Gilead to license technology from EVOQ to develop RA, lupus immunotherapies",118100384,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bfc75c08bb4f46444245053edf64c35e7bf5e33431f0602fce1c24d6ea826f76
company,2023-01-03 02:44:00,EVOQ to potentially receive $658.5M in Gilead collaboration on immunotherapies,118100385,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c69b193857ac184bca631f8ad3f7768ddef664afa5669a7f53b3f57fdd083634
company,2023-01-03 02:21:00,Gilead downgraded at RBC Capital Markets after recent rally,118100386,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1471081146a118991ebe817e1f89aa7a7b0acb838f262fe07a4cf9d8ba1806e7
company,2023-01-03 00:23:00,"RBC downgrades Gilead, says drivers need time to play out",118100387,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5bfb5b17eb74828a90bc92915ddf3c3816e9dc7960ac9faba1f7c8b30dc1d6d7
company,2023-01-02 23:15:00,Gilead downgraded to Sector Perform from Outperform at RBC Capital,118100388,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d3f65e5e6485a45fb138d3055d16e91b7ca654c40162eaf93899ec0a4c9275b2
company,2023-01-10 11:56:00,Gilead Sciences Inc. stock outperforms market on strong trading day,118218384,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rallied 2.40% to $87.14 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=a3a862e1d0c63fc99716f835d655fc98c0503402d66164ed6b2283689849f2ab
company,2023-01-09 11:56:00,"Gilead Sciences Inc. stock falls Monday, underperforms market",118218385,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 3.38% to $85.10 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=a88e4dabe10cf39e87ea50e0c0ad39c3cef81d93635114f023da84b9afff0b31
company,2023-01-13 13:44:51,2023 Market Preview: Value Should Continue To Lead,118250466,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344940351/image_1344940351.jpg?io=getty-c-w750,GILD,SeekingAlpha,The market's history after negative years is usually positive. What we expect to work in 2023: Industrials and consumer staples. Click for our market preview.,https://finnhub.io/api/news?id=ed6dadfd041d01fcf204e271214fd54344dadd1258e3f4c673c485e48e407d40
company,2023-01-12 11:56:00,"Gilead Sciences Inc. stock falls Thursday, underperforms market",118218381,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 1.69% to $85.72 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=27378b92418cc33b15e87a5fd1243111c9cf66190c8f915f5f8fbe4937c34d0e
company,2023-01-12 09:00:00,Meet Gilead’s COVID-19 Virus Variants Hunters,118215669,https://s.yimg.com/ny/api/res/1.2/b0CZVpo7pVoH2vUvF7C1Tw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://media.zenfs.com/en/accesswire.ca/79a9ec50fe669a7e3610663285b7f054,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / January 12, 2023 / Gilead Sciences Every time a serious new COVID-19 virus variant emerges, Gilead virologists Charlotte Hedskog and John Bilello, alongside their teams, mobilize as so-called ""variant hunters."" Their ...",https://finnhub.io/api/news?id=56a278a39347e6d10e7c800c667090a46234649bd64f2493aaff696eed856e92
company,2023-01-12 04:39:56,IBB: A History Of Outperformance During Recessions,118202247,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1354171890/image_1354171890.jpg?io=getty-c-w750,GILD,SeekingAlpha,iShares Biotechnology has outperformed the S&P 500 during all 3 recessions in the U.S. since inception in early 2001. See why I'm bullish about IBB ETF now.,https://finnhub.io/api/news?id=51425a6aa3e767d662d77e31f174f1780fac56c748fa207e446de56f107023b7
company,2023-01-11 23:00:00,Moat Stocks Outperformed In Volatile 2022,118199703,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1369104225/image_1369104225.jpg?io=getty-c-w750,GILD,SeekingAlpha,U.S. equity markets ended 2022 on a down note in December as the typical year-end Santa Rally failed to materialize. Find out read more.,https://finnhub.io/api/news?id=21e3402aa1f998c7555ccb4df2bdc4b38e49357b217c0637b647e9b67d640c18
company,2023-01-11 17:50:10,Gilead Sciences (GILD) Gains But Lags Market: What You Should Know,118215670,https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4,GILD,Yahoo,"In the latest trading session, Gilead Sciences (GILD) closed at $87.19, marking a +0.06% move from the previous day.",https://finnhub.io/api/news?id=3c7eabd80ad7d8879d6d1afd77539d4d1b43a30815a034f727e9ea68019dccc3
company,2023-01-11 14:17:55,FDRR: Designed For Inflation And Still Unconvincing,118195947,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414784871/image_1414784871.jpg?io=getty-c-w750,GILD,SeekingAlpha,Fidelity Dividend ETF for Rising Rates ETF invests in dividend stocks that should profit from rising rates. Here's a rundown on FDRR and whether it is right for you.,https://finnhub.io/api/news?id=ea1388b540e607278586062403205be9eebe03ade9b7268303a0dfb4dd83002b
company,2023-01-11 11:56:00,"Gilead Sciences Inc. stock rises Wednesday, still underperforms market",118218382,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.06% higher to $87.19 Wednesday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=67800ab7cda8c3bfaa63a7aa64006034ed968a9d1018114fa617ef9ac8fdf258
company,2023-01-11 10:08:07,Top Dividend Stock: Gilead Sciences Nears Buy Point Ahead of Earnings,118215673,,GILD,Yahoo,This biotech superstar is in the spotlight as it nears a buy point amid continued stability and a growing dividend.,https://finnhub.io/api/news?id=0770a5ea3db7f74cdb0745124a3e0adb1bb5e3a8273737c2559b72f4716ffa27
company,2023-01-11 08:45:00,2 Unstoppable Stocks That Could Beat the Market Again In 2023,118205013,https://s.yimg.com/ny/api/res/1.2/3yRshmmmW1B8HJqoKumrYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/cdf3ed8f5ceaa40fe56f1cbcf1b21c50,GILD,Yahoo,"Biotech giant Gilead Sciences (NASDAQ: GILD) and payment technology specialist Visa (NYSE: V) were among them.  Gilead Sciences ended 2022 on a positive note.  On Dec. 22, the drugmaker announced that the U.S. Food and Drug Administration (FDA) had approved Sunlenca, a long-acting HIV treatment option.",https://finnhub.io/api/news?id=9474bfd33a3f08c6655c2aad254d5d5d5b3c4337252d75c9d3b14177759a9846
company,2023-01-11 07:34:48,Ranking The 10 Largest Biotechs By Pipeline,118194522,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153436387/image_1153436387.jpg?io=getty-c-w750,GILD,SeekingAlpha,"The pipeline is the heart of all drug discovery companies, leading to all growth in the future. Here we rank biotechs by pipeline, click to see the list.",https://finnhub.io/api/news?id=32dc11f2a46a529f7c54d43a690b9fed88795676b63d86e10b9ff57ba95fd9bd
company,2023-01-18 10:44:41,"Gilead plans 175,000-square-foot research center in Foster City",118312104,,GILD,Yahoo,"The structure, on the south side of Gilead's campus, will house 300 to 350 people and could open in late 2026.",https://finnhub.io/api/news?id=b613ff6db68b3897b6a7b1b1c27f0ea8412c53bddfe0efbb7b3b9b007f2001dc
company,2023-01-18 08:58:00,7 Cheap But Risky Biotech Stocks,118504178,https://images.barrons.com/im-705520/social,GILD,MarketWatch,"Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.",https://finnhub.io/api/news?id=ef0a006f0f97ebc7dd1157c0c5e0106433b179ad63a8229341661bd8b729e6f4
company,2023-01-18 06:35:00,3 Stocks That Beat the S&P During the Great Recession,118302548,https://s.yimg.com/ny/api/res/1.2/oXmO36gIK10ShSWuTszY8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/motleyfool.com/1eae1d9f4514d7cdfdc73195d0dccd7e,GILD,Yahoo,"Three stocks that outperformed the S&P 500 during the 2007-09 Great Recession were Gilead Sciences (NASDAQ: GILD), McDonald's (NYSE: MCD), and Walmart (NYSE: WMT).  Let's take a look at why these three stocks are recession resistant (including resistance to the effects of inflation), and why they make safe investments to hold in 2023.  Gilead Sciences is a top healthcare stock that is safer than most in a recession.",https://finnhub.io/api/news?id=451b8b4bb8984c5211b65909041d0d36b1f1f2b0af5967a92f860ed06f960b68
company,2023-01-18 02:48:00,Covid Isn’t Going Away. New Drugs Are Coming.,118300258,,GILD,Yahoo,Drug makers are preparing everything from a vaccine that comes as a pill to a better version of Paxlovid.,https://finnhub.io/api/news?id=dff92ab2ec395845c899a5a7835adb13488e020aedcafabe757f6c7c7f0b3c52
company,2023-01-17 17:50:10,Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know,118297708,https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2,GILD,Yahoo,"Gilead Sciences (GILD) closed at $85.41 in the latest trading session, marking a -1% move from the prior day.",https://finnhub.io/api/news?id=ee67f04583283b0a12511c9557e83912d49705d1988e74136e26a4db5a5e3fe0
company,2023-01-16 07:00:29,"With 82% ownership of the shares, Gilead Sciences, Inc. (NASDAQ:GILD) is heavily dominated by institutional owners",118280251,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the...",https://finnhub.io/api/news?id=03f758a9b0e6435dc7faacd5cba74485726fcaf014d5ab8708766af66427afb6
company,2023-01-15 10:00:11,25 Biggest California Companies and Stocks,118274312,https://media.zenfs.com/en/insidermonkey.com/eeed882247613dabcd00c9d73a545b37,GILD,Yahoo,"In this article, we will be taking a look at the 25 biggest California companies and stocks. To skip our detailed analysis, you can go directly to see the 5 Biggest California Companies and Stocks. California is not just the most populous state in the U.S. with over 39 million residents, but it is also […]",https://finnhub.io/api/news?id=c2bb039aa6279ae62acc2df46f7f97558306beadb1e201f9846e6d29915ad509
company,2023-01-22 15:58:46,Gilead Sciences: Potential To Continue Its Upward Trend,118346096,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"While Q3 results were not great, Gilead Sciences could beat expectations. See why the chances are high for GILD stock to continue its bullish upward trend.",https://finnhub.io/api/news?id=9c771ac37853b7dd1cfbb04909cc1e93e1a73ce03335c578991a52310a00d579
company,2023-01-22 15:48:28,Gilead Sciences: Finally A Breakthrough,118346098,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1221879711/image_1221879711.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Gilead's solid earnings report is accompanied by many regulatory approvals for various products. See why there is ample room for GILD shares to rise further.,https://finnhub.io/api/news?id=f03dd71dd1f0939382811bb85294ba7bc9d5f90fa6b55086491c7357700092b8
company,2023-01-21 06:55:00,3 Smart Stocks to Buy if a Recession Is on the Way,118340522,https://s.yimg.com/ny/api/res/1.2/iNJyMItTGopZ3nU9bdg1GQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04Nzg-/https://media.zenfs.com/en/motleyfool.com/77d5e9a25b406b743e731099805e43ae,GILD,Yahoo,"Here's why they picked Gilead Sciences (NASDAQ: GILD), Johnson & Johnson (NYSE: JNJ), and Vertex Pharmaceuticals (NASDAQ: VRTX).  David Jagielski (Gilead Sciences): Investors can minimize their risk in the event of a recession by investing in businesses that provide essential products and services and that also pay a dividend to help offset declines in the event of dropping share prices.  Gilead Sciences meets both of those criteria, as its HIV treatments are vital to patients.",https://finnhub.io/api/news?id=df03dde8d7f33132f5dc996d8f8dfd1d6945e4b3d4d3f8484104ab1dcf783452
company,2023-01-20 06:00:32,The total return for Gilead Sciences (NASDAQ:GILD) investors has risen faster than earnings growth over the last three years,118332731,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...",https://finnhub.io/api/news?id=1057cdeed7d63e75c95a09acf0df20cd120c8330171c3611074faf5a34d85c8b
company,2023-01-19 23:00:00,Price Negotiations Are About to Reshape the Drug Industry,118504177,https://images.barrons.com/im-706187/social,GILD,MarketWatch,A new U.S. law could push big pharma companies toward more diverse drug pipelines and away from an era of high-priced and complex medicines.,https://finnhub.io/api/news?id=5fd114eb336993e1ee4923c02ec8e231939e68a789cf7272ceddb227fb1fc606
company,2023-01-19 21:20:00,ClearBridge Sustainability Leaders Strategy Q4 2022 Portfolio Manager Commentary,118328358,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1337917194/image_1337917194.jpg?io=getty-c-w1536,GILD,SeekingAlpha,The ClearBridge Sustainability Leaders Strategy underperformed its Russell 3000 Index benchmark during the fourth quarter. Click here to read the full fund letter.,https://finnhub.io/api/news?id=0b90c262ad88a11de3136bd24fff7b9b03859b86742304f0b9bd2fa5b97846fa
company,2023-01-19 16:05:00,"Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023",118324708,https://media.zenfs.com/en/business-wire.com/67987a2c4a642151ed9e44d7c569e66c,GILD,Yahoo,"FOSTER CITY, Calif., January 19, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2022 financial results and full year 2023 financial guidance will be released on Thursday, February 2 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2022 financial results and provide a business update.",https://finnhub.io/api/news?id=d4c05627c3c85502bc3b5398a19f875b53fccdc339b8a2881b0dc7a67adbce85
company,2023-01-19 09:00:00,Decades-Long Effort to Enact Universal HIV Screening for Pregnant Women in Israel,118319259,https://s.yimg.com/ny/api/res/1.2/u0OAkyzyYy1d11u3wb3o8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://media.zenfs.com/en/accesswire.ca/48740c012efa5857a0b44b3a72608220,GILD,Yahoo,Dr. Hila Elinav burst into tears of joy when the Israeli Ministry of Health announced a sweeping new HIV screening policy for pregnant women in September.,https://finnhub.io/api/news?id=c104ee80739c2971bfc1b4140c5c5c0641ee817d890610205c7668aa436f6fe6
company,2023-01-26 17:45:10,Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know,118384462,https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781,GILD,Yahoo,"Gilead Sciences (GILD) closed the most recent trading day at $83.62, moving -0.54% from the previous trading session.",https://finnhub.io/api/news?id=f9a6e0bf7d013e9023ac0053345320f036f07b8596fc3e42acad7188295810b5
company,2023-01-26 10:01:03,Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?,118384463,https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba,GILD,Yahoo,Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=f7158ad9db9ffdeeba92b107399306e68f1b4404840a0456e44a3eaa3cc289d2
company,2023-01-26 08:55:00,Could Gilead Sciences Stock Help You Become a Millionaire?,118384464,https://s.yimg.com/ny/api/res/1.2/rGVXLDcrMdZinkvr1chvPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/47ae0c6da2e4f9465c5a47fcaf018d22,GILD,Yahoo,"Consider investing in stocks that have both attractive growth opportunities and that pay an above-average dividend.  Before the end of last year, Gilead Sciences investors received some great news: The company's twice-yearly injectable treatment for HIV obtained approval from the Food and Drug Administration.  With the approval, Gilead has added a potential blockbuster to its portfolio as analysts project Sunlenca could hit a peak of $1.5 billion in annual revenue.",https://finnhub.io/api/news?id=bbdf96353bb021988ef3df3a1510c058acd86caae9d6ec1bed9f46001fec08a2
company,2023-01-26 08:29:42,Gilead Sciences (GILD) Presents at the J.P. Morgan 41st Annual Healthcare Conference - Slideshow,118378463,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"The following slide deck was published by Gilead Sciences, Inc.",https://finnhub.io/api/news?id=a35c0ff426a314dd493cb5cd7a6f86748aa694b85ef0dd81ac60cc92ddd89426
company,2023-01-26 05:30:00,Companies Fight Back Against Premium Increases for Crucial Insurance,118384465,https://s.yimg.com/ny/api/res/1.2/SDVlQb_iKraL4LNxGGSBew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/315501ff8188028c47ccae1501380bbf,GILD,Yahoo,"Insurance rates are up for cars, homes and commercial property.  Insurers have raised premiums by 100% or more in recent years as demand for so-called directors and officers policies surged due to a wave of newly public companies and mounting lawsuits with large payouts.  Insurance that protects directors and officers when they are sued is essential for businesses.",https://finnhub.io/api/news?id=78fec0c80143d0a0563de451b99b1914bcb501dd6130543657ee4a4bc087093d
company,2023-01-24 17:50:10,Gilead Sciences (GILD) Gains As Market Dips: What You Should Know,118369928,https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619,GILD,Yahoo,"Gilead Sciences (GILD) closed the most recent trading day at $84.02, moving +0.95% from the previous trading session.",https://finnhub.io/api/news?id=a6510c99624a84cbddfe1ce073746c240080049d039a30e47c2692e4e9d19c2e
company,2023-01-24 13:53:06,Gilead (GILD) to Report Q4 Earnings: What's in the Cards?,118369930,https://media.zenfs.com/en/zacks.com/1e03bd5371d946db7dcb5dd132cfe169,GILD,Yahoo,Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2022 results.,https://finnhub.io/api/news?id=a2db1298285c4a77a7220e45cdfaaab4d19b61c9c0ab304c74131a45b064df67
company,2023-01-24 07:00:22,"Gilead Sciences, Inc. (NASDAQ:GILD) Delivered A Weaker ROE Than Its Industry",118369931,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",https://finnhub.io/api/news?id=ef7bb96e0c0f4f02d9e53b4e9b87087a9da9d56e05a85fd98310dd1f9f52a71b
company,2023-01-24 01:00:00,Gilead Sciences: What To Do Ahead Of Q4 2022 Financial Report,118354820,https://media.gettyimages.com/id/1370591144/ru/%D1%84%D0%BE%D1%82%D0%BE/%D0%B2%D1%80%D0%B0%D1%87-%D0%BF%D0%BE-%D0%B2%D1%8B%D0%B7%D0%BE%D0%B2%D1%83-%D0%BD%D0%B0-%D0%B4%D0%BE%D0%BC-%D0%BF%D1%80%D0%BE%D0%B2%D0%BE%D0%B4%D1%8F%D1%89%D0%B8%D0%B9-%D0%BC%D0%B5%D0%B4%D0%B8%D1%86%D0%B8%D0%BD%D1%81%D0%BA%D0%BE%D0%B5-%D0%BE%D0%B1%D1%81%D0%BB%D0%B5%D0%B4%D0%BE%D0%B2%D0%B0%D0%BD%D0%B8%D0%B5.jpg?b=1&s=170667a&w=0&k=20&c=bLDSBIJMQhtTqVDgVXFsk-3L1AsooxcZUwJrZiP6cxQ=,GILD,SeekingAlpha,"As a leader in various therapeutic areas, Gilead Sciences' total revenue was $7,042 million in Q3 2022, up 12.5% QoQ. Read why I rate GILD stock a Sell.",https://finnhub.io/api/news?id=943c8763e21600a0d681d0ab70274594365989427764a1facb0306a266e92e94
company,2023-01-23 19:45:31,Gilead Sciences May Still Be Lowballing Q4 Guidance,118354176,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1221948883/image_1221948883.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Gilead Sciences is overdependent on their HIV franchise, but sales are still increasing. See why we are bullish on GILD stock at the current price.",https://finnhub.io/api/news?id=4308df247543bf7c43ad607ae1168f8baf953332fe15ad70d4333b23d434ebce
company,2023-01-23 11:40:04,GILD or GMAB: Which Is the Better Value Stock Right Now?,118349717,https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1,GILD,Yahoo,GILD vs. GMAB: Which Stock Is the Better Value Option?,https://finnhub.io/api/news?id=e54ec4bfe488fc804a8b1ebe790562fd43fde5b35f15eb7e46ce209f9cd89cc2
company,2023-01-23 10:20:03,Gilead (GILD) Gains 21% in a Year: Will the Trend Continue?,118349719,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,Biotech giant Gilead (GILD) gains 21% in the past 12 months as its core HIV business maintains momentum despite volatility.,https://finnhub.io/api/news?id=7afff301c9e6180d4c268f71996fea586146187fb14923d2b673767d6229caab
company,2023-01-23 05:02:02,Healthcare Outlook 2023,118347941,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345347757/image_1345347757.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. Read more here.",https://finnhub.io/api/news?id=901fdf5f20709c0abeea555b7f59a1eaa98eed8a4b5ad266ce3d68b4334a0ed4
company,2023-01-23 00:33:19,Gilead Added To Our 2023 Model Portfolio (Technical Analysis),118347267,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1221879709/image_1221879709.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Gilead is a low beta stock and portfolio managers have to be in these stocks during a bear market. Find out why I'm bullish on GILD stock.,https://finnhub.io/api/news?id=3022a643f40d4e6b7c514b67d17d230b5cf0f99adec537620dc34dc544a9a2ae
company,2023-01-22 22:51:12,Gilead Looks Fully Valued For 2023,118346992,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1221879711/image_1221879711.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Gilead ended up delivering impressive returns for shareholders in 2022, although these gains only manifested fairly late in the year. Click here to find out why GILD stock is a Hold.",https://finnhub.io/api/news?id=688d5cd2b2871e7f09d8c7f499007e5182ac7ce6cba7ff0f715d5a1ca44e53a5
company,2023-01-30 12:10:05,Why Gilead (GILD) is Poised to Beat Earnings Estimates Again,118404173,https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee,GILD,Yahoo,Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://finnhub.io/api/news?id=06d2646f134e1dc027c07870cdf0c541bbe2b155e3180af668e26e5c082d4026
company,2023-01-30 09:00:00,Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma,118400138,https://media.zenfs.com/en/business-wire.com/e786f0a2b98be345aefd433f29647cd3,GILD,Yahoo,"SANTA MONICA, Calif. & REDWOOD CITY, Calif., January 30, 2023--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, sa",https://finnhub.io/api/news?id=05146f86e2c775de54cc21e0d8eae4b644843e112ad21604a970bff128a39ca1
company,2023-01-27 16:05:00,Gilead Sciences to Present at Upcoming Investor Conferences,118384461,https://media.zenfs.com/en/business-wire.com/4455c91f7bb0926619d6dbf47bd0bf45,GILD,Yahoo,"FOSTER CITY, Calif., January 27, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",https://finnhub.io/api/news?id=13a8d9ef5c1ac265b7199186b7c6e281201a2684ec36fe444eb3919f7b455cde
company,2023-01-27 10:30:41,Tango Therapeutics: Upcoming Proof Of Concept Data Is A Major Catalyst,118383732,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Tango Therapeutics' SPAC entry to the market and Gilead deal has put a large dollar figure besides its name. Click here for a major catalyst for TNGX stock.,https://finnhub.io/api/news?id=5ca9ce4184e6186bf37f970810e981345716c5d2eb7558c990a21a415e9ff522
company,2023-02-03 16:16:09,Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology,118467564,https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071,GILD,Yahoo,Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.,https://finnhub.io/api/news?id=df87dba1c06692a7c4173d2d10efd851e0939e8003ffb8da87340064f2b3ba08
company,2023-02-03 16:01:45,Gilead Snags Another Cancer Win On The Heels Of Its Best Growth In 7 Years,118475275,https://media.zenfs.com/en/ibd.com/42ec1eee4c32ef9fd681c92c689f33f4,GILD,Yahoo,"Gilead Sciences followed up a strong quarterly report with a third FDA approval for cancer drug Trodelvy, and GILD stock popped.",https://finnhub.io/api/news?id=72a9177de22c335ecccb4cae8fbf1924b59d33de35b2c3db73bd22ebbe6af962
company,2023-02-03 15:57:16,"Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2022 Earnings Call Transcript",118475276,https://media.zenfs.com/en/insidermonkey.com/d7c533f57fc7f3b50b241a030dcb0de4,GILD,Yahoo,"Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2022 Earnings Call Transcript February 2, 2023 Operator: Good afternoon. Thank you for attending today’s Fourth Quarter and Full Year 2022 Gilead Sciences Earnings Conference Call. My name is Henna, and I will be your moderator for today’s call. I would now like to pass the conference over to our […]",https://finnhub.io/api/news?id=afbec97dfbcbf53306562f3c2d4714a64c951eeceecb5f081aaba5d448e389ed
company,2023-02-03 13:34:26,Gilead's breast cancer drug gets U.S. FDA approval for third indication,118470151,https://static.reuters.com/resources/r/?m=02&d=20230203&t=2&i=1622386464&r=LYNXMPEJ120NY,GILD,Reuters,"Gilead Sciences said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option for patients with the most common type of breast cancer.",https://finnhub.io/api/news?id=784514b0192a80d87178dc346b850a854d56f1b89022f9457b343c3ac8ce0ca1
company,2023-02-03 12:54:22,Gilead Sciences' Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting,118475277,https://media.zenfs.com/en/Benzinga/e352b3db34f1f7a3f2ef1d1ed13cb7ac,GILD,Yahoo,"The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for adult patients with advanced or metastatic breast cancer. The approval covers unresectable locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The approval is based on statistically significant and clinically meani",https://finnhub.io/api/news?id=e035e1246339604a27eedffcb973dfc7476d1a1f2c2c228f354ec055a2b99b7f
company,2023-02-03 12:51:26,"Dan O'Day delivers clear Gilead message: stability, sustainability",118475278,https://s.yimg.com/ny/api/res/1.2/ywCjBSMsrUM4wufXYbnLRw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bizjournals.com/328ce928c4ccd604e569eb73640e8c36,GILD,Yahoo,"Through acquisitions and organic research, the HIV and cancer drug developer is in a better position than it was three years ago, its chairman and CEO says.",https://finnhub.io/api/news?id=15c4d03aa2e517ac8760ded5296e9eedbbca285c3af45a1dd8a89067c372a0ef
company,2023-02-03 12:46:19,15 Best Dividend Leaders to Buy According to Hedge Funds,118461274,https://media.zenfs.com/en/insidermonkey.com/394d78a96196c831f8a051078ee598ea,GILD,Yahoo,"In this article, we discuss 15 best dividend leaders to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Dividend Leaders to Buy According to Hedge Funds. First Trust Morningstar Dividend Leaders Index Fund (NYSE:FDL) is based on the 100 highest yielding stocks that have […]",https://finnhub.io/api/news?id=d2b79f7b23e1772a16887378a364eb72c4f31b616c609be469812926983d42a0
company,2023-02-03 11:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,118504169,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 3.82% to $84.50 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=61e7cc6401970e2f909e77fa4c76aea4b2e2167101ce9b0b69fefde7b95d089e
company,2023-02-03 11:38:03,Gilead's breast cancer drug secures U.S. FDA approval for expanded use,118451957,https://static.reuters.com/resources/r/?m=02&d=20230203&t=2&i=1622375818&r=LYNXMPEJ120NY,GILD,Reuters,"Gilead Sciences Inc said on Friday the U.S. Food and Drug Administration had greenlighted expanded use of Trodelvy to treat the most common type of breast cancer, marking the third approval for the drug.",https://finnhub.io/api/news?id=2a1154679fe25bcbece2ab852382e93128722eeec2e6803ad02579eafc5fdc8c
company,2023-02-03 10:50:15,UPDATE 3-Gilead's breast cancer drug gets U.S. FDA approval for third indication,118475280,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"Gilead Sciences said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option for patients with the most common type of breast cancer.  The drug was approved for an advanced form of breast cancer with a subtype known as HR-positive/HER2-negative in patients, who had stopped responding to a hormone-based therapy and at least two earlier systemic therapies.  Gilead's Trodelvy will likely face competition from AstraZeneca-Daiichi Sankyo's Enhertu, which is approved to treat breast cancer patients with HER2-low type, a subset of HER2-negative breast cancer.",https://finnhub.io/api/news?id=097d75488caa2e5c61781613fda6c638a333868fd2644ec00007b4c29761143a
company,2023-02-03 10:35:43,U.S. FDA approves expanded use of Gilead's breast cancer drug ,118451959,,GILD,Reuters,"The U.S. Food and Drug Administration on Friday granted approval for expanded use of Gilead Sciences Inc's cancer drug, Trodelvy, the company said. (Reporting by Raghav Mahobe and Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli)",https://finnhub.io/api/news?id=0b02b7ab45350fc0e7948dfd81a030f19123c55a5320506c9f6425a632d0f93b
company,2023-02-03 10:29:00,U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer,118475281,https://media.zenfs.com/en/business-wire.com/9d05c0234afb8356fa40e03e9cb4d3c8,GILD,Yahoo,"FOSTER CITY, Calif., February 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in",https://finnhub.io/api/news?id=0a57ac98c62739f8ef5cb6b521dc65753f8acf15f7bcd0ce6d13604d8fb012bc
company,2023-02-03 05:51:00,Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?,118475282,https://s.yimg.com/ny/api/res/1.2/tMzKU2l.jQYemIMEo0J53Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/0db103a188f8d9a4170cd8eda63f5f4f,GILD,Yahoo,"Despite a slower start this year, Gilead appears to be in pretty good shape to resume its momentum.  CEO Dan O'Day stated in the press release announcing the numbers, ""2022 marked Gilead's strongest full-year growth in our base business since HCV sales peaked in 2015.""  Is Gilead Sciences stock a buy after its strongest results in seven years?",https://finnhub.io/api/news?id=0ad93e6a173525bbdeedbc0dfa14e1c2093de0574b1a7836fbf7ce6f3c6eb5bb
company,2023-02-03 04:26:09,Gilead (GILD) Reports Q4 Earnings: What Key Metrics Have to Say,118475283,https://media.zenfs.com/en/zacks.com/d09a586ae00ecb333775f9766ec152a7,GILD,Yahoo,"Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",https://finnhub.io/api/news?id=23a751427683fab2175055c5684d0620d90ef9f37c9de8df01f8b35bf03043d4
company,2023-02-03 02:30:00,"S&P 500 Futures Fall in Premarket Trading; Bill.com Holdings, Atlassian Lag",118482279,https://s.wsj.net/public/resources/MWimages/MW-HA919_barron_NS_20181226134502.png,GILD,MarketWatch,"With U.S. stock markets set to open in two hours, (BYD) was up 5.8% in pre-market trading, and (FLR) was up 4.5%. (CLX), (GILD), and (BEP) were all posting...",https://finnhub.io/api/news?id=d6d1a10f0c98f9229a529d583e5b8fbdd8941c9e3f2e6d67302e29bbc6f3d2a2
company,2023-02-02 21:00:23,Gilead Sciences (GILD) Q4 2022 Earnings Call Transcript,118475284,https://media.zenfs.com/en/motleyfool.com/ce68ea0b0cd2631701fe87e542e7a165,GILD,Yahoo,"Thank you for attending today's fourth quarter and full year 2022 Gilead Sciences earnings conference call.  Just after market closed today, we issued a press release with earnings results for the fourth quarter and full year 2022.  The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson.",https://finnhub.io/api/news?id=964f7bb093808b158d43d9f6a502212d5d971b81ee45709dc903a46d6beb42bf
company,2023-02-02 18:05:22,Gilead profit beats Street expectations on COVID and HIV sales,118441892,https://static.reuters.com/resources/r/?m=02&d=20230202&t=2&i=1622248464&r=LYNXMPEJ110ZF,GILD,Reuters,"Gilead Sciences Inc on Thursday reported a higher-than-expected fourth-quarter profit driven by strong demand for its HIV and cancer drugs, while COVID-19 antiviral Veklury had sales that were double Wall Street estimates.",https://finnhub.io/api/news?id=de6715dd5d2fe0f91477cf50c3b94937f7dd647e097ceefa64076d1e7209ba3d
company,2023-02-02 17:35:10,Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates,118475285,https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83,GILD,Yahoo,"Gilead (GILD) delivered earnings and revenue surprises of 11.33% and 12.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",https://finnhub.io/api/news?id=625388e9cc6b6eba9fb011d9d87aedc11ccb34547746afdb9e92f24af360de06
company,2023-02-02 17:14:00,"Gilead stock jumps 5% after Q4 beat, dividend increase",118475286,https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,GILD,Yahoo,"Shares of Gilead Sciences Inc.  (GILD)  rose more than 5% in the extended session Thursday after the pharma company reported fourth-quarter earnings and sales above Wall Street expectations, saying higher sales elsewhere took the sting of falling revenue for its COVID-19 drug.  Gilead earned $1.6 billion, or $1.30 a share, compared with $376 million, or 30 cents a share, in the year-ago period in 2021.",https://finnhub.io/api/news?id=2abafa4c173033919b93c0cde4671a8385662de2b929a85deea912943e8ad7ca
company,2023-02-02 17:04:05,"Gilead Sciences, Inc. (GILD) Q4 2022 Earnings Call Transcript",118445673,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q4 2022 Earnings Conference Call February 2, 2023 4:30 PM ETCompany ParticipantsJacquie Ross - VP, IRDaniel O'Day - Chairman and CEOJohanna...",https://finnhub.io/api/news?id=1f0d1f1fe05b1760cbbd270ef21641095dfedeb4555054698f54f66b6404e25d
company,2023-02-02 16:55:56,"Gilead Sciences, Inc. 2022 Q4 - Results - Earnings Call Presentation",118445493,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"The following slide deck was published by Gilead Sciences, Inc.",https://finnhub.io/api/news?id=bb11392a88268aa0eb5ef9d0ff1d352d2175f0190e2166aa2ed2f95028d11fdf
company,2023-02-02 16:05:00,Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend,118475287,https://media.zenfs.com/en/business-wire.com/0eb781e4719b772d023a9fc28e8ef0e2,GILD,Yahoo,"FOSTER CITY, Calif., February 02, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2023. The increase will result in a quarterly dividend of $0.75 per share of common stock. The dividend is payable on March 30, 2023, to stockholders of record at the close of business on March 15, 2023. Future dividends will be subject to Board approval.",https://finnhub.io/api/news?id=75450d1222d6da10704f02d99cde792f801de34588639361af31510895e94f30
company,2023-02-02 16:01:00,Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results,118475288,https://media.zenfs.com/en/business-wire.com/ecf06cf8fc63b718bbeabc0f0e756849,GILD,Yahoo,"FOSTER CITY, Calif., February 02, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2022.",https://finnhub.io/api/news?id=a3605e43166667219a31552327264eca681ee84098cb3fe5fdc8c3522b5a9801
company,2023-02-02 12:24:55,"Stocks making the biggest moves after hours: Apple, Amazon, Ford and more",118472061,https://image.cnbcfm.com/api/v1/image/107174930-1672984092100-gettyimages-1243947448-APPLE_iPhone_14_Series_Price_Reduction.jpeg?v=1675376695&w=1920&h=1080,GILD,CNBC,"Several major U.S. companies reported disappointing results for their latest quarters, including a decline in sales for Apple. ",https://finnhub.io/api/news?id=90d45e19f70ae06c29c4234bc1f932a8e9456598bd3baf299a60e3c5be71473c
company,2023-02-02 11:56:00,Gilead Sciences Inc. stock underperforms Thursday when compared to competitors,118504172,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 3.11% to $81.39 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=d250545aae10576f5568d00f8dd895ff8e89494dcbf8c9b268769c1923b44d98
company,2023-02-02 11:16:00,"Gilead Sciences 4Q Profit Surges on Oncology, HIV Sales",118504173,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,"By Denny Jacob Gilead Sciences Inc. posted a surge in profit in the latest quarter, as sales grew 2% based on higher sales in oncology and HIV coupled with...",https://finnhub.io/api/news?id=2e08561c284f953be83834319b9306848cd4cf89b8a754c19969a18da290ba09
company,2023-02-02 09:00:00,Gilead Sciences: Toward Health Equity for Black People Impacted by TNBC,118475289,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / February 2, 2023 / Gilead Sciences Originally Published by Gilead Sciences Racism and the impact of social determinants of health drive disparities in outcomes for Black women impacted by triple-negative breast cancer ...",https://finnhub.io/api/news?id=4c6456c2de1b1f8ee181fe9217003334d2d0230ec6f647c156598cc952286fb6
company,2023-02-01 11:56:00,"Gilead Sciences Inc. stock rises Wednesday, still underperforms market",118504175,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.07% higher to $84.00 Wednesday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=b43b613f123d2ff3a6a114c2f1fe7b982f94cdfa3707a6968a720feb0ec9132a
company,2023-02-01 10:44:03,"Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others",118441510,https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0,GILD,Yahoo,Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.,https://finnhub.io/api/news?id=d2f12eabbeae275a0e46f8adae785c804fb9915f2a95ea8b5ecdbe66f40e8f0c
company,2023-02-01 10:16:19,Top 25 Smartest Companies To Buy According To Hedge Funds,118418136,https://media.zenfs.com/en/insidermonkey.com/f2be6cdaebf0756384c85c09099e48f8,GILD,Yahoo,"In this piece, we will take a look at the top 25 smartest companies to buy according to hedge funds. For more companies, head on over to Top 5 Smartest Companies To Buy According To Hedge Funds. Surviving in the modern day corporate world is not for the faint of heart. Business is a ruthless […]",https://finnhub.io/api/news?id=46eeda16f64ea23e7da6ee1cab9c199cd87637a58ca42ea239a84953f98bc78a
company,2023-02-01 09:00:02,How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings,118472454,https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2,GILD,Yahoo,Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.,https://finnhub.io/api/news?id=5bffec9dfba78f4047921eecea32868aec97e03e1ae93e8f30d66b709b73a030
company,2023-02-01 08:35:00,Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer,118475293,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"FOSTER CITY, Calif., February 01, 2023--Gilead awards $7.6 million in grants to 24 U.S.-based organizations through the newly created Toward Health Equity Oncology Grant(TM).",https://finnhub.io/api/news?id=d1722520dc645f0058a2b497a062f48e12b890477eabdcbeed1fa136629ee8f0
company,2023-02-07 11:56:00,"Gilead Sciences Inc. stock falls Tuesday, underperforms market",118504165,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. sank 0.36% to $86.05 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=456253f53ee1edf851035c285384fc7eee5f3764b54108832ca12483c299e9b7
company,2023-02-07 05:19:46,Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75,118510330,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Gilead Sciences, Inc. ( NASDAQ:GILD ) will increase its dividend on the 30th of March to $0.75, which is 2.7% higher...",https://finnhub.io/api/news?id=1392a31d801b4dfa3fd67ebff0e123b08912f38695b763dce36d1fa38f7e4fec
company,2023-02-06 13:27:06,Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod,118485756,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,"Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult patients.",https://finnhub.io/api/news?id=754b000f708aca31cac7281dec529e478deec200f030cbb5564d7e266a5de3aa
company,2023-02-06 11:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,118504167,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rallied 2.20% to $86.36 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=bcbc2bceafa01884c1cae1dc4edc486ac14cb89acd2d01f416c9c245ae58ba9e
company,2023-02-06 05:41:00,Is Gilead Sciences a Good Stock to Buy Now?,118485757,https://s.yimg.com/ny/api/res/1.2/ZWi4D7nrL8C4RzPwW0Zl4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/44e767033d17495edf995b8683a98e4d,GILD,Yahoo,"Shares of Gilead Sciences (NASDAQ: GILD) marched higher on Thursday, Feb. 2 in response to a fourth-quarter earnings report that exceeded expectations.  A day later, the U.S. Food and Drug Administration (FDA) agreed to dramatically increase the addressable patient population for an important cancer drug called Trodelvy.  Gilead Sciences splashed out with a $21 billion acquisition of Immunomedics in 2020 for access to Trodelvy.",https://finnhub.io/api/news?id=a646ec7921dbf11fabf4a7e2bf4fd53019bfbb2a671d3bd4b92464a992008732
company,2023-02-04 22:21:13,"Dividend Champion, Contender, And Challenger Highlights: Week Of February 5",118473163,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Dividend Champions list is monthly compilation of companies that consistently increased annual dividend payouts. Check out the full report of the week of February 5.,https://finnhub.io/api/news?id=71f39ee737aa96084d4099b9ea26844e20bfcfd67fbf06a0be1ec1e31d48b767
company,2023-02-03 22:00:00,Gilead Sciences and 9 More Companies That Boosted Their Dividends This Week,118504168,https://images.barrons.com/im-714912/social,GILD,MarketWatch,"Old Dominion Freight Line, which handles freight shipping logistics, said it will raise its quarterly dividend by 33% to 40 cents from 30 cents.",https://finnhub.io/api/news?id=889328dbf910b3443462eabea1566b81a9b413a43c071172327dd2cd27be8ed3
company,2023-02-11 02:07:14,"Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating",118549367,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/674781548/image_674781548.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Read more here.",https://finnhub.io/api/news?id=b3272c564e99047e0095081416463db109a5c87898e6e1d690da574e55ba3aa8
company,2023-02-11 01:11:00,"Galapagos: Crohn`s Disease Trial Failure, Still Maintaining A Buy Rating",118708209,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=610d18d639fb479985283e8827f2a864abd3da717f56182891cd6031ec56388d
company,2023-02-10 11:03:04,Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy,118525775,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.,https://finnhub.io/api/news?id=be935f0997ddbc7446158d19f592c9fe9201a678b5f182eea7eb0177bab97d80
company,2023-02-10 01:38:00,Gilead price target raised to $95 from $90 at Cowen,118708210,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ac3b7c90aea26d523664506f5e1d4a4350f695d56ecc35adf8eeac4c52b815f1
company,2023-02-10 01:18:00,Medicare mulls rebates in 2025 for drug prices rising faster than inflation,118610760,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0ab3a739858e7a584faafc6d4765cafa54aa69e80a46b5edb6c754d67b219bca
company,2023-02-09 22:57:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,118708212,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=48e2975c7788a311d636a1d2e11c40f93194b9d2f838bb85fcedfdf8f9dec7e7
company,2023-02-09 12:17:32,Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings,118524984,https://media.zenfs.com/en/Benzinga/cbdc06988018f23017190a0775e62bfd,GILD,Yahoo,"Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel). The analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), with a consistent safety profile observed since the two-year analysis. In the Phase 2 treated patient cohort (n=55",https://finnhub.io/api/news?id=eaaee0837dac3d93c0c5e672349a3dcec2572269fb78ff6ce46767c6b8397dae
company,2023-02-09 12:00:05,"Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update",118524985,https://media.zenfs.com/en/zacks.com/8b33b42379a93cd496db139197a8738b,GILD,Yahoo,"Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.",https://finnhub.io/api/news?id=6f32190c405c2d087d26beb33f95ab22380bb04413faf756db2fa5a0eac1cdae
company,2023-02-09 08:00:00,2 Biotech Stocks That Could Make You Richer,118524986,,GILD,Yahoo,The biotech industry is a great place to look for such companies.  Let's look at two biotech stocks that could help make investors richer in the years ahead: Gilead Sciences (NASDAQ: GILD) and CRISPR Therapeutics (NASDAQ: CRSP).  Gilead Sciences is a biotech giant famous for its leadership in the market for HIV drugs.,https://finnhub.io/api/news?id=c0be8a9c594eb52acf409bd93493c3153fe36bad8a7d0d4b6574b1e8e1068210
company,2023-02-09 07:15:00,Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia,118524987,https://media.zenfs.com/en/business-wire.com/0c928af851d655d1b543748969f5bfd6,GILD,Yahoo,"SANTA MONICA, Calif., February 09, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel). Results from the analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with a consistent safety profile observed since the two-year analys",https://finnhub.io/api/news?id=aa6263b660bb2664df3b55ddd893f2b09487664a998470f834fdc32a60db19e7
company,2023-02-09 06:38:00,IN BRIEF: Gilead Sciences reports positive follow-up for Tecartus,118708213,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f6da598555dc9cea735a2f0181e58c0cd28a5f4fcf233c142cdfa2857f3f7414
company,2023-02-09 05:04:00,Gilead`s Tecartus shows long-term overall survival in type of lymphoma,118708214,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b61b2c75ab16107fadac42008186129d7230fe784ccd7e6dc7937d965d325edf
company,2023-02-09 02:59:00,Moat Stocks Take Early Lead In 2023,118602246,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cae6b5fabdea22f62c189a94706142f5c7f7f910b7169908409c39ca03f59609
company,2023-02-08 23:49:00,"Thoughts For Thursday: Risk-Off, Risk-On",118618125,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=33db5e62259be79743b1ccb479e8e471f396b46e26b71ed106d7e9a322d0b815
company,2023-02-08 22:57:00,Gilead Sciences Inc. stock outperforms market despite losses on the day,118708220,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ebeef4cbfaecce1b97d52f2454286f26624529e7eb9464fdfd77ff7f3c77caea
company,2023-02-08 21:01:00,"Goodman Financial CORP Buys 2, Sells 3 in 4th Quarter",118658969,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c75321b93ad82aa1d669eebabb1181e7117b5c0177c1df86b42ac2dfc1235192
company,2023-02-08 08:30:00,Gilead Sciences: 4 Questions With See Phan: Discovering New Therapies in Breast Cancer,118510328,https://s.yimg.com/ny/api/res/1.2/771NWU3RgWsPhc6y9uKquQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://media.zenfs.com/en/accesswire.ca/dc9d1c466258f86dc9ca330ba43dab7e,GILD,Yahoo,"As a practicing physician and cancer researcher for more than 20 years, See Phan is all too familiar with the need for innovative new treatment options, especially for breast cancer.",https://finnhub.io/api/news?id=0ce6a46160badc3e3dbef8f810897f9a31b07c912da1f3cf509c5961bca65dae
company,2023-02-08 06:15:00,NeurAxis: Should You Buy This IPO?,118618135,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=28a264cb9678472c0a4f6982d4e0a625d2b21e39069ca2a07fa63ffb5906e777
company,2023-02-08 05:01:00,"Oak Asset Management, LLC Buys 2, Sells 3 in 4th Quarter",118632808,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d0cfa99a7775ec50e7d41a2d47a7b62edb02af9e48903f795c5a2d17895d49e3
company,2023-02-08 05:01:00,Top 5 4th Quarter Trades of ICICI Prudential Asset Management Co Ltd,118603270,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=87bb115dc30764c8548328515eed424014891736ac314134f89dbfa81702cfb7
company,2023-02-08 03:00:00,Top 5 4th Quarter Trades of COZAD ASSET MANAGEMENT INC,118593371,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d10ada596f5a4a1351bea1026566f5840b4cf362f6d205a66e3e8f797a031c7b
company,2023-02-08 01:17:00,Why Gilead Sciences is a Top 25 Dividend Giant (GILD),118708230,,GILD,ETF Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=372fe94bb7451350bb1e0e9b5a88c5c2c1014b370e9a30868e9693db1265022e
company,2023-02-15 11:56:00,Gilead Sciences Inc. stock outperforms competitors despite losses on the day,118672724,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 0.74% to $85.05 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=962facc7d34cda7c1f76d5bd1b21b28381f29d39c88a597315d1ccea4bf1935f
company,2023-02-15 11:30:00,4 Questions With Flavius Martin: Enhancing Innovation by Expanding Gilead’s Research Footprint,118597664,https://s.yimg.com/ny/api/res/1.2/Tg9JeHjSdYGTqfHaqMycTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://media.zenfs.com/en/accesswire.ca/f3db2155a218543eb2c0376e4cef3627,GILD,Yahoo,"Innovation is at the core of Gilead's 35-year history of life-changing medicines. Through bold and transformative science, Gilead has developed therapies that have brought about a cure for hepatitis C, helped to transform the treatment and prevention of HIV and provided breakthrough therapies for people with cancer.",https://finnhub.io/api/news?id=f022b09089f6793b622e8a001ed6edfb42b08b705476b1caf87bb2fe2f1340b3
company,2023-02-15 07:17:00,Medicare mulls limiting per month costs for generic drugs at $2,118610732,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a6b8cf78b81c3f51b5cac2b71fed1624ea3f23eefc552053e92dbe9a40e5d870
company,2023-02-15 05:30:00,4 Questions With Flavius Martin: Enhancing Innovation by Expanding Gilead`s Research Footprint,118708190,,GILD,Accesswire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5cfa7ae09bbfc59fcd7fe1a446ede0799402ecef29973b218ad6d538d332ae3f
company,2023-02-14 21:01:00,Top 5 4th Quarter Trades of Avalon Investment & Advisory,118680742,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f2251fd31bde066a76504c433b07201e281148e7018a95d9e9ad8f4bebc169c6
company,2023-02-14 11:56:00,"Gilead Sciences Inc. stock falls Tuesday, underperforms market",118672727,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 2.07% to $85.68 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=e329eba9f167fe7965a9c9a16a817e8a4d95d4c507214c7c85e720fa0914eb0a
company,2023-02-14 08:45:00,Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023,118597665,https://media.zenfs.com/en/business-wire.com/b38ad980cea116f537bd72b016702d56,GILD,Yahoo,"FOSTER CITY, Calif., February 14, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new clinical and real-world data from the company’s HIV, COVID-19 and viral hepatitis research and development programs at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) from February 19-22. Seventy abstracts, including late-breaking data, demonstrate Gilead’s continued expertise and leadership in virology with a commitment to advance the next wave of",https://finnhub.io/api/news?id=5551ecb56bf7c6ff6fd3c4ce33e967ce73ee4be909184a3687e3d14e4ac2b69e
company,2023-02-14 05:01:00,"John Rogers Buys 3, Sells 2 in 4th Quarter",118651995,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bf2cabf800d70b1f70153b901a11a326c97f0466379659e7e0634b74c085ce8f
company,2023-02-14 01:01:00,"Caxton Associates Buys 4, Sells 1 in 4th Quarter",118676960,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=edd009bc22c5329274a4807de5f1c9c6bd537117104e235e1e364d81285c2044
company,2023-02-14 00:36:00,Gilead price target raised to $101 from $88 at Mizuho,118708196,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9bdf5e8d1c34cbfdae1fe436efac61ae66ecba819a8044be566c1b7124a37e9f
company,2023-02-13 21:42:00,"Gilead Sciences, Inc. (GILD) SVB Securities Global Biopharma Conference (Transcript)",118708198,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5fc96ead6eb7a60bfac8e1bda38e7d4afdc34d020347b827a3ae90d9d45585aa
company,2023-02-13 11:56:00,"Gilead Sciences Inc. stock rises Monday, still underperforms market",118672729,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.91% higher to $87.49 Monday, on what proved to be an all-around positive trading session for the stock market, with...",https://finnhub.io/api/news?id=93671d6bd78f6510eb5a7d8186ccd90d24fd54dea51f44fb313a7254b35286dc
company,2023-02-13 04:59:00,"Wainwright initiates Arcellx with a buy on CAR-T pipeline, partnership with Gilead`s Kite",118617382,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c822a1647959dab1608bb38f93fadb6421f50c7ccd802cecd8b574d0265a5eee
company,2023-02-13 04:05:00,Mizuho Securities Sticks to Its Buy Rating for Gilead Sciences (GILD),118685529,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b19d1571414a09485ce050d0834285287f9f33548d1dc0bd48046d6d8608925a
company,2023-02-12 23:39:00,Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers,118592318,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=10f08388234bf361f3f17cd986888c2f377c7bf59f6e899a840fb4850b3dd7c3
company,2023-02-12 23:34:00,Large Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers,118592319,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e6051668d3b39c62d477e1c3305e73c31b5437fed8ea9d8961632f332b36e4da
company,2023-02-12 23:10:00,Guild Esports extends Fortnite contracts with two professional players,118708203,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a179e2c67c33e31c867a823f2a93470ac898dee51dead7ca9ae1466ce6e2c76a
company,2023-02-12 20:53:00,ARK Invest: The 7 Words That Explain Why Wall Street Can`t Stand Cathie Wood,118605873,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e88856163950f64ea175b7ac9baf270496aecf35a5e97f930f6994f22f0f20ed
company,2023-02-12 06:04:00,COVID-19 emergency is ending; What it means for free vaccines and drugs,118615493,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8e60b642168bd1f95d2ef204a88809eb62589ef6fd0ef4ba6e4467b9f21ac176
company,2023-02-11 23:01:00,"GLOBEFLEX CAPITAL L P Buys 4, Sells 1 in 4th Quarter",118620370,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b6ac97b2b5039f70691dab071738ef3310d5656802b78152faf16b997e33e81f
company,2023-02-11 23:01:00,"Top 5 4th Quarter Trades of KLCM Advisors, Inc.",118652004,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=00f7510fcc81c80ad2537249dd13f061a2186ac90de2f150312f9887d321b0c2
company,2023-02-17 11:56:00,Gilead Sciences Inc. stock outperforms market on strong trading day,118672720,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. advanced 1.64% to $84.76 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",https://finnhub.io/api/news?id=dcbf66363b6019cf6aa439b14e784801c40ff81afd3a4f4959feed7af8a12000
company,2023-02-17 09:30:00,Mobile Clinics Expand Access to Cancer Screenings in the U.S. South,118664569,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"Sharneitha Bradford spends her days helping people access cancer diagnostic care, a role she embraces as a nurse navigator.",https://finnhub.io/api/news?id=b202ca586cd540dbac2357ea0a4835f204d464f7a3345d3be4aebfd5c1b4765f
company,2023-02-17 09:00:00,"Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer",118664571,https://media.zenfs.com/en/business-wire.com/a4cd019e94a151a20d39eaf6cdd4c103,GILD,Yahoo,"FOSTER CITY, Calif., February 17, 2023--Trodelvy Demonstrates Positive Efficacy in Metastatic Urothelial Cancer",https://finnhub.io/api/news?id=722e631f8e649347dd6aab41a3102cac9ffb25fd491fca711011aa90c3e2cd1a
company,2023-02-17 05:01:00,"AQR CAPITAL MANAGEMENT LLC Buys 3, Sells 2 in 4th Quarter",118651971,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a875c050884d2a4646a8693a7bbf2aaa7c04653b5f9d52d982c985de8dd7450f
company,2023-02-17 03:50:00,Kite CEO Christi Shaw leaving Gilead at end of March,118708179,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b1eb8e5fc27fe5cc378da6f5de4067537233bc3291a386cc302f8453d9d7e4db
company,2023-02-17 03:45:00,Gilead updates Phase 2 data for bladder cancer therapy Trodelvy,118689799,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d41ec8905b4aa2288f0eeee3763236035e6671b1a6a8138669af11f1863c9ea6
company,2023-02-17 03:27:00,Gilead announces updated results from three cohorts of TROPHY-U-01 study,118708182,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a015241efcf04826aba16c2195dc250731418c1b09265cd975baf071baa5ad5a
company,2023-02-17 03:01:00,"VALUEWORKS LLC Buys 1, Sells 4 in 4th Quarter",118634525,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1590ed031b940c22d88eb89ea42fd2f4fa0e8112b272bea4b87f605caa18709c
company,2023-02-17 01:01:00,Top 5 4th Quarter Trades of HealthInvest Partners AB,118656230,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=730695cb23be1b86a892ad3db585cdb8d10a2767729098dd5b9513d0c85b5036
company,2023-02-16 11:56:00,"Gilead Sciences Inc. stock falls Thursday, underperforms market",118672723,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.95% to $83.39 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=080f3e491c8012819b46480989a7a533e1b17745f6fc2fa940ec9a9901fc265a
company,2023-02-16 03:30:00,Elliott Wave Technical Analysis: Gilead Inc.,118708186,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=39515a09bf49f7efa6e522e3f31fa565a1ad5d89f783d97210eac5279e86a5a5
company,2023-02-15 21:01:00,"Top 5 4th Quarter Trades of Nan Shan Life Insurance Co., Ltd.",118708188,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c1f4d97ae754c412fa3cfe78c3aaac2618c6e1bf087833578961396f854f018e
company,2023-02-23 16:26:12,"Cambridge biotech Jounce to cut staff, merge with U.K. drug developer",118875583,https://media.zenfs.com/en/bizjournals.com/625537cf3614e3e277660ed4334199c3,GILD,Yahoo,"A Cambridge-based cancer company and longtime partner of pharma giant Gilead Sciences Inc. is merging with another firm, one day after announcing it would lay off most of its staff.",https://finnhub.io/api/news?id=de737565fcc9624414cf67b751ba472c538a6bc552c87183853e4185bf999ceb
company,2023-02-23 11:56:00,"Gilead Sciences Inc. stock falls Thursday, underperforms market",118916750,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 1.15% to $82.54 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=aa51a47e0be248f564fa9c07e6f7b0ab446f32c2576a96aecbb25b2c18ae48d6
company,2023-02-23 10:30:00,Gilead Sciences: Black HIV/AIDS Awareness Day,118875584,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / February 23, 2023 / Gilead Sciences: This Black HIV/AIDS Awareness Day, we recognize the major strides made to combat the disproportionate impact of HIV on Black communities - but there is more work to do. Learn ...",https://finnhub.io/api/news?id=f327d841d663ec0d7a9dd865724a21c8b0cda539ec0f579957b7be6c681856a4
company,2023-02-22 14:14:03,Lightning Round: Stay long Berkshire Hathaway,118841483,https://image.cnbcfm.com/api/v1/image/107198532-1677110912MM-Block-E-022223.jpg?v=1677111243&w=1920&h=1080,GILD,CNBC,"Mad Money host Jim Cramer takes questions on specific stocks, including Berkshire Hathaway, VF Corp., Tesla, Teva Pharmaceuticals McKesson Corp., Equinix, Gilead Sciences and EQT Corp.",https://finnhub.io/api/news?id=73b95b31a8f52b8d35a047c601075efae7e4ea7251f6052aa65533b2df70c6e3
company,2023-02-22 11:56:00,"Gilead Sciences Inc. stock falls Wednesday, underperforms market",118839977,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.35% to $83.50 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=bd31bf489e47418d1bb12b5794047f37584514c5aed3130f467e2791fd5561f6
company,2023-02-22 11:37:26,Gilead Sciences Touts Encouraging Data From Real World Studies Of Its Flagship COVID-19 Treatment,118831362,https://media.zenfs.com/en/Benzinga/72984ec2893397f99132a0c87221a3b9,GILD,Yahoo,"Gilead Sciences Inc (NASDAQ: GILD) announced data from three retrospective real-world Veklury (remdesivir) studies for COVID-19 treatment. The studies demonstrated that initiating Veklury within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity. A reduction in mortality was also observed in vulnerable populations. Related: WHO Recommends Gilead's COVID-19 Therapy For Seve",https://finnhub.io/api/news?id=89a8e01d049ad3a97770b698ff5edbfbe05dfd44acb3e1bc7671e4d2614f22f2
company,2023-02-22 11:21:00,Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV,118831364,https://media.zenfs.com/en/business-wire.com/5437631bb968a9d7c70392fcd9ed9058,GILD,Yahoo,"FOSTER CITY, Calif., February 22, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data evaluating lenacapavir in combination with broadly neutralizing antibodies (bNAbs) teropavimab and zinlirvimab as a potential long-acting treatment regimen with twice-yearly dosing. Results from the Phase 1b clinical trial demonstrated the investigational combination was generally well tolerated with high efficacy in select virologically suppressed participants living with HIV. These data were prese",https://finnhub.io/api/news?id=22e3dc8aae13aa5d87ced29f561865d29c56bfe0b0694c1e55f3c77300b89040
company,2023-02-22 11:12:00,IN BRIEF: Gilead hails results of study for Covid-19 drug Veklury,118836703,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5045c24ba93dfbecdef82b1309517dbb05ccd539a79286e1387320e8063a4589
company,2023-02-22 11:08:30,GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill,118830484,https://static.reuters.com/resources/r/?m=02&d=20230222&t=2&i=1624383063&r=LYNXMPEJ1L0NC,GILD,Reuters,"British drugmaker GSK's HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc.",https://finnhub.io/api/news?id=440e372297dc1e7a90bbef11cbab0e43f145c1581fb0e4862b8da9e56af44f4a
company,2023-02-22 09:00:00,Kite Completes Acquisition of Tmunity,118831367,https://media.zenfs.com/en/business-wire.com/ed75b2867402ff4b6921454866ca1606,GILD,Yahoo,"SANTA MONICA, Calif., February 22, 2023--Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.",https://finnhub.io/api/news?id=96c624ff5ef4c55679237d4dd3db20d69bc4d2b23248a84e781bd8f45911ee1c
company,2023-02-22 06:10:00,Gilead posts Phase 1 data to support twice yearly potential of HIV therapy,118836706,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=51da14247cd737dd9e558d02b7adc92aa2543b7c67996827dc1ecbdb4056067c
company,2023-02-22 05:41:00,GSK`s long-acting HIV med Cabenuva equals Gilead`s daily Biktarvy,118836708,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c831914693d6227f4fbc46c6654d8a58cbd1de3ba1ab91a411679ef2fdf1729f
company,2023-02-22 05:24:00,"Gilead presents PoC data for investigational combination of lenacapavir, bNAbs",118836709,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1047483474dee3e2cb6b4345ef01d63531e346b3a7f7b7ba35174a64b1325232
company,2023-02-22 00:35:00,Mizuho Securities Sticks to Its Buy Rating for Gilead Sciences (GILD),118867191,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=99b876b68ac5c604f9b993c4b749d73a5acbd391d0e527b4e101774d3f93cf33
company,2023-02-21 22:55:00,"John Rogers` Firm Enters Carlyle Group Stake, Powers Up Generac Position",118836714,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=164e279f9a08c23b7b38c9b8ceb919bad24233e6adb20f6b8596941095cd2083
company,2023-02-21 20:55:00,S&P 500 Q4 2022 Earnings Review: Swing And A Miss,118825601,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344606317/image_1344606317.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"As we exit the peak period of earnings season, we review the S&P 500 2022 Q4 earnings season in more detail, providing both aggregate and company level insights.",https://finnhub.io/api/news?id=c0cc35ed6fc6b2811990a0cd0ba5145d057da04899d6f9ca1648db5ddf162852
company,2023-02-21 17:46:00,"Gilead says its COVID-19 drug can help reduce deaths, shorten hospital stays",118831369,https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,GILD,Yahoo,"MARKET PULSE Gilead Sciences Inc. (GILD) said Tuesday that its COVID-19 drug can help reduce deaths and readmission rates among patients hospitalized with COVID-19 and who received the drug, remdesivir, shortly after their hospital admission.",https://finnhub.io/api/news?id=0d3f7fc3fd5499f6b602ae5c01f1ec345b3d9a7f72a4572af6c4d190c6476be5
company,2023-02-21 17:30:00,"Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients",118831370,https://media.zenfs.com/en/business-wire.com/4ba0e98229d2577f0ceef23e8535bc26,GILD,Yahoo,"FOSTER CITY, Calif., February 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive data from three retrospective real-world studies which demonstrated that initiation of Veklury® (remdesivir) within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity. A reduction in mortality was also observed in vulnerable populations, such as people living with cancer o",https://finnhub.io/api/news?id=7f2ec9be1bbc1b347b9bcb5d85af62a576a0bef73ae947edcc86f0252b121ea9
company,2023-02-21 15:01:00,Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies,118831372,https://media.zenfs.com/en/business-wire.com/cc4c6ddfe2787b60a9fbbac3270b1a54,GILD,Yahoo,"FOSTER CITY, Calif., February 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from four collaborative studies evaluating novel investigational combinations and strategies with the potential to target the HIV viral reservoir or enhance immune response to maintain virologic control in the absence of antiretroviral therapy (ART). These latest findings represent an ongoing multi-pronged approach in Gilead’s HIV cure research program. The data were presented at the Conference o",https://finnhub.io/api/news?id=2d6bc83fda6073b1720d9f4b3835e2edf3f620a6c3b86589abeddf8461e616e0
company,2023-02-21 11:56:00,Gilead Sciences Inc. stock outperforms market despite losses on the day,118839980,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 0.14% to $84.64 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=9b35257a6c0aba8966baa9da16c7c35d70e4c866d957e59221df4e3d16c48fa2
company,2023-02-21 09:25:00,Gilead Listed on the 2023 Bloomberg Gender-Equality Index,118789104,https://media.zenfs.com/en/accesswire.ca/298be2f41ff97573acfa47883e8c00a9,GILD,Yahoo,Gilead's been listed on the 2023 Bloomberg Gender-Equality Index for our support of women's empowerment.,https://finnhub.io/api/news?id=2b1a49bba119c21ca66623b835b12d1aaee2b951be9cbbb8394a0ec631326d1d
company,2023-02-21 05:22:20,Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75,118789105,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Gilead Sciences, Inc. ( NASDAQ:GILD ) has announced that it will be increasing its dividend from last year's comparable...",https://finnhub.io/api/news?id=cd6494f204610a73d58bd54aa2f2817f1c2bbc02d3734d99ddb9e78639fcd342
company,2023-02-20 23:32:00,Gilead reports `positive data` from real-world studies of Veklury,118836723,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=69d862b558d03d34cc11655f16e2335ed1089a13bff8480a2a3763905116e0c2
company,2023-02-20 21:03:00,Gilead says new data from four collaborative HIV studies reported at CROI,118836726,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=10e4c0379f20ab9de49fe91fff0e7d3fb0c00aed412b4a762f5dd7cd161a45f6
company,2023-02-20 11:53:04,Gilead (GILD) Reports Positive Data From Urothelial Cancer Study,118753000,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.,https://finnhub.io/api/news?id=9f95fcc65c8b20543968fb28d1d7c982e542603ff1cc9d1badd24f5cf914765a
company,2023-02-20 10:34:56,25 Most Profitable NASDAQ Stocks Today,118735034,https://media.zenfs.com/en/insidermonkey.com/539c1476c92038449b5d6db89592cd32,GILD,Yahoo,"In this article, we will look at the 25 most profitable NASDAQ stocks today. If you want to explore similar stocks, you can also take a look at 10 Most Profitable NASDAQ Stocks Today. 2022 was one of the worst years for the NASDAQ, primarily because it is dominated by tech, and tech stocks crashed as […]",https://finnhub.io/api/news?id=46c243eb27931c44e28ce6ab9a4ea19be96b4014088a839ceb0bbb603c881906
company,2023-02-20 10:17:22,Billionaire Ken Griffin’s Top 10 High Dividend Stock Picks,118738626,https://media.zenfs.com/en/insidermonkey.com/5e10b7d436d0889c610b18e545065be2,GILD,Yahoo,"In this article, we discuss billionaire Ken Griffin’s top 10 high-dividend stock picks. You can skip our detailed analysis of Ken Griffin’s investment strategy, and go directly to read Billionaire Ken Griffin’s Top 5 High Dividend Stock Picks. Ken Griffin’s Citadel Investment Group is one of the 15 Biggest Hedge Funds in the World by […]",https://finnhub.io/api/news?id=077763d692e2ffd30d3bee598bfdb12a2391026e16f7663ce0e2b1c2063f148c
company,2023-02-27 16:11:57,Top 10 Drug Companies in USA and Their China Reliance,118956096,https://s.yimg.com/ny/api/res/1.2/vHK7nPQRMeCWZZgibmLvSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/insidermonkey.com/e064e59836b880f2abe5ba1c0fce3a66,GILD,Yahoo,"In this article, we will be taking a look at the top 10 drug companies in USA and their China reliance. To skip our detailed analysis of the pharmaceutical sector, you can go directly to see the Top 5 Drug Companies in USA and Their China Reliance. The US has long been reliant on China […]",https://finnhub.io/api/news?id=86958b0c5a58ac9101f66221457a58bbb2e1acac6ce275e356e019d479d123aa
company,2023-02-27 11:56:00,"Gilead Sciences Inc. stock rises Monday, still underperforms market",118957053,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.29% higher to $80.89 Monday, on what proved to be an all-around favorable trading session for the stock market, with...",https://finnhub.io/api/news?id=9d404992933428dcc1505ee86674248014b4d8d3822b8aa5c84a28558f523d1f
company,2023-02-27 05:53:00,UK shareholder meetings calendar - next 7 days,118948414,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=896e83d7649c04adbf58b772cce08d2cb5ba44fdac4e31ae116f51f296f56f67
company,2023-02-26 14:12:53,7 Cash-Rich Companies to Invest in During Economic Uncertainty,118998917,https://media.zenfs.com/en/investorplace_417/e3157a3f4c17ef0827ab1ebcbffa8929,GILD,Yahoo,"While it’s generally good to be optimistic, in the market, it also pays to be realistic, thus incentivizing consideration for cash-rich stocks to buy. Here, we’re not necessarily talking about the most exciting ventures available. Rather, we’re targeting enterprises that have plenty of green-colored paper in the bank. This way, these cash-imbued entities can weather whatever storms might break out. At the same time, it doesn’t make too much sense to have plenty of cash if you’re also waist-deep",https://finnhub.io/api/news?id=a0628d7e18c9a80987e93a3b28e6c1b8c88972c9b60ba31b013197d07979452b
company,2023-02-26 13:49:22,Here's What David Siegel's Two Sigma Hedge Fund Loaded Up On to Close Out 2022,118941269,,GILD,Fintel,,https://finnhub.io/api/news?id=1a14697e34f9c938d40401d3b0e2763327f3d96715404077ee2f685e6abe9ffc
company,2023-02-26 09:00:28,"The one-year decline in earnings for Gilead Sciences NASDAQ:GILD) isn't encouraging, but shareholders are still up 38% over that period",118939411,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right...,https://finnhub.io/api/news?id=f43936697db1593b5da55231acfaf73560a51e189630d13b8eb489120119ff53
company,2023-02-25 06:25:00,3 Stocks to Buy Right Now That Are Cash Cows,118926132,https://s.yimg.com/ny/api/res/1.2/CLyHUyNF29gSySsuwPig_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/03bc61dcb9632c1fff4868badc266ade,GILD,Yahoo,"With this in mind, three Motley Fool contributors were asked to pick stocks to buy right now that are cash cows.  Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Vertex Pharmaceuticals (NASDAQ: VRTX).  Prosper Junior Bakiny (AbbVie): There are many ways in which a company can be deemed a ""cash cow.""",https://finnhub.io/api/news?id=270c6552e4335281db7b9a734822244f30569f3dc2db76d1106d921de007ea00
company,2023-02-25 04:07:10,Regeneron: Innovation And Disruption Done Right,118926893,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1370480661/image_1370480661.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Regeneron Pharmaceuticals' collaborative energy is strong and the medium-term looks good. Check out why we rate REGN stock a Hold for now.,https://finnhub.io/api/news?id=a0537f0792321a4426cd98a5b6e3902631dc380c93824d6f0fe41d50d6e21c46
company,2023-02-24 11:56:00,Gilead Sciences Inc. stock underperforms Friday when compared to competitors,118916747,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 2.28% to $80.66 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=9b8903c2a0a4cf1c3e5c23d9ca76eba14ef8a7aa736b04ca50cd7e4b75e524d6
company,2023-02-24 11:40:00,"WHO panel is reviewing whether COVID vaccines need updating, as agency monitors 7 omicron subvariants",118910094,https://s.yimg.com/ny/api/res/1.2/.s4iB8Q7nwx7gqRwsPJU6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/marketwatch.com/feb4a09890a4ec776af41ed10878a0d3,GILD,Yahoo,"Most of the week's COVID news is focused on vaccines, including the big slide in Moderna's revenue caused by falling demand.",https://finnhub.io/api/news?id=83b7d536c9d44399d935dd12d7efb213db204da80c6a1056c4853da33f338f8b
company,2023-02-24 06:40:00,WHO panel is reviewing whether COVID vaccines need to be updated ,118899172,https://images.mktw.net/im-731459/social,GILD,DowJones,"Most of the week's COVID news is focused on vaccines, including the big slide in Moderna's revenue caused by falling demand.",https://finnhub.io/api/news?id=af045eb0e47ade301fe9245de671f6f828875e5ea7fddc36f36ef1e4bda046fa
company,2023-03-03 17:45:10,Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know,119061557,https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209,GILD,Yahoo,"Gilead Sciences (GILD) closed the most recent trading day at $81.07, moving +1.82% from the previous trading session.",https://finnhub.io/api/news?id=7b8d9c1d84752c01ac4693d7c8b5d7ccae0d1ff790c054a1cee71c54a9c510f0
company,2023-03-03 11:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,119048140,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 1.82% to $81.07 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=36d8ac96aab3345e6a18f6df58de087a6d5c6dd2a199d6f76af505a61ea57915
company,2023-03-03 02:10:00,"Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Veru (VERU) and Gilead Sciences (GILD)",119053007,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=45818f6986352f9d5eaab05717d3988696b89e1af7905b0b6e6d8db09889ad4b
company,2023-03-02 11:56:00,"Gilead Sciences Inc. stock rises Thursday, still underperforms market",119048141,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.04% higher to $79.62 Thursday, on what proved to be an all-around great trading session for the stock market, with...",https://finnhub.io/api/news?id=09f63ba89d1ec5264bec9a320967a70915effbc34c02650467d79692685d3bd4
company,2023-03-02 10:25:00,Gilead Foundation Donating $1 Million for Relief Efforts in Türkiye and Syria,119024999,https://media.zenfs.com/en/accesswire.ca/b0f5629df72aa174187575592b6b8184,GILD,Yahoo,"As a way to support those impacted by Monday's devastating earthquake in Türkiye and Syria, the Gilead Foundation is donating $1 million for on-the-ground relief efforts.",https://finnhub.io/api/news?id=d9c616c61ca83e6400229e66338b7ac9cc3c1f663db4b0938390b1c9f0c7be37
company,2023-03-02 06:00:42,"How Did Gilead Sciences, Inc.'s (NASDAQ:GILD) 22% ROE Fare Against The Industry?",119025000,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...,https://finnhub.io/api/news?id=f78e38b7df16b6a8d70d9f848ff51c26533e01d07d371e60b3b747506cd47dd9
company,2023-03-02 05:47:00,UK shareholder meetings calendar - next 7 days,119018799,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cbf481f43e127d6799469a9c6479921f46e7643fa0d8e9c082bbe279aae2b2cb
company,2023-03-02 05:34:00,Interesting GILD Put And Call Options For April 14th,119053010,,GILD,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=16956c71baa84de6638dbe4045a8ca41ad7863969b9a0994d2fcc9253d2f704a
company,2023-03-02 04:25:00,Gilead Foundation Donating $1 Million for Relief Efforts in T��rkiye and Syria,119053011,,GILD,Accesswire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=648137ab8478c97f2fa85cb199ef8d434079c66defc20084dfd06a7dcf0cae10
company,2023-03-01 11:56:00,Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors,119009526,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.17% to $79.59 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",https://finnhub.io/api/news?id=d0fe87d91187f959c4890dc7e99a3df03288aef0a00ebf81bad7a077573d2345
company,2023-03-01 08:17:03,Gilead: Good 3.7%+ Yield But More Growth Required,118996343,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1221879708/image_1221879708.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Gilead punches above its weight with its very attractive 3.7%+ dividend yield. Read to know if GILD stock can get back to its dividend growth rate.,https://finnhub.io/api/news?id=0a237b3cc63e3a4be920bb8f1dcf33a178a33a08af0ccd0abfe821dce6be230a
company,2023-02-28 11:58:00,Gilead Sciences Inc. stock outperforms competitors despite losses on the day,119009527,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 0.45% to $80.53 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=468f5ae557dee15ac3bd62bb939c12712ac387fb739d5492bb7b0c29c2b22f0c
company,2023-02-28 09:30:00,Honoring the History and Impact of the Aids Memorial Quilt,118974331,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,The San Francisco-based AIDS Memorial Quilt is the world's largest living memorial project.,https://finnhub.io/api/news?id=6a2c14b69e3c028218ad948f9b11e582b4fb1d85e2b76ef4abd266331c9fe462
company,2023-02-27 19:30:00,Moderna’s Covid Boom Is Ending. Why the Outlook Isn’t All Grim.,118972610,https://images.barrons.com/im-732633/social,GILD,MarketWatch,"Troubles that were put off during the biotech’s pandemic-era boom, notably various intellectual property wrinkles, are now coming home to roost.",https://finnhub.io/api/news?id=45ca6ca79b88efbde7fb9fb2e7f28765623ec67c4a8ee15fb1b49846056c291c
company,2023-03-07 11:56:00,"Gilead Sciences Inc. stock falls Tuesday, still outperforms market",119126851,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 1.02% to $80.28 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=0e43a79a1a42f3d7764e5096126d304c1bf259543b5ff635644cd89cc91837e4
company,2023-03-07 09:37:00,2 Healthcare Stocks That Could Help Set You Up for Life,119103924,https://s.yimg.com/ny/api/res/1.2/fCeQHF8DOMz39j505B9fqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/cf374b70e160ec9071c4fae3237e0c13,GILD,Yahoo,"Let's look at two stocks that can help you grow your wealth for decades: Gilead Sciences (NASDAQ: GILD) and Medtronic (NYSE: MDT).  Gilead Sciences is a major biotech company whose primary therapeutic area of focus is HIV.  The company has become a leader in this field thanks to products such as Biktarvy and Descovy, which are among the most-prescribed medicines in the HIV and HIV pre-exposure prophylaxis (PrEP) markets, respectively.",https://finnhub.io/api/news?id=57588b183bd44e65606755da25018080909cd516e1de73f55ee0d83626c045dd
company,2023-03-07 09:16:05,"Gilead Sciences, Inc. (GILD) Presents at Cowen 43rd Annual Healthcare Conference (Transcript)",119101372,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Cowen 43rd Annual Healthcare Conference March 7, 2023 11:10 AM ETCompany ParticipantsAndy Dickinson - Chief Financial OfficerConference Call...",https://finnhub.io/api/news?id=2d47acab3c98b6545246a8e36c42a8730d79fa5300dec3f02606e388cb067a5c
company,2023-03-07 04:15:00,My Dividend Stock Portfolio: New February Record - 99 Holdings With 32 Buys And 4 Sales,119099099,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Click here to read more about the dividend stocks.,https://finnhub.io/api/news?id=8d7ce14f74dea06ff3b2e25a9a8427cabcf1adaf41a501e4b098afb386afbcd7
company,2023-03-07 02:58:00,"Blue Star Capital swings to loss after fair valuation movements, costs",119110781,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=27f5177d725fe4957b18a2683ca5cade3e58dc085fd1eba2aa85d7da829ef972
company,2023-03-07 01:37:00,Biden to announce plan to keep Medicare solvent beyond 2050,119099835,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f2cde5b9d169fc7f9afbda045573f4bfbae3b62fa9fa0877e9d5ebf3b9936fe8
company,2023-03-06 11:56:00,"Gilead Sciences Inc. stock rises Monday, still underperforms market",119097053,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.05% higher to $81.11 Monday, on what proved to be an all-around favorable trading session for the stock market, with...",https://finnhub.io/api/news?id=57bfe93edb6c12ff1c2c389a03c4f93b19f6c969f2615960430aab2831fff49d
company,2023-03-06 07:35:00,Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading,119086631,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8b8302d6b1a7654c3b2ff6725677b6687c4c7322180b7eda4b335ed1ef243f2c
company,2023-03-06 07:29:27,What Contributed to Gilead Sciences (GILD)’s Outperformance in Q4?,119094504,https://media.zenfs.com/en/insidermonkey.com/d7b54ab6c172424f8eb29273c1277201,GILD,Yahoo,"ClearBridge Investments, an investment management company, released its “ClearBridge Sustainability Leaders Strategy” fourth 2022 investor letter. A copy of the same can be downloaded here. The strategy underperformed its benchmark, the Russell 3000 Index, in the fourth quarter. In the quarter, the strategy gained in eight of the ten sectors it invested in on an absolute […]",https://finnhub.io/api/news?id=cbdd536e1438a5b8727a3d5b080ecf7cba181ca863f787f81f7b21962dda888a
company,2023-03-06 05:31:00,"Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Gilead Sciences (GILD) and Surgery Partners (SGRY)",119086223,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5b6f432d2935cfc7e957dbf1084078081d18f9900cc884ce4f5a0e7fe1a2b7de
company,2023-03-05 22:11:42,What To Expect From Pfizer In The Post-COVID-19 Era,119080395,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1226994328/image_1226994328.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19.",https://finnhub.io/api/news?id=f0266308bf3d1ecfb85e06d98bccea73e8532b3ad94dcf2391f7bcda60a0a54e
company,2023-03-11 04:08:52,"Dividend Champion, Contender, And Challenger Highlights: Week Of March 12",119177303,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.",https://finnhub.io/api/news?id=909bbbc88adc0aa71b3e099195cfacb315165850893f190993a0ba12a25e5520
company,2023-03-10 11:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,119166587,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.70% higher to $79.50 Friday, on what proved to be an all-around grim trading session for the stock market, with the...",https://finnhub.io/api/news?id=578ac50be963fa33d7357048adcc3d6159a6228b8704d8276d70db73e6e54428
company,2023-03-10 04:14:00,"Ex-Dividend Reminder: Gilead Sciences, Atrion and CONMED",119178694,,GILD,Dividend Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=35171cd6fe962ce11a86c17f7a31b43ec10a700d44039bc819c9183fac9f1b2c
company,2023-03-10 03:46:53,"Assuming No-Growth, Gilead Is The Safest Choice Among The Large Biotechs",119157633,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499085898/image_499085898.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Gilead has a strong credit profile and a low cost of equity. Find out why for an investor seeking relative safety, GILD stock is worth a look.",https://finnhub.io/api/news?id=37f87166aa917c96d0c456343168b5c34998381bef44ce3a1ef676ec949fe4de
company,2023-03-09 17:45:10,Gilead Sciences (GILD) Stock Moves -1.55%: What You Should Know,119150263,https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781,GILD,Yahoo,"In the latest trading session, Gilead Sciences (GILD) closed at $78.96, marking a -1.55% move from the previous day.",https://finnhub.io/api/news?id=d689075bb4180e0104441a4ce14afcce524965346de200942e5c349bb5ce1889
company,2023-03-09 11:56:00,Gilead Sciences Inc. stock outperforms market despite losses on the day,119166588,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.56% to $78.95 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=44c5c549ebb0365bccad084d8c593cadfbbbcdf04e919536adf9f65e33c54475
company,2023-03-09 11:04:21,"37 Upcoming Dividend Increases, Including 2 Dividend Kings",119142970,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/942897276/image_942897276.jpg?io=getty-c-w1536,GILD,SeekingAlpha,All these stocks have at least 5 fiscal years of dividend growth history and come from the U.S. Dividend Champions List. Click here to see our exclusive list.,https://finnhub.io/api/news?id=4d686ebe1817e935f61c73e490a5c0e159a230bd95ecf15d0edcd8b49a8fb677
company,2023-03-09 09:00:52,Gilead Sciences: Underlying Growth Obscured By Veklury Swings,119140194,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Gilead Sciences, Inc. got very lucky with its Veklury anti-viral, as it proved very valuable in combatting Covid-19. Click here for more on GILD stock prospects.",https://finnhub.io/api/news?id=ea227e3c552ee5e3472effee71df0db6a199a8567c0b530e7e719e9309ce8ce7
company,2023-03-08 11:56:00,Gilead Sciences Inc. stock outperforms competitors despite losses on the day,119126850,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 0.10% to $80.20 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=59d202d486cce93258d4b79ba8b2d78c67541d54d13d06fa5518adaa2fb89a4f
company,2023-03-08 09:25:00,Gilead Sciences: Global Community Accountability Groups Pave Way Forward for Inclusive Clinical Trials,119123303,https://s.yimg.com/ny/api/res/1.2/5O9ZMI6HleiyhFZbAa3iwQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://media.zenfs.com/en/accesswire.ca/b251521ee061d1bfe92d18291a64d771,GILD,Yahoo,"Gilead Sciences (left to right) Bridget Ndagaano Jjuuko, Executive Director, ACTS 101 Uganda and Yvette Raphael, Executive Director, Advocacy for the Prevention of HIV/AIDS in South Africa.",https://finnhub.io/api/news?id=179c8629111d4d744bcb4d800f0cd9c5570e729682440f119c6768b0161fcf46
company,2023-03-08 09:00:18,"Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 50% Discount?",119123305,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,Key Insights The projected fair value for Gilead Sciences is US$159 based on 2 Stage Free Cash Flow to Equity Gilead...,https://finnhub.io/api/news?id=3d953655f60fea020c80d1aaeecff655c75eb20f176530d7e6bc02f7c0627d1a
company,2023-03-07 22:09:55,U.S. Wide-Moat Stocks On Sale - The March 2023 Heat Map,119105828,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912585074/image_912585074.jpg?io=getty-c-w1536,GILD,SeekingAlpha,We are only interested in those targets that are attractively valued in historical comparison. Click here for our 3-step process that focuses on wide-moat stocks.,https://finnhub.io/api/news?id=7022d378ea8cb95f1300fc45c61a80c9738b88402ddac47b5ff9f699e6e5d1f3
company,2023-03-15 15:38:58,Medicare identifies drug makers that will owe penalties for raising prices on 27 drugs faster than rate of inflation,119258876,https://s.yimg.com/ny/api/res/1.2/UgX6J8rHMvz_rV_Gvtw5wA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2023-01/d3fc0510-9c02-11ed-badc-48acde60085b,GILD,Yahoo,"The Biden administration is making good on promises to help lower drug costs, though the impact is largely for Medicare patients.",https://finnhub.io/api/news?id=f06592cb98f2b7572ca2baaf61e7a5b1db637a48831de9da3d2c3be2dd0cdce5
company,2023-03-15 12:56:00,Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors,119288970,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 0.15% to $79.65 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=ba79657dbfa104d921e52b5c135a0eba7322352b86983402eea50316db58d606
company,2023-03-15 12:50:00,First Drugs Facing Medicare Price Penalty Are Named,119258877,https://s.yimg.com/ny/api/res/1.2/WTUOZO3Oa5aqhtpv6vzKqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/bfd845ff459629a7469a075399b54bf8,GILD,Yahoo,"U.S. health officials listed 27 medications whose prices rose faster than inflation, triggering rebates under a new federal law.",https://finnhub.io/api/news?id=466c24767736460af65c90330187fb6958fe538a487728b1676652db86d601f7
company,2023-03-15 10:27:02,"Gilead Sciences, Inc. (GILD) Presents at Barclays 2023 Global Healthcare Conference (Transcript)",119254657,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Barclays 2023 Global Healthcare Conference March 15, 2023 10:00 AM ETCompany ParticipantsMerdad Parsey - Chief Medical OfficerConference Call...",https://finnhub.io/api/news?id=dd16deafca64fdf4a2e9a1af87fb3d1d0a25da17a190a83619786d44d4425a9d
company,2023-03-15 10:25:00,Stacey Bledsoe's Resolve To Make Clinical Trials Available to Everyone,119258878,https://s.yimg.com/ny/api/res/1.2/UYJuKfBJH_Sf3lgWpxYAXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://media.zenfs.com/en/accesswire.ca/0783f704d95a809c81c5584e254604fe,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / March 15, 2023 / Gilead Sciences Stacey Bledsoe's life took a personal and professional turn in 2015, when her father was diagnosed with lung cancer. A nurse by training, Stacey asked his oncologist whether she could ...",https://finnhub.io/api/news?id=9537170cad81d74af1f42277490572a286e446180d09c71fe9fa1bb01230594c
company,2023-03-15 06:37:00,The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector,119251784,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=859fe55302bf1e8c62a6c49ca81800a5404438c89f0b1f6d9cf12581d8f075e0
company,2023-03-15 05:29:00,Stacey Bledsoe`s Resolve To Make Clinical Trials Available to Everyone,119259499,,GILD,Accesswire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=81daed0ba1c22ec4c46bfd892de93db90628902ac27139d18078b0b825fb6d53
company,2023-03-15 04:11:00,"AbbVie, Gilead, Seagen among firms fined for raising prices faster than inflation",119254851,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=451819a0624e360d97f88a513a74e8ea3911cb91b49fe26dd58f4f1d155fcdc0
company,2023-03-14 12:56:00,"Gilead Sciences Inc. stock rises Tuesday, still underperforms market",119237953,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rallied 1.28% to $79.77 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=e3c6c0cf4a52dc5bb5d764ae85077e235a2a782e4e77ceed13f40a205e5f587d
company,2023-03-13 12:56:00,Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains,119221354,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.01% higher to $79.51 Monday, on what proved to be an all-around grim trading session for the stock market, with the...",https://finnhub.io/api/news?id=ecf203c6bb967080e801db704d2b6e648c88af68a68e5739bbb96ab005cc6bbe
company,2023-03-12 23:13:00,Arcellx initiated with a Buy at Stifel,119205251,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3fc742519ea71ee944f73e50a1f8b0c9507dff7703a357429bccb26692e49960
company,2023-03-12 09:00:36,"Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst institutional investors who own 84%",119190578,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...",https://finnhub.io/api/news?id=9510a9683b3c91aa87140a85ae62062fbb16e8fbfc424024c37777180d707329
company,2023-03-19 06:41:00,Nurix: Promising Early Data From This Protein Degrader Company,119303703,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7318bfd25ae12614229b0f250a3d97bfc71b8a7978e64a9207ad4ece7c9a322e
company,2023-03-17 12:56:00,Gilead Sciences Inc. stock underperforms Friday when compared to competitors,119299387,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 3.18% to $77.31 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=2c187acfe06e1446e4dac79845f2fc72532cb61c888a7bc87544923c5e8e6077
company,2023-03-16 17:45:09,Gilead Sciences (GILD) Gains But Lags Market: What You Should Know,119299850,https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462,GILD,Yahoo,"Gilead Sciences (GILD) closed at $79.85 in the latest trading session, marking a +0.25% move from the prior day.",https://finnhub.io/api/news?id=8bc0c2c28217fda7e958eb190aff62bceed6ae032eff7898e2667adbf02d3b9e
company,2023-03-16 12:56:00,"Gilead Sciences Inc. stock rises Thursday, still underperforms market",119288969,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.25% higher to $79.85 Thursday, on what proved to be an all-around great trading session for the stock market, with...",https://finnhub.io/api/news?id=2cbe7c333e7545f1445f4bfdb12488d69f3d7c6bfb0a15ece155c1810e3b834c
company,2023-03-16 12:10:04,Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?,119299851,https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7,GILD,Yahoo,Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.,https://finnhub.io/api/news?id=50b3f7b1e9293bba793359316377cc1e29158526a6d94dac8dae67df3e0284dc
company,2023-03-16 10:00:00,IN BRIEF: Guild Esports enters AI-driven technology partnership,119277004,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4a1cb6ea73aae759bf6fbda201cd2f37fc5a3a6aac5df8906d154f43aa1ccee7
company,2023-03-16 07:30:50,Here’s Why Gilead Sciences (GILD) Outperformed in Q4,119270175,https://media.zenfs.com/en/insidermonkey.com/91d6221e3df11e4933938a3082c41da1,GILD,Yahoo,"Ariel Investments, an investment management company, released its “Ariel Global Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the Ariel Global Composite delivered a 10.72% gross of fees compared to a +9.76% return for the primary MSCI ACWI Index and a +14.21% gain for the MSCI ACWI […]",https://finnhub.io/api/news?id=72d45f9fa89e5c0f09284b9dd8ace4c89d8371ee42be4e2cb7aa7bb133097cc8
company,2023-03-16 07:00:50,Gilead Sciences (NASDAQ:GILD) Seems To Use Debt Quite Sensibly,119270176,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...",https://finnhub.io/api/news?id=3dac50ddd33c439f169240a0cd8531171cb38c8d3f6e2fd0afff69dfc1ae182c
company,2023-03-16 04:54:00,JPMorgan biotech/pharma analysts to hold KOL analyst/industry conference call,119272992,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b97c9172af8989afb21f50cd85f2a8fdd5d054666450123c1b45a9688c3f50d7
company,2023-03-16 02:31:14,PBE: Healthcare Dashboard For March,119269693,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1175270464/image_1175270464.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Healthcare equipment is the less attractive subsector regarding both valuation and quality. Click here to find out why PBE is a Hold.,https://finnhub.io/api/news?id=c7491c8078cc18110f8ca9e1d2dcf1d8feefea9645b61548bc31df0b181e1f03
company,2023-03-23 13:51:05,"Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval",119382453,https://media.zenfs.com/en/zacks.com/378e912f39550fd9d3e26da87fee4c8a,GILD,Yahoo,Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=4f3a6df994f0e5aaee56937484fb6240ed063767275e3031e3d582a2462a87a8
company,2023-03-23 12:56:00,"Gilead Sciences Inc. stock rises Thursday, outperforms market",119481933,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 1.22% to $78.76 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=76484e3c3aeb204317dca74862cd3d1ebc2ed739598436937e26041d11e2f78f
company,2023-03-23 02:30:00,Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement,119382079,,GILD,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=75c899cf3460ea70cb74d8de02ad955bf035cc8864a3c068f7fc45bd4db409f7
company,2023-03-23 02:10:00,Gilead waives rights to acquire immune-oncology biotech Pionyr,119382080,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1f7119bacfcef8163c7761b55e20baab71deebacc413ce2abd6f83c122e3e244
company,2023-03-23 01:34:00,"Gilead, Pionyr Immunotherapeutics change 2020 exclusive option agreements",119382081,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c776b2c8d2d0ea7d4825082b564cfce805f4d2212e5117bb9e6e71f76c14c885
company,2023-03-22 23:50:00,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Akero Therapeutics (AKRO),119379271,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3b640c64a238a052db1adc1d0b3a73d2a359c09b71c532ac4c2cf28b2c7ec29b
company,2023-03-22 17:50:09,Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know,119359971,https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2,GILD,Yahoo,"Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.",https://finnhub.io/api/news?id=c58d008210646e626889e6a5b871ccc7dc8fc7c4777ee4ea94dc9bf02d5d599f
company,2023-03-22 14:38:06,Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study,119359972,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.,https://finnhub.io/api/news?id=03f86dd3b44719a446f9476640ebba1ffe544cefeaa9fb7d91fd7bae8dc7b914
company,2023-03-22 12:56:00,Gilead Sciences Inc. stock outperforms competitors despite losses on the day,119481936,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.68% to $77.81 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=09033fb50efa28f422e7c11f3d84d1080456ff188b1f128f872429d1dab33839
company,2023-03-22 12:00:00,Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities,119359973,https://media.zenfs.com/en/business-wire.com/ddfd7c7c3e116b2daeb433d888f54031,GILD,Yahoo,"FOSTER CITY, Calif., March 22, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States. My Brother’s Keeper, based in Ridgeland, Mississippi, will provide technical assistance and capacity building to the organizations funded through this initiative. These grants are part of Gilead’s ongoing Zeroing In™ program",https://finnhub.io/api/news?id=c554dd32c1b29f6d1972d5ef8b8f3a1c01887f413cd6e0610e4abb7808e64fc4
company,2023-03-22 09:30:00,Groups Around the World Work to Eliminate Hepatitis C by Meeting People Where They Are,119359974,https://s.yimg.com/ny/api/res/1.2/BHqbTCo5f.5OTZp2FQSX4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://media.zenfs.com/en/accesswire.ca/6211eae25ef23dcbff1cad19d4a11adc,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / March 22, 2023 / Gilead Sciences Every Friday for more than two years, a community church in North Wales, U.K., would transform into a one-stop shop of social services for people experiencing homelessness. Everything ...",https://finnhub.io/api/news?id=b23abc6c0e89dfe5f0f525f49aa4d474cee288d7f671eb33ae2b83a4d8fd3f43
company,2023-03-22 04:51:49,Vectoring In On Vir Biotechnology,119351253,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1348139157/image_1348139157.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Vir Biotechnology is a San Francisco-based commercial-stage immunological concern focused on the development of treatments for infectious diseases. Read more about VIR here.,https://finnhub.io/api/news?id=f4ec48a11588164838e946f63e4ad7f01e738679a8c2997e0ead2ec7999276f9
company,2023-03-21 23:40:00,Oppenheimer emerging biotech analyst to hold analyst/industry conference call,119358134,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5b33c728e2874cbe22c2dac09b249f7e7b1db9d27ff2902d9e40954cac8d9ee5
company,2023-03-21 13:19:40,Gilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma Patients,119343529,https://media.zenfs.com/en/Benzinga/c6cec0d9f027d2c022ca1cf488d909ed,GILD,Yahoo,"Kite, a Gilead Science Inc (NASDAQ: GILD) company, announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy. Historical SOC is a",https://finnhub.io/api/news?id=5ac1619044becc4c8da9efea2133101178241a876443577a61a8c9033810dcd7
company,2023-03-21 12:56:00,Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors,119346766,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. dropped 0.40% to $79.14 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=bab529328ccc6b1004596049db88771a8761140e1b2fb3db1316924f28068ef7
company,2023-03-21 10:05:02,Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead,119342295,https://media.zenfs.com/en/zacks.com/7de283b2224f57ff914c609b38092b2c,GILD,Yahoo,Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.,https://finnhub.io/api/news?id=54be05c44baf98ce55bbf1097a596a81c1bd36ed76288a9d02bbbc65b9af3d1b
company,2023-03-21 09:37:00,Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma,119343531,https://media.zenfs.com/en/business-wire.com/e74cef808a28314a65430957513de35c,GILD,Yahoo,"SANTA MONICA, Calif., March 21, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-li",https://finnhub.io/api/news?id=0fc807a120a545540513de8618dd02cf098ed767f32f819ccd1c6c017ada361f
company,2023-03-21 07:01:00,Gilead`s Kite unit touts survival benefit of Yescarta in large B-cell lymphoma,119336742,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=211e4abeeb08cf759f2991cfbd2f58b00d06c03789401bf226adac364dcdc1d9
company,2023-03-21 04:40:00,Kite announces primary OS analysis results of Phase 3 ZUMA-7 study,119336744,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fe6c65d725660bf53e42292872dc4b2513c37af745439002b87226ff12546383
company,2023-03-20 12:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,119325125,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rallied 2.78% to $79.46 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=1a63b66c4e4290c565b11590bcd89dace2e36af2f3156707438cc741b74d443e
company,2023-03-20 12:17:29,Gilead Exercises First License Option Under Agreement With Nurix Therapeutics,119316237,https://media.zenfs.com/en/Benzinga/76ccc30719c18783bd60396c2a39e60a,GILD,Yahoo,"Gilead Sciences Inc (NASDAQ: GILD) has exercised its option to license Nurix Therapeutics Inc's (NASDAQ: NRIX) investigational targeted protein degrader molecule NX-0479 exclusively. This bivalent degrader, GS-6791, is the first development candidate from the previously announced Nurix-Gilead collaboration. GS-6791 is a potent, selective, oral IRAK4 degrader with potential applications in rheumatoid arthritis (RA) and other inflammatory diseases. Under the terms of the Collaboration, Nurix will",https://finnhub.io/api/news?id=96dbf92f142541da8e0b5bf3dc9fc11ea6ad5456ce6ea25fc06e37e64ea9d694
company,2023-03-20 09:00:00,Nurix’s stock rallies on Gilead’s option,119302460,https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,GILD,Yahoo,"MARKET PULSE Shares of Nurix Therapeutics Inc. (NRIX) gained about 6% in premarket trading on Monday after Gilead Sciences Inc. (GILD) said it exercised the option to exclusively license Nurix’s targeted protein degrader molecule, which is being considered as a tool to treat inflammatory conditions like rheumatoid arthritis.",https://finnhub.io/api/news?id=679e125d2135d87e6e70e2d2944ce0977ac478742f4b1f41351724541e2b33ba
company,2023-03-20 08:36:00,Oppenheimer reiterates Outperform on Nurix Therapeutics following Gilead news,119313970,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d19a2830bdd0535cf41088e4a399744fd7da750f235892d179bcb776dbfb6cfd
company,2023-03-20 08:30:00,"Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479",119302461,https://media.zenfs.com/en/business-wire.com/e6b85ff482676fef5a7d7682a8b75e50,GILD,Yahoo,"FOSTER CITY, Calif. & SAN FRANCISCO, March 20, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX‑0479. This bivalent degrader, designated GS-6791, is the first development candidate resulting from the previously announced Nurix-Gil",https://finnhub.io/api/news?id=6c2bb1090ded88a497fbe1f7c3d871af42edec1e4f414a1a8014bb89d4b8763d
company,2023-03-20 07:58:00,"First Republic Bank`s stock plummets and Peloton`s stock falls while New York Community Bank shares soar, and other stocks on the move",119312818,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=aa853ebaca605c60d69bba3001e1c93d60b276497f8c82f6545649e8c8f46bbb
company,2023-03-20 05:04:00,Gilead licenses protein degrader from Nurix Therapeutics,119313972,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=91e20c8875f12e307c15812c6a03656483532e14c57672dad08c5bfdfd95a0bc
company,2023-03-20 04:15:00,"First Republic Bank's stock plummets and Peloton's stock falls while New York Community Bank shares soar, and other stocks on the move",119325127,https://images.mktw.net/im-746997/social,GILD,MarketWatch,NYCB stock benefits from news it is snapping up some assets of failed Signature Bank.,https://finnhub.io/api/news?id=bc07acdf26b08487514464013d97861069011974adb495940ab9986da3f2c7c3
company,2023-03-20 04:02:00,Nurix`s stock rallies on Gilead`s option,119303700,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a9ff72d6ba086ec0f7629bb59e2f67e48bae3327a26d109b3cdfdce7ceca052e
company,2023-03-20 03:34:00,Gilead exercises option to license Nurix`s NX-0479,119303701,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f6a40bb58fc0bf7ad227271f8e1a62062c3dffb9acac30dfa093c4e0f437c889
company,2023-03-20 03:33:00,Gilead exercises option to exclusively license NX-0479 from Nurix Therapeutics,119303702,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9fcff74587cdfe961167922f210516927e69c90d27778d1e34f5446e42a69708
company,2023-03-27 12:56:00,"Gilead Sciences Inc. stock falls Monday, underperforms market",119481930,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slumped 0.53% to $79.58 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=4ec514785fec9085fdc3c289d116ea32ddc114e3399dc1268c6af2808883c958
company,2023-03-27 09:25:00,Gilead Sciences Could Retreat Further From Here,119456673,,GILD,Yahoo,Biopharmaceutical company Gilead Sciences  makes and distributes many drugs but today I am more interested in the position of the charts and indicators.  Bottom-line strategy: GILD is a volatile stock that can move up or down quickly depending on the results of any given drug or treatment.,https://finnhub.io/api/news?id=392b64971516c92941c70e3d14368ccb2614a4111c9229e6d83c4b02af2739e0
company,2023-03-27 08:25:00,Oppenheimer emerging biotech analyst to hold analyst/industry conference call,119441776,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=882adbd9dca51b28c94d71e1214ee0f6c9f322a2a6eb720e9592d435f756be9f
company,2023-03-27 05:02:00,NuCana falls 36% after setback for patent dispute in EU for Gilead`s antiviral,119441644,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3fb667da6a169613ddcfda12810bfb224eed465fa0231fb0546bdf81e2607dac
company,2023-03-27 03:15:00,Model N stock rises as Morgan Stanley starts coverage with overweight rating,119441778,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a1d05a28d85d38061389647ea3c450e431922908ae24305ed470d332e24ee230
company,2023-03-26 22:25:00,NuCana Craters after EU Patent Problems,119441780,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1a48b12e6cb5a1fd7537f3fd10ac45b63cb9e3a6c09798d612aa4151118b7f4f
company,2023-03-25 06:44:38,"Dividend Champion, Contender, And Challenger Highlights: Week Of March 26",119385432,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the companies with upcoming ex-dividend dates.",https://finnhub.io/api/news?id=bc86deb2a9ce527dcf25efd490764077e238bc55bb4d8a79b57f634f13bb291a
company,2023-03-25 04:20:00,The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket,119441782,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ec51f41072ecdc7cb78e8946d7705defc2abd68fa2efb4eb4f16bc8f894c19b7
company,2023-03-25 00:16:00,"MCN: Strong Performance, But Premium Persists",119441783,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a3d8b48980dbfac897d7fb410629ae2d2ba97679d57ed5a62929167b4331a98a
company,2023-03-24 12:56:00,Gilead Sciences Inc. stock outperforms market on strong trading day,119481931,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 1.57% to $80.00 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=c44c1ff9eedfec8254e59fa9990e6fe98a7053a1c0e3c9ac9a78911325b9ce28
company,2023-03-24 09:42:29,"Final Trades: Bunge, Hershey, Gilead & more",119420408,https://image.cnbcfm.com/api/v1/image/107214916-16796787266ED3-FMHR-FINAL-032423.jpg?v=1679679749&w=1920&h=1080,GILD,CNBC,"The ""Halftime Report"" traders give their top picks to watch for the second half.",https://finnhub.io/api/news?id=7944b5494a92504de1618c43dbf801f78e15c524f0594ea938b86551b3f3609e
company,2023-03-31 12:57:00,"Gilead Sciences Inc. stock rises Friday, outperforms market",119557945,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rallied 1.87% to $82.97 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=c9ec0011ebf8af5866a7598d0223a094ef01f67fbc363fd0a4ab33fa17a351fe
company,2023-03-31 10:00:00,My Top 10 High Dividend Yield Stocks To Invest In April 2023,119537381,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1425438588/image_1425438588.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"In todayâs article, I will present you with my top 10 high Dividend Yield stocks to invest in for April 2023. Read more here.",https://finnhub.io/api/news?id=be97c98d216a3848e89ffbfa29f23133b5e1fe3b1a52bb2ee4713ba427adf154
company,2023-03-30 12:56:00,"Gilead Sciences Inc. stock rises Thursday, still underperforms market",119557946,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.20% higher to $81.45 Thursday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=6c838490a2bd16cc8e8bac7d1b9e79cbd590957f12c11ad60c618f233136897c
company,2023-03-30 07:27:00,"Texas judge blocks Obamacare for free HIV drugs, cancer screenings",119518619,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=29363f6e191760154c0b9cc219ee8ef0ff77d0f767a5b30e94c750d102bca941
company,2023-03-30 07:18:55,Gilead Sciences: Don't Be Scared Post Run-Up,119516838,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/516794016/image_516794016.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"There's no denying that Gilead has made poor acquisition choices. However, the cost is gone and the GILD cash flow should come. Click for more on GILD stock.",https://finnhub.io/api/news?id=575a8ea29a487d0cb7dfc65e26e15b3b1ca92babbcd8b1749f9ba4c4dd26114b
company,2023-03-30 07:11:00,"Texas judge blocks Obamacare for HIV drugs, cancer screenings",119518620,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9712f69d2b59bc2c45b2e31e88c3593a5e18e9eb93d8c3202fbf5cfd58a333a2
company,2023-03-30 06:22:00,Gilead Sciences: Don`t Be Scared Post Run-Up,119521666,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e47d9e83550ae9ca2a1a25df1ebf5d2d136084281eecbf5f35346dc0b2291e46
company,2023-03-30 01:59:00,Arcellx price target raised to $39 from $35 at SVB Securities,119519975,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4317c942fd906de2fb5d3a6bfbb1a09747d496ee04e1291a10bcff446da6e111
company,2023-03-29 16:00:00,Is It Time to Buy These Ultra-Cheap Dividend Stocks?,119499469,https://s.yimg.com/ny/api/res/1.2/TIeAKsRRCZ_R89Kvg.O0.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04Mjk-/https://media.zenfs.com/en/motleyfool.com/ea4946d17359020a0b2dc2011ca677f4,GILD,Yahoo,High-quality dividend stocks can be a great way to tilt the odds in your favor as an investor.  The core reason is that top-shelf dividend stocks generally have a long-standing shareholder base due to the reliability of their payouts.,https://finnhub.io/api/news?id=7f2f1ded736c82cb150402e635a20e7a69d71853bf3ca83568c8b97cfa8ab68f
company,2023-03-29 12:56:00,"Gilead Sciences Inc. stock rises Wednesday, still underperforms market",119510379,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.40% higher to $81.29 Wednesday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=76f124f1affd97923aa648faad1d5d8972ad21620bd1650cbfd0159f4991a085
company,2023-03-29 10:35:00,Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities,119504121,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"Gilead Sciences, Inc. (Nasdaq:GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States. My Brother's Keeper, based in Ridgeland, Mississippi, will provide technical assistance and capacity building to the organizations funded through this initiative.",https://finnhub.io/api/news?id=ec2e7c027a57accecaebf0db91fe06e1899495e979ddf761fede8428337023d5
company,2023-03-29 08:00:38,"Investors more bullish on Gilead Sciences (NASDAQ:GILD) this week as stock climbs 4.1%, despite earnings trending downwards over past year",119504122,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...",https://finnhub.io/api/news?id=37ada69eebbeebc46b74ee4c736c67cbf8de36c4be10fdec51a19b1a8ee5c6e8
company,2023-03-28 17:50:09,Gilead Sciences (GILD) Gains As Market Dips: What You Should Know,119504124,https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba,GILD,Yahoo,"Gilead Sciences (GILD) closed at $80.99 in the latest trading session, marking a +1.77% move from the prior day.",https://finnhub.io/api/news?id=23c743b63ddf98b9f77f27b366337ec2f8abf4e2391ca42babcc9b27d771a1b6
company,2023-03-28 12:56:00,Gilead Sciences Inc. stock outperforms market on strong trading day,119481928,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. advanced 1.75% to $80.97 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=1417ba379c9824ca7fcc06db7c3052f69c413041bd108dbb89759f60b9fb3dd7
company,2023-04-04 18:22:07,"Gilead details promising early COVID antiviral data, setting up larger studies",119621728,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"Gilead Sciences Inc on Tuesday unveiled data from the first human study of its experimental oral COVID-19 antiviral, saying the results in healthy volunteers cleared the way for two large Phase III trials of the drug that have begun enrolling patients.  The drug, obeldesivir and previously known as GS-5245, is designed to keep the coronavirus that causes COVID from replicating in the body and overwhelming a patient's immune system.  Once metabolized, it works in the same way as Gilead's older intravenous COVID treatment Veklury (remdesivir), which targets virus replication through inhibition of the viral RNA polymerase.",https://finnhub.io/api/news?id=10bb75881fde93c7d72950d534ba671a4aa9e921f44eeb0e14d53ef77e7ee229
company,2023-04-04 12:56:00,"Gilead Sciences Inc. stock falls Tuesday, underperforms market",119638717,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.35% to $82.12 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=d7b95b446b52ebc4510c2c5c418961efe8223dad406059b2d5250092e7a7f6a3
company,2023-04-03 17:50:09,Gilead Sciences (GILD) Gains But Lags Market: What You Should Know,119600650,https://media.zenfs.com/en/zacks.com/a41b81fe729c761f3f94f42ff348f70c,GILD,Yahoo,"In the latest trading session, Gilead Sciences (GILD) closed at $83.24, marking a +0.33% move from the previous day.",https://finnhub.io/api/news?id=6fb15136266400e7326a5123133758b66af53203e794a7c034776195f2092da4
company,2023-04-03 12:56:00,"Gilead Sciences Inc. stock rises Monday, still underperforms market",119596752,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.33% higher to $83.24 Monday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=2559866d4b07a5e26f9cbfccdd4018f3e057ec9172c657def7dd953a7bd53ca6
company,2023-04-03 08:20:00,Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags,119590517,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=78d71d6fb7416983a527b8205e3b9fd6a0f8f68532f13bb7711c4a906774ce7c
company,2023-04-03 07:20:00,CMS shortens list of drugs subject to new Medicare rebates in 2025,119598698,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f87ec7134b63ee02317c3944a1f6ff3dd905d789b49411c80748769667d73220
company,2023-04-02 07:00:29,"Is Gilead Sciences, Inc.'s (NASDAQ:GILD) 22% ROE Strong Compared To Its Industry?",119572530,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...",https://finnhub.io/api/news?id=99e084f0fae90a4af8182148e9c437b55e543d7e7987bec880b6977361d6e97f
company,2023-04-07 07:03:02,Magic Formula Dividend Portfolio For April,119669063,https://media.gettyimages.com/id/1412637153/photo/magic-book-with-open-pages-and-abstract-lights-shining-in-darkness-literature-and-fairytale.jpg?b=1&s=170667a&w=0&k=20&c=Ppfi8KUg5lN6X9uhktpl0MwHzUHl_tcb9F-WFjNxnHo=,GILD,SeekingAlpha,The following is a dividend portfolio strategy for large caps that score the highest amongst Joel Greenblatt's Magic Formula screener. Read more about the list here.,https://finnhub.io/api/news?id=bfe0b8a96d9dce8d5f503a2254ef6a7ca0cded7f4e09b4338f929d24973c1bbf
company,2023-04-07 04:46:00,RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD),119686097,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d896103bdee0bfbd09524ff13894e6a61d5da3ac6b450d57d52f7c690c646792
company,2023-04-06 12:56:00,Gilead Sciences Inc. stock underperforms Thursday when compared to competitors,119688453,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slumped 0.33% to $83.37 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...",https://finnhub.io/api/news?id=7840d616276cf687d40b49493855d58eb02b92f469b86bca6aee4c59d1933995
company,2023-04-06 08:15:00,6 Reasons to Buy Gilead Sciences Stock,119663707,https://s.yimg.com/ny/api/res/1.2/AMdRBrxA8XH0dr.aGG_T0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/df11c17dbb8562646cbc63717aa8a1b5,GILD,Yahoo,"Gilead Sciences (NASDAQ: GILD) is a top healthcare company with a market capitalization north of $100 billion.  Whether you're a dividend investor or interested in growth, this is the type of investment that has something for everyone, and that can be a good fit for any portfolio.  What I like a lot about Gilead is that the company has a strong, sound HIV business at its core.",https://finnhub.io/api/news?id=4a77a5873fc30e80810925fae07956d475b53de18f31108907d6cc3474b05d25
company,2023-04-06 07:38:00,FDA forces pre-term birth drug off the market after 12 years,119652508,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=36b4531d32d650b41ea739b23b3a10be33d6d7d3825b7ab427eacf3df35d3aeb
company,2023-04-05 21:16:00,WHO chief expects COVID emergency to end this year,119654047,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e745477481cf89928da696ac613e754e736ead79a46ce8f78c503a4b890dc76c
company,2023-04-05 12:56:00,"Gilead Sciences Inc. stock rises Wednesday, outperforms market",119688454,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. advanced 1.86% to $83.65 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the...",https://finnhub.io/api/news?id=82a86858af2d2485d4775c57b4673efc527da0c84ab6c10684b1b8f629211ece
company,2023-04-05 08:30:00,Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith’s Story,119641822,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"Early in 2020, Keith Prowell was making the most of his retirement in New York and staying active with swimming and tai chi.",https://finnhub.io/api/news?id=6465cd413641f560804c58f51bda04b35f1a026a3f68179f9f2719423e7f106c
company,2023-04-05 06:35:00,InflaRx upgraded to Buy at Guggenheim after Gohibic gets COVID EUA,119631957,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=377cacfe0538ca7daf7d84a0e2a435e87fee54b242a54f8b15bf87a76ac82317
company,2023-04-05 04:33:00,Gilead said to be in late-stage trials for oral COVID therapy,119631403,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a524d4a4857b9139f148fd6905aec2c82ce28c07bce38db78a1571fd7e7e8b96
company,2023-04-05 03:31:00,Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith`s Story,119634993,,GILD,Accesswire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=878bd7946ccef1ce635346c2078c0f3101395cfce21ee7f776b39610fb6645fe
company,2023-04-05 00:36:00,GILD - Chart Of The Week,119643589,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=592c178a9027c6fa01554dfc908fd19f893f55f37a3ee11b2024a7eadffbe89b
company,2023-04-04 23:09:19,U.S. Wide-Moat Stocks On Sale - The April 2023 Heat Map,119625466,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912585074/image_912585074.jpg?io=getty-c-w1536,GILD,SeekingAlpha,We believe that the most widely used valuation multiples are terribly flawed. Click here for a complete analysis.,https://finnhub.io/api/news?id=ee4a063d864b68349f62d6e6a2993e7d9717d761f34297b653f46dc56aac3632
company,2023-04-12 19:00:24,Morgan Stanley Maintains Gilead Sciences (GILD) Equal-Weight Recommendation,119734676,,GILD,Fintel,,https://finnhub.io/api/news?id=630cc91bd15edd1371996d1ff3908ae6a2d56dc6244658ea2350d6ba85bbc9da
company,2023-04-12 18:00:10,Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know,119786422,https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba,GILD,Yahoo,"Gilead Sciences (GILD) closed at $82.16 in the latest trading session, marking a -0.46% move from the prior day.",https://finnhub.io/api/news?id=4214751c8cdcf826f41fac3eed4f75421bda64ecf1a5d45a42ffd3b9075938ff
company,2023-04-12 12:56:00,"Gilead Sciences Inc. stock falls Wednesday, underperforms market",119755914,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 0.46% to $82.16 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=af125f80cec6eccebfac4ac8ec2d73357cf446f5985cc4e8516234768f9752b9
company,2023-04-12 08:25:00,Gilead Sciences: 4 Questions: Global Experts Convene To Identify Key Measures to Long-Term Success in HIV,119786423,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / April 12, 2023 / Gilead Sciences: Originally published by Gilead Sciences Dr. Jeffrey Lazarus was studying at New York University in the late 1980s when he saw first-hand the devastation of the HIV epidemic. ...",https://finnhub.io/api/news?id=f139e073af45ed04f07560e6c9d2d05e7788b3e038e31cf542aa7f2df8b9bb3f
company,2023-04-12 06:00:00,My Dividend Stock Portfolio: New All-Time Dividend Record - 99 Holdings With 25 Buys,119726730,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1406742992/image_1406742992.jpg?io=getty-c-w1536,GILD,SeekingAlpha,My dividend income in March amounted to a record $950. This represents growth of 61% Y/Y and 40% sequentially. Click here for a detailed analysis.,https://finnhub.io/api/news?id=6533a263ba77f76dae5f576b18b69f02c1f8bfb1a90f1b90835132b1e55c2f3b
company,2023-04-12 05:31:00,Could Gilead Sciences Stock Help You Become a Millionaire?,119786424,https://s.yimg.com/ny/api/res/1.2/_wrdGZECQL_20h4UYtenjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MzM-/https://media.zenfs.com/en/motleyfool.com/8f8c295695371a9736441a573587d5c7,GILD,Yahoo,"Gilead Sciences (NASDAQ: GILD) stock has been a standout among biotech companies over the past year, with its shares up more than 36%.  Fourth-quarter sales rose 2% year over year to $7.4 billion, led by increased sales of oncology, HIV, and hepatitis C virus therapies.  This year, Gilead expects revenue to slide to between $26 billion and $26.5 billion, with Veklury sales hard to gauge.",https://finnhub.io/api/news?id=f025679c273867605671570b8868de4d6dcd11a500b24c9f3083ab4f21f80330
company,2023-04-12 05:07:03,"Gilead Sciences Now Barely A Hold, Market Looks Uninspired (Rating Downgrade)",119726545,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1221884665/image_1221884665.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Gilead Sciences has lagged the broad market since previous coverage. Guidance is lackluster. Despite that GILD is a hold now, explore more here.",https://finnhub.io/api/news?id=d1717be3027ca09225390a6473be83399987dd45530dfa0485321bedd9570ef4
company,2023-04-12 02:42:00,Gilead price target raised to $85 from $81 at Morgan Stanley,119729201,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=72996b267c536c0faf7eb70757a9fde723c68352fff712b665a600a39106ecd7
company,2023-04-12 01:30:00,Dividend Income Update March 2023,119727268,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ca4acc9827314eaf6553500da252f7b6fd83703fcb130f4a5d67c20d9c978e30
company,2023-04-11 22:26:28,Why Healthcare Stocks Are A Prescription For Investors In Q2 2023,119725087,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413600685/image_1413600685.jpg?io=getty-c-w1536,GILD,SeekingAlpha,The recent drop in biopharma stocks presents a buying opportunity for investors. Find out why XLV seems like the best fit.,https://finnhub.io/api/news?id=69173de72e70bacb9558918aee06ad651655d4ae31b435a26de7f0e4e7d3ba03
company,2023-04-11 20:11:00,DivHut Portfolio Update: March 2023,119724915,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/943401146/image_943401146.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"The system is clearly broken, and has been for a while; however, I could find comfort in one thing, my dividends. Four figures in a month is a win in my book.",https://finnhub.io/api/news?id=31edb3c988ed329dbd5595e54a46460206bde5c17e4e4de251a6c3db3291717e
company,2023-04-11 10:51:25,12 Best Covid Treatment Stocks to Buy Today,119724373,https://media.zenfs.com/en/insidermonkey.com/b59f475277cb8c4b57fab9a05923d82d,GILD,Yahoo,"In this piece, we will take a look at the 12 best covid treatment stocks to buy today. For more stocks, head on over to 5 Best Covid Treatment Stocks to Buy Today. If there’s one thing that can be said for sure, it’s that the coronavirus pandemic has changed the world. The deadly disease, […]",https://finnhub.io/api/news?id=fd0f172fc848f1ff1c605cdb4fcfd12850983672dad9f0febd405312d292ac29
company,2023-04-10 23:57:00,Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors,119729205,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8c8e7e59bd1d8be4fc416b7393b8e9caa3e7741e9132b97c09700fb5951776d3
company,2023-04-10 13:38:08,Gilead Sciences: Patience,119707602,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Gilead Sciences ended 2022 on a solid note. The 2023 guidance (ex-Covid-19 contribution), though, feels a touch light. Click here for my take on GILD stock.",https://finnhub.io/api/news?id=4ebeb67a1c411180a8c0b42dca6848b4c6b6c4cf4635f33af171eb26d56f61ba
company,2023-04-10 12:56:00,"Gilead Sciences Inc. stock falls Monday, underperforms market",119712960,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 0.92% to $82.60 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=f638214a57ac920cbd9c1aac6efd63f16b3182579cfde84bf56dc6ed008a0301
company,2023-04-10 09:15:00,"If You Invested $10,000 in Gilead Sciences in 2013, This Is How Much You Would Have Today",119710187,https://s.yimg.com/ny/api/res/1.2/lvyAq6EII3bvFylfvcE2LQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/3aaf3cc3d3310058efc1b45516860de9,GILD,Yahoo,"Gilead Sciences (NASDAQ: GILD) is a top HIV treatment company that has a bright future ahead.  In 2022, Gilead's top line was flat as a drop in COVID-related sales offset gains the company achieved in other areas of its business.  In 2017, for instance, Gilead's revenue declined by 14% to $26.1 billion as the company saw double-digit declines in revenue for multiple products.",https://finnhub.io/api/news?id=eb603d77c12cacb9e5f47b7947d52d497089a082f14862fecd181c3d0cdc57eb
company,2023-04-10 04:26:10,GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market,119701387,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365749374/image_1365749374.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. BMY's EBITDA margin was 43.7% for 2022, 11.4% more than GSK. Read more here.",https://finnhub.io/api/news?id=e40a30d8690c0777466a7237fc2ec01321a46e522555e287a37fdb3d28ebec26
company,2023-04-10 03:28:00,GSK Vs. Bristol-Myers Squibb: Who`s More Underrated By Mr. Market,119703326,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dfdd9a0ae6c915f7604373695064ece219a6010fb74e1318c733583f7d341ce4
company,2023-04-09 10:00:12,"Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 49% Discount?",119699443,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,Key Insights Gilead Sciences' estimated fair value is US$163 based on 2 Stage Free Cash Flow to Equity Gilead Sciences...,https://finnhub.io/api/news?id=1e32fcf2f24fc6a1287f2421beade7b6063b24df9c079233203938ecef58345b
company,2023-04-09 07:30:00,3 Dividend Stocks Billionaires Seem to Love,119698214,https://s.yimg.com/ny/api/res/1.2/xJoNYRZ_AWtLNsgd12BchQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/64e909b3c6e7b95fac2285be22efe7b7,GILD,Yahoo,"There is no shortage of corporations that pay dividends, but they aren't all created equal.  Let's look at three dividend stocks that got the investing attention of some billionaires: Gilead Sciences (NASDAQ: GILD), Microsoft (NASDAQ: MSFT), and Apple (NASDAQ: AAPL).  Gilead Sciences is a leading biotech company with a particular focus on the HIV drug market.",https://finnhub.io/api/news?id=9664be50aea1363ebe8e00b1ba81008160bdd45107ff20f8f6217d23d8388072
company,2023-04-16 04:00:00,Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations,119786418,https://media.zenfs.com/en/business-wire.com/8dc69855103dce5668b8fbaaa5449c69,GILD,Yahoo,"FOSTER CITY, Calif., April 16, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). A Phase 3 clinical study demonstrated that Veklury® (remdesivir) was generally well tolerated in people with moderate to severe renal impairment. Additional data includes a retrospective real-world study which demonstrated that",https://finnhub.io/api/news?id=b4c6b3df6f0d4b2620473fd955f033dfe055617733187d301bc7e48e207b8b24
company,2023-04-16 03:56:00,"Gilead announces results from several COVID-19 clinical, real-world studies",119789663,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=244217a4beb3a257ec16f8dd1a34a02531bc910d7ffe313700f4d8bd70bd409f
company,2023-04-15 06:14:00,3 Dividend Stocks to Buy and Hold for the Next Decade,119777921,https://s.yimg.com/ny/api/res/1.2/uM4jD2f_3Pnkbr1D_4kUcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/motleyfool.com/5e27b2dd3badeab4724c3488bb0922e3,GILD,Yahoo,"The best ones even pay you to hold them for years via generous dividends.  Three Motley Fool contributors identified their picks for dividend stocks to buy and hold for the next decade.  Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ).",https://finnhub.io/api/news?id=b819623df4d996aab7272cccb9a35230081d5aa7473cd5e6b18712ad10ac2061
company,2023-04-14 08:07:00,Nurix Therapeutics Shares Rise 21% on 1Q Performance,119865902,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Denny Jacob Nurix Therapeutics Inc. shares rose 21% to $12.21 after narrowing its loss and posting higher revenue in the latest quarter. The clinical...,https://finnhub.io/api/news?id=5e5f1c99a756363af0976c171784b9426f14833c9d268f8aae0dbadbfd9b3306
company,2023-04-13 23:57:00,"Gilead Sciences Inc. stock falls Friday, underperforms market",119779686,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c8778a5648d8a82c8d1457513ea3d508e7c76946fa4c25ab563ac269c55f0456
company,2023-04-13 16:05:00,"Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023",119786420,https://media.zenfs.com/en/business-wire.com/dad8d85cd43208f196c6ced6f51f6b6c,GILD,Yahoo,"FOSTER CITY, Calif., April 13, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2023 financial results will be released on Thursday, April 27, 2023 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2023 financial results and provide a business update.",https://finnhub.io/api/news?id=67fab640f45189ad2f18d131476b8042571723866b9e55aa30f99d08058c00cb
company,2023-04-13 12:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,119755913,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rallied 1.35% to $83.27 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=511eed691d1b9d30564943b34d47aa617c46d8e98060f6dbb2d3faf66fff1f75
company,2023-04-13 07:00:30,"Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst institutional investors who own 84%",119786421,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,Key Insights Institutions' substantial holdings in Gilead Sciences implies that they have significant influence over...,https://finnhub.io/api/news?id=6af03edffa317043015739430c0131787dff03c7da0b762d18a5b69bc0874dfe
company,2023-04-20 12:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,119943506,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.69% higher to $84.69 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=a85357b6f08af2b7c387d3f0021f66df7558dd52abac38145d1f761f8f7d19fa
company,2023-04-20 10:03:02,Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release,119849935,https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926,GILD,Yahoo,Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=e8246da27144b942e8b9446f2f2c15adbef8cea4c479354ab874dc5ad6c58f12
company,2023-04-20 10:00:58,"Get Income On Gilead Stock, Or Buy It At A Discount With This Option Trade",119849936,https://media.zenfs.com/en/ibd.com/b8066fe61603e0a00cb19aadc939e17d,GILD,Yahoo,"Gilead Sciences is showing high volatility due to the upcoming earnings announcement next Thursday.  The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the current price.  It's important that anyone selling puts understands that they may be assigned 100 shares at the strike price, if the stock is below the strike price at expiration.",https://finnhub.io/api/news?id=ddbbe9054d84066780850ca0bac8ee83cf65d0a7dd3cdccf44de954d16c0d04d
company,2023-04-20 09:36:25,"Final Trades: Gilead, Vertex, Wynn & more",119846816,https://image.cnbcfm.com/api/v1/image/107228772-5ED4-FMHR-042023-FinalTrades.jpg?v=1682012185&w=1920&h=1080,GILD,CNBC,"The ""Halftime Report"" traders give their top picks to watch for the second half.",https://finnhub.io/api/news?id=e24a04a8dcfdfc402c46ff887d0a1f93a82a2af5b75b706a1b7182d6d1a7e821
company,2023-04-19 19:50:48,Strong Quant Screens Say These 7 Growth Stocks Are a Buy,119889485,https://media.zenfs.com/en/investorplace_417/d19c812b11e570bbadef2f5722cf436b,GILD,Yahoo,"Strong quantitative screens will show investors a variety of growth stocks to buy. For example, StockRover is a screening service that scores stocks on three key metrics. One, growth scores are based on five year historical growth, compared to forward EBITDA estimates. Two, quality scores depend on profitability and a healthy balance sheet. Three, value scores are based on the usual price-to-earnings multiple and earnings per share predictability. Quant scores offer investors a numerical charact",https://finnhub.io/api/news?id=052b2cafe3d65444be6900c90b297644c45c7ae8b8cfbf37bbd10aec0bbe89b3
company,2023-04-19 12:56:00,Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains,119943507,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.39% higher to $84.11 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=4e2c2d069950e0907fa6a7ac9df83fab3f1fe649d2a06a3ebd42ffe0a7efdc94
company,2023-04-19 12:10:04,Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?,119849937,https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee,GILD,Yahoo,Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://finnhub.io/api/news?id=2bb700037cb7eb260c03cfc540ecf053c1f0cf0335b61b1faee730cec858f893
company,2023-04-19 08:55:00,Gilead Sciences: Breaking Down Barriers To Access in HIV and Beyond: A Perspective,119849938,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / April 19, 2023 / Gilead Sciences When I came to Gilead in 2019, I did so in part because of the revolutionary way this company thinks about bringing therapies to those who could benefit. Health equity and access ...",https://finnhub.io/api/news?id=3f2a27ee2a2b17f9d36dee02e099138b6b31515b5ace7a8b755a5a62377af912
company,2023-04-18 18:00:10,Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know,119849939,https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee,GILD,Yahoo,"In the latest trading session, Gilead Sciences (GILD) closed at $83.78, marking a +0.18% move from the previous day.",https://finnhub.io/api/news?id=149c7337bfda98762636a7a486f3aaf1c26cd69863cca7489261dba757131633
company,2023-04-18 13:23:51,Hookipa Pharma: A Speculative Biotech Worthy Of A Spot On My Watch List,119818401,,GILD,SeekingAlpha,,https://finnhub.io/api/news?id=9e07fa0f411b1f9aa55d9627af9f687636b04b44a34d9f5d9dcdacef04b95370
company,2023-04-18 12:26:35,Jounce Acquisition: Exploring Whether It Is Worth It To Pay Up For CVR Value,119818289,,GILD,SeekingAlpha,,https://finnhub.io/api/news?id=5b02f7a13d90eaea9b5307ff769655d1add2a306aabe203fa3d1290a0a93c2cb
company,2023-04-18 09:00:15,Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet,119849940,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...",https://finnhub.io/api/news?id=d85326f68cd9b3fa691fbe2264a33df3cf888e03a1d79bd5c11da7241c8518ac
company,2023-04-18 04:25:00,COWZ ETF: A Cash Cow for Your Portfolio,119824519,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1bd2f2852c860c865041c31809b2fc709b64d49dce2b791c1860fb4ef9c77cc1
company,2023-04-17 23:57:00,"Gilead Sciences Inc. stock rises Tuesday, outperforms market",119824521,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=32f341c5445b6e5cdacd6fc6b66e99288391eb1cb455f7e272478e673b64b329
company,2023-04-17 11:52:17,Johnson & Johnson: 4 Key Areas Of Focus Ahead Of Q1 Earnings,119803893,,GILD,SeekingAlpha,,https://finnhub.io/api/news?id=413f4b7beca531b071d2a4807fea9c0a02b2d985ab3b85d89cccad87e07fb731
company,2023-04-24 17:05:00,Gilead Sciences Releases Inaugural ESG Impact Report,119911263,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"Gilead Sciences recently released its inaugural Environmental, Social and Governance (ESG) Impact Report.",https://finnhub.io/api/news?id=22f1504cb510e0026361dfbb7acf3b7bfec67764423ec8acfe74ee1b149f5faf
company,2023-04-24 12:56:00,Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains,119943504,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.15% higher to $86.70 Monday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=5ed18d8753f0dd87db72a372655a8e1972070b5912c2c3979fb1059d9598422d
company,2023-04-24 01:44:38,"SDOG: ETF With A Simple And Sensible Strategy, But Average Result",119900540,,GILD,SeekingAlpha,,https://finnhub.io/api/news?id=8bde83e6cf1e8287cd49ced9a47c5473b490881908a317888ed5c071c85a7c4b
company,2023-04-24 01:31:06,Second Quarter Outlook For Biotech Stocks,119900551,,GILD,SeekingAlpha,,https://finnhub.io/api/news?id=3480cc3264f6b2d34dd4cc517961cd6de011088287042e735a3127dd26c3056f
company,2023-04-21 18:37:44,Unusual Call Option Trade in Gilead Sciences (GILD)  Worth $140.52K,119873134,,GILD,Fintel,,https://finnhub.io/api/news?id=be5a444b40d0f8006bded20894135a331539089e56f0c05d0bcafa4a176ed17f
company,2023-04-21 12:56:00,Gilead Sciences Inc. stock outperforms market on strong trading day,119943505,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rallied 2.22% to $86.57 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=0c88492c244094fca2c07880553e1b6e2a8e630b789226f836c7a8b7a539e5d1
company,2023-04-21 12:55:04,Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?,119875201,https://media.zenfs.com/en/zacks.com/1dd22d8e7df86bbdfeb760975615675b,GILD,Yahoo,Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.,https://finnhub.io/api/news?id=2c11cd63631a11f2927ff14d89ebec5a8fd4ad1eb141f6f87a3b14aa16a90eb8
company,2023-04-21 12:16:42,12 Best Pharma Dividend Stocks To Buy in 2023,119875202,https://media.zenfs.com/en/insidermonkey.com/9c6e203d79cdfc8f70e0db85087abef8,GILD,Yahoo,"In this article, we discuss 12 best pharma dividend stocks to buy in 2023. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2023. The pharmaceutical industry in the US is one of the largest in […]",https://finnhub.io/api/news?id=399d0ee7bc101458aa71396ff29de296dbd7ff208fd92b4c2ea1f3f976e0260e
company,2023-04-21 08:32:00,"Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more",119868296,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7b5d1a1eba315838a32653301dce0a7b204eb1db04060a6a6033253c51d13efa
company,2023-04-21 05:42:00,OmniAb a new buy at Benchmark on technology to develop monoclonal antibodies,119867087,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c3f742864371c5288c52636962e645d15e02278230e1b4cd7dfec44a608e7a47
company,2023-04-20 23:44:00,"Gilead Sciences Now #76 Largest Company, Surpassing Elevance Health",119874959,,GILD,The Online Investor,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ae0cda66f38d0fee7a7d1ca3847e3099ec2fabbf599af739953972cb8935edb9
company,2023-04-20 23:18:00,"Notable Friday Option Activity: GILD, SAVA, SONO",119874960,,GILD,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=240c627f7928b165a82303ff8d724ee98661d610158b4157d0501a59157195ad
company,2023-04-28 15:34:03,Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript,120022841,,GILD,Yahoo,"Jacquie, please go ahead.  The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson.",https://finnhub.io/api/news?id=bfe7d15f4eb2d7832af9c3fd2aa51f399d581c7643ec5036dd15ebd6e7c5f67c
company,2023-04-28 13:07:05,"Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge",120029586,https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071,GILD,Yahoo,Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.,https://finnhub.io/api/news?id=2a791a030894ff740b9b4e9f2a4eecd542515eb410ff3d7e5620f90435dba7b4
company,2023-04-28 12:56:00,"Gilead Sciences Inc. stock falls Friday, underperforms market",120112923,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 1.60% to $82.21 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=81dfd9eb483039dfe1b312e307f14bdbf4268a25c2d97554c4ea4a35d5e7bd85
company,2023-04-28 12:29:03,Why Gilead Sciences Stock Is Falling Today,120029587,https://media.zenfs.com/en/Benzinga/a608349ea447f2c59ffa77c37d87c45e,GILD,Yahoo,"Gilead Sciences Inc (NASDAQ: GILD) reported Q1 FY23 sales decreased 4% Y/Y to $6.35 billion, slightly above the consensus of $6.33 billion, due to lower Veklury (remdesivir) sales, partially offset by increased sales in HIV and Oncology. ""Biktarvy outperformed once again, and Oncology revenue increased 59% year-over-year, driven by Trodelvy and Cell Therapy,"" said Daniel O'Day, Gilead's Chairman & CEO. Product sales decreased by 3% to $6.3 billion; excluding Veklury, product sales increased 15%",https://finnhub.io/api/news?id=43e8ab645851a1f1a663055ee3d4f207c516fe948ccc3d45b4dd7a81f481b1d1
company,2023-04-28 06:44:00,Gilead`s hepatitis B therapy Vemlidy gets EMA nod for use in kids above 6,120029239,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=488648d01aa103cc2ab2d57fee95bcb7b71d8e27c2e11541615cc7319354da16
company,2023-04-28 05:29:00,"Video: Nasdaq 100 Movers: GILD, INTC",120029240,,GILD,Market News Video,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fab49a65ed3a2d40c241290704a7507633f3929bcc87b66adc8f01d559615e25
company,2023-04-28 04:49:00,"Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations",120014888,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7b078291a8a65b4bdef28dd5980fc0b26e5b48fbec23ec74bcf034d4f12cc65d
company,2023-04-28 03:25:00,Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD),120029242,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e962675e9f7007a7e11ed3551fc38aad38ae903f7215eb5a7be832621477cc13
company,2023-04-28 02:02:00,Gilead assumed with an Overweight at Piper Sandler,120029243,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=12b9bcbbce355506491d6a77e0858e556166bd9fe2b566aff800fc0b8ec09153
company,2023-04-28 01:50:00,"Analysts` Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Encompass Health (EHC) and PROCEPT BioRobotics (PRCT)",120019905,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=032188e84c425f5ff20533e120bc941e30ca3d7a276b696fb5aaaa9fa1291216
company,2023-04-27 23:32:00,"Analysts Conflicted on These Healthcare Names: Edwards Lifesciences (EW), Gilead Sciences (GILD) and Revance Therapeutics (RVNC)",120029246,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4a6a2f53a5f4b5b188a392c5ce30acb038f83e1d5a2c9647e1d3b31b908597a9
company,2023-04-27 17:45:09,Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates,119990523,https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a,GILD,Yahoo,"Gilead (GILD) delivered earnings and revenue surprises of -15.95% and 0.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?",https://finnhub.io/api/news?id=0848267195149b69dd7d6bbe95a6cc8c147e53ee4373b3585a568ecad7c642e1
company,2023-04-27 16:57:06,"Gilead Sciences, Inc. (GILD) Q1 2023 Earnings Call Transcript",119982496,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q1 2023 Earnings Conference Call April 27, 2023 4:30 AM ETCompany ParticipantsJacquie Ross - VP, IRDaniel O'Day - Chairman and CEOJohanna Mercier...",https://finnhub.io/api/news?id=44bf0eb2f3356b38c2a95c89c9c61027c5d133999579b02075ae1be7ab48a9c7
company,2023-04-27 16:49:49,Gilead Stock Dives As Light Profit Hamstrings Strong Cancer Drug Sales,119990524,https://media.zenfs.com/en/ibd.com/42ec1eee4c32ef9fd681c92c689f33f4,GILD,Yahoo,Biotech giants Gilead Sciences and Amgen posted mixed quarters on Thursday — leading GILD stock and Amgen stock to topple.,https://finnhub.io/api/news?id=db5336b07c17db196578487ec89ef9e9f835b06049ecc9661b5a52006b3bfd32
company,2023-04-27 16:37:07,Gilead profit misses Wall Street expectations as COVID drug sales decline,119984317,https://static.reuters.com/resources/r/?m=02&d=20230427&t=2&i=1631578245&r=LYNXMPEJ3Q0Y5,GILD,Reuters,"Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%.",https://finnhub.io/api/news?id=df57664e00a133ba70ac729ccf65d84570a8cb2fd6ec4c35c2bbf54dbdb1bac0
company,2023-04-27 16:30:38,UPDATE 1-Gilead profit misses Wall Street expectations as COVID drug sales decline,120002865,,GILD,Reuters,"Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%.",https://finnhub.io/api/news?id=2a7f60737533632427d44f24a14a7e85062d18ea0ea84ca810df14b76e55df93
company,2023-04-27 16:02:00,Gilead Sciences Announces First Quarter 2023 Financial Results,119990525,https://media.zenfs.com/en/business-wire.com/488efd4a46ba9a32ebfb72d918fdb129,GILD,Yahoo,"FOSTER CITY, Calif., April 27, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2023.",https://finnhub.io/api/news?id=ef068514c94b5081e2106092457e7c0cbf098c9806840e9ddb49a61c150cd98a
company,2023-04-27 13:19:38,"Stocks making the biggest moves after hours: Amazon, Intel, Snap, Pinterest and more",119977593,https://image.cnbcfm.com/api/v1/image/107229035-1682051609980-gettyimages-1136867731-hennessy-amazonsn190412_npreP.jpeg?v=1682630378&w=1920&h=1080,GILD,CNBC,These are the stocks posting the largest moves in extended trading.,https://finnhub.io/api/news?id=6987b7c041f682a24a51b96353e46bdfac5ed6ca9124b85efe65acd0d61f9258
company,2023-04-27 13:16:00,Gilead reduces earnings guidance as first quarter sales fall 2%,120029247,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cdae6eb3b6528795e8d10644622b656e72309fedcf9f13e0a5facadf243f6dc6
company,2023-04-27 12:54:12,"Gilead Sciences, Inc. 2023 Q1 - Results - Earnings Call Presentation",119970785,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"The following slide deck was published by Gilead Sciences, Inc.",https://finnhub.io/api/news?id=b23405ac20effbd3e7e1e391c9d9cd2e63900cd007ba2470e0d27144a01f03d9
company,2023-04-27 12:35:00,Gilead: Q1 Earnings Snapshot,120029248,,GILD,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e1ce701dc355097726137baa4983da376c8421fc8b01f20febc2f8a5c8b26bb3
company,2023-04-27 12:31:00,"Gilead shares fall after mixed results, as weaker COVID-19 drug remand weighs",120112925,https://images.mktw.net/im-771567/social,GILD,MarketWatch,Gilead Sciences Inc. on Thursday cut one of its profit forecasts and reported first-quarter profit that missed expectations.,https://finnhub.io/api/news?id=bda523019185b0ba93a5a0e168f76daf7105a31d990b0b921b377f2259835c3d
company,2023-04-27 12:30:00,"Gilead Sciences 1Q Adjusted Earnings Decline on Lower Revenue, Higher Expenses",120112926,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Bob Henderson Gilead Sciences Inc. on Thursday reported a first-quarter adjusted earnings decline of 65% that it attributed to lower revenue and higher...,https://finnhub.io/api/news?id=a2e207f10d88b4f0a7f5d3fb0e3ff39e5aaafb1843d03be50fc9a44fbed9647c
company,2023-04-27 12:05:00,"Gilead Earnings Fall Short, Stock Tumbles",120112927,https://images.barrons.com/im-771348/social,GILD,MarketWatch,"Aales of its cancer and HIV drugs rose, while sales of its Covid-19 antiviral fell.",https://finnhub.io/api/news?id=229a77d5c3b786612a76a0687b722080ace01a63512d953742201a6c7d619237
company,2023-04-27 06:10:55,Merck Q1 Earnings: Delivering Strong Results,119956065,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/56293183/image_56293183.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Merck reported Q1 results and beat estimates on both lines. Read why I believe that MRK is a good long-term holding, but not a great buy any longer.",https://finnhub.io/api/news?id=e343a467dc359acd927e768c5529964abf1931fa428ced0a4f55ee3c9e180a07
company,2023-04-27 05:30:00,Better Buy: Pfizer vs. Gilead,119951947,https://s.yimg.com/ny/api/res/1.2/iTSFO_Bugaq_3x0cN.KRjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/31d5ee16eed51e4321c060222d757a81,GILD,Yahoo,"Two great examples are Pfizer (NYSE: PFE) and Gilead Sciences (NASDAQ: GILD).  Pfizer is facing two challenges right now.  First, demand for its coronavirus vaccine and treatment is falling as we move toward a post-pandemic situation.",https://finnhub.io/api/news?id=0808713bcffa0403df26a4f42a9aa7dde15d3715126232d17bdd0842fc87deb4
company,2023-04-26 23:55:00,Gilead Sciences (GILD) Gets a Buy from Mizuho Securities,119996207,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5f553c0167d801c175677e49673139b816526165b40f61d380f4c75a79e8305b
company,2023-04-26 23:54:00,Gilead slips after cutting 2023 earnings guidance,120029258,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d20c98c3891331af16e28803bc1baed6a495b0656386ef2630d25106c1d4150a
company,2023-04-26 23:08:00,Gilead Sciences beats revenue estimates but misses profit consensus,120029259,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=252eaa1b2129c3974c39a3a0ef6a2dbbe18547d7d052743a5cbd3b78501cd175
company,2023-04-26 23:04:00,"Gilead backs FY23 adjusted EPS view $6.60-$7.00, consensus $6.84",120029260,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b8c4de9b385e52d7e28e47133373601f7609217b25d06fa105187c3ca0f8c0ed
company,2023-04-26 23:03:00,Gilead reports Q1 Biktarvy sales up 24% y/y,120029262,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9d4e7252581f61c193da0fed3a6e0a09abcd2bc5d34ca94091c4c855c13b706e
company,2023-04-26 23:03:00,"Gilead Sciences reports Q1 adjusted EPS $1.37, consensus $1.54",120029261,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9ddbaa9b06e5863d1ce355020b0f497a26a2421e20579db3651adf4dab72d460
company,2023-04-26 21:49:00,Gilead options imply 3.8% move in share price post-earnings,120029263,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ac3d0d91e8be6fc6b5ce109cbb91d602ab74b0752274540b1c27feb9c826b8d9
company,2023-04-26 21:11:00,Notable companies reporting after market close,119971199,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ea50c75eae2dae4b03bc7eb8e23a551994ffca80d45c2f20fa8a98a5e0dd2d80
company,2023-04-26 20:30:00,GLOBAL BRIEFING: Samsung posts weakest profit in 14 years in Q1,119957841,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=44c8ce8cf3666132a5eb0585bf5bfe79988b769eb9ce6488d1c255f767628a1f
company,2023-04-26 12:56:00,Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors,119943502,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 2.16% to $83.74 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=403e3c93974cfd9f11358e36b832c76548f1a66ddccc596d9505356e1effa6ef
company,2023-04-26 09:28:01,"Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More",119945687,https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707,GILD,Yahoo,Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.,https://finnhub.io/api/news?id=1df3956ae2c81d791aa50d25066a8418efc520e28fdb803800f08fc53813d59b
company,2023-04-26 06:01:00,Gilead set to continue revenue beat streak with Q1 results,120029269,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7016c8c26f46a3f50934ff755c8788edf8d0c609d3547fa12f5890bda25779b7
company,2023-04-26 04:32:00,EU publishes proposed reforms for pharma industry,119957848,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c795f4e4b500619999f1bd65cb14ef1432b14bd429939cbe862a4d74e21a77f3
company,2023-04-25 14:28:14,RBC Capital Reiterates Gilead Sciences (GILD) Sector Perform Recommendation,119918436,,GILD,Fintel,,https://finnhub.io/api/news?id=c32f11af72bfa575178205dffebb1ac8ae3b1d42e54ec102e712ec55f2ad4cda
company,2023-04-25 13:00:00,3 Biotech Stocks To Watch Today,119917018,https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/04/biotech-stocks-to-watch.jpg,GILD,StockMarket,Biotech stocks for your late-April 2023 watchlist.,https://finnhub.io/api/news?id=f454f77dee373668f5207d0fb9c803ff8972ad13ea05656eede8fd08306e2def
company,2023-04-25 12:56:00,Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors,119943503,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.28% to $85.59 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=d54071faea7d30d1f31521618ca0322acb7ef60b6da3d0477e740eea36681cf5
company,2023-04-25 10:01:02,Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release,119928631,https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462,GILD,Yahoo,Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=041e86d342ff1ab5fc9d49fa5a3d5fe324b76f67e9a3bdd4e85dfa4a295c082d
company,2023-04-25 09:51:15,3 Cash-Rich Biotech Stocks to Bet on for the Long Haul,120015154,https://media.zenfs.com/en/investorplace_417/814bf4787de3c720fc4dce9747086b2d,GILD,Yahoo,"The Federal Reserve’s recent interest rate hikes mean banks charge much higher interest rates for loans. The interest on loans can be considered the price of borrowing more money. And since acquiring cash now costs more money, it’s becoming much more complicated for companies to invest. For biotech stocks, the pain is clearly borne by investors, who choose to dive into these capital-intensive businesses. For a cash-strapped company, the rising cost of money can be a death sentence. But cash-rich",https://finnhub.io/api/news?id=7012f2c658af39cf7a7bd7f7c9431db810b6146069182d89ed7013509af8f07c
company,2023-04-25 08:25:00,Robert W. Baird Reaffirms Their Hold Rating on Gilead Sciences (GILD),119920001,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3b704c0cb1fc645225bcbb2c349b61367dea030488db40e20ec480d0f1bc6af9
company,2023-04-25 07:45:00,2 Excellent Dividend Stocks to Buy for Less Than $100,119936066,https://s.yimg.com/ny/api/res/1.2/MXckjTYMo1QxWUHTZ9TU2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/d04cc879b02a9819b173099fb2c3d415,GILD,Yahoo,"With that in mind, let's look at two dividend-paying companies whose shares are trading for less than $100 right now: Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE).  The past three years have been an up-and-down battle for Gilead Sciences.  Filgotinib was supposed to be Gilead Sciences' next blockbuster, so this was a blow for the company.",https://finnhub.io/api/news?id=f50a421613e8589ccd80365e8c8be388ee95e54dcccfbdc17f26baef228f76d2
company,2023-04-25 07:31:00,"Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Legend Biotech (LEGN) and GE Healthcare Technologies Inc (GEHC)",119920123,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=821664fd7f62f9d5dd0cb4a29dba5918f9fc9e3bd6d6e26ac3f948f0ddd6d6d4
company,2023-04-25 07:22:48,Gilead Sciences Q1 2023 Earnings Preview - Keeping The Faith,119914465,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Gilead's Q1 2023 earnings will be announced on Thursday, April 27th. Check out my long-term and post earnings price targets for GILD stock.",https://finnhub.io/api/news?id=27468fbdb9e0399493103efc69b88ee40d0873614e8b7a6017556324a7c4b60f
company,2023-04-24 23:40:00,COWG ETF: Investing in Stocks with High Free Cash Flow Margins,119921987,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=06770b90b9fa3851f1e9b3f881857a065944480e550494a6b0f5e9645d4ac892
company,2023-05-02 14:08:45,Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits,120131259,https://media.zenfs.com/en/Benzinga/a2178cbe1700be991182e8be40deb04b,GILD,Yahoo,Gilead Sciences Inc (NASDAQ: GILD) is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help prevent the disease. It generated sales of $147 million in 2022 compared to $371 million a year ago. The FDA approved Gilead's Truvada for HIV prevention in 2012 and its related drug Descovy for the same purpose in 2019. Descovy sales came in at 1.87 billion versus $1.7 billion in 2021. The government i,https://finnhub.io/api/news?id=f7936d2adb9dd0364064776eb4fa21f695c57b34bcf260d5c6343d320152289b
company,2023-05-02 12:56:00,"Gilead Sciences Inc. stock falls Tuesday, underperforms market",120112921,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 1.20% to $80.44 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=1fd542fc6123064070327583565dc7d37ef836c3b04231ffd8f5a9adae98e391
company,2023-05-02 10:46:58,Gilead Sciences battles U.S. government in court over HIV prevention patent,120117392,https://image.cnbcfm.com/api/v1/image/107234190-1683049933852-gettyimages-1235965784-porzycki-companie211018_npov4.jpeg?v=1683053218&w=1920&h=1080,GILD,CNBC,The U.S. claims Gilead's drugs Truvada and Descovy infringe on CDC patents. ,https://finnhub.io/api/news?id=6c1374031043a01f93aedf496bb4dd46241bffb38e219a02b84c848f3b2efd89
company,2023-05-02 06:13:43,Gilead Sciences' (NASDAQ:GILD) Shareholders Will Receive A Bigger Dividend Than Last Year,120103676,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Gilead Sciences, Inc. ( NASDAQ:GILD ) will increase its dividend from last year's comparable payment on the 29th of...",https://finnhub.io/api/news?id=f099806c24db6afa392d17e9b4059e790f4cac4cb2f3ccc572f3cb469651bd5b
company,2023-05-02 05:08:35,"Gilead, US square off in billion-dollar HIV drug patent trial",120102572,https://static.reuters.com/resources/r/?m=02&d=20230502&t=2&i=1631955083&r=LYNXMPEJ4108M,GILD,Reuters,Gilead Sciences Inc is headed to trial in Delaware federal court this week to fight claims that it owes the U.S. government a share of multibillion-dollar profits from its HIV-prevention drug regimen.,https://finnhub.io/api/news?id=6bd14e66b005dca84817c81ca80e34e73177ecf2b99bd2c05a9879a80bfacfec
company,2023-05-02 02:51:00,Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX) and Gilead Sciences (GILD),120106424,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=91fd4a77bfd82634f122e54dee11b3a1237f2c373065f04fac3371bc89dde632
company,2023-05-01 16:05:00,Gilead Sciences to Present at Upcoming Investor Conferences,120094238,https://media.zenfs.com/en/business-wire.com/be4585c1328052ddf94d7ec9edbc6c7d,GILD,Yahoo,"FOSTER CITY, Calif., May 01, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",https://finnhub.io/api/news?id=555513d228e7b194bf26c04cc3d6505a3d25187322b75809284d44cce6e77c2d
company,2023-05-01 14:07:37,Morgan Stanley Maintains Gilead Sciences (GILD) Equal-Weight Recommendation,120083597,,GILD,Fintel,,https://finnhub.io/api/news?id=1b22ed9bfc8c82266401d80219db372cada7c35b1d459d34eea7ff81c614fbb6
company,2023-05-01 12:56:00,Gilead Sciences Inc. stock underperforms Monday when compared to competitors,120112922,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 0.96% to $81.42 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=89d17bac171a4aaa7e3cf75e2d71b315acee9792571d26ceba346dae7fb27930
company,2023-05-01 05:56:00,SVB Securities Remains a Hold on Gilead Sciences (GILD),120089670,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f6439a7f426fc7cf1cdfd0cfa376cc6f4abb5c6aeaaef52cb054aa2532be211f
company,2023-05-01 01:43:26,Gilead Sciences: A Mixed First Quarter,120077208,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Gilead Sciences saw strong sales growth in the first quarter. Click here to find out why GILD stock is a Buy.,https://finnhub.io/api/news?id=5fb1ee9f2ddbae3d8fd295a58232ca03df96ebf095ead50a1d4c4453a33978b8
company,2023-04-30 20:54:02,Gilead Sciences (GILD) Declares $0.75 Dividend,120075262,,GILD,Fintel,,https://finnhub.io/api/news?id=71fb7380892ff8a6a2f928afdebcc4b19f8ab7e944afe87a9835b5f8b6d34654
company,2023-04-29 21:53:06,27 Largest Biotech Companies in the US,120066562,https://media.zenfs.com/en/insidermonkey.com/b5dad9919dcf999502a6a0d2fc5a1f43,GILD,Yahoo,"In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in […]",https://finnhub.io/api/news?id=1c88312f585716d7e65015addc46c9783ad8f961f7a60a18a6b2d39dd896ff7a
company,2023-04-29 08:00:31,"Gilead Sciences (NASDAQ:GILD) sheds 5.0% this week, as yearly returns fall more in line with earnings growth",120052167,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...",https://finnhub.io/api/news?id=201eba1d5d85c4044fb97ad2a3a369134dfdd0e627a424ecd820931d203e9731
company,2023-04-28 20:26:22,RBC Capital Maintains Gilead Sciences (GILD) Sector Perform Recommendation,120032149,,GILD,Fintel,,https://finnhub.io/api/news?id=f7f0dac411344643d1cdc1f4ee2af2e77ef4a836a961bd8472287cffb74f0dfe
company,2023-05-05 12:57:00,"Gilead Sciences Inc. stock rises Friday, still underperforms market",120253430,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 1.57% to $79.75 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=3a37d1f7872dcbe380d47564d42215346ad4f0ae3c390395679cbf56135843fd
company,2023-05-05 10:41:55,"Final Trades: Chevron, American Express & Gilead",120183903,https://image.cnbcfm.com/api/v1/image/107236559-16833081975ED3-FMHR-FINAL-050523.jpg?v=1683312115&w=1920&h=1080,GILD,CNBC,"The ""Halftime Report"" traders give their top picks to watch for the second half.",https://finnhub.io/api/news?id=ca51ef751aed08535eba9317cab8313aa88d16842cc89ea87f53c7e195577515
company,2023-05-05 09:45:00,2 Magnificent Dividend Stocks to Buy Before the Next Recession,120176894,https://s.yimg.com/ny/api/res/1.2/pFNLJvGh1Qkui4XJbZj.NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/b98134e41d42b34e032fa56239bc8174,GILD,Yahoo,Let's look at two great dividend stocks to consider buying before the economy worsens: Gilead Sciences (NASDAQ: GILD) and Amgen (NASDAQ: AMGN).  Gilead Sciences is a biotech company with a particular focus on developing HIV medicines.  It has helped Gilead Sciences' revenue stay afloat as the company failed to earn approval for important candidates.,https://finnhub.io/api/news?id=ae83501a414436acba151a4ee9d41b67e827ca5be33aeffee9c7dea80a5d5937
company,2023-05-05 08:28:41,10 Best Stocks To Buy For A Stock Market Game,120175097,https://s.yimg.com/ny/api/res/1.2/IkagRrpf6IyIILaejIB2hg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/3396bb4f3022d56ffc3c8e8fadaaf1c7,GILD,Yahoo,"In this article, we will be taking a look at the 10 best stocks to buy for a stock market game. To see more of these stocks, you can go directly to see the 5 Best Stocks To Buy For A Stock Market Game. Investing in Penny Stocks In a time when the markets are […]",https://finnhub.io/api/news?id=3ab44b39752976fa02ac3d984abba8c7e5a8fc103a684e4819838b2462167f4e
company,2023-05-04 12:57:00,"Gilead Sciences Inc. stock falls Thursday, underperforms market",120171779,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.17% to $78.52 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=00f35b2e07e09fc155204d86be7ad3883c7dbb660ae9e14e7312a5bc5e528825
company,2023-05-04 07:50:00,Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years,120156038,https://s.yimg.com/ny/api/res/1.2/k7TNnLKxr8ZUAXd.eW1grw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/f4e05e8d519c9750d41d63dc97632c04,GILD,Yahoo,Gilead Sciences (NASDAQ: GILD) has a bright future ahead with HIV treatment Sunlenca obtaining approval from the Food and Drug Administration last year and cancer drug Trodelvy continuing to show strong growth.  Why has Gilead Sciences stock struggled?  The simple reason for Gilead's woes is that the business has had trouble generating growth.,https://finnhub.io/api/news?id=0996671c14cd0311257fae611b4f28fc5544b2c02f707c8792d285bef1692b37
company,2023-05-04 07:00:00,CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV),120156040,https://media.zenfs.com/en/business-wire.com/6e945f39718751c7092ec17e9a5dc619,GILD,Yahoo,"FOSTER CITY, Calif., May 04, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Hepcludex® (bulevirtide) for the treatment of adults with chronic HDV and compensated liver disease, and recommended granting full Marketing Authorisation (MA) that is no longer subject to specific obligations. Bulevirtide was initially granted conditional marketing authoris",https://finnhub.io/api/news?id=9a49d4f00fbff277755a75f13417d79aed942b0804f56c303b361c56686be6ae
company,2023-05-04 03:26:00,Gilead wins EU nod for full approval of hepatitis delta virus therapy,120155436,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=91af5df9fd74ec054a4f4c841ccb5b0b13ae71b7625220fb241685172e68a110
company,2023-05-03 21:30:00,WHO meeting is set to decide whether to end COVID emergency,120154386,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cb27eb61f00c161735bf8db3c861806863f50976b11da1bae0649bf62e6aaa17
company,2023-05-03 21:16:00,GILD June 23rd Options Begin Trading,120155440,,GILD,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=60f08589a1528f6c3f54fcaab9c77716d467bfff56515a9bac6ed0f00836410a
company,2023-05-03 12:57:00,Gilead Sciences Inc. stock outperforms competitors despite losses on the day,120171780,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 1.23% to $79.45 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=227e39091579a593476e0fd1dd663aff155c3a4f835aec1d25b5a281bce7694d
company,2023-05-03 08:20:00,Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts,120131257,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination. Gilead is proud that its medicines have treated over four million individuals living with HCV globally.",https://finnhub.io/api/news?id=27cb66c7e5ea7f05187eeda5f24cf19f4c67122ffb3ee1e11d9352aab1c13ed3
company,2023-05-03 03:00:00,"Gilead Versus AbbVie: The Better Bet After Q1, 2023 Earnings",120118920,,GILD,SeekingAlpha,,https://finnhub.io/api/news?id=0d4c230942ba68dc30952a6cd2c4401d337606bfdba12f5e1b5bfb1fedab8d22
company,2023-05-03 02:00:00,Big Pharma Stocks Offer Income and Growth Potential. The Case for Gilead Sciences and Merck.,120131258,https://s.yimg.com/ny/api/res/1.2/x2Ka12dUg1SE3Y63.JOzeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/1ca4bf28518a6bd571ab5ac634ac797b,GILD,Yahoo,Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy.,https://finnhub.io/api/news?id=61d0a2a0b7cfd8d869755924045f85e16e94a90c0edc294fc81d297bda079596
company,2023-05-02 22:00:00,You Can Have Dividends and Growth. Here’s How. ,120251305,https://images.barrons.com/im-774170/social,GILD,MarketWatch,Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy.,https://finnhub.io/api/news?id=bd7ddc571e6bfe1d56165e6232266a3fb17536cdeb73f5b456e4b0d1c289ed4d
company,2023-05-02 21:45:00,Gilead call volume above normal and directionally bullish,120137396,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1aff4056fe275f12cc9bed489c9b373eb51b9236275d3eff27558422124ce605
company,2023-05-02 20:35:00,GLOBAL BRIEFING: European stocks called up ahead of Fed rate decision,120123695,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b9012660c559255421eab42c8f053d9262db15639a13341095970e4f05906654
company,2023-05-10 12:56:00,"Gilead Sciences Inc. stock falls Wednesday, underperforms market",120376467,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 0.88% to $78.11 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=2930a420711ea61309b67c1b5621d4c141088cccb4c599be47ad7db7190733ca
company,2023-05-10 08:25:00,Gilead Emphasizes Unique Ways To Hire Top Talent,120276260,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"When Jamari Brooks was looking for a new job last fall, he knew he wanted his future employer to have a few key qualities.",https://finnhub.io/api/news?id=ea90748391950b98ce3494db137022b7ebc1e0c91e73c057db355df2f1b5b82b
company,2023-05-10 05:55:00,First Week of July 21st Options Trading For Gilead Sciences (GILD),120272072,,GILD,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=03285ebe72085a146e8d014ea3a79ae803044b538c13cc8f05dc02defde9bda5
company,2023-05-10 05:37:00,Guild Esports expects revenue growth on strong first half trading,120272073,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f09759bad7ba8bf8a4ec95f9cc9b42e941fe45f77f6df5ee4c60076ea91a097f
company,2023-05-10 03:47:00,G1 Therapeutics trilaciclib cuts adverse events linked to Trodelvy in breast cancer patients,120272074,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c0e6eb1b5e97d833a2927917c9e77a36c19619c7dd6d3b35c3b38087396d2a27
company,2023-05-09 16:09:59,15 Biggest Immunotherapy Companies in the World,120248234,https://media.zenfs.com/en/insidermonkey.com/152faade4bb55ed2f80bad06096a951e,GILD,Yahoo,"In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […]",https://finnhub.io/api/news?id=8f2ad8892373ea11de72ee1fef425193dffda9002847b675f7de14867872dc5b
company,2023-05-09 13:24:54,Gilead Sciences prevails in US government lawsuit over HIV drug patents,120259312,https://static.reuters.com/resources/r/?m=02&d=20230509&t=2&i=1632376869&r=LYNXMPEJ480PX,GILD,Reuters,"A federal jury on Tuesday found that Gilead Sciences Inc did not infringe U.S. patents with its HIV-prevention regimens using the drugs Truvada and Descovy, handing the government a defeat in its billion-dollar lawsuit.",https://finnhub.io/api/news?id=2ac1d5298f1496b4f07260143a88cde4d26e222a7f2ca8ff6288d4413153d621
company,2023-05-09 13:23:52,UPDATE 1-Gilead Sciences prevails in US government lawsuit over HIV drug patents,120248541,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"A federal jury on Tuesday found that Gilead Sciences Inc did not infringe U.S. patents with its HIV-prevention regimens using the drugs Truvada and Descovy, handing the government a defeat in its billion-dollar lawsuit.  The Delaware jury found the government's patents were invalid and not infringed following a five-day trial and a morning of deliberations.  The federal government had argued that Gilead failed to compensate the U.S. Centers for Disease Control and Prevention (CDC) for discovering that its drug Truvada, which was first approved to treat HIV, could also help prevent infection by the virus.",https://finnhub.io/api/news?id=93ca5c4cc88ae6464d7db0e4f32d528f31ddbec31099c570f0b6f9c8a84be19d
company,2023-05-09 12:56:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,120253423,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.27% higher to $78.80 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=3374cdcfabdb6bc0f3b34d6dfbe4280c807b6913a5193644502b318e6302c739
company,2023-05-09 08:43:29,Gilead Sciences defeats U.S. government lawsuit alleging HIV drug patent violations,120263533,https://image.cnbcfm.com/api/v1/image/107188826-16754420682023-02-03t155622z_1796503087_rc2q3z99gxf6_rtrmadp_0_gilead-sciences-fda-cancer.jpeg?v=1683650609&w=1920&h=1080,GILD,CNBC,The U.S. government had accused Gilead Science of violating patents for drugs used in the HIV prevention regimen PrEP.,https://finnhub.io/api/news?id=bcae73a567cffa90c797ac41b0c4618c068dc03600f1fe65d17619984e0fba18
company,2023-05-09 08:30:00,Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera,120243069,https://media.zenfs.com/en/business-wire.com/fb9d2ec3762320f95efdde2ab1ba0820,GILD,Yahoo,"FOSTER CITY, Calif., May 09, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation.",https://finnhub.io/api/news?id=3bb835c3b5e2b1f56e9986c520b86f39dcd54582879c90c4d67f686b19011259
company,2023-05-09 08:23:00,Gilead wins jury verdict in patent battle with U.S. govt. over HIV therapy,120258647,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=baa57567f159edce8ac741cbd46f4371189ce3d052809588c204f8f5b2416ecc
company,2023-05-09 05:17:00,"Gilead adds to oncology, inflammation portfolio with XinThera acquisition",120258649,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=47287f752cbae5d2adbd6c31575d8250318ca8657576a2e06fc989e9a6d9d43f
company,2023-05-09 04:44:00,Gilead Sciences to Buy Private Biotech XinThera >GILD,120253424,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Colin Kellaher Gilead Sciences on Tuesday said it is bolstering its early pipeline in oncology and inflammation through the acquisition of privately held...,https://finnhub.io/api/news?id=956b4f08dae4a4efe5866b2af3c30d9ad3883793cf7e271f73a4077900ded71b
company,2023-05-09 04:07:00,"Gilead acquires XinThera, terms undisclosed",120258652,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=20199cdf84ad9fdd914cd002f2ce3e4325371e7b047d9e77efc93141806721e4
company,2023-05-09 02:54:00,Hookipa Pharma announces first patient dosed in Phase 1a/b trial of HB-400,120246238,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f6a8365af1eeeb067813169a388333ba14f630177d8a680c34497a6232f3d734
company,2023-05-08 12:57:00,Gilead Sciences Inc. stock underperforms Monday when compared to competitors,120253426,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.45% to $78.59 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=1c9e122b97857f2982570ba1c426130025d737adca17a3f94d5caa343c36fc57
company,2023-05-08 09:02:00,You Can Have Dividends and Growth. Here’s How.,120232358,,GILD,Yahoo,Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy.,https://finnhub.io/api/news?id=0512e694a5fc732a2a695786b3824c66bc49bef0c491fca4a3f1c678c12eb9cb
company,2023-05-08 05:37:00,Rates Have Risen. Here Are 5 Stocks With Little Debt,120221230,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3924f741acba7f3e5a8db9b92217ef56e50217c80565c08f752b090c3ed8d5d6
company,2023-05-07 22:16:00,Gilead management to meet virtually with Oppenheimer,120230863,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cf5645a5518ccae3866c0b010049fcf72011435ad7036d4a82eba82aea4c064c
company,2023-05-07 08:00:53,"Gilead Sciences, Inc. (NASDAQ:GILD) Delivered A Better ROE Than Its Industry",120210111,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",https://finnhub.io/api/news?id=df901ff2023177069e6493a0b476beaa6620db9687fb6cc3776f6e830f861999
company,2023-05-07 01:30:18,InvestingPro exclusive: 5 biotech beasts to get your hands on,120200602,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"Here is your VIP list of Pro Picks for the week, offered exclusively to InvestingPro subscribers: a hand-picked selection of S&P 500 stocks that InvestingPro awarded a high financial health score of at least 2.75 out of 5.00.",https://finnhub.io/api/news?id=9ed853bc0c6bb8e70c716a25162c328e95befdfcc7a98b39db25e1ce9146f51d
company,2023-05-13 15:10:24,"Gilead Sciences, Inc. (GILD) Presents at BofA Securities 2023 Health Care Conference (Transcript)",120339244,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) BofA Securities 2023 Health Care Conference May 9, 2023 2:20 PM ETCompany ParticipantsAndy Dickinson - CFOConference Call ParticipantsGeoff...",https://finnhub.io/api/news?id=059706fa6065f4f26b44c4720123c1067a65bd2d84ee25b196ee0fb7fbc1c771
company,2023-05-12 12:56:00,Gilead Sciences Inc. stock underperforms Friday when compared to competitors,120376465,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 0.67% to $78.17 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=5843d1ef51ab782bb49356fee2926750d130a1f5f4bdd1d19477ab0ce59b0f71
company,2023-05-12 05:30:00,Gilead Sciences Stock: Bear vs. Bull,120315697,https://s.yimg.com/ny/api/res/1.2/Hrc1M8GDUr23rXMcU6NY6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/5cf361ea6594feca0409c0d767cf36d5,GILD,Yahoo,"You may know of Gilead Sciences (NASDAQ: GILD) because of its blockbuster coronavirus treatment Veklury.  In fact, the S&P 500 has outperformed Gilead over the past five years.  Gilead has struggled to consistently deliver annual revenue growth ever since its hepatitis C portfolio's revenue reached a peak back in 2015.",https://finnhub.io/api/news?id=64d1c765c5d6978906893c9cdf170426950ab6b6b2188fcb7cc317722197dfe2
company,2023-05-11 12:56:00,Gilead Sciences Inc. stock outperforms market on strong trading day,120376466,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.76% higher to $78.70 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=ca19dd09e8e6f99f7ca9c67d8d456e97eeeda01bb7a365a2fd3145d8b5cd9a7b
company,2023-05-11 10:00:36,Here's Why We Think Gilead Sciences (NASDAQ:GILD) Might Deserve Your Attention Today,120313103,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...",https://finnhub.io/api/news?id=1d4489f56e9e1e02aec7b3c899de0e2131420587e0edfd34dbd7ade83b9cffc1
company,2023-05-10 23:55:00,Gilead management to meet virtually with Oppenheimer,120298938,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cf3ed5f57c640f519f59c63316fa0affd23868e80c8d49135f5085ede2bf5556
company,2023-05-18 14:00:00,5 High Yield Stocks With Steady Dividend Growth And An Attractive Valuation,120429097,https://media.gettyimages.com/id/1388913039/de/foto/l%C3%A4chelnder-erwachsener-mann-der-sein-einkommen-f%C3%BCr-den-monat-aufschreibt.jpg?b=1&s=170667a&w=0&k=20&c=uGqYlXbFHJ2MDzlW99xltDtfFbtxYbMkWWGsf1IM-Bg=,GILD,SeekingAlpha,I consider companies that combine a relatively high Dividend Yield and Dividend Growth Rate to be particularly attractive for dividend income investors. Read more here.,https://finnhub.io/api/news?id=f0b9fb79b635e4e5478fb993d8ca9c4362184b62bfd1fe71fba35e74603a89ce
company,2023-05-18 12:56:00,Gilead Sciences Inc. stock underperforms Thursday when compared to competitors,120511403,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 0.76% to $78.21 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...",https://finnhub.io/api/news?id=0bcf4739431cc902db66f3ae22352b178841e291cf04b9dbafccbd422536b657
company,2023-05-18 06:27:00,Arcellx a buy at Truist on unique cancer cell therapies,120419492,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0d137fea305c5cc8e752542260b7977339c915b86f63cb9a760cc045bb83b76c
company,2023-05-17 17:12:09,Former Immunomedics CFO pleads guilty to insider trading,120405915,,GILD,Reuters,"The former chief financial officer of a New Jersey biotechnology company pleaded guilty on Wednesday to insider trading, after prosecutors said he had given nonpublic information about a new breast cancer drug to his girlfriend at the time.",https://finnhub.io/api/news?id=969cbf3f5b65dec2cca9efa7908cec88b16897f75f01336dfb09c5be72be9f82
company,2023-05-17 13:29:03,3 Analyst Upgrades That Smart Investors Won’t Ignore,120476345,https://media.zenfs.com/en/investorplace_417/2f393333fea4657d87e3935ec85b6021,GILD,Yahoo,Even the most experienced investors have only so many hours in the day to perform their due diligence. That’s where analyst ratings can be helpful. Analyst upgrades and downgrades frequently move stocks. Analysts spend a great deal of time covering a particular stock or an entire sector. This gives them access to information and company insiders that retail investors don’t have. One of an analyst’s key responsibilities is to issue a rating and/or price target for the stocks that they cover. Many,https://finnhub.io/api/news?id=fb4e28eb6e000a71d2deaa6c1662b2748619edc8b5013cac1821fb558ea7f9c9
company,2023-05-17 12:56:00,"Gilead Sciences Inc. stock rises Wednesday, still underperforms market",120511404,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.63% higher to $78.81 Wednesday, on what proved to be an all-around great trading session for the stock market, with...",https://finnhub.io/api/news?id=e6f494385787b32d3e51d4ad74ecb3e48beeee0ea8671cf56c3816dd0fe80e89
company,2023-05-17 08:32:00,3 Analyst Upgrades That Smart Investors Won`t Ignore,120399065,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e2300345991ab36a14016adef015493a2bfa1d1791e4fd0ffe4e693e9cee4351
company,2023-05-17 08:30:00,Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023,120391749,https://media.zenfs.com/en/business-wire.com/8b8d7e72a60225cce5ce5abfa1279965,GILD,Yahoo,"FOSTER CITY, Calif. & SANTA MONICA, Calif., May 17, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 30 abstracts during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These data reinforce the strength of Gilead and Kite Oncology’s transformative science in hard-to-treat cancers.",https://finnhub.io/api/news?id=1bc0cb8791faf9ae47e36f2bf5d99f0d6be20f2d37c8b1680e4004735a445c7b
company,2023-05-17 07:11:00,Gilead taps former Roche exec to lead Kite unit,120404191,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2486909f67bc7366374676ff3c4047e079be6baba54b64ec9fb7727ad1bd5d33
company,2023-05-17 06:25:00,GILD Makes Notable Cross Below Critical Moving Average,120405215,,GILD,Dividend Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1bea7fcd15ffbce8ac90b2f30ef91102c817d277c9dfcce948d5fb7fcce8acde
company,2023-05-17 03:38:00,Gilead to present advances across its oncology pipeline at ASCO Annual Meeting,120405217,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fa91a17bc2f1187ca845e8fc89db029eed5dc80f946b5692e3e439fb78da114d
company,2023-05-16 16:01:00,Gilead Appoints Cindy Perettie Executive Vice President of Kite,120385568,https://media.zenfs.com/en/business-wire.com/50c3628bae40b8c48064a88f30ba24ad,GILD,Yahoo,"FOSTER CITY, Calif., May 16, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’s senior leadership team, effective May 30.",https://finnhub.io/api/news?id=eba55f5a5e031667eeddaadf742d2b6a26f9c5df1e10b89ac7bef595b564c48f
company,2023-05-16 12:56:00,Gilead Sciences Inc. stock outperforms market despite losses on the day,120376463,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. dropped 0.08% to $78.32 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=c7a5e39d034616f6e5dd31f125a83bd63662d091dcc6419a9f0548cb8eb1cad3
company,2023-05-16 12:27:37,BMO Capital Upgrades Gilead Sciences (GILD),120370423,,GILD,Fintel,,https://finnhub.io/api/news?id=bab2812f154db395dce2cc723aa1d2f1e925ada8a2982430220d46b9ef00d0b2
company,2023-05-16 09:31:01,Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases,120383735,https://media.zenfs.com/en/zacks.com/3b6072b30ddd43fb75a7496ced0a8833,GILD,Yahoo,"Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.",https://finnhub.io/api/news?id=a661d51ee36c9edb6419dd13f5ac4ba9753027bb4d9d3005d79359c7d42667ee
company,2023-05-16 09:22:11,"Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference (Transcript)",120371395,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) RBC Capital Markets Global Healthcare Conference May 16, 2023 11:00 AM ETCompany ParticipantsMerdad Parsey - Chief Medical OfficerConference Call...",https://finnhub.io/api/news?id=b15ec4f40929edbded6800ad0925cfb29ce146ca79178ea42ffbf29cdc98a8b4
company,2023-05-16 08:32:00,What To Expect From GSK In 2023,120370173,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=462be399f26d8a6c2d424b91befe84f483c52f1d4a2219706d661c0be8aee284
company,2023-05-16 07:05:00,What You Missed On Wall Street This Morning,120369873,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=aaaec78e94cd93d328c41da1afc5a78bd224604a5e6e8bdc989a1a0e6cfc0577
company,2023-05-16 06:45:00,Abortion pill case heads back to federal appeals court: What`s at stake,120370977,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4d88ae8b28b60020362cb3ba3dffea97428cba30947a9ffb85c5da98db589f50
company,2023-05-16 06:15:00,GDC Stock Alert: Why Is GD Culture Group Up 106% Today?,120370978,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fa94329acd3a709c8bfff157d973f258693394e31046e5307ae783cabf530c72
company,2023-05-16 06:14:13,Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year,120365736,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"The board of Gilead Sciences, Inc. ( NASDAQ:GILD ) has announced that it will be paying its dividend of $0.75 on the...",https://finnhub.io/api/news?id=a9910c57258dba29bc3381a3f946b22c01f2200073ef889bdfa38bec1dd9339e
company,2023-05-16 05:42:00,Why Is Guardforce AI (GFAI) Stock Up Today?,120370813,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=10d18a3dd4ffafde63fa339f6190d0ec1e63e2ec285665b3f96332003914bfe5
company,2023-05-16 05:25:00,GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100?,120370814,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=14f450d6d8c7997e66d09c30d032387bb0d4b8ceca5636f2ebb11d223802e502
company,2023-05-16 04:59:00,"Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations",120369589,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=59ad2917a6aa52955086f8a07192d79e292c80eda28ed87ef579d759da1d5ed0
company,2023-05-16 04:00:00,"Ensoma Closes Series B Extension, Bringing Total Round to $135 Million",120370982,,GILD,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8d5640af8ce1ccb13c49216143a3ce1c7c8fe8768ceea2d1fced4a319a356712
company,2023-05-16 03:39:00,What You Missed On Wall Street On Tuesday,120394064,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7b4d84ec843554905c23b7c7d576c85d897d1dbe35c75751500919afdd166069
company,2023-05-15 23:40:00,Gilead upgraded to Outperform from Market Perform at BMO Capital,120370983,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c4fefcb6973bd888358480b7c417ee01139ea09d88b0fec51514d78030bd502a
company,2023-05-15 23:35:00,Positive Report for Gilead Sciences (GILD) from BMO Capital,120370984,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b917d3db24536b7de153c5d5bd20a9644e56ac1f131f54a866b44d3778a1ed58
company,2023-05-15 12:56:00,"Gilead Sciences Inc. stock rises Monday, still underperforms market",120376464,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.27% higher to $78.38 Monday, on what proved to be an all-around favorable trading session for the stock market, with...",https://finnhub.io/api/news?id=30d6e342f2eba3a0abac897546efe626d5bc9373fc6bd6ac3d72302125ce7fd9
company,2023-05-15 08:30:00,Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation,120359244,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"FOSTER CITY, Calif., & HAYWARD, Calif., May 15, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead’s growing presence in inflammatory disease and serves as a step towards broadening Arcus’ capabilities and portfolio beyond oncology and into",https://finnhub.io/api/news?id=73900228227a335bf6f6fbfa15b2c65f46430db42f913427c957d4db402d9d87
company,2023-05-15 05:29:00,Gilead expands research with Arcus to include inflammatory disease,120353850,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=beb23a20394846f08bd231aa34e31747288da8bbe06af68ef566d31fa650276e
company,2023-05-15 04:27:00,Gilead projects earnings impact after expanding research deal with Arcus,120353853,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c1b2f92bc6a1127f6a5f00eccf628857e4ed1ad982a011cbd0968019dd8fc4fa
company,2023-05-15 04:05:00,Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead,120353854,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=186243160e963dae15c9b3932aa24772c7faa3fc3b17d77cf5c8582820a13c0f
company,2023-05-15 03:56:00,Gilead: Arcus deal may reduce Gilead`s FY23 GAAP and non-GAAP EPS by 2c,120353855,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e548cf232c09cbcda890ba659dc035bc50590ba98ea15ccf12c7fa052a7de008
company,2023-05-15 03:52:00,Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus,120353856,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=94aa5bf211b0ac19100e70a020e600b7daacc5d46789e2ef427149b457c7a6c4
company,2023-05-15 03:49:00,Arcus to receive upfront payment of $35M from Gilead in expanded research pact,120353857,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=516eaa0a57e58a774e67a868a0942169234b382b781a7fa6eb4b666b8b898965
company,2023-05-14 23:13:00,Gilead Sciences Strikes New Deal with Arcus Biosciences,120370986,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=de163ccc387464fefd4aa2eedcfa178431a45f9e9ea49c76013defc2d05c5cca
company,2023-05-22 12:56:00,"Gilead Sciences Inc. stock falls Monday, underperforms market",120511401,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. sank 0.29% to $78.62 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=2facf747c920981820004ad23bd757f244e354d1a468643d78d60ea2b92317fa
company,2023-05-22 05:33:00,Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years,120489024,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=158c733784999860cc8f031ff17a1ce741e3e06c5e36df327f645a2396627cdb
company,2023-05-21 10:00:13,"Gilead Sciences, Inc. (NASDAQ:GILD) is favoured by institutional owners who hold 85% of the company",120473409,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...",https://finnhub.io/api/news?id=e40b91120a05dabf0a3975d72cb03c2c08e0a898f158664cca483ca63f70dc71
company,2023-05-21 07:01:00,Billions of dollars at stake as FDA shortcut allows half-proven drugs - report,120472958,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a50e5b8a8c0517c654a3de5252893321a2f0444c3f5d49324a52104d8618c929
company,2023-05-20 06:14:00,3 Relatively Safe Stocks to Buy if a Recession Is on the Way,120461726,https://s.yimg.com/ny/api/res/1.2/BaeG7ifM.K1cghyjC8_Q2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/f333844b90310ae3b29796b868e66197,GILD,Yahoo,"Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year.  Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.",https://finnhub.io/api/news?id=a096cb3518b734960d6adf5e90be617f93dcf506dd2e0c0689a494595d2538d7
company,2023-05-19 12:56:00,Gilead Sciences Inc. stock outperforms market on strong trading day,120511402,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.81% higher to $78.85 Friday, on what proved to be an all-around dismal trading session for the stock market, with the...",https://finnhub.io/api/news?id=e150d92f3c7728c951a7202224a383b35f4146d322df80e4d98500003d1e6fe0
company,2023-05-18 22:03:00,"Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference",120451038,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fa5a19489018c331692b679586f7a46c492b8c8b70ffa4ac8352f9264b0f101b
company,2023-05-26 12:56:00,Gilead Sciences Inc. stock underperforms Friday when compared to competitors,120677621,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 0.72% to $77.09 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=ecf99f86c302522f2ef1022d5770d91e3e6e505dab36c77a1361a8d2c6f9675b
company,2023-05-26 11:39:00,Gilead's Veklury gets positive opinion from EU's CHMP for Covid,120587326,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=09f8b6cbcf96bef835bc8fd87a06e283a6ded7db225b15c37cb07dc1f42f1dda
company,2023-05-26 10:30:00,Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use,120581420,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,"Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.",https://finnhub.io/api/news?id=99cebdc08e4ad949a3585fbb26c2e0bd2de11b711054a5ab2e8bd82e555417aa
company,2023-05-26 08:40:00,10 Health Care Stocks Whale Activity In Today's Session,120570829,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d3029cec4039e56d2e83ccb14764ccd9a0882bd26c7ecc6f2310c54e4d64df6a
company,2023-05-26 07:42:00,Drugmakers Released a Ton of New Cancer Treatment Data. The Biggest Developments.,120573421,https://images.barrons.com/im-789674/social,GILD,MarketWatch,"Ahead of the American Society of Clinical Oncology meeting, Pfizer, Merck, and other companies released scientific abstracts of papers that they'll present...",https://finnhub.io/api/news?id=e4def52fb8da15bb0346c2a0ace3cd2fdf6c721d7879cfef0736ecbb12e894aa
company,2023-05-26 04:25:00,TD Cowen pharma/biotech analysts hold an analyst/industry conference call,120570461,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=95a1f011294a9e01a64863124222cc67d32e52e6ebbb3223817f565854938a54
company,2023-05-26 02:09:00,Gilead's COVID drug Veklury gets EMA greenlight for expanded use,120570832,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ee0ddbb385c1976bacf36e8ca3aeb6c172dfc0bc19c26810f5efc4db5063f111
company,2023-05-26 01:00:00,"CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis",120560054,https://media.zenfs.com/en/business-wire.com/6bfba4c86c842b700160e2bc7df96089,GILD,Yahoo,"FOSTER CITY, Calif., May 26, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that",https://finnhub.io/api/news?id=e4ae41cc4581274693d68e064e824d4921be37645856cf48d050b43c42e7827c
company,2023-05-26 00:09:00,Gilead announces CHMP reccomendation for the use of Veklury,120570833,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a54f90c39248e4b3c3e10bf6b20ecdde693b71886c0fd3cbb8ade937fad0cee7
company,2023-05-25 16:05:00,Gilead Sciences to Present at Upcoming Investor Conference,120553142,https://media.zenfs.com/en/business-wire.com/d5295968838ab35ce63b6952275ae95e,GILD,Yahoo,"FOSTER CITY, Calif., May 25, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:",https://finnhub.io/api/news?id=33be5f6116509e7484ffb47e25a9b4a54c2106b24cd74525d83abbeeb83e2e6e
company,2023-05-25 13:58:00,Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark,120553144,https://media.zenfs.com/en/ibd.com/3417047a4b024123b3a81ee1e1f53d5e,GILD,Yahoo,"Gilead Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.",https://finnhub.io/api/news?id=7e9b51ebcf00278b52f01bb0d47122fa1c43eedb0aaca635003cdc9b55c9e5c5
company,2023-05-25 09:40:00,How Gilead’s Supportive Culture Helps Working Parents: LJ’s Story,120543303,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / May 25, 2023 / Gilead Sciences When LJ Mizzi joined Gilead in 2013, she already had a personal connection to the company. ""A Gilead medicine saved the life of a loved one, so I was excited to begin a career here ...",https://finnhub.io/api/news?id=c1ee00f7d7cbb0458e1c33116254b068dca9cdef8344b71e02600965370cef59
company,2023-05-25 09:00:18,Here's Why Gilead Sciences (NASDAQ:GILD) Can Manage Its Debt Responsibly,120543304,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...",https://finnhub.io/api/news?id=e88319360166574e58ec6a04352e5f217ba98dd31d8cc99d5cd04dd1d49d3d90
company,2023-05-25 07:25:00,Gilead call volume above normal and directionally bullish,120570837,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f2e79472718ab873e0a1d8aa2b9544356ee67c94c01d2927ef898842a7f2e326
company,2023-05-25 04:03:52,14 Best Biotech Stocks To Buy According To Hedge Funds,120540154,https://s.yimg.com/ny/api/res/1.2/RCKFyA_Orx5i7EcMSHyUbA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/bbad2545b3b325a6c633bba783765287,GILD,Yahoo,"In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […]",https://finnhub.io/api/news?id=ff97a82c779b607e8ec2abb9b141fe2da3a4c3bcde3559a105108d76f5c06c56
company,2023-05-24 23:58:00,"Gilead Sciences Inc. stock falls Thursday, underperforms market",120570838,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=312a44f052932b69a77e1908c7b44e474667fd803dbe3e3ace8533fef7524e7b
company,2023-05-24 16:08:36,Lightning Round: Cloudflare has had a couple bad quarters but should be able to 'get it together',120536554,https://image.cnbcfm.com/api/v1/image/107246348-MM-Block-E-052423_mezz.jpg?v=1684973316&w=1920&h=1080,GILD,CNBC,"Mad Money' host Jim Cramer weighs in on stocks including: RB Global, Cloudflare, Bank of Hawaii, Mosaic Co., Gilead Sciences, and Lendingtree.",https://finnhub.io/api/news?id=641a8433fb456f92d085909603914a9cd93c5c4fb08f9b3cbeb4dc57a62a729b
company,2023-05-24 15:35:46,Cramer's Lightning Round: Stay away from Gilead Sciences,120536532,https://image.cnbcfm.com/api/v1/image/103507374-104044814.jpg?v=1684971346&w=1920&h=1080,GILD,CNBC,"""Mad Money"" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.",https://finnhub.io/api/news?id=5ab00767ed2e4c667d30b84551e5c1278fe58f0a8b0d6039f6b336940f2970bb
company,2023-05-24 09:33:42,14 Best Healthcare Dividend Stocks to Buy,120523010,https://s.yimg.com/ny/api/res/1.2/LpeLzVwmxDy9X.S3vQSw6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/d444fce460f8346168e0a6e22d29c70d,GILD,Yahoo,"In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and […]",https://finnhub.io/api/news?id=11f85b0d3f236c244a28f1baaff6e1091900b3b55ea41612a6751b76dc852a53
company,2023-05-23 23:58:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,120531287,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=98bac8d49985f9bf37150954617f7b9852603e6ec2afdd90b9503230b7e7f73e
company,2023-05-23 12:56:00,Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors,120511400,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 0.05% to $78.58 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=2b854ec0844552a2f1e0f8ace993f6228844537120235b9514b0fa5e79252208
company,2023-05-23 05:45:00,My Dividend Stock Portfolio: New April Dividend Record - 99 Holdings With 21 Buys,120496046,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1406742992/image_1406742992.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Markets are racing higher as earnings season turned out much better than expected. Click here to read more.,https://finnhub.io/api/news?id=a3705ed2635688ef318e1f8897fb904ce4ece3cfd6569f71f3c54e17a5509aca
company,2023-05-30 12:57:00,"Gilead Sciences Inc. stock falls Tuesday, underperforms market",120677619,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. dropped 0.99% to $76.33 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=022cb3dff7cdb004d337f2c3481408d94146b73867d52d38bfe6c8f72b30f013
company,2023-05-30 06:15:28,Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year,120610915,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Gilead Sciences, Inc.'s ( NASDAQ:GILD ) dividend will be increasing from last year's payment of the same period to...",https://finnhub.io/api/news?id=8c74e02e3c38234152bad048d066ce23608eb81879114ce721d3281bf6e6afcd
company,2023-05-29 22:24:00,Oppenheimer biotech analyst to hold a reception,120616066,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=09626c437766390c804e459da5921cff37bf9bd1321d149b0fb3cb9eca301c4f
company,2023-05-28 22:01:00,Drug pricing watchdog raises alarm over upcoming liver disease meds,120603357,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d7f242e500168e71b77543e060f2f8e93537bf675e5a009c9ea0f9821d37a4c9
company,2023-05-27 08:41:00,Stocks Going Ex-Dividend In June 2023,120587325,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a01a256b2b94fad49214703620bc3288854cd1a1108315bd534adee239cc8f2d
company,2023-06-03 13:30:00,Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study,120696841,https://media.zenfs.com/en/business-wire.com/afeeeacbae95ca23db882948521d71aa,GILD,Yahoo,"FOSTER CITY, Calif., & HAYWARD, Calif., June 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. ARC-7 is the first Phase 2, randomized, open-label study evaluating the comb",https://finnhub.io/api/news?id=923a05644495480578ac99bb6f784c10686e6dd316fba4626929e8b8082e377e
company,2023-06-03 06:14:00,3 Dividend Stocks You Can Buy Without Any Hesitation,120689009,,GILD,Yahoo,"Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors.  Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation.  David Jagielski (Bristol Myers Squibb):  Bristol Myers Squibb has been paying dividends for more than 90 consecutive years.",https://finnhub.io/api/news?id=c34ac526147347a0638c200a91c7d048e726c95b0be7041d1c03f91c23303062
company,2023-06-02 23:53:00,"Gilead, Arcus announce updated results from interim analysis of ARC-7 study",120695037,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a7f57421691473adc601385197d45107576ac660a837867bad75187d7c36b1eb
company,2023-06-02 12:41:00,Gilead Sciences Inc. stock outperforms market on strong trading day,120677614,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 2.20% to $77.89 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=a8666a33f1237302717fb7f62377136b4f3e9fd50eea43ff45e351466de4f3e2
company,2023-06-02 07:55:32,3 Undervalued Biotech Stocks to Buy Before They Blast Off,120773075,https://media.zenfs.com/en/investorplace_417/82c6c2cedce4e93bbf33a1bd53260198,GILD,Yahoo,"When investors hear the words “undervalued biotech stocks to buy,” they frequently think of companies in the clinical trial stage. That’s understandable. If you can buy a company’s stock before it releases a game-changing drug or therapeutic into the market, you can make a fortune. That line of thinking was displayed in 2020 when many biotech companies raced to produce a Covid-19 vaccine. But every investor also knows that many of those moonshots never pan out. That’s not the kind of uncertainty",https://finnhub.io/api/news?id=1ca9c88f62ee25365944b5ba5e2f8bc9136d6f2e691ee32c3fc5a651cf788026
company,2023-06-02 03:26:00,"Gilead continues to make regulatory progress, says Argus",120679563,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a9d72f81024f3021c52bc0c65a2b5796e76e8ee4f41b0a1b5cfe48612200da1f
company,2023-06-02 00:55:00,Oppenheimer biotech analyst to hold a reception,120679379,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=086230cd9ef7a222e6c074fd1496c6441cfb9f73161603984e43a88393bc3de1
company,2023-06-01 23:39:00,Cantor Fitzgerald biotech analyst to hold analyst/industry conference call,120677328,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2507bec23db23883270ab9913737f5dfd5ccb09cf05dae59e402940d59a0768b
company,2023-06-01 22:06:00,"Catalyst Watch: Apple's WWDC event, OPEC fallout and REITs on display",120674384,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f71b988360cb9235012c51a5240d20a870a41fa0baf4ccc41cf044a64892ace9
company,2023-06-01 12:57:00,Gilead Sciences Inc. stock underperforms Thursday when compared to competitors,120677615,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slumped 0.95% to $76.21 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=99c2050501153bdd87a27f72aec0a066c4283f3b605eeb28a4a5e0b852a34865
company,2023-06-01 10:04:07,15 Best Healthcare Stocks To Buy Now,120643076,https://media.zenfs.com/en/insidermonkey.com/d7b54ab6c172424f8eb29273c1277201,GILD,Yahoo,"In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products […]",https://finnhub.io/api/news?id=ebea16d843bf7aab37bb8209b8787431f61c079024b1439aa6de40c2b8485f1a
company,2023-06-01 08:34:00,Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA,120652184,https://media.zenfs.com/en/business-wire.com/c6ab28cbe591b884b5d4605ae1830072,GILD,Yahoo,"FOSTER CITY, Calif. & SANTA MONICA, Calif., June 01, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15.",https://finnhub.io/api/news?id=b237beb3d43d4326f825aa5cdb61b2f033db24aedd662d667e60f1b1a5cc54a4
company,2023-06-01 06:40:00,July 14th Options Now Available For Gilead Sciences,120649571,,GILD,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5a3954f435e1970b1f54bcf1ee499af43496638e6b4809c48e37312d34289b03
company,2023-05-31 16:29:15,2 Large Cap Biotech Stocks To Watch Right Now,120632455,https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/05/large-cap-stocks.jpg,GILD,StockMarket,Large-cap biotech stocks to check out in the stock market today.,https://finnhub.io/api/news?id=0ffc0d197a737838838fe1d82b5095fe1b49ab34888c21a8c3f6e44b1a1b26a4
company,2023-05-31 15:11:44,Gilead: Pharma Play Worth Watching On Multitude Of ASCO Data Readouts,120635288,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458990823/image_458990823.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Gilead Sciences, Inc. is expected to offer 30 Abstract Presentations at the ASCO 2023 meeting to be held between June 2 - 6 of 2023. Click here for more on GILD stock.",https://finnhub.io/api/news?id=e5c2f03693dc99f48d4d6222830e105cf364724fe199b40f2b17005b2da1ade2
company,2023-05-31 10:45:00,Bilal Piperdi on How Gilead Is Striving To Create New Possibilities for People With Lung Cancer,120640171,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"After finishing medical school in the late 1990s, Bilal Piperdi wanted to follow his mentor into the field of thoracic oncology, the specialized area that focuses on lung cancer.",https://finnhub.io/api/news?id=63c6c8b7a099595ec20f51ff8fa940ffb5a8c27314d9e0984b51afff856f831c
company,2023-05-31 01:55:18,Gain Therapeutics: Undervalued Based On Drug Development Platform And Lead Parkinson's Asset,120625179,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284442724/image_1284442724.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Gain Therapeutics is furthering drug development in unique way and SEE-Tx platform may be useful for a larger pharma company. See why I rate GANX a strong buy.,https://finnhub.io/api/news?id=b8358a8b1cdecc145d4daf2efba32f1aee8546ac3ea5cd412a630441ffec20ea
company,2023-06-07 17:50:11,Gilead Sciences (GILD) Stock Moves -0.16%: What You Should Know,120769287,https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af,GILD,Yahoo,"Gilead Sciences (GILD) closed the most recent trading day at $76.08, moving -0.16% from the previous trading session.",https://finnhub.io/api/news?id=6640a11faa0b6b969e78cdb2f0f839f4638d7181698bcfb06409586d8bd957a3
company,2023-06-07 12:41:00,"Gilead Sciences Inc. stock falls Wednesday, still outperforms market",120764437,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. sank 0.16% to $76.08 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",https://finnhub.io/api/news?id=7d8d876b2e871569a8b4e6bf046399fc620c6ef99f5b9ca21ad345a63aeedfc7
company,2023-06-07 11:02:09,"Gilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference Transcript",120755902,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Jefferies Global Healthcare Conference June 7, 2023 11:00 AM ETCompany ParticipantsJohanna Mercier - Chief Commercial OfficerConference Call...",https://finnhub.io/api/news?id=6770977138c242cf5d649010496f7b584a0f065f13e6b088fca0d6b484906d5c
company,2023-06-07 09:45:00,Gilead Sciences: Living with a Rare Blood Cancer: Marion’s Story,120748927,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"Marion grew up very healthy, never even getting colds or the flu - but that changed as she got older.",https://finnhub.io/api/news?id=fc1032e78322a34d3804de9d0cdb03efe93df945c93e586150cc90eefd909734
company,2023-06-07 08:55:15,3 Biotech Stocks That Could Skyrocket in the Next 12 Months,120842766,https://media.zenfs.com/en/investorplace_417/abb62565aa02e0bf792b5122cb8c7077,GILD,Yahoo,"Navigating the turbulent waters in the biotech space is no mean feat. With the sector’s inherent volatility due to testing clinical trials and regulatory hurdles, the road toward market approval can be incredibly challenging. However, for the savvy investor, promising biotech stocks to buy can translate into significant returns. According to Grand View Research, the global biotech market reached an impressive $1.37 trillion valuation last year. Additionally, analysts anticipate a compound annual",https://finnhub.io/api/news?id=9e352f5e86e9f4e9b3af192db2b5f68760dccba3ca4d4fea375cc4ed749de62c
company,2023-06-07 06:31:00,Gilead Sciences Enters Oversold Territory,120754354,,GILD,Dividend Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b0bc36f86e465247968e89b3a5a80d818d0926c3583a87c42d8c0d8cf45729eb
company,2023-06-07 06:00:00,AbTherx Announces License Agreement with Gilead,120748928,https://media.zenfs.com/en/accesswire.ca/768ca10f7dc1c42287dbcea13c1375f7,GILD,Yahoo,"AbTherx, Inc., a privately held biotech company focused on accelerating the discovery and development of antibody therapeutics, today announced a license agreement with Gilead Sciences, Inc. (NASDAQ:GILD). The license agreement will provide AbTherx rights to Gilead's recently acquired novel transgenic mouse technologies, which were developed by three of the AbTherx founders.",https://finnhub.io/api/news?id=6f49cdc36b3ccec4c2dfed240249c749cce06acbd07f9a55e68f55bcbc25b864
company,2023-06-06 12:47:00,IN BRIEF: Gilead reports Tecartus study shows good response rates,120738738,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a3b6de50fa748117cca097c458d45b1957ee0e838bb236ff6cd82ed792ed4a86
company,2023-06-06 12:41:00,Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors,120764438,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 1.96% to $76.20 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=1882f4f86985950c6e2a17099dd7a90da968955f26d7a15c48b6c2a3aa41117d
company,2023-06-06 10:45:00,Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma,120733684,https://media.zenfs.com/en/business-wire.com/661638fbb8f6cbd47ea15e2dd7b43608,GILD,Yahoo,"SANTA MONICA, Calif., June 06, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announces findings from the largest real-world analysis to date of Tecartus® (brexucabtagene autoleucel) in patients with relapsed or refractory mantle cell lymphoma (R/R MCL), which show that outcomes of Tecartus therapy had consistent high complete response (CR) and overall response rates (ORR), regardless of type of prior treatment, including: Bruton's tyrosine kinase inhibitor (BTKi), bendamustine or autologous",https://finnhub.io/api/news?id=ee541f82afbd5ac3aa57abf6ef15484909141b82adc4795060fd87672d763977
company,2023-06-06 08:25:12,U.S. Wide-Moat Stocks On Sale - The June 2023 Heat Map,120730335,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912585074/image_912585074.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Our 3-step process focuses on wide-moat stocks (as per Morningstarâs rating). Click here to see the heat map of the most investable candidates for June 2023.,https://finnhub.io/api/news?id=77ade76b1d189a7ba56be21588d13cc29c5e5a671975736cb6fd8e2e32be1295
company,2023-06-06 05:49:00,Gilead says Tecartus demonstrates 78% CR rate in real-world evidence analysis,120738741,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d52e6768b4023924906dc7676f5ee476131888568b82504b74e0a2490a4e5d79
company,2023-06-06 05:36:00,Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today,120738742,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a47c9d909f04d0ba21abb580969288debd1122a1c5b91edf542f91ec054e71f7
company,2023-06-06 02:46:00,Why Gilead Sciences is a Top Socially Responsible Dividend Stock (GILD),120738744,,GILD,ETF Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7ce5115643af4f6c81e982cab629ee255e49a00bac51797a8bf4d5fcf461459d
company,2023-06-05 23:36:00,Barclays Reaffirms Their Hold Rating on Gilead Sciences (GILD),120737517,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1c701fbdcecc9483246b51d952c7c7455837631a15f27c2b55586395a940c9c0
company,2023-06-05 14:59:00,"Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study",120719330,https://media.zenfs.com/en/zacks.com/b88587d85bdf7a8fc9be77361a35fcb2,GILD,Yahoo,Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.,https://finnhub.io/api/news?id=b33bbdb0b05e543574e41eedbd841e276886235cbb8ad048aba871a8b239a2dc
company,2023-06-05 12:40:00,Gilead Sciences Inc. stock underperforms Monday when compared to competitors,120721244,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. dropped 0.22% to $77.72 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=c21bd4b6e39fb0cf6bcac1e4603414b6a75b8037a865c9a952dbf7b9e8321a63
company,2023-06-05 12:30:00,Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer,120713078,https://media.zenfs.com/en/business-wire.com/7757394bc21351ccf65a000232bd337c,GILD,Yahoo,"FOSTER CITY, Calif., June 05, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced longer-term overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- (IHC0, IHC1+, IHC2+/ISH-) metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In this exploratory analysis, Trodelvy demonstrated a clinical",https://finnhub.io/api/news?id=a9684e27c8157f3e98642aec3081e88c7b1e48d745db9a62470bed738bca91bd
company,2023-06-05 11:25:00,Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma,120713079,https://media.zenfs.com/en/business-wire.com/a188f63ea8afac44bda5480445e0ee86,GILD,Yahoo,"SANTA MONICA, Calif., June 05, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announces detailed results from the overall survival (OS) analysis of the landmark Phase 3 ZUMA-7 study of Yescarta® (axicabtagene ciloleucel [axi-cel]) CAR T-cell therapy compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Yescarta is the first treatment in nearly 30 years to demonstrate a significan",https://finnhub.io/api/news?id=9dbaf7d5768555a7f1770ba511d70aea2ea4d04e758130aad17d07e4e9d05efe
company,2023-06-05 10:44:00,IN BRIEF: Gilead says Trodelvy shows survival advantage in study,120738747,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1213b54ea8634f9e0ca6155883a0ff863f1ab6c2441710dc2c2d7f2b5ef74284
company,2023-06-05 07:34:00,Gilead: Trodelvy delivered meaningful improvement in median OS in study,120712723,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4c7a2a2260c651bf52bec14c07d7315c4da7f7647d8ac2b68444201f4ff5eccb
company,2023-06-05 06:28:00,Kite's Yescarta CAR T-cell therapy shows longer OS vs. SOC in study,120712725,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=38187ea1e354d68ed3252ac982c3419d5de780e2449d98a9dba1964a3861f0b9
company,2023-06-05 03:20:00,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), IGM Biosciences (IGMS) and GT Biopharma (GTBP)",120712726,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=aea2ef6dd7922c476b9e74f8415cf0e62ea458b4bada4b02d4e684c521f2338d
company,2023-06-05 02:15:00,Gilead Sciences (GILD) Receives a Buy from BMO Capital,120712727,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2e88ac4a6646b275874743cde79cee7e196ff5b8d43239401fc62ff7cc65a87d
company,2023-06-04 23:43:00,Gilead says new lung cancer antibody still improving survival rates,120712728,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3dd11efc105349ab514fb94de9e4adc3a10c8d8fcbc353e45aad4e8d9170947d
company,2023-06-04 22:25:00,Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.,120716191,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=07781a4488da2a2f2b16143ab9086452b067198e0b71b6f3453946b1aa0779a5
company,2023-06-04 07:00:15,Those who invested in Gilead Sciences (NASDAQ:GILD) a year ago are up 28%,120698947,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...,https://finnhub.io/api/news?id=c67876f31bb3aee7f185188468ae5bd95fab7d8bba741184956ea8e7a22157d4
company,2023-06-04 04:16:00,Mizuho Securities Keeps Their Buy Rating on Gilead Sciences (GILD),120712729,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4e6a6d19c5da7b62513c4f24c3c119f114b555bc64da6bc6508764abbf160c9a
company,2023-06-04 03:30:00,Wall Street Breakfast: The Week Ahead,120698237,https://static.seekingalpha.com/uploads/2023/6/3/stock_market___generic_13__5_.jpg,GILD,SeekingAlpha,Investors head into next week with the debt ceiling crisis resolved for the near term.,https://finnhub.io/api/news?id=53b32f5589ce875fff458b1a890f740bc67e95765ab4201ed25b912884262d3f
company,2023-06-11 04:41:55,"Dividend Champion, Contender, And Challenger Highlights: Week Of June 11",120817256,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the full weekly update.",https://finnhub.io/api/news?id=611bc93b2758edd80788ff91d3fca6d2a56bb93df004c26f704fa3765f0dca1d
company,2023-06-09 12:41:00,Gilead Sciences Inc. stock underperforms Friday when compared to competitors,120807284,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 0.36% to $78.12 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=58afbce5ba944bb7d3deb0cbb5af5e62bdc89888266f452a0cc61da49ef28934
company,2023-06-09 10:15:00,2 Top Biotech Stocks to Buy in June,120793310,,GILD,Yahoo,"Biotech stocks have taken investors on an unpredictable ride so far in 2023.  Two of the better biotech stocks I see this month are Gilead Sciences (NASDAQ: GILD) and Vertex Pharmaceuticals (NASDAQ: VRTX).  While Gilead's shares are down more than 11% so far this year, Vertex's shares are up more than 14%.",https://finnhub.io/api/news?id=d9909a360e307178cb36e5cec25366e9704d85664b5b2303a594d22cd0869861
company,2023-06-09 08:40:00,10 Health Care Stocks With Whale Alerts In Today's Session,120796131,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=08adfb7881b969b0fa8835224c94b30e5d9dd6c771c8464fee7b4ae713a753b3
company,2023-06-09 06:50:02,"Gilead Sciences, Inc. (NASDAQ:GILD) Will Pay A US$0.75 Dividend In Four Days",120793311,,GILD,Yahoo,"It looks like Gilead Sciences, Inc. ( NASDAQ:GILD ) is about to go ex-dividend in the next 4 days. The ex-dividend date...",https://finnhub.io/api/news?id=57d42f5cfeea6959fee9227dbc64e8dc4f285542c1b22f5c6f04de34d3139fb0
company,2023-06-09 05:55:00,Cantor Fitzgerald biotech analyst to hold analyst/industry conference call,120794083,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9dd8de765d2fa9be9178504efb97464cf582e1832c56205923f2bea231903627
company,2023-06-08 17:45:26,Pfizer Or Gilead Sciences? Let's Ask Peter Lynch,120786887,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/485712204/image_485712204.jpg?io=getty-c-w1536,GILD,SeekingAlpha,This article employs Lynch's approach to evaluate Pfizer and Gilead Sciences. Read on to see which of the two is a better dividend stock according to Peter Lynch.,https://finnhub.io/api/news?id=248bced9c01a38d250882709e57ff51e711baba33711d920848e16c304e6e0e8
company,2023-06-08 12:41:00,Gilead Sciences Inc. stock outperforms market on strong trading day,120807285,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 3.05% to $78.40 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=4cff189a9f8cc1f506a8102110ddff1b2c4d8eba96fbff8f41356c2325e9e383
company,2023-06-08 06:37:00,Interesting GILD Put And Call Options For July 28th,120781061,,GILD,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2decb368a1c726a2fcb151684f35af0e7e946d99071fe13188c15867f2a00313
company,2023-06-08 03:05:00,Bank of America Securities Sticks to Their Hold Rating for Gilead Sciences (GILD),120794564,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3776a24ed46bed541425a23718d999d0a52d2fcba3c36aedc062be289d529a9f
company,2023-06-07 23:35:00,Gilead Sciences (GILD) Shares Cross Above 200 DMA,120794567,,GILD,Dividend Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e58c8eee8dd0bcbae258c899b3c4f7acf937ead6cf151823b019420298813e24
company,2023-06-15 12:41:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,120941875,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 1.35% to $79.00 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=0f01d99c85762f1cd5b3bd08dc83504ca59c68b9d1a982e7b028bb16dfbd5592
company,2023-06-15 08:08:00,Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates,120895030,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=32f5ac8e1c55cadaf5facb0ac534551c9b1ef9c15fc214a445b8b4ba46f9d9be
company,2023-06-14 23:07:00,Galapagos appoints Thad Huston as CFO and COO as of July 1,120900281,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8177dd64bdcf93d46c115d1b89738fc11d024545bb3dfcc2b2dfd4fcfece9339
company,2023-06-14 12:41:00,"Gilead Sciences Inc. stock rises Wednesday, outperforms market",120941876,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.32% higher to $77.95 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...",https://finnhub.io/api/news?id=35fe437f395c887755c1663aac0b08cdfe9d3cbfba7240aedcbf2d2ed57d6fd3
company,2023-06-14 08:15:00,Asian American Women Engineers Find Community and Purpose at Gilead,120862681,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / June 14, 2023 / Gilead Sciences When Vicky Choi began her career as an engineer, she noticed that women and Asian people overall were well represented in the field - but that Asian women weren't reflected in upper ...",https://finnhub.io/api/news?id=7b6ba783b76e217e079792693fb8a81f0ec9f6b26687ac3adcb0fff8ac3f5280
company,2023-06-14 05:10:00,My Dividend Stock Portfolio: New All-Time Dividend Record - 99 Holdings With 25 Buys,120861139,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1406742992/image_1406742992.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"US stocks ended May with solid gains and extended their strong performance into June, boosted by positive labor market data and the debt ceiling bill's progress.",https://finnhub.io/api/news?id=d2a6d8701dc9ef8c26ccdb11113d3f838eb20cff9e4d1ff26f155869181a7a37
company,2023-06-14 03:00:00,Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023,120858713,https://media.zenfs.com/en/business-wire.com/f726bca22772034c3f655ba5ce3c66bc,GILD,Yahoo,"FOSTER CITY, Calif., June 14, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new data to be presented at the European Association for the Study of the Liver (EASL) Congress 2023, June 21-24, 2023. Key findings from more than 70 presentations will include Week 96 data from the pivotal Phase 3 study of Hepcludex® (bulevirtide) evaluating the efficacy and safety for the treatment of hepatitis delta virus (HDV) and late-breaking data on the impact of continued treatment with bulevirtide.",https://finnhub.io/api/news?id=d56bf2022257e76011a46072f4efb4f213ed7b4e0f438ea17cb6dbfca7ee9073
company,2023-06-13 18:00:22,Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know,120857402,https://media.zenfs.com/en/zacks.com/3cb5117fc22f5e37890d1860dcd61f9f,GILD,Yahoo,"Gilead Sciences (GILD) closed the most recent trading day at $78.45, moving +0.76% from the previous trading session.",https://finnhub.io/api/news?id=145d9bc499e77509b5f98c6985ccd6f45749571d1ef9213fadd4c8c09d0db31e
company,2023-06-13 13:42:00,Gilead Sciences Inc. stock outperforms market on strong trading day,120941877,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.76% higher to $78.45 Tuesday, on what proved to be an all-around positive trading session for the stock market, with...",https://finnhub.io/api/news?id=f8a15169c31284e1d7f5bc4ae3332963012a722950f5a19c221aac3e5d556880
company,2023-06-13 08:29:00,Gilead Sciences goes ex dividend tomorrow,120846814,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=33a7a71edcb4b1912160300de0d9d1f024c72d5873704a64da30728c827596d8
company,2023-06-13 06:52:15,Top 20 Most Profitable Pharmaceutical Companies In The World,120841576,https://media.zenfs.com/en/insidermonkey.com/05091c2b4af540bdca13bdc30e634918,GILD,Yahoo,"In this article, we will be covering the top 20 most profitable pharmaceutical companies in the world. If you wish to see the top ones, head straight to the Top 5 Most Profitable Pharmaceutical Companies In The World. Undoubtedly, the pharmaceutical industry stands as one of the most financially rewarding and essential sectors worldwide, leading […]",https://finnhub.io/api/news?id=f9453e0ad0f9118449511fe1790b1a08bef5c3c5e71d8572193ad52a813a0e87
company,2023-06-13 06:17:04,Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75,120843192,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Gilead Sciences, Inc. ( NASDAQ:GILD ) has announced that it will be increasing its dividend from last year's comparable...",https://finnhub.io/api/news?id=9510099ad78a895c2146ccae711c7b1dcec5f7be085fc51e43e0eec7628939be
company,2023-06-12 12:41:00,Gilead Sciences Inc. stock underperforms Monday when compared to competitors,120941878,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slumped 0.33% to $77.86 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=67c1099a4c45c40f2cada33f48e10b97ccfd33bf3858d36ccb1dcdbe73e01e8f
company,2023-06-12 12:19:09,"Gilead Sciences, Inc. (GILD) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)",120833256,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023 1:40 PM ETCompany ParticipantsDaniel OâDay - Chairman & CEOMerdad Parsey...",https://finnhub.io/api/news?id=7755e0f525a39f2023c22597b3da1f87cb7868bf79a393d04592e506089b57d0
company,2023-06-12 06:55:00,5 Stocks to Buy With Explosive 500% Potential,120828096,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c6becc1b4ad733fb8ac26f86c7fb00db42d1834a36d4285394caa59baa248154
company,2023-06-12 00:41:00,IN BRIEF: Guild Esports signs deal to build 'sim racing' facility,120835283,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=afebdf0b3b1328fdd946b4d576db47199c23d383029d1bd96c29d0d0bb5db450
company,2023-06-19 01:16:46,PBE: Healthcare Dashboard For June,120943664,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/655188172/image_655188172.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Click here for the June edition of the Healthcare Dashboard.,https://finnhub.io/api/news?id=b567e115a5c67f869d3513574b36147a748861f565307e34181e9fd2427d266f
company,2023-06-18 16:56:10,How to Retire Rich: Biotech Stocks Edition,121032614,https://media.zenfs.com/en/investorplace_417/155568656c3c7c82033d9d467e5e2a90,GILD,Yahoo,"Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector – which falls under the broad healthcare industry – is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement",https://finnhub.io/api/news?id=30a100653ec7406368a3a5492184101887e35c42255ecfcadc8086b9b655a955
company,2023-06-16 12:41:00,"Gilead Sciences Inc. stock falls Friday, still outperforms market",120941874,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slumped 0.18% to $78.86 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=200999b56a93dc551ce102cea42b613da3e9d2eef3238d06e8beb36a57a548cf
company,2023-06-23 12:58:00,Gilead Sciences (GILD) Announces Positive HDV Treatment Data,121021476,https://media.zenfs.com/en/zacks.com/15cc5e716d93716d17510d9e62d58b8b,GILD,Yahoo,"Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.",https://finnhub.io/api/news?id=3d1e040db6b83a6622100aba965d82644392d7063029d422c1168df8c67337d5
company,2023-06-23 12:41:00,"Gilead Sciences Inc. stock falls Friday, underperforms market",121123271,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 0.82% to $77.47 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=b4d30071de2815de19d69c2d72342fa226ba9f0be6c2240fc9c5ab46cf5daccf
company,2023-06-23 12:38:16,"Gilead's Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two Years",121021478,https://media.zenfs.com/en/Benzinga/7b0d282cf838165dc0da908890a1f0df,GILD,Yahoo,"Gilead Sciences Inc (NASDAQ: GILD) announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for chronic hepatitis delta (HDV) infection. Bulevirtide is the only approved treatment for HDV in Europe and is not approved in the U.S. The Week 96 findings demonstrated improved combined response compared to Week 48, with no signs of treatment resistance and sustained virologic response with continued bulevirtide monotherapy. Prolonged bulevirtide treatment showed clinica",https://finnhub.io/api/news?id=35da7f34d4d7e24b56cf3ac989edf25d6e65fe53c87649214d8a5bf533001116
company,2023-06-23 08:21:00,IN BRIEF: Gilead Sciences says test results show Hepcludex effective,121023605,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=00da3cb7cb253a6cb915658c5dc85c41668d7be5cdc07de9da346bf4755050c1
company,2023-06-23 08:11:00,Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer,121015878,,GILD,Yahoo,"FOSTER CITY, Calif., June 23, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Trodelvy® (sacituzumab govitecan) as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the adva",https://finnhub.io/api/news?id=38be9d1a9e0b1135bdcfcc24e72e1535e7ca0fb425e1786d194e2b58829cddaf
company,2023-06-23 07:41:00,"Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)",121023606,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e2a0918681e0ee95051eaa50da4898aa5cca78d8558fd3ac5561dfcd0ffc8f2e
company,2023-06-23 04:29:00,Gilead Gets Positive European Opinion for Additional Indication for Trodelvy,121123272,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Robb M. Stewart Gilead Sciences has received a positive response from the European Medicines Agency's Committee for Medicinal Products for Human Use on an...,https://finnhub.io/api/news?id=ab181290609b264b329b9bc5031f2fd598f97543c3e2ca93316fe5a4fbb8097e
company,2023-06-23 03:56:00,Gilead's Trodelvy for breast cancer endorsed by EMA panel,121023609,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0b4a2b5973f1b4343be4d3c24afd2564a396ffa5b3d4ebf4787d8370a6c3300a
company,2023-06-23 03:20:00,Gilead announces CHMP recommendation for the use of Trodelvy,121023610,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=75a2daddcf3e3a43e53d2c095978f78b0d367ddc1db789c21ed036ef561fd813
company,2023-06-23 02:30:00,Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks,121014145,,GILD,Yahoo,"FOSTER CITY, Calif., June 23, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex® (bulevirtide) for the treatment of adults with chronic hepatitis delta (HDV) infection. These new data presented at the European Association for the Study of the Liver (EASL) Congress 2023 reinforce the role of bulevirtide as an efficacious and well-tolerated treatment for the management of",https://finnhub.io/api/news?id=ee948e8370759eb1056a2533c61f590522531df8feefb0b42eecfe0eaf69b190
company,2023-06-23 01:51:00,IN BRIEF: Guild Esports inks one-year deal with Secretlab for chairs,121023611,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cd0789c5a0d886261a32c254d0f1370cbd8f278443b1170979b0091a2b5976ee
company,2023-06-23 00:17:00,Gilead announces Week 96 results from MYR301 clinical trial,121023612,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=de95c42fe4bd3f93679f5eb79d95c377dc9fd02f0a0fc5ae47062d34bc8b565c
company,2023-06-22 12:41:00,"Gilead Sciences Inc. stock rises Thursday, outperforms market",121006776,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.64% higher to $78.11 Thursday, on what proved to be an all-around mixed trading session for the stock market, with...",https://finnhub.io/api/news?id=d655fc80a46388b30c3b4177f40615f47d24b9e5ebfb5bf56cac4102a267db87
company,2023-06-22 12:15:00,Gilead notes transfer of Yescarta marketing authorisation from Daiichi,121005752,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=44a13c27f56d130870bfedc71b5775b37692e0e65885e4220a53558973e7fa86
company,2023-06-22 08:30:00,Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan,121002675,,GILD,Yahoo,"SANTA MONICA, Calif., June 22, 2023--Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing Authorization in Japan for Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has been transferred from Daiichi Sankyo Co., Ltd. to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc.",https://finnhub.io/api/news?id=6b1574c5acbc35410061c3087588784df656db95da3cd2ebc482032717882cb8
company,2023-06-22 03:49:00,Gilead announces completion of marketing authorization in Japan for Yescarta,121005754,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0e0d2c937c42fde065e74f99c0884d55826a4969350fc3b5585565fa2a5faca4
company,2023-06-21 12:41:00,Gilead Sciences Inc. stock outperforms competitors despite losses on the day,120994137,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. sank 0.13% to $77.61 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=a87341545551ab804b759e1681993a4dd2b4624c69997279353d53c72a38a262
company,2023-06-21 08:22:00,2 Biotech Stocks You Can Buy and Hold for the Next Decade,120973193,https://s.yimg.com/ny/api/res/1.2/VX9pu2GVHS1QuVPoV3K6iw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MTY-/https://media.zenfs.com/en/motleyfool.com/ceac878ca1dd9c8a2000dd46a9942847,GILD,Yahoo,"Biotech companies use living organisms to develop their therapies, and much like some living things, biotech stocks can be notoriously volatile.  Part of that is due to the complexities of making biotech therapies.  The success rate for biotech start-ups is low, but Gilead Sciences (NASDAQ: GILD), founded 36 years ago and Regeneron Pharmaceuticals (NASDAQ: REGN), founded 35 years ago, have already stood the test of time.",https://finnhub.io/api/news?id=681e779585ed939c6a71bd3129ea66868301d3cb83176fb04ae7208516417dbc
company,2023-06-21 08:15:00,Gilead Sciences Supports the LGBTQ+ Community in Oakland: Love Is the Answer,120973195,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / June 21, 2023 / Gilead Sciences: As a young gay man growing up in Detroit, Joe Hawkins witnessed the stigma and discrimination against the LGBTQ+ community. And when he entered the military in the 1980s, during the ...",https://finnhub.io/api/news?id=105cdf271fa0258b371df189dfd32be2784fc905cbb77b2df149aa070b41b38b
company,2023-06-21 03:00:30,"Arcellx's CAR-T Hold: Turmoil, Triumphs, And Trading Tips",120972428,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1405420709/image_1405420709.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Arcellx's CART-ddBCMA program faces a clinical hold due to a patient's death. Find out why I advise investors to hold ACLX stock.,https://finnhub.io/api/news?id=747c9df2502c0ad13fb6fc7e5e6b2818c6f934f1e6ac3e7694e8b54f7caae2e5
company,2023-06-20 18:00:22,Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know,120969067,https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209,GILD,Yahoo,"Gilead Sciences (GILD) closed the most recent trading day at $77.71, moving -1.46% from the previous trading session.",https://finnhub.io/api/news?id=01393affb6c07070a36bc8aadde4a3c01395a72437f3000709b85bcc9fba798e
company,2023-06-20 12:41:00,"Gilead Sciences Inc. stock falls Tuesday, underperforms market",120994138,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 1.46% to $77.71 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=d23ecfd390987ca0e79cf27170f83ad9c08d8440381243f90ce41559efb54ddd
company,2023-06-20 10:38:15,"Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death",120957396,,GILD,Yahoo,"The FDA placed a study of Arcellx's multiple myeloma drug on hold after a patient died, leading ACLX stock to crumble Tuesday.",https://finnhub.io/api/news?id=7e8e6aa4e6980b58e210b507f8316f1585a4449de1a5bff2f375a81b113a31c4
company,2023-06-20 05:09:00,IN BRIEF: Guild Esports completes fundraise for working capital,120962392,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a11b88421040c7bf4508c94c768d31d35c01bfb3971e125d8e45c47348397367
company,2023-06-27 13:48:51,10 Martin Shkreli Stock Picks and Their Performance,121073004,https://media.zenfs.com/en/insidermonkey.com/efdbbcf0a508c37b56e2a6ea0302e3d2,GILD,Yahoo,"In this article, we will take a look at the 10 Martin Shkreli stock picks and their performance. To see more such companies, go directly to 5 Martin Shkreli Stock Picks and Their Performance. Martin Shkreli a.k.a. “Pharma Bro” is known for a variety of reasons, many of which are tinged with notoriety. He cofounded […]",https://finnhub.io/api/news?id=0c143d9b7797f5eabda3d45e2bb5641bf88c208b5275d436890bf87c97ce26ec
company,2023-06-27 12:41:00,Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors,121123269,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 0.72% to $76.01 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=f4ff9ccf7d6550395aa53016d53d7a4b846252bac62ebca7b2b6c39283d5f1ff
company,2023-06-26 18:00:21,Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know,121062604,https://media.zenfs.com/en/zacks.com/f541c90e0d995722d10914cb76a7c653,GILD,Yahoo,"Gilead Sciences (GILD) closed the most recent trading day at $76.56, moving -1.17% from the previous trading session.",https://finnhub.io/api/news?id=015c2648f3722335c6bdaf642b94b7397dc046fd83b685bb3ad8abbd001cbe3b
company,2023-06-26 12:48:00,Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion,121053172,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.,https://finnhub.io/api/news?id=abf1ddd666a1aaf43a8473ff41e11d1b041f49071d664a8ce5da063f6d393774
company,2023-06-26 12:41:00,Gilead Sciences Inc. stock underperforms Monday when compared to competitors,121123270,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 1.17% to $76.56 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=81c87a1b921b2734cbf9cf9b995b53eaea6758ba6750cb36d023b09078153a96
company,2023-06-25 22:40:00,GILD Crosses Above 4% Yield Territory,121068267,,GILD,Dividend Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bec7c8172397b7cb620076c7d4187b32af40ecd817e51415ae5b424815ca2c4a
company,2023-06-25 06:28:54,"Dividend Champion, Contender, And Challenger Highlights: Week Of June 25",121035645,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the June 25th weekly update.",https://finnhub.io/api/news?id=81e90207ebed3f6816df22e46103793ac5367397ef4ec4aa68fc1e18b77b55d2
company,2023-07-01 06:44:00,"Gilead, Teva acquitted in pay for delay generic HIV drugs case",121165352,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=853db203dfb5c7a68b487f87402d4f8c404fb68b30969cc18ca8b671c077899f
company,2023-06-30 23:48:14,AlloVir: Several Late-Stage Programs Make This Worth A Look,121161842,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1500837932/image_1500837932.jpg?io=getty-c-w1536,GILD,SeekingAlpha,A good thing about AlloVir is that it is already having its drug posoleucel being explored in several phase 3 studies. Read more about ALVR here.,https://finnhub.io/api/news?id=58b8df79dcf1e76d35d1b8fdeecdd3219e18cda3d4d8f64a61bbcf0bb43d83d4
company,2023-06-30 13:46:02,Gilead Sciences : Prevails in HIV Antitrust Trial,121153075,,GILD,Finnhub,"Foster City, Calif., June 30, 2023 - Gilead Sciences, Inc.  announced today that a jury in the U.S. District Court for the Northern District of California returned a verdict in favor...",https://finnhub.io/api/news?id=b4859327320d83a01157c178ac0ed84be78c7864af49d97c2fe1c5f1a3c0adbe
company,2023-06-30 12:41:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,121178011,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. advanced 1.39% to $77.07 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=466f478eebbb82e0a1fa48833bef87de1fa38e54bd1000c55ad8c429b3fc9c1c
company,2023-06-30 08:42:00,10 Health Care Stocks With Whale Alerts In Today's Session,121145492,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2eb0dd773f7fa5a55128e450f726689bb4392a998f40ed3a14e5730774e9958e
company,2023-06-30 07:45:00,Medicare revises guidance on drug price negotiations amid lawsuits,121143519,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9995d69366d1eb03a503aedbca7566d037f9ef099dec3aaed5ff87e49f1a862a
company,2023-06-30 06:07:00,This Is What Whales Are Betting On Gilead Sciences,121155441,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f77d4651e291baa0f4659db3e5ef81de4b50873932c3ff8b52dd6f0aabedc4f1
company,2023-06-30 00:03:00,Amgen Inc. Dividend Stock Analysis,121144152,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=db4cfe5426261e2de5cc92c868ea1f3362aa544720c00ac5e66b8332e7c50e7b
company,2023-06-29 12:41:00,Gilead Sciences Inc. stock underperforms Thursday when compared to competitors,121123266,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slumped 0.22% to $76.01 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=4899f81e7ec44d7b1da8fe056219b7e0b7e915089d4f1257d4cdce1914dab6f1
company,2023-06-29 09:47:37,Hepatitis C cure is not reaching overwhelming majority of patients due to financial barriers,121122617,https://image.cnbcfm.com/api/v1/image/101448696-151050768.jpg?v=1688060857&w=1920&h=1080,GILD,CNBC,Hepatitis C is often referred to as the silent killer because the initial infection has few to no symptoms. ,https://finnhub.io/api/news?id=864dc162f1296243c1ebb480d85b7297fa5cda377e80808d21f58c36d84624b1
company,2023-06-29 07:01:18,"With 85% ownership, Gilead Sciences, Inc. (NASDAQ:GILD) boasts of strong institutional backing",121108831,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,Key Insights Institutions' substantial holdings in Gilead Sciences implies that they have significant influence over...,https://finnhub.io/api/news?id=83a1e422a9f7a2bab3bc41770f939477c3113b74e0e20b5fbb66547e95b6511f
company,2023-06-29 06:34:00,GILD August 11th Options Begin Trading,121114961,,GILD,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c5997bc29733e2e8c6c7aacb3800f01a998f49ebf38d889bcc86feb6eb0da949
company,2023-06-29 03:30:00,"A Drug for Itchy Dogs Costs $1,200. Why Is the Human Equivalent $43,000?",121106847,https://s.yimg.com/ny/api/res/1.2/jNB0zCRWciZhCrbycvzXqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/20eff2ba61bc987eff5fc3a5972377eb,GILD,Yahoo,"If your eczema is making you itchy, your doctor might prescribe Dupixent, a Sanofi monoclonal antibody therapy with a U.S. list price of around $43,000 a year.  On a biological level, there’s little difference between them: Dupixent targets proteins in the human immune system called interleukin-4 and interleukin- 13, while Cytopoint targets a protein in the dog immune system called interleukin-31.  While Cytopoint was licensed by the U.S. Department of Agriculture, Zoetis’ (ticker: ZTS) other two monoclonal antibodies were approved by the Food and Drug Administration.",https://finnhub.io/api/news?id=84d90e1f058e8f72fb1f59daac9c9fbdc21f3931b140bd0b7cca9a666d1c143e
company,2023-06-28 23:17:00,Looking Into Gilead Sciences's Recent Short Interest,121155449,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5557d9110857ac1b7e1f68ca977b7a01d9d8a1d4e99eb326def553febd46ac25
company,2023-06-28 21:06:00,Gilead Sciences' Debt Overview,121155451,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=855c88a08657a2368726e054d8e28d616387391efa702b97c7b33621d5929dd6
company,2023-06-28 12:41:00,"Gilead Sciences Inc. stock rises Wednesday, outperforms market",121123268,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.22% higher to $76.18 Wednesday, on what proved to be an all-around grim trading session for the stock market, with...",https://finnhub.io/api/news?id=51fb6442f832f957e8e64bd3e60c2138dd35c0ec4c58abf0ea2118a2e27db929
company,2023-06-28 00:36:00,Gilead Sciences adds $10.99M to AlloVir stake,121113325,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ac2eb19e5e04244523075f66690aabce008231622799dcbe4688e31eb4b6a1cd
company,2023-07-05 13:05:57,The 3 Best Biotech Stocks to Buy In July,121317565,https://media.zenfs.com/en/investorplace_417/180ce84be58b62c67d477717f09599bb,GILD,Yahoo,"Although it’s been a difficult year for biotechnology stocks, there are still plenty of reasons for investors to be bullish on the sector. Many of the biggest innovations in medicine are occurring at small and midsized biotech companies in the U.S. These are the incubators for medical advancements and where important scientific breakthroughs are happening. New products and treatments are boosting sales and earnings at biotech companies, making them great long-term investments. Although the S&P B",https://finnhub.io/api/news?id=77104d3f0a6a2071dc5cedc055579fa8a7c1bbd6a9d87a1e565ac28cefd3b46e
company,2023-07-05 12:41:00,"Gilead Sciences Inc. stock rises Wednesday, outperforms market",121220065,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.68% higher to $77.24 Wednesday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=73a51fdf69d0e2ce9b65c3d940763fa78394ef3d75ebbc2a96f3e9c8df09f67f
company,2023-07-05 07:01:05,Those who invested in Gilead Sciences (NASDAQ:GILD) a year ago are up 27%,121207805,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...,https://finnhub.io/api/news?id=a5533b5e0da3c137f6ecb5b394a81243cc67b698fa7fd654e414322b18ed3bcb
company,2023-07-05 03:05:00,Gilead Sciences (GILD) Gets a Buy from Jefferies,121234124,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=13680bd2c68dfae27c47445f0558e2c09860a7a8efc624f84cc839c5e0c67898
company,2023-07-05 02:53:00,"NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment",121209685,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b661ed4ebd2fe32f6617fdd41f6917bc78fb881867577fc2c1a30bfc82088087
company,2023-07-05 02:09:00,Why the 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With the Red-Hot Summer Rally,121209438,,GILD,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=12d415991b83185510add0a9b324fdda739acfb548e9e915196d2bc4ed28ae35
company,2023-07-05 00:11:00,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amneal Pharmaceuticals (AMRX), Replimune Group (REPL) and Gilead Sciences (GILD)",121209544,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b2d9907bfe5033a3ab6cc48962797635ee3d8e4fa4e55b0bd85dfecdadebbd52
company,2023-07-04 23:27:11,Gilead Sciences: An Evolving Biopharma Navigating Through Challenges And Opportunities,121205076,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417761158/image_1417761158.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Gilead's Q1 2023 revenues fell to $6.4bn, offset by positive developments in their promising oncology drug, Trodelvy. See why GILD stock is a Hold.",https://finnhub.io/api/news?id=03b8ac660008be38925ecdbd558c6455050c85ac8cd18a130dc6cfc8ba24aaa1
company,2023-07-04 04:06:00,Guild Esports sees shares rise on first British F4 Esports entry,121198189,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=771ad7b419da3a9bff7bc24441f586c55b9b783e74ba6f15b205c88d457aafd2
company,2023-07-03 18:00:18,Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know,121193443,https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a,GILD,Yahoo,"Gilead Sciences (GILD) closed at $76.72 in the latest trading session, marking a -0.46% move from the prior day.",https://finnhub.io/api/news?id=421e059ca054e2e42f39579388a65680b93ee29af169caa0bccee09e7f8dc696
company,2023-07-03 11:45:45,HQH: Deep Discount Presents An Opportunity,121188140,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1408559089/image_1408559089.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Tekla Healthcare Investors focuses on biotech subsector of healthcare, leading to potential volatility and potential for high returns. Read my analysis of HQH.",https://finnhub.io/api/news?id=6d360222ad61c590a8ba331d93c43a73a605fc5af169d4d6e6399a28852c44e1
company,2023-07-03 04:00:00,Gilead receives positive verdict from US court in HIV antitrust trial,121185499,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e2334c401e12495228ed465f5aebfc5506f7d86105a829238a1990efbf566c9b
company,2023-07-09 07:00:00,Goldman Sachs sees rays of hope in underperforming health sector,121283860,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=06213154d705d1d21de35238e56a94d433ff70c58826c039c5a22b1ac80ef9b3
company,2023-07-09 03:26:00,"Pfizer among big pharma stocks on sale right now, Barron's says",121284211,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2c746dea3c724354cd40c7897160bae1806b763538c5d78768407a7d4e314adb
company,2023-07-09 03:02:00,Fly Intel: Top five weekend stock stories,121292914,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=17ef3e1c5650553415e43f807f6c235ba4a86845155e0ffe0db4c29b1b9236d8
company,2023-07-09 01:21:00,"Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023",121292680,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=930c7ea0f22e0aee7bfc5fb2cb0302d90080ebe38e104577fec4dec540988c1c
company,2023-07-07 12:41:00,"Gilead Sciences Inc. stock falls Friday, underperforms market",121279953,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 2.39% to $74.42 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=90a0ebe5266325f687888591b8b897bed5ded579cc46d27646359497f1e1d6be
company,2023-07-07 12:07:26,14 Best NASDAQ Dividend Stocks To Buy,121257310,https://media.zenfs.com/en/insidermonkey.com/7bccf1845e2d3cc33d5cf6ac7b385a2a,GILD,Yahoo,"In this article, we discuss 14 best NASDAQ dividend stocks to buy. You can skip our detailed analysis of dividend stocks and their returns over the years, and go directly to read 5 Best NASDAQ Dividend Stocks To Buy. NASDAQ is commonly associated with technology and growth-oriented companies that usually don’t pay dividends but there […]",https://finnhub.io/api/news?id=0e3aa3174e55dbc19f94dd9dc178db3a36de996b4898dfa64c54d028b168c768
company,2023-07-07 01:43:00,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Biogen (BIIB) and Crinetics Pharmaceuticals (CRNX)",121261215,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fdb463c0ae108ee947412cef95bfa983f75627aa9be9b6c0312b87c3489de7e5
company,2023-07-06 12:41:00,Gilead Sciences Inc. stock underperforms Thursday when compared to competitors,121279954,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. shed 1.29% to $76.24 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=e39190b94dc2557ad81ff29f8bffd1a372890422904bd9cfa1b122adf1632bb9
company,2023-07-06 06:53:00,4 Big Pharma Stocks On Sale Right Now ,121242258,https://images.barrons.com/im-812412/social,GILD,MarketWatch,"The key is to buy a basket of the cheap ones, so that gains in a few of them can offset disappointing performance in others.",https://finnhub.io/api/news?id=9cb68835784bd525c9725c559220a74bc7eba7254f80c274922db032fc0b4007
company,2023-07-06 05:31:03,U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map,121230596,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912585074/image_912585074.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Our 3-step process focuses on wide-moat stocks. We're only interested in targets attractively valued in historical comparison. Read what investors need to know.,https://finnhub.io/api/news?id=d1c977c4217647aa1e4024d94a38bb2e25fd80e3d508cf8b838976a6fff7db6f
company,2023-07-06 04:48:00,Gilead raises stake in Arcus Biosciences to 35%,121234036,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0897cf858dc622d29ec7077c6271bff1926c5d1529c23f6d43a760ab2b030678
company,2023-07-06 01:35:00,DBS Keeps Their Buy Rating on Gilead Sciences (GILD),121234120,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=884126c4de70bee8cc75795934c5a3e96056a6e2b97f174c419b4de832d7a244
company,2023-07-13 18:00:20,Gilead Sciences (GILD) Gains But Lags Market: What You Should Know,121375234,https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2,GILD,Yahoo,"In the latest trading session, Gilead Sciences (GILD) closed at $76.71, marking a +0.43% move from the previous day.",https://finnhub.io/api/news?id=d373cc6f7696f8053560203fa0e2cb41d04a1e0a68d434d7a7df237883c033d6
company,2023-07-13 12:42:00,"Gilead Sciences Inc. stock rises Thursday, still underperforms market",121394372,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.43% higher to $76.71 Thursday, on what proved to be an all-around great trading session for the stock market, with...",https://finnhub.io/api/news?id=aca0b743026629a6e6d501ad6216b816a52886359f3ab04f3879eb0454d7ca44
company,2023-07-13 11:41:08,Gilead: Assessing How Shares Will Trade Over Upcoming Months (Technical Analysis),121368661,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1407983911/image_1407983911.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Gilead Sciences' 12-month dividend growth rate of 2.8% is behind the inflation rate, suggesting a negative real return over the next year. Click here to read more.",https://finnhub.io/api/news?id=08ac5d19b18c057bf89b9a9bcf1c6582e2909437f3ee69ad9eda06f422022a9d
company,2023-07-13 06:38:00,Interesting GILD Put And Call Options For September 1st,121361868,,GILD,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c6f9c8fd2555f27e33092d276f13ae978644d6761707beeb86d724fc2a6c289d
company,2023-07-13 06:00:00,Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries,121359610,https://media.zenfs.com/en/business-wire.com/3fb37946311981b94c0df0d6a7cc782e,GILD,Yahoo,"FOSTER CITY, Calif., July 13, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation containing emtricitabine and tenofovir alafenamide (F/TAF). The second aims to develop investigational pediatric formulations of TAF and sofosbuvir (SOF) designed to eliminate bitterness.",https://finnhub.io/api/news?id=870c91c70d3724470a02a58671c453e8c35f22514817f0110f1dbc9a922e4dbc
company,2023-07-13 02:32:00,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Regeneron (REGN),121361870,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7458b51d8932dbface52b89cec0c7d67e1d56eb6f4e031a24f8b0914dafe46bc
company,2023-07-13 02:30:00,With The Massive NASDAQ Rebalance Coming Soon 7 ‘Strong Buy’ Stocks Could Explode Higher,121361871,,GILD,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d769be0ca1d97894650593b30b60690c504b93d2f03b25f240c824f022282270
company,2023-07-13 02:10:00,Gilead inks deals to improve HIV treatment uptake in children,121361872,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=71956bf9aaeae3797f2ab3be35277710e0e213ec9068153532fbc4f3741c4286
company,2023-07-13 01:03:00,Gilead announces two public-private partnerships,121361874,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4401375874a37f5dcbeb972e4bbd6cded4098801814f07fe6f622f4146389944
company,2023-07-12 23:35:00,Half-Time Heroes: Moat Stocks Lead As Second Half Kicks Off,121357238,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1283813790/image_1283813790.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Morningstarâs strategy of focusing on quality companies at attractive prices has powered its Moat Index to its strongest first-half performance since 2007, putting it ahead of the S&P 500.",https://finnhub.io/api/news?id=d1fdb0c2de8874635c5bbf67b0dd71c430ca8dbe44376751a3d1ffc54fc3f31e
company,2023-07-12 12:41:00,"Gilead Sciences Inc. stock rises Wednesday, still underperforms market",121348249,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.34% higher to $76.38 Wednesday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=532d70151311b77c9ab2e85e1365cea8c9a119247cd364593ee06dd60e973df9
company,2023-07-12 08:44:00,10 Health Care Stocks With Whale Alerts In Today's Session,121339340,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c0994db55278aa524d565c735d5a584dcab08bb20846f9aa51ee1c3f4f08bd5b
company,2023-07-12 04:15:00,ClearBridge All Cap Value Strategy Q2 2023 Portfolio Manager Commentary,121331398,https://media.gettyimages.com/id/1514159521/photo/financial-graphs-statistics-diagram-and-data-annual-presentation-infographic-economic-report.jpg?b=1&s=170667a&w=0&k=20&c=ORU1JMkOlba30dgizwg8TbgobYat2-IFg71CObJHgv8=,GILD,SeekingAlpha,The ClearBridge All Cap Value Strategy outperformed its Russell 3000 Value Index during the second quarter of 2023. Click here to read the full fund letter.,https://finnhub.io/api/news?id=136fa8d79549e5410d2a5b4a27347266574f7353ba5d0bb8b426d5f04e0de7bf
company,2023-07-11 23:12:00,Gilead Just Bought $30 Million More of 2 Biotech Stocks,121348251,https://images.barrons.com/im-815093/social,GILD,MarketWatch,"Gilead recently increased stakes in AlloVir, a developer of drugs to treat or prevent viral diseases, and Arcus Biosciences, a biopharmaceutical firm...",https://finnhub.io/api/news?id=e12f95533fd5de95e4d8364c1da0a09c6e0f0c0e5758fa968bf62881af0c7d59
company,2023-07-11 21:19:00,7 Tech Stocks to Watch on July 14,121340447,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b4e78bfe4023fb7df7564970e95fdf1d20c0eb93cc7ff84d57ad580a17a85212
company,2023-07-11 12:41:00,"Gilead Sciences Inc. stock rises Tuesday, still underperforms market",121348254,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.57% higher to $76.12 Tuesday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=b9a92db241fbb56c7536ac465d1eb08e26552f77daef8d5ade618d8378bdf815
company,2023-07-11 11:34:33,Morgan Stanley Reiterates Gilead Sciences (GILD) Equal-Weight Recommendation,121310305,,GILD,Fintel,,https://finnhub.io/api/news?id=6e7bc0e0b486d5c5af9d5f7620b9bb9ee0d6f315690f2641e576364d9e716ccf
company,2023-07-11 08:27:26,Barclays Maintains Gilead Sciences (GILD) Equal-Weight Recommendation,121307786,,GILD,Fintel,,https://finnhub.io/api/news?id=4d93970733fc5b4a1c175c48a9a8ff41295dea91b095231bf475602016fab02c
company,2023-07-11 05:07:00,Starbucks and 6 More Stocks That Could Get a Boost From the Nasdaq 100 Rebalance,121348256,https://images.barrons.com/im-615730/social,GILD,MarketWatch,"Starbucks, Mondelez, and Booking are among the possible outperformers from the index’s weighting changes, according to Wells Fargo.",https://finnhub.io/api/news?id=5c1dd0e2258a8fe9a3a3f03fc4b40cafdb4304e078397da058a9daaeb1f96b0a
company,2023-07-11 03:11:00,Wells Fargo highlights Nasdaq 100 rebalance trade opportunities,121311050,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f545dc82f8d769d370a009a15ad17a2efb1c3e2f9fe1554edcd1183ce22b5bf7
company,2023-07-11 00:35:00,Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD),121314054,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0935ba4e342091b09ac08c29cf85950e031ae2cbd7e9d72465c18f3f90b7181a
company,2023-07-11 00:22:00,Gilead price target lowered to $81 from $84 at Barclays,121314055,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=63c319c938b647c48574ebb1971516bebab7ff9131c00349e3e5b335d4182310
company,2023-07-10 15:13:34,AlloVir: 'Takes One To Know One',121301553,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1439788224/image_1439788224.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Allovir's lead product, posoleucel, is in Phase III clinical trials and targets six viral pathogens in immunocompromised individuals. Find out why ALVR stock is a Strong Buy.",https://finnhub.io/api/news?id=f00b444bb952ac876221a1f72344bc878d5ea249bebff2c0e60f4e21545e7a28
company,2023-07-10 12:41:00,"Gilead Sciences Inc. stock rises Monday, outperforms market",121348258,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. advanced 1.71% to $75.69 Monday, on what proved to be an all-around positive trading session for the stock market, with the...",https://finnhub.io/api/news?id=08bde52f511495a8aae6caddba508989b018276c1f4ce2982e0a3465706b47e2
company,2023-07-10 10:00:58,We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt,121292745,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...",https://finnhub.io/api/news?id=512afed104a03bccf50a1ff570220c468441b5732b510a58de96fe06f738b422
company,2023-07-10 04:46:00,RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD),121314056,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1ebade3fcf7af607f381603e77c4fe05ae202c0e0cb86e5c2bcc605332117213
company,2023-07-10 04:18:00,Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?,121292911,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e7c10eea7715946a00a295f16fd589af87a321c3e97a08824a516d6de64d7674
company,2023-07-09 22:05:00,Gilead call volume above normal and directionally bullish,121314059,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c785f6c067610d9b9c01dd440cd549189465f80094e4647d1009cbbb4dd14a4a
company,2023-07-17 12:43:00,"Gilead Sciences Inc. stock rises Monday, still underperforms market",121513995,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.38% higher to $77.48 Monday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=39372d2171932d687341f3cb7d742babdb1ab43c308ce68ec3ae9d5a768fcd34
company,2023-07-17 11:40:00,Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion,121428588,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,"Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.",https://finnhub.io/api/news?id=700ec7705044ccd2e8b53defc65440a793cb88ba7e4ceea0ebb7d6590d379fae
company,2023-07-17 07:53:00,Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash,121426117,,GILD,Yahoo,"If you're worried about the stock market crashing, then now is a good time to review your portfolio allocation.  Gilead (NASDAQ: GILD) is a biotechnology company with a broad portfolio of drugs focused on the treatment of HIV, viral hepatitis, and several cancers.  Gilead's pipeline also has dozens of candidates at various stages of development and clinical trials.",https://finnhub.io/api/news?id=035df62de210029a3757e8952d71aef953929435fdc9789c3d8b81e9da807721
company,2023-07-17 07:33:36,"Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023",121425789,,GILD,Finnhub,"FOSTER CITY - Gilead Sciences, Inc.  announced today that its second quarter 2023 financial results and guidance will be released on Thursday, August 3, 2023 after the market closes.
At 5:00 p.m....",https://finnhub.io/api/news?id=6764b02aec35d86c8e89354cd649173bcc2a7578ce20c5d0c2aa08f3feada86e
company,2023-07-17 01:54:00,IN BRIEF: Guild Esports signs digital advertising deal with Pixels AI,121432768,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8e2ee22707a57e6644bd2df62451665396d7463f15703fccc55f983f131d9645
company,2023-07-16 23:01:00,Price Over Earnings Overview: Gilead Sciences,121432769,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b0650132d59436c2a0989c0dffda3d8d844fed6b3cb4d96886a6cc9713859dae
company,2023-07-16 07:01:00,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",121414757,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c2c9a2ea7de3c0791fb606978f40b1cc363b868fac7a37d1f4210a3e4e826e6f
company,2023-07-14 16:15:00,Dividend Income Update June 2023,121399644,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1339956397/image_1339956397.jpg?io=getty-c-w1536,GILD,SeekingAlpha,The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. ,https://finnhub.io/api/news?id=90bb8baac4aeeed895452e4312aabd3f6024e4f082c39d409844827b59e827d0
company,2023-07-14 13:23:57,FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment,121401661,https://media.zenfs.com/en/Benzinga/51d5868878ae6e507a345ccc32d5c064,GILD,Yahoo,"The FDA approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental new drug application for using Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. More than 1 in 7 (37 million) people in the U.S. are estimated to have chronic kidney disease (CKD) and are at increased risk of COVID-19-related morbidity",https://finnhub.io/api/news?id=ff0598512f7c51e2c750a7ba80200c710b802c2efe4f6df016424f1e74c10f72
company,2023-07-14 12:54:37,More Challenges Await AbbVie Following A Disappointing Quarter,121394328,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1374841003/image_1374841003.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"AbbVie Inc., one of the leaders in the global immunology market, will release its financial report for the second quarter of 2023. Click here to read more.",https://finnhub.io/api/news?id=5dcefae653c6ddb97d78b5ea409041ed34cc77beab6f76dc5c9437d3a76dc4c0
company,2023-07-14 12:42:00,Gilead Sciences Inc. stock outperforms market on strong trading day,121431939,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.63% higher to $77.19 Friday, on what proved to be an all-around mixed trading session for the stock market, with the...",https://finnhub.io/api/news?id=c7485c7c269f68bb49d70738eb66c89bd8a4c073baf885d926bf84652ee0bac1
company,2023-07-14 08:00:00,"FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis",121384491,https://media.zenfs.com/en/business-wire.com/597ef74e8823eb4b3ae62087c5bacfe0,GILD,Yahoo,"FOSTER CITY, Calif., July 14, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. More than 1 in 7 (37 million) people in the U.S.",https://finnhub.io/api/news?id=7e5c3a926e69a3bedcd9e52e16365f29dc769df00205011d3466f30edd584a71
company,2023-07-14 06:15:00,Gilead COVID therapy Veklury approved for those with renal impairment,121407152,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2248cbae31bdcb7ccc0c9c6905d75b5d81186b8d57e657ddb29d039f1f86ea6b
company,2023-07-14 05:30:00,IN BRIEF: Gilead gets FDA approval for Veklury to treat renal disease,121407153,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=69d344138ee5227a13601bd54ea3ec7dfb04aba352d1b98118d9c29a1b53aa0b
company,2023-07-14 04:41:03,Gilead Covid-19 Drug Remdesivir Cleared by FDA to Treat Renal Disease,121382080,,GILD,Finnhub,"By Dean Seal 


  Gilead Sciences said regulators have approved its antiviral remdesivir, sold under the name brand Veklury, for Covid-19 patients with severe renal impairment, including those on...",https://finnhub.io/api/news?id=2a79078e15e33616922e4611bd5b8ec841b0533a1ed2cf38bbe5ff5c52b69ea5
company,2023-07-14 04:25:00,Gilead Sciences says FDA has approved Veklury in COVID patients with severe kidney disease,121407154,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dbe7ad18144033fef2c038ee6ed8cfacb9be79b3750fbd693732ccfd4a763019
company,2023-07-14 03:09:00,Gilead announces FDA approval of Veklury sNDA,121407157,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1d4c52532db869da7e987d99563827355ebdecafa36982aa597c887c31f58b12
company,2023-07-21 17:02:00,Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS,121544055,https://media.zenfs.com/en/business-wire.com/a99b8471938276356af96486a2bf2b71,GILD,Yahoo,"FOSTER CITY, Calif., July 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in this patient population. Gilead recommends discontinuing treatment with magrolimab in patients with MDS. Magrolimab is a potential first-in-clas",https://finnhub.io/api/news?id=9d9de54c66c4c7dab474268b7481c22e886e013e4afba8a8ff4d825f5d6788fd
company,2023-07-21 13:39:00,Gilead Discontinues Study of Immunotherapy to Treat Blood Cancers,122013562,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Denny Jacob Gilead Sciences has discontinued its Phase 3 study of magrolimab in higher-risk myelodysplastic syndromes. The biopharmaceutical company said...,https://finnhub.io/api/news?id=62ff627dd2ebd4c3f56853e22cd893fd0f5a94bc4a79855e417a1e22c4a19130
company,2023-07-21 13:28:00,Gilead ends late-stage trial of blood cancer treatment,122013563,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,GILD,MarketWatch,Shares of Gilead Sciences Inc. dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial of a treatment...,https://finnhub.io/api/news?id=225a825938d1e2a7003f95a65d74fa7b139615726aab2937ec192249730b042b
company,2023-07-21 01:21:00,Gilead abandons phase 3 study of magrolimab for myelodysplastic syndromes,121550245,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a20de3baabe36c262f0fec6b69c80169721c9cf9a87868b543f5c9a451e943b2
company,2023-07-21 00:05:00,Gilead to discontinue Phase 3 ENHANCE study of magrolimab plus azacitidine,121550247,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c44a1d552504978be9f90c5112f5882ac7b1417d0eb3c96675a99cfdff05e7bb
company,2023-07-20 23:42:00,Gilead Sciences Inc. stock outperforms market on strong trading day,121537898,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b757e438dcf6a77b50f2434ab37e776e4368235e66b97f698e46101a961bd369
company,2023-07-20 12:41:00,Gilead Sciences Inc. stock underperforms Thursday when compared to competitors despite daily gains,121513992,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 1.24% to $79.94 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",https://finnhub.io/api/news?id=204913a942a742ebd225b886a3a90c6ace39c91aea31e1e2f8565147f99d385c
company,2023-07-20 12:00:00,Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.,121499541,https://media.zenfs.com/en/business-wire.com/1198df729781087b1376df7797cde8db,GILD,Yahoo,"FOSTER CITY, Calif., July 20, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $8 million in funding through a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with hepatitis C virus (HCV) or hepatitis B virus (HBV) back into care. The CDA Foundation (CDAF), based in Lafayette, Colorado, will act as the lead organization for the program and be responsible for implementing and overs",https://finnhub.io/api/news?id=ae05b5471e0469593d9c2fde8b4925af6de71631f8eb62dcd2fc2293c0475aa6
company,2023-07-20 12:00:00,Center for Disease Analysis Foundation  Announces Receipt of an $8 Million Grant from Gilead Sciences  to Relink Hepatitis B and C Patients to Care in the United States,121499540,https://media.zenfs.com/en/globenewswire.com/ee63222733d710909336754ce620a0bb,GILD,Yahoo,"LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr",https://finnhub.io/api/news?id=81ee42ac362a78bc9966c0af343a55b39b1bcb779f8d67858d06b10b72f0cd39
company,2023-07-20 11:53:35,Cantor Fitzgerald Maintains Gilead Sciences (GILD) Neutral Recommendation,121499981,,GILD,Fintel,,https://finnhub.io/api/news?id=96a75655f8ce3af1034c2c0f98cc14beebcff383e70b07b68e25e664b5042a3d
company,2023-07-20 08:02:01,Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States,121499109,,GILD,Finnhub,The Center for Disease Analysis Foundation  announced today that it received an $8 million grant from Gilead Sciences  as part of Gilead’s Relink grant program. CDA Foundation will disperse the...,https://finnhub.io/api/news?id=53cb1c127e300c1e96aed1bb33f678335f437e383c4746b4329a4282a37a9363
company,2023-07-20 08:00:39,"A Note On Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE and Debt To Equity",121499542,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...,https://finnhub.io/api/news?id=0fdfd6c5f6b7cdde531f355ea9037911f7b3406d521fba756823d5b72a1682ea
company,2023-07-20 07:02:00,Gilead announces $8M in funding through Gilead Relink program,121505421,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=87548551a4faedaadae08a41e429b7b19584ee06b0f1d01711bdfdf00c91af39
company,2023-07-20 06:53:00,Bullish Two Hundred Day Moving Average Cross - GILD,121505423,,GILD,Dividend Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2641d58b138feda520dbfc009964471b8fb607970895cad53eabf8f320e31fdb
company,2023-07-19 18:00:19,Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know,121487338,https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a,GILD,Yahoo,"Gilead Sciences (GILD) closed the most recent trading day at $78.96, moving +0.95% from the previous trading session.",https://finnhub.io/api/news?id=6b3ac257cf25be5a8124a7c9464237c54cf4b9bc77b71f88d5e6af8fc8adf6ac
company,2023-07-19 15:07:41,The 7 Most Undervalued Nasdaq Stocks to Buy Now: July 2023,121591136,https://media.zenfs.com/en/investorplace_417/8126dcd0728fdff6bf835c727a60c52e,GILD,Yahoo,"The Nasdaq is known for its high-flying growth stocks, and with good reason. But there’s more to the index than just those aggressive names. In fact, there are even many Nasdaq stocks suitable for people following value investing strategies. The Nasdaq isn’t just a technology index either. There are Nasdaq stocks to buy in industries as diverse as telecom, banks, and financial service companies. The Nasdaq 100 Index has been off to a roaring start in the first half of this year. But fear not; th",https://finnhub.io/api/news?id=90065a6e10c696602ee96070a96c027c709b4ad32b072ea4bf8dd7d48ad47a56
company,2023-07-19 10:15:00,Gilead Sciences: Putting a Spotlight on the Mental Health Needs of LGBTQ+ Youth,121489386,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"Across the country, LGBTQ+ youth face challenges that are negatively affecting their mental health. Some find themselves not feeling accepted by their family or friends, or being verbally harassed at school.",https://finnhub.io/api/news?id=30968b48aee9ba123df037f64f7350b8919a764eff95c334903f86e15032a55e
company,2023-07-19 08:30:00,Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023,121467589,https://media.zenfs.com/en/business-wire.com/7479a0efca385f854f95c401b080fbbe,GILD,Yahoo,"FOSTER CITY, Calif., July 19, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 12th International AIDS Society Conference on HIV Science (IAS 2023), taking place in Brisbane, Australia, and virtually, from July 23-26, 2023. As the leader in HIV innovation, Gilead will provide updates on its signature initiatives and key collaborations while sharing new scientific data from its research and development programs. The breadth of data presented at the meet",https://finnhub.io/api/news?id=09a6b49a6de0ea9681df97996c1397b82bc24483045a5bbb7e69b28128b831bb
company,2023-07-19 08:15:00,3 Healthcare Stocks to Buy and Hold for the Next 10 Years,121467591,,GILD,Yahoo,"The healthcare sector is unlikely to become obsolete anytime soon, but individual companies can very much get left behind if they fail to keep up with the changing dynamics of the industry.  Let's look at three healthcare stocks that are leaders or innovators in their respective niches and could provide excellent returns in the next 10 years: Vertex Pharmaceuticals (NASDAQ: VRTX), Moderna (NASDAQ: MRNA), and Gilead Sciences (NASDAQ: GILD).  Vertex Pharmaceuticals has soundly beaten the market in the past 10 years, and the company is in an excellent position to do so in the next decade.",https://finnhub.io/api/news?id=3e43132bf1b25824695836d51c4ae2e3164951f80dde0a7d54271dac92bb74ac
company,2023-07-19 07:50:00,Peering Into Gilead Sciences's Recent Short Interest,121479204,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=576f571e7bce8bcffb54ff0156c16b4c3fbf3a4cdec4f96bb2e0f60c69d48f86
company,2023-07-19 02:13:00,Gilead price target lowered to $80 from $85 at Cantor Fitzgerald,121479207,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d5b1292e2c482ef47c057ead0e69d0cbd2bd3f6468739a52da4f7a1273e78e3b
company,2023-07-18 12:42:00,"Gilead Sciences Inc. stock rises Tuesday, outperforms market",121513994,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.96% higher to $78.22 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with...",https://finnhub.io/api/news?id=f873a39ec16cba246ba5a00ee9f9eef28c4fcafac98bbaada399196e3c03fb9a
company,2023-07-18 05:34:00,Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today,121458499,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=210eb717f97c492a84c12b403589e4aba9e723cdf98c657cd115e5a54d7a9b25
company,2023-07-18 05:15:46,My Dividend Stock Portfolio: New June Dividend Record - 99 Holdings With 28 Buys,121445404,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1406742992/image_1406742992.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"The broad S&P500 edged up 1.2% in June, while the Dow Jones rose slightly by 0.8% during the month. Click here to see my complete dividend stock portfolio list.",https://finnhub.io/api/news?id=0f1b6b13cb554ee3096c627030bc107845e5558f10eccf1a689e1c0517664792
company,2023-07-18 03:13:00,SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?,121448549,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=db921d741bd456d6b92a099873fbcc38c3c01da32a55f9693a84837d8bc56729
company,2023-07-18 02:05:00,Gilead price target lowered to $95 from $100 at BMO Capital,121458502,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4e00155c2f4a6acf10682b0814e83ebb35e9c23bdf74653f2573971ecb689728
company,2023-07-25 18:00:19,Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know,121601734,https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0,GILD,Yahoo,"In the latest trading session, Gilead Sciences (GILD) closed at $77.23, marking a -0.55% move from the previous day.",https://finnhub.io/api/news?id=1313e30105366b20c5dcf20a8846aa2d4770474a8481d928c86c6ccd33c390e4
company,2023-07-25 07:29:00,"GSK, J&J tout Cabenuva preference over Gilead's Biktarvy",121588583,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8ce60f7d0f92d21a90b0bbcf142ad653fd20c411ce9f95464e10c1f016be35cf
company,2023-07-25 05:29:55,"Gilead Sciences, Inc. - Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People with HIV",121583646,,GILD,Finnhub,"FOSTER CITY - Gilead Sciences, Inc.  today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes  from the Phase 2/3...",https://finnhub.io/api/news?id=af008315d533070edc5aaa0085d56331940ede0056b0c809ed520383e7b7e79b
company,2023-07-25 03:21:00,"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Tonix Pharma (TNXP) and Gilead Sciences (GILD)",121585893,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f468bb22dfcb8695c88fb48bac6de8964e8e0bb5deee0dba6a08c96a21aab531
company,2023-07-24 23:44:00,"Gilead Sciences Inc. stock falls Tuesday, underperforms market",121680900,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=737131d93d92433c1ac3cebf306c1b2794481f4e5ac5ee77e876ba9bb96e0f72
company,2023-07-24 23:26:00,"Gilead says twice-yearly lenacapavir has ""sustained impact"" on HIV",121585894,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b15add7b993f5ec137abb45c76745ba5ecb80afa5e37c1bd767509450270c14c
company,2023-07-24 20:34:00,GLOBAL BRIEFING: Beijing pledges support for faltering economy,121578551,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4a904b778520cdff7984df9ffecb54f2b08db7419c7077c6fcd55d2d46578913
company,2023-07-24 19:00:00,Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV,121579696,https://media.zenfs.com/en/business-wire.com/5d4a09e7587a1ec7026e55587e62ef84,GILD,Yahoo,"FOSTER CITY, Calif., July 24, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes (PRO) from the Phase 2/3 CAPELLA trial. These latest findings underscore the role of lenacapavir, the first long-acting injectable HIV treatment medication administered twice-yearly, as a person-centric therapy option and its transformative potential impact on the future of coordinated HIV",https://finnhub.io/api/news?id=d1cf1c62c44edfa244351913b65d917d2c0b5331f77069f124379424bcb60445
company,2023-07-24 18:01:00,Gilead stops trial of cancer drug that was central to $4.9 billion deal,121588054,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"A Gilead Sciences Inc. drug targeting a protein — usurped by cancers to send a ""don't eat me signal"" to the immune system — failed a late-stage clinical trial three years after the company made it the center of a $4.9 billion acquisition.  Foster City-based Gilead (NASDAQ: GILD) said it recommended stopping the late-stage study of the drug magrolimab, which headlined the company's April 2020 acquisition of Forty Seven Inc., in higher-risk myelodysplastic syndromes.  Studies of the drug are continuing in two ongoing trials in solid tumors and two pivotal studies in acute myeloid leukemia.",https://finnhub.io/api/news?id=cae5c20f90f8416c22bf677a41c4c03ccbec2f27911c847a0a974a6485003ace
company,2023-07-24 17:15:13,S&P 500 Gains and Losses Today: Oil Industry Stocks Surge as Oil Prices Rise,121573993,,GILD,Yahoo,"U.S. equities gained after better-than-expected second quarter earnings reports, with the S&P 500 rising 0.4% on Monday, July 24, 2023.",https://finnhub.io/api/news?id=4c73b13008a4b72a33309e77259feb4cba089806f8b76d09e840e9e5ce9cb0c5
company,2023-07-24 16:01:34,Piper Sandler Maintains Gilead Sciences (GILD) Overweight Recommendation,121570328,,GILD,Fintel,,https://finnhub.io/api/news?id=4b2607e96f30097c886b306b595a509be85ddb8cf660395d2b8517154eed25e9
company,2023-07-24 15:59:48,Cantor Fitzgerald Reiterates Gilead Sciences (GILD) Neutral Recommendation,121570332,,GILD,Fintel,,https://finnhub.io/api/news?id=9d767bd4673a7c0c5dfdb2fef2955e54046713f8e36c2ab7aa1e9d1dfd74d47f
company,2023-07-24 15:59:48,Barclays Maintains Gilead Sciences (GILD) Equal-Weight Recommendation,121570331,,GILD,Fintel,,https://finnhub.io/api/news?id=8e6d0c3abbc92c4868f0ac494c51513a1b02b9dabbc003602ff42897fdca71bd
company,2023-07-24 14:00:00,"Gilead Sciences, Inc. Presents New Data Reinforcing the Efficacy, Safety, and Tolerability Profile of Lenacapavir from the Phase 2/3 Capella Trial",121579122,,GILD,Finnhub,"Gilead Sciences, Inc. presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes  from the Phase 2/3 CAPELLA trial. These latest...",https://finnhub.io/api/news?id=d0a694ec84e5afbff810c7ede7cb6d6d9fc27f2d605da3a73a0aaea16201107e
company,2023-07-24 10:44:00,Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab,121569198,https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071,GILD,Yahoo,"Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.",https://finnhub.io/api/news?id=94423551e7b14e545020c7e2eac32024823413255d1b2929ad78ed928340cd63
company,2023-07-24 09:00:23,"Stocks making the biggest moves midday: AMC Entertainment, Mattel, Chevron, Spotify and more",121572068,https://image.cnbcfm.com/api/v1/image/106850109-1614971556103-gettyimages-1231535869-AFP_94D4PJ.jpeg?v=1690218023&w=1920&h=1080,GILD,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=bb48bf6b089e530cb3ae392260a4911f7808506a2f40ba6ddc7533ee4b5a779d
company,2023-07-24 08:00:00,Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million,121565971,https://media.zenfs.com/en/prnewswire.com/c8de4a7538ab6b3d5d3fe951dc211baa,GILD,Yahoo,"Cognizant (NASDAQ: CTSH) today announced an expansion of its relationship with Gilead Sciences (NASDAQ: GILD). Gilead is a leading biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases. Under the agreement, Cognizant will manage Gilead's global IT infrastructure, platforms, applications and advanced analytics, and lead initiatives designed to accelerate its digital transformation. The agreement includes renewal and expansion of Cognizant services",https://finnhub.io/api/news?id=b8d5d3efa5d3f8e2c58a33234e6118640f7dd4e892884c362fc9e21ae057686a
company,2023-07-24 07:51:00,Cognizant agrees USD800 million IT infrastructure deal with Gilead,121569745,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f3a9e1dbf3caac92957466e82ca395a9c51ce7fa509e5f37d9fd5798e36615e8
company,2023-07-24 05:41:18,Gilead to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS,121564820,,GILD,Finnhub,"FOSTER CITY - Gilead Sciences, Inc.  today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes  has been discontinued due to futility based on a planned analysis.
The...",https://finnhub.io/api/news?id=ca3ad15ddb5ab00b7640ef9bff4af98d9c49cb0332a3a048a4eda49af68811c1
company,2023-07-24 05:40:21,"Gilead Sciences, Inc. - New Biktarvy Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic",121564825,,GILD,Finnhub,"FOSTER CITY - Gilead Sciences, Inc.  today announced results from multiple studies reinforcing Biktarvy  as a treatment option for a broad range of people with HIV.
The latest findings include key...",https://finnhub.io/api/news?id=4761bfc1e0ecd714953602fc8f5f044cbffe961816f5e926de1c66eeb7211d52
company,2023-07-24 05:08:00,"Cognizant and Gilead sign a $800M agreement, expands partnership",121569747,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=837331970b8abe4c1a9c95b1c134678590959788040e48dbe7437a3fe4091377
company,2023-07-24 04:30:14,"Cognizant, Gilead Extend Service Agreement Worth $800 Million",121563591,,GILD,Finnhub,"By Ben Glickman 


   Cognizant Technology Solutions said Monday it would continue to manage Gilead Sciences' global information technology infrastructure for five years in a deal worth up to $800...",https://finnhub.io/api/news?id=9547780a2fad25f45c772c5124a4356b5c7f74aabd24aea8b926ddf72be329dc
company,2023-07-24 04:14:00,"Cognizant, Gilead Extend Service Agreement Worth $800M",121573445,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Ben Glickman Cognizant Technology Solutions said Monday it would continue to manage Gilead Sciences' global information technology infrastructure for five...,https://finnhub.io/api/news?id=5b3c6a1423868750b7bdc70c17b12637fda11066bf4341ed598d41e4bfae13dd
company,2023-07-24 04:11:00,"Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Becton Dickinson (BDX)",121575386,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=79aff0bded03b581c7b1405bf257ad33fdd831e352896db4323544d445d54b3b
company,2023-07-24 03:44:00,Gilead price target lowered to $100 from $105 at Piper Sandler,121577796,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=83e5a2f91f7e3285e3aec29ba370a54f4b929d800fa98ec1ff9bfd43925d9821
company,2023-07-24 03:41:00,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Exelixis (EXEL) and Becton Dickinson (BDX)",121575387,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=46c99b4c157ebb4295bdff30dab234c7616b6c8f20bc029f03f7d70359daa4cd
company,2023-07-24 03:13:00,"Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling",121567848,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ad4eb1854eb6284588dad7adb8824c9e97ecdfdaacde1cdd51d2e95f5cd7398f
company,2023-07-24 03:03:00,Expert Ratings for Gilead Sciences,121577802,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=edd180465e466646f8e721c66cea211fa6c81a7dcd3f4e6246ca4e5c264246a1
company,2023-07-24 03:02:00,Cognizant expands relatonship with Gilead,121569749,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=757490c0b8f3a776a92ce0f3187b6776d8b65ca279928f00389878186dd43ac4
company,2023-07-24 02:20:00,Gilead presents new data on lenacapavir,121577808,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=175f44ae3a68a93214de1d063406fe47edb697ae49299252707b39f9631ef21e
company,2023-07-24 01:53:00,Gilead price target lowered to $80 from $81 at Barclays,121577809,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e6ece006502409ad04ed10eda8f96cdfd4887ae435760c05daf21f6f7cd14147
company,2023-07-24 01:46:00,Bank of America Securities Reaffirms Their Hold Rating on Gilead Sciences (GILD),121577810,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2a44e2df0956e2118b8d313c5187dc9492a3c10cf242a4168def7f22338ee461
company,2023-07-24 01:10:00,"Gilead profited by delaying new version of a drug, NY Times reports",121577811,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=255229c2d89f8117cd908e5fb07fc6834d4ee16f837f7f620721c591eadacea7
company,2023-07-24 01:04:00,"AMC shares surge after judge rejects APE conversion plan, Tesla stock slips on downgrade and other stocks on the move",121573479,https://images.mktw.net/im-822406/social,GILD,MarketWatch,"Here are some of the biggest movers of the day: AMC Entertainment, Tesla and Gilead Sciences.",https://finnhub.io/api/news?id=c0e6e802e0a1a7948321eb4ae998d7f537c81196edd8144769802005e55ea2e9
company,2023-07-24 00:36:00,Gilead announces results from multiple Biktarvy studies,121577812,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e39309dbfeaeec15293a8bca7f678f6c8191dbca0aa8d80a393ccbd53cb33425
company,2023-07-24 00:09:00,Gilead lambasts patent lawsuit coverage in mixed week for drug trials,121577813,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=21756eb2da0feaf849429719b616053bbc788974a527dc72044edf3d76a96d65
company,2023-07-23 23:43:00,"Gilead Sciences Inc. stock falls Monday, underperforms market",121577815,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=28b15d2b61ebec8c12df9cabb9b78101ac57bfb8f4ecfff8e69c08a6863d9e85
company,2023-07-23 23:30:00,"Eaton Vance Worldwide Health Sciences Fund Buys Vertex Pharmaceuticals, Exits Dechra Pharmaceuticals",121577063,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=655f312d941a2ad7d4e7e1e336fc13f804f6e2712735be7d18852727ba5056ea
company,2023-07-23 21:51:00,New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic,121566069,https://media.zenfs.com/en/business-wire.com/296658e8f5e9f01113608ffbbafee943,GILD,Yahoo,"FOSTER CITY, Calif., July 24, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from multiple studies reinforcing Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a treatment option for a broad range of people with HIV. The latest findings include key insights into the treatment of virologically suppressed pregnant women and children two years of age or older (weighing at least 14 kg to less than 25 kg) and positive Week 96 data",https://finnhub.io/api/news?id=cbfd0643643ec15b97c0ffd1dd7491eeb1f7bcd2c7b1ef4ca0f087ef3a97b2b3
company,2023-07-23 17:00:00,Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities,121566071,https://media.zenfs.com/en/business-wire.com/b6313770d8ffecb2ee629e8dee9fe22b,GILD,Yahoo,"FOSTER CITY, Calif., July 23, 2023--Gilead Sciences Inc. (Nasdaq: GILD) today announced its largest commitment to health equity for Australian and Canadian Indigenous communities. The initiative will support programs addressing societal barriers to care that persistently contribute to the transmission of HIV and viral hepatitis within Indigenous communities.",https://finnhub.io/api/news?id=b7a819f683164e1a40ef362605e439f49437d020a423d4d4a13d00a6383189cf
company,2023-07-23 03:39:00,Governor DeSantis Says He Would Sue the Drug Company Gilead for Trying to Save Lives,121560220,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=76baa0da019254b088aa20b401dec924dbfd4d0503af15876162a6b8026a995c
company,2023-07-22 09:54:01,Gilead Sciences : Statement on New York Times' Story on TDF and TAF Development for HIV,121550256,,GILD,Finnhub,"Foster City, Calif., July 22, 2023 -Gilead Sciences provided the following statement pre-publication to the reporters for the New York Times in response to their questions before their...",https://finnhub.io/api/news?id=f80c17de1ff70e2cec017f5b43451b982f1e98a106eb76b0d3c97a0b3624ebca
company,2023-07-21 21:00:00,"Pfizer, Gilead, GSK set to dominate infectious diseases market",121553070,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1ea6c341bc21062c4ed6dab48a7649a46643d3b1c0c5a53b5225a4d6f989d5bb
company,2023-07-29 06:14:00,3 Stocks Retirees Should Absolutely Love,121695733,https://s.yimg.com/ny/api/res/1.2/nuSTYOnvwYZVZLXCI.fulw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/af1013ee322f10ee4ef3dad18e7407c6,GILD,Yahoo,"Dividend stocks can practically be a retiree's best friend.  Three Motley Fool contributors were asked to identify healthcare dividend stocks they think retirees should absolutely love now.  Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).",https://finnhub.io/api/news?id=068e1af1b9afdc1fafc5a28a7f6128e9799a6f5455fd8a4c3319694e3136bac2
company,2023-07-28 12:29:00,Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?,121672091,https://media.zenfs.com/en/zacks.com/b5a65fa858bdba9ae21498c7eb062c70,GILD,Yahoo,Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.,https://finnhub.io/api/news?id=0d8dc229e69cadef19dc4a5920d5edbeb15de891464300856dec81c8f2048c4b
company,2023-07-28 08:20:14,Unveiling AbbVie's Hidden Risks: Cautionary Notes For Investors,121668799,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1454448091/image_1454448091.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"AbbVie's Q2 2023 financial results exceeded expectations, driven by strong sales of innovative drugs Skyrizi and Rinvoq. Click here to read more.",https://finnhub.io/api/news?id=6361f3e615549838584f6975f2f4d7a4213a326210c0d1f905ccac72e8fc76b7
company,2023-07-28 08:00:55,Here's Why We Think Gilead Sciences (NASDAQ:GILD) Might Deserve Your Attention Today,121668413,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...",https://finnhub.io/api/news?id=3d31ab059a94be75a3677ac8395eb8a04e76b6862ca728608fe8d7bb0edac6c7
company,2023-07-28 00:00:00,GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030,121668414,https://media.zenfs.com/en/prnewswire.com/18ef42744c262c27f9ba2cdb133c621b,GILD,Yahoo,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of the 2023 Gilead ALL4LIVER Grant, a grant program with the theme of 'Test. Link. Prioritize', designed to support innovative projects that drive testing, improve linkage to care and/or elevate viral hepatitis on the public health agenda. The ALL4LIVER Grant will support initiatives around the world (excluding the United States) across hepatitis C, hepatitis B or hepatitis D. Eligible organizations can submit funding applications o",https://finnhub.io/api/news?id=8752a1523fa726ce088202964d1abe6d81cc15c1dcc0eb00a00ecac3b33a6dda
company,2023-07-27 23:43:00,"Gilead Sciences Inc. stock rises Friday, still underperforms market",121680892,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2105938fdd6c2add7c5cd76a862a61798e9647d0f91708b5752c8fe772d3c226
company,2023-07-27 21:38:00,"Earnings week ahead: Amazon, Apple, Pfizer, Starbucks, Uber and more",121672775,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b0a2a0be8b2d7a46fc56480c580ed87cd56a0b43d1ffccdb0ab7eac0511782b8
company,2023-07-27 13:23:00,European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer,121644428,https://media.zenfs.com/en/business-wire.com/64d35b55af3478a89ab066630c868dd0,GILD,Yahoo,"FOSTER CITY, Calif., July 27, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) approved Trodelvy® (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.",https://finnhub.io/api/news?id=bade3b22ef76f631692ad5862de8cd30cca3ef305535ee697e7543e39684b4cb
company,2023-07-27 09:24:01,European Commission Approves Gilead's Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer,121626651,,GILD,Finnhub,-- Approval Based on Clinically Meaningful Overall Survival Benefit Demonstrated in the TROPiCS-02 Study in Pre-Treated HR+/HER2-  Metastatic Breast Cancer vs. Physician’s Choice of Chemotherapy...,https://finnhub.io/api/news?id=31c1f90ccc7f6ec106c449168aa8bc2698836731734935373d7987598cdf6607
company,2023-07-27 08:30:00,EC approves Gilead's Trodelvy for pre-treated HR+/HER2- metastatic breast cancer,121680895,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1351628e77cb299d1ff9721a8b96eaaa8cef23f9a25e7aa57f0f6fa05961f85d
company,2023-07-27 05:12:28,20 Countries With Highest Rates Of AIDS,121618503,https://media.zenfs.com/en/insidermonkey.com/8a09c4944b2a32058460b34f9c02ab47,GILD,Yahoo,"In this article, we will be taking a look at the 20 countries with the highest rate of AIDS. If you are not interested in reading the details, head straight to the 5 Countries With Highest Rates of AIDS. AIDS, or Acquired Immunodeficiency Syndrome, remains a pressing global health concern, and its impact varies significantly […]",https://finnhub.io/api/news?id=ee016e1561ecc521c9016de17e0b9e5c24067a72851d241bab64ac6d4f90ebb2
company,2023-07-26 23:44:00,"Gilead Sciences Inc. stock falls Thursday, underperforms market",121680896,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=14ac716e59d9ef8e4665b2e9382455d582870693c71c929dbd4da2cd54cf51a9
company,2023-07-26 17:50:19,Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know,121611116,https://media.zenfs.com/en/zacks.com/a41b81fe729c761f3f94f42ff348f70c,GILD,Yahoo,"In the latest trading session, Gilead Sciences (GILD) closed at $77.19, marking a -0.05% move from the previous day.",https://finnhub.io/api/news?id=6bdaa32e03c1acebce14ef7b4183653e9f40c5d655586721bfa12870e6912510
company,2023-07-26 05:26:00,Truist Financial Reaffirms Their Buy Rating on Gilead Sciences (GILD),121654815,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2a0f8565f882b729230099f740031a2dba7b5d6aa21c272eafb730e226b7fce7
company,2023-07-25 23:44:00,Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors,121680898,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9d75ebd5133b41486434d5038796218b22911640b45cba9819999d7a733b3bca
company,2023-08-02 13:55:00,Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities,121775664,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,Gilead Sciences Inc. (Nasdaq:GILD) announced its largest commitment to health equity for Australian and Canadian Indigenous communities.,https://finnhub.io/api/news?id=e0432c939451687b6cd9d9a3b2874c306641630bb1563eaabab257d95e40ab6e
company,2023-08-02 04:40:00,Unusually active option classes on open August 2nd,121773300,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ec1dcd56f5b2c1245a990ab3b0bdedd5696b5e4039b56f0c26ecab2de0d8230b
company,2023-08-02 01:44:00,"Gilead seen reporting higher Q2 earnings, despite drop in COVID-19 drug sales",121784039,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=044874d58fe20530eeef3388cb9a51b657fd985630fe4cb9f957cccdaad0ab01
company,2023-08-02 01:06:00,Mizuho Securities Sticks to Their Buy Rating for Gilead Sciences (GILD),121775023,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=25cf77dcf72314467145b441a6f2127bba10609bdc558bc7a5ce37abcba5c32f
company,2023-08-01 23:44:00,"Gilead Sciences Inc. stock remains steady Wednesday, still outperforms market",121784041,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=157e1b533e3af3bf799ba810564cff571b51ebde9ce488c2d1d1273728208c61
company,2023-08-01 14:59:01,Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points,121878063,https://media.zenfs.com/en/investorplace_417/b65ecbd3cc97c34115d1ca93c78611f0,GILD,Yahoo,"The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%. Despite the massive amount of revenue being generated, most biotech companies remain small and medium-sized enterprises. Many of the companies operating in the space are start-ups. Yet they are performing cutting-edge research and developing life-saving innovations that are in high demand. This presents an opportunity fo",https://finnhub.io/api/news?id=c105937fcc560d724aa85e8cd4194f96e95e1d05251f6a5ec0535fe595fbb268
company,2023-08-01 08:00:40,"With 85% ownership, Gilead Sciences, Inc. (NASDAQ:GILD) boasts of strong institutional backing",121737256,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...",https://finnhub.io/api/news?id=5a889453330ea0e0f29bcd4641ec89cb2d05bb55227a41b9a4421652fb42d9cb
company,2023-07-31 23:44:00,Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors,121753945,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=72c1adc9ca5bd51188b8957fc50a1207824f6a837297acc93f8acffea1523ad1
company,2023-07-31 22:35:00,See Which Of The Latest 13F Filers Holds Gilead Sciences,121753946,,GILD,Preferred Stock Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4d44e73b0854a968034e51558f5514108e697bfb4907cca6894291d24bfc4bf2
company,2023-07-31 00:47:00,Robert W. Baird Remains a Hold on Gilead Sciences (GILD),121716898,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7ac628bda43f4d0ce732fcaac5584c295ad8ef76c33ca66e79e8e84a39b569bd
company,2023-07-30 23:44:00,Gilead Sciences Inc. stock outperforms competitors despite losses on the day,121753949,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ff3a0b996ebccce914c32806b9724a83e6503bc715ccd3db68a98d5781624bd0
company,2023-08-06 07:00:47,"Gilead Sciences, Inc.'s (NASDAQ:GILD) Intrinsic Value Is Potentially 68% Above Its Share Price",121858134,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,Key Insights Gilead Sciences' estimated fair value is US$132 based on 2 Stage Free Cash Flow to Equity Gilead Sciences...,https://finnhub.io/api/news?id=a87c17eb3703fcb0d8fee91a7aef0a7abd8d33f0ae809fb6cab393dcc6e2f8dc
company,2023-08-06 01:34:00,Is Gilead Sciences (GILD) Stock Worth Your Investment? A Comprehensive Valuation Analysis,121882076,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=057ff528eb391429fc1d1d19ac370264f81b1475dd0152d0633fa572685ccb5c
company,2023-08-05 01:50:23,RBC Capital Maintains Gilead Sciences (GILD) Sector Perform Recommendation,121844702,,GILD,Fintel,,https://finnhub.io/api/news?id=3aa9fb82e4fbfb4b8bc40864d2825751bb187ee4206b972f7fc976086ff2d725
company,2023-08-05 01:50:23,Morgan Stanley Maintains Gilead Sciences (GILD) Equal-Weight Recommendation,121844701,,GILD,Fintel,,https://finnhub.io/api/news?id=15087c22eb427eab0f0d4a25ed92b705d41067181d41aa84b9bc282be85bba32
company,2023-08-05 01:35:00,Is Gilead Sciences (GILD) Stock Fairly Valued? A Comprehensive Analysis,121882077,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=84584cb3120f766b7948604f934af7eb04f577d5d8f0db9862f601a96b9b2be7
company,2023-08-04 16:12:59,Gilead Plots A Massive Move Into Oncology: A Third Of Sales By 2030,121836112,https://media.zenfs.com/en/ibd.com/c6cfe7add5b7036f7dbc3d507c2e8b7f,GILD,Yahoo,"Gilead expects a third of sales to come from its cancer treatments by 2030, and GILD stock jumped Friday despite a mixed earnings report.",https://finnhub.io/api/news?id=d276cca0b5b3109af6a31acbd09cc68f3a779a274972d23b30169edc219c4be3
company,2023-08-04 13:00:00,"Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology",121829855,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.,https://finnhub.io/api/news?id=d244036e21362b2c6b25257e060631f477e7e3ae5690b9f7ea30742758b1b90c
company,2023-08-04 12:35:33,Is Gilead Sciences (GILD) Fairly Valued? An In-Depth Analysis,121829856,https://media.zenfs.com/en/us.finance.gurufocus/42989b2604cbbb7f6956a5b8352b3bdd,GILD,Yahoo,"With a daily gain of 4.63% and an Earnings Per Share (EPS) of 4.43, Gilead Sciences Inc (NASDAQ:GILD) has been attracting attention in the investment community.  This article aims to answer the pressing question: is Gilead Sciences (NASDAQ:GILD) fairly valued?  Gilead Sciences, a company with a rich portfolio of therapies for life-threatening infectious diseases, has a history of acquisitions that have expanded its focus to pulmonary and cardiovascular diseases and cancer.",https://finnhub.io/api/news?id=efabff1001bc03e76156539b54e859cb2cae42c5753da07436f4fe4c2ca19b8e
company,2023-08-04 09:38:59,Gilead's Plots A Massive Move Into Oncology: A Third Of Sales By 2030,121829858,,GILD,Yahoo,"Gilead expects a third of sales to come from its cancer treatments by 2030, and GILD stock jumped Friday despite a mixed earnings report.",https://finnhub.io/api/news?id=ba2434815f79407dafe57ad61c9e2b8f7ec933d62f2422001d5fb60ee4c15f3d
company,2023-08-04 07:59:00,Amgen Inc: A Strong Contender in the Drug Manufacturers Industry with a GF Score of 85,121827108,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9b56e7c94fe466651472f6266c6d91a8b7a990f288dfb894fdeb3e50769c9542
company,2023-08-04 07:45:41,Gilead Sciences Q2 Earnings: 'Transitional' Quarter Delivers Mixed Results,121822587,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Gilead's HIV division contributed $4.6 billion and its oncology division generated $728 million in revenues. Read how one-off costs hit profitability in Gilead's latest earnings.,https://finnhub.io/api/news?id=94830df55f340401a60add722ce84659474763d800037c4bcdfbb89f0e6cb073
company,2023-08-04 06:07:00,Piper Sandler Sticks to Their Buy Rating for Gilead Sciences (GILD),121823314,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=428eed605a9ee05153f541a1f0c8b6aa2aaabafb4f8d75c9851a40f14c4dddbb
company,2023-08-04 03:20:00,Gilead Sciences second quarter net profit falls; lowers profit outlook,121823316,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=46e5db8c642d08644a28c96f8589c4d599aa41e34c3bc49585c735d846376c84
company,2023-08-04 02:46:00,BMO Capital Releases a Buy Rating on Gilead Sciences (GILD),121823317,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3d6fd51c3bc7b05c957f246f64fe3dbeea347cee19f8ce2c2408554edf3d3042
company,2023-08-04 01:30:00,Gilead files for mixed shelf offering,121882079,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ae326867510eba9ddbb8b94d23ae9beebb49fe9cac3e3ad6b16300dba742ca0f
company,2023-08-04 00:27:00,Gilead files automatic mixed securities shelf,121882080,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=07cb8bbe195f57b9653c2e2fcc2d03855f291004b75a6b5820670cc85383f11c
company,2023-08-04 00:00:29,Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript,121829859,,GILD,Yahoo,"Thank you for attending Gilead Sciences second quarter 2023 earnings conference call.  The press release, slides and supplementary data are available on the Investors section of our website at gilead.com.  The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day, our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey, and our chief financial officer, Andrew Dickinson.",https://finnhub.io/api/news?id=8fc1479d8957c51294a31ab4309e63c061ab37ffe3dbc2ddef9b301f08726a2c
company,2023-08-03 23:43:00,"Gilead Sciences Inc. stock rises Friday, outperforms market",121882081,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=af84913fe0c880b3591d25e8db96cad60f3bc242fd7fdb68c1d5a4ec40f93bbb
company,2023-08-03 23:06:00,Barclays Remains a Hold on Gilead Sciences (GILD),121823319,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9156d2cca1234b83b46b8270e9c7d1c899bf2f9b897f9b5417378642cc1af53e
company,2023-08-03 21:40:00,"Amazon shares rally 10%, but Apple’s dip, and other stocks on the move",121829802,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=478abf959d04bbc09c25c112155dd2b356a57b56ba4ec9eaeb8e56b1ad426bc0
company,2023-08-03 19:00:07,Gilead (GILD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates,121807417,https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0,GILD,Yahoo,"The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",https://finnhub.io/api/news?id=a562b4fe467c7ff08688d037096cc6a5a290d6628101aa7a769abf8c1444091d
company,2023-08-03 17:45:13,Gilead Sciences (GILD) Q2 Earnings Lag Estimates,121807418,https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9,GILD,Yahoo,"Gilead (GILD) delivered earnings and revenue surprises of -16.25% and 2.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?",https://finnhub.io/api/news?id=87d68c9bfa2c256d58d7e63868a4ed27605d20d18f2e795b0d38427032ceeeae
company,2023-08-03 17:34:59,Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth?,121807419,https://media.zenfs.com/en/ibd.com/c6cfe7add5b7036f7dbc3d507c2e8b7f,GILD,Yahoo,Two of Gilead's cancer drugs topped second-quarter sales expectations Thursday. GILD stock rose slightly in late action.,https://finnhub.io/api/news?id=c5c8efa40e2b5b8222748d3c7ffba87fa926f507551dd67150c90c522aa88edf
company,2023-08-03 16:59:05,"Gilead Sciences, Inc. (GILD) Q2 2023 Earnings Call Transcript",121805159,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ETCompany ParticipantsJacquie Ross - Vice President, Investor RelationsDaniel O'Day -...",https://finnhub.io/api/news?id=7a74732ffb8c9dbf98aa26b1c68a1cb58d64123a2444b2d9e4393bc10a7e9ca0
company,2023-08-03 16:53:17,"UPDATE 1-Gilead quarterly profit falls on COVID sales drop, legal settlement charge",121807420,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"Gilead Sciences on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs.  The drugmaker raised its full-year revenue forecast, even as it trimmed its estimate for COVID antiviral Veklury due to lower pandemic-related hospitalizations.  Gilead reported second-quarter earnings of $1.34 per share excluding items, on total revenue of $6.6 billion, down from $1.58 a share and revenue of $6.26 billion in the year-ago quarter.",https://finnhub.io/api/news?id=5565596983286ece45ed7053c32c731bf1dc4d999347c0b87b2993a1e8b0479f
company,2023-08-03 16:43:00,Gilead Sciences Cuts Profit Forecast on Legal Settlement,121807421,https://s.yimg.com/ny/api/res/1.2/Ff_4_9f2CCMyKs0kZvqCpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/a7f7b32e12ea4aad7a8f98f9d7f93577,GILD,Yahoo,"CEO Daniel O'Day said the biopharma company is ""overperforming significantly, excluding one-time items.""",https://finnhub.io/api/news?id=8a1ac85333f794cdb31ee3006f435e3d899f8dd71f9f1809a9c24710814308f9
company,2023-08-03 16:05:14,"Gilead quarterly profit falls on COVID sales drop, legal settlement charge",121807422,https://media.zenfs.com/en/reuters-finance.com/e1146f3261299364fae21186242ecce0,GILD,Yahoo,"(Reuters) -Gilead Sciences on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs.  The drugmaker raised its full-year revenue forecast, even as it trimmed its estimate for COVID antiviral Veklury due to lower pandemic-related hospitalizations.  Gilead reported second-quarter earnings of $1.34 per share excluding items, on total revenue of $6.6 billion, down from $1.58 a share and revenue of $6.26 billion in the year-ago quarter.",https://finnhub.io/api/news?id=d6afd80aab5403840e65dbb38474c820be0e1746ae8b4c642b08488f2af3685b
company,2023-08-03 16:02:00,Gilead Sciences Announces Second Quarter 2023 Financial Results,121807423,https://media.zenfs.com/en/business-wire.com/023f8c740b50b08b33591d5e0f3b1432,GILD,Yahoo,"FOSTER CITY, Calif., August 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2023.",https://finnhub.io/api/news?id=bb207117ed255b9cbccf9297a11f23c40b13a5949d688769824572f10432ef47
company,2023-08-03 12:30:07,"Gilead Upgrades Product Sales Outlook, Cuts EPS View",121798287,,GILD,Finnhub,"By Paul Ziobro 

  Gilead Sciences raised the midpoint of its full-year guidance for product sales while reducing the range for its earnings outlook after posting mixed second-quarter results. 

 ...",https://finnhub.io/api/news?id=4255162e8aab74affee376f619f132255e57d37c3ebd30698bcc2af4eb52d274
company,2023-08-03 12:21:07,"Gilead Sciences 2Q Profit Down On HIV Litigation, Higher Costs",121798044,,GILD,Finnhub,"Gilead Sciences 2Q Profit Down On HIV Litigation, Higher Costs 

  By Paul Ziobro 

  Gilead Sciences posted a drop in second-quarter profit, which was hit by a settlement in HIV antitrust...",https://finnhub.io/api/news?id=a32c74838acda74d4ef8057f9520be75ba8d2bf34928416c5e2162ccab6a2288
company,2023-08-03 12:15:00,"Gilead's profit lags consensus but sales beat, sending stock up after hours",122013556,https://images.mktw.net/im-829529/social,GILD,MarketWatch,Gilead's quarterly revenue topped estimates and it tweaked guidance.,https://finnhub.io/api/news?id=98837f946569e942f17d588b0057a43ed8d9716d0914f74b93a5e8d03528c0c4
company,2023-08-03 12:14:00,"Gilead Ups Product Sales Outlook, Cuts EPS View",122013558,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,GILD,MarketWatch,By Paul Ziobro Gilead Sciences raised the midpoint of its full-year guidance for product sales while reducing the range for its earnings outlook after...,https://finnhub.io/api/news?id=e85c0788e3fe2cf138a6294ed23e7aa24a80c6bc5d364f67951ef989be6ac46c
company,2023-08-03 01:57:00,"US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month",121791830,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a69a25984d84eddb2a3c618822a5ee84d3886fb297a182644239b6d0d75e76e7
company,2023-08-03 01:41:00,"Analysts Are Neutral on Top Healthcare Stocks: Definitive Healthcare Corp (DH), DENTSPLY SIRONA (XRAY)",121794104,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=db88d27324484a30081d12061d772ebbe83b1d02bb863a3856c7412469aeebc0
company,2023-08-03 01:29:00,Gilead boosts 2023 sales projection but cuts EPS outlook,121801412,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=84871421c3bf06512431927870aa8bbe9e3c5a3d6e0328099cf5583d88292ce5
company,2023-08-03 00:12:06,Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities,121788915,,GILD,Finnhub,- $6 Million USD in Funding Will Help Address Health Disparities Among Indigenous Communities with a Focus on HIV and Viral Hepatitis - Type of Content Press Release Layout Standard Format...,https://finnhub.io/api/news?id=bb3e4323a3bcea43edf0e893a5058e97686416888c17bbe2ebeadf402c353264
company,2023-08-03 00:08:00,"Gilead’s profit lags consensus but sales beat, sending stock up after hours",121801413,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6f21734988fe0cbe0b33fdc649eabfa5f5b7ebdb5989ace1a35dc26927159ccc
company,2023-08-03 00:05:00,Apple among BofA picks for options opportunity on earnings surprise,121792210,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cf2f097f91d0eecc6a7e7b5be7e505fad4200f69fa2e8cb8abec27d6d3a91969
company,2023-08-02 23:44:00,Gilead Sciences Inc. stock outperforms market despite losses on the day,121801415,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c2815bd807a0b252b7862d567382d273085ad8cb9b34c1aaa3f95ef4c59e28ed
company,2023-08-02 23:16:00,Gilead’s stock slides 2% after Q2 profit lags consensus and as company lowers guidance,121801416,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=621f6956b2399a5a23228e18343b9a4cfd555ba742eaedc3529eb2772cfb19ab
company,2023-08-02 23:11:00,Gilead Sciences declares $0.75 dividend,121801417,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c8f85b10a90dc551d88c4b001981f1719c7694c11c071f1cb3a582e6ad61457e
company,2023-08-02 23:06:00,"Gilead Sciences Non-GAAP EPS of $1.34 misses by $0.30, revenue of $6.59B beats by $140M",121801418,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=292129356a64dc9e49d70f0d937b468dc507f6b64d1db639ecdd5f68bef4d90e
company,2023-08-02 23:05:00,"Gilead cuts FY23 EPS view to $6.45-$6.80 from $6.60-$7.00, consensus $6.73",121801419,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8856a65d3fce89a6b26a09daf76db36d3ae5513c204066f30140c8bbf26fdaa6
company,2023-08-02 23:04:00,"Gilead reports Q2 adjusted EPS $1.34, consensus $1.64",121801420,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=89d6375d23547049b5ffbc662fc4e287bc06adf04a17473dbefd028b67c7ce54
company,2023-08-02 21:36:00,Notable companies reporting after market close,121795699,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7f303c49de532bf051147aa70fce998ee69737e75f86b39a8f614dad5fb65403
company,2023-08-02 21:00:00,"Stocks Mitigate Losses Ahead Of Apple, Amazon Earnings; Treasury Yields Rocket On Debt Frenzy: Thursday's Market Drivers",121794673,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=642841f6a54caf69dac834fcffd7f0ae103f0a8bc061191288125f462016e44f
company,2023-08-02 20:34:00,GLOBAL BRIEFING: China's services see strong growth in July,121791844,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dc1b26b1a1ed6bf21fdc67a8cf6d8c88dac6ec1224ceef2d099495af2fc8f1cd
company,2023-08-10 12:42:00,Gilead Sciences Inc. stock outperforms competitors despite losses on the day,122013552,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 0.21% to $80.00 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=0b1d2ea7b21f4250b4c53bb060205f771e18ca27d02af0322c5686d66b9e7776
company,2023-08-10 05:18:00,How Is The Market Feeling About Gilead Sciences?,121962544,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2d193a40a9a94042e7fcdb12ee134c56b0dd0a217426cd656983cbb53489db1e
company,2023-08-09 16:00:01,The 3 Best Biotech Stocks to Buy in August,122060960,https://media.zenfs.com/en/investorplace_417/03737c9cbe7ca910ba80c3b95d561df1,GILD,Yahoo,"Many healthcare stocks suffer from COVID fatigue as profits fall amid a global decline in the virus’ spread. But medical innovations and technological breakthroughs are rapidly transforming the healthcare landscape, and biotech stocks are garnering unprecedented attention in the investment community. These companies, operating at the intersection of biology and technology, promise groundbreaking treatments, therapies and solutions to some of the world’s most persistent medical challenges. As the",https://finnhub.io/api/news?id=82bc769aa4fe67c98d905a67a6997e8465708f78fc1828a2011f22d7c5fc058d
company,2023-08-09 13:58:16,U.S. Wide-Moat Stocks On Sale - The August 2023 Heat Map,121936438,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912585074/image_912585074.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Discover our 3-step process for identifying undervalued wide-moat stocks, including a heat map of top investable candidates. Click here to read our picks.",https://finnhub.io/api/news?id=68c46811154f6adbf26935b5b28e1742a72b043138abf648690f4393dd19ba5f
company,2023-08-09 12:42:00,"Gilead Sciences Inc. stock rises Wednesday, outperforms market",122013553,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.11% higher to $80.17 Wednesday, on what proved to be an all-around poor trading session for the stock market, with...",https://finnhub.io/api/news?id=3190a8146e7e91f5b680d87ac53d07584a805c80506b53c83bf77dafd44eb5ba
company,2023-08-09 08:05:00,Gilead Sciences: A Cut Above the Rest: Innovative Barbershop Program Educates Indigenous Men About HIV,121937019,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / August 9, 2023 / Gilead Sciences: How do you educate people about difficult-to-talk-about, yet incredibly important, health topics? And which settings are ideal for such conversations? Those were the questions plaguing ...",https://finnhub.io/api/news?id=81ecb55e7eb3d19b28962013d1a622f578ec17f048329e2c505e96325fd58319
company,2023-08-09 06:26:00,Gilead Sciences a Top 25 Dividend Giant With 3.75% Yield (GILD),121940805,,GILD,ETF Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=01e6261e44c7f27c6180ccf16875795029aa625a24728442c9093976f95ab834
company,2023-08-08 12:42:00,Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors,122013554,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 0.73% to $80.08 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=84338359474d055ff565e1c41112bc7fd5e2681f2b72e259c72a0c834a4019b7
company,2023-08-08 12:01:00,Ligand Reports Second Quarter 2023 Financial Results,121903196,,GILD,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c1e069b9ec550e9102ae473b13b3229aa1f1d781a73c72d6d5ba3a0a40125b05
company,2023-08-08 07:59:00,Amgen Inc: A Strong Contender in the Drug Manufacturers Industry with a GF Score of 85,121901977,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ee0bf798c4b640e8cfe5f1170278d90f291224b728adf8fc4075b83ec9f57049
company,2023-08-08 07:04:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,121907202,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f64ac99d29b181f390001e8b845786f7a9ccae6073c9abeba22a8fa47a15f784
company,2023-08-08 05:26:00,Gilead Sciences (GILD) Receives a Buy from Truist Financial,121923150,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e19ec573cfd907efde29f79388e244d6c5c57e3b560d8fbeb54439466b5a3b9f
company,2023-08-08 05:26:00,2 High-Yield Dividend Stocks to Buy on the Dip,121893077,https://s.yimg.com/ny/api/res/1.2/r2_xE9wU7jAFnwKsESW64A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/918edcb7ddeffc8b4156e58525eb716d,GILD,Yahoo,Income-seeking investors tend to be drawn to high dividend yields.  A high yield from the dividend of a great company is highly sought after.  There are plenty of stocks with competitive dividend yields worth serious consideration for investors.,https://finnhub.io/api/news?id=2b647e2226f7d7836e6ecec2027b9d7c9e36e45fe1a914fa34c68324aa98c350
company,2023-08-08 05:10:00,My Dividend Stock Portfolio: New July Dividend Record - 99 Holdings With 26 Buys,121890514,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1406742992/image_1406742992.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Investment activity remained robust, and dividend income hit a record high. Additionally, passive income equivalent to almost 5 weeks of work was earned in 2023.",https://finnhub.io/api/news?id=dee934baa8db2aa81ef2d7f77920e2d57b070b2c89484d107522296ae414ef7d
company,2023-08-08 02:50:00,GLOBAL BROKER RATINGS: Deutsche Bank cuts WPP; UBS ups Smith & Nephew,121895299,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=91f1837c6d6fe564f2e3cbc95d79a8b2b3e14847a98211c02683ebbc41349245
company,2023-08-08 00:16:00,Robert W. Baird Keeps Their Hold Rating on Gilead Sciences (GILD),121907205,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e7aa54b3d9c37d8d646aa23068178942e745714a64dc0e9f35f5d85c8e0cfc9a
company,2023-08-07 12:42:00,"Gilead Sciences Inc. stock rises Monday, outperforms market",122013555,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rose 2.53% to $80.67 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=9a65e8011f67339101816c4dc26e35ae8f021b38ea57cc2f293f62fae11acc85
company,2023-08-07 07:11:00,Amgen Inc: A Strong Contender in the Drug Manufacturers Industry with a High GF Score,121873512,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0a90dec1ee6fdd9857b978c37f25a5eb559a24fcdf620ecf09993b96081a9a92
company,2023-08-07 04:25:00,"Monday’s Top Wall Street Analyst Upgrades and Downgrades: Amazon, Apple, Block, Coinbase, Datadog, Fortinet, Gilead Sciences, Moderna, Nvidia, PayPal, Petrobras and More",121871907,,GILD,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=31e01da046173d79704b27bf82218e1200c10799c2853f3bec81e5605ff05b99
company,2023-08-07 01:47:45,"Gilead Sciences: Mixed Signals, Again",121867620,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Gilead Sciences seeks future growth through diversification and pipeline conversion. Click here to see why GILD stock is a Buy.,https://finnhub.io/api/news?id=66fccbc00f43f5da4459a6984520b3ff9d05dece03a7e4a986d3a1ac311417eb
company,2023-08-06 22:21:00,Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and Gilead Sciences (GILD),121875506,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8a96e0610bdd4083d47824849dd4271d86e5711a0d9af0f05e9d50b14e8c5371
company,2023-08-06 21:35:00,Ikena falls on acquisition of Pionyr in all-stock deal,121879249,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e1398397eaf44eda64abf497b452377d0ac3258ba664ab5d437a827e72f720a0
company,2023-08-14 04:26:00,Piper Sandler Remains a Buy on Gilead Sciences (GILD),122024314,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fcd1053ca954d1dc568562afbdd8ca1cd84dbd98093503ba626a3e0b43b3356a
company,2023-08-14 01:36:00,Arcellx up 10% as FDA lifts clinical hold,122045917,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5ae2eda32b2a393541d82a5ed8711f1b4cb5b8f623d5236a13f8be7b153fa3f3
company,2023-08-13 23:43:00,Gilead Sciences Inc. stock outperforms competitors despite losses on the day,122051323,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=01f3d109e133e1a0ff0550b48274db68529177e88c5b295f3c0b88c344fdbf8d
company,2023-08-13 09:12:48,13 Best Wide Moat Stocks To Buy According To Hedge Funds,122012396,https://s.yimg.com/ny/api/res/1.2/Cn4Bl.9c6p2ILDyjTXZ2Sg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/insidermonkey.com/fb93572079378a3999d8bfe3ea4298a9,GILD,Yahoo,"In this piece, we will take a look at the 13 best wide moat stocks to buy according to hedge funds. If you want to skip our primer on wide moat investing, then head on over to 5 Best Wide Moat Stocks To Buy According To Hedge Funds. Among the countless ways in which companies […]",https://finnhub.io/api/news?id=e2b4f99bf62293fa7dc6dc9f143fcd827e5bda07ab3152ddf8f4cd45e8878c22
company,2023-08-11 12:42:00,"Gilead Sciences Inc. stock remains steady Friday, still outperforms market",122013551,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. were unchanged Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",https://finnhub.io/api/news?id=d42a6d3aac0609c034563149aacb255ce86bd14d61dd9f92496006df03820874
company,2023-08-11 07:37:00,$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today,122004391,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d488cfa9385285084d8c6d64f6b688c9475b941d22b0fde16e73dc51d550e821
company,2023-08-11 07:00:33,Gilead Sciences (NASDAQ:GILD) stock performs better than its underlying earnings growth over last year,121990075,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors can...",https://finnhub.io/api/news?id=cdfd94d461611de14a0ab4ec18019626820939c45192a4826bc639774ac0ebe1
company,2023-08-11 06:05:00,Gilead call volume above normal and directionally bullish,121983933,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=28c6733918133be4a9a9f475037f0594d3725f2a85dfcabed97b5d02b11a2e53
company,2023-08-18 12:00:00,Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States,122115644,https://media.zenfs.com/en/business-wire.com/6be1cbe559cdb2cbde3286c18c68e6ee,GILD,Yahoo,"FOSTER CITY, Calif. & NASHVILLE, Tenn., August 18, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Meharry Medical College, one of the nation’s oldest and largest historically Black academic health science centers, today announced the publication of a new supplemental issue of Meharry Medical College’s Journal of Health Care for the Poor and Underserved. It details the impact of the Gilead COMPASS Initiative® – the company’s 10-year, more than $100 million collaborative initiative that seeks to e",https://finnhub.io/api/news?id=74f0c39a156ca9d7742ab7df0427c9b25c17cda3c51b4df13a707aaddd38f2b6
company,2023-08-17 23:43:00,Gilead Sciences Inc. stock outperforms competitors despite losses on the day,122122617,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c1a8418b0ac932585f8800301de07803090211f06798fe9579a56d108a6b3b8a
company,2023-08-17 08:58:00,"Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More",122098259,https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96,GILD,Yahoo,Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector.,https://finnhub.io/api/news?id=d364923ae8aa5266839aea3e0877b9d9506440410bfb162e011be365811bd9bb
company,2023-08-17 08:39:00,10 Health Care Stocks With Whale Alerts In Today's Session,122089114,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=43d024973c22e5149f0464ce08b64099aea45a1db7ca54e8f44483a34c9a4e2e
company,2023-08-17 08:26:00,Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia,122097089,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=103b409c9dd494b811ae177a5d68d6a63e9fc549bacfd99f0a084917eed87952
company,2023-08-17 05:29:00,Undervalued Biotech Gems: 2 Stocks Combining Dividends With Healthy Returns,122097090,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c9b9c9d8227e9a268802e85261b4274b2caf8a98d00bc4462d13921d8735f5d0
company,2023-08-17 05:28:00,Undervalued Biotech Gems: 2Stocks Combining Dividends With Healthy Returns,122097091,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e205d1ca3f2a1ca025bf191d473452c72c5407d06c949c22b2ac58f407815c6b
company,2023-08-17 04:52:01,Undervalued Biotech Gems: Two Stocks Combining Dividends with Healthy Returns,122103628,https://media.zenfs.com/en/us.finance.gurufocus/04eeffc972ddfcb93f3ec3f87e9cd35b,GILD,Yahoo,Distinguishing genuine value from market noise is essential for successful investments,https://finnhub.io/api/news?id=798d256b6034af75488848f7d2a0f0e9f92a7f493305e20813b91121b446b8d9
company,2023-08-17 03:26:00,Gilead Sciences (GILD) Gets a Buy from Jefferies,122088074,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4d4deb6e3c48b5ec00771e66f7b127d8d4222352149b7879ae4642bce91e878e
company,2023-08-17 02:20:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Paycor HCM (PYCR), Legend Biotech (LEGN) and Gilead Sciences (GILD)",122085296,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=245b32b25be2249cc80cb576ad6f9471d540c829065c3bc38121b99e46945ac9
company,2023-08-17 01:03:00,Morgan Dempsey Capital Management LLC Reduces Stake in Polished.com Inc,122094491,,GILD,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=faf73a6149b2b7063e545d716de512276497c22dccdbb39ecb88d86528f5b855
company,2023-08-17 00:32:00,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and CVS Health (CVS),122096226,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=23ea7fa6ee252f51bc27375d732f4c3b764190688d2ad0357477067e3f860597
company,2023-08-16 23:43:00,"Gilead Sciences Inc. stock falls Thursday, underperforms market",122097096,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5ae232cf5ca73929ee51c2110e603674c8555b5c6eff8b4d06b73ef259d3919e
company,2023-08-16 13:21:00,"Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies",122072341,https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2,GILD,Yahoo,Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.,https://finnhub.io/api/news?id=efee0678de7a9f7f0878f6b51522d0c55951ebcf589a5919fa5b51ce21d21924
company,2023-08-16 08:00:00,Gilead’s Focus on Ending the HIV Epidemic for Children Everywhere,122067187,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / August 16, 2023 / Gilead Sciences ""I am tired, so tired. When will this end?"" That's the refrain that Dr. Eva Natukunda, a pediatric HIV specialist at the Joint Clinical Research Center in Kampala, Uganda says she ...",https://finnhub.io/api/news?id=43431baa8e6e744070d0b0f0e73b4be245f15a6f2e6a441f9af9e2edbfd9bd1c
company,2023-08-15 23:43:00,Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors,122097100,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0a68767e5a442489bcdcf6c173ce972ac3051c4a60657a46898b71e4754b92c3
company,2023-08-15 22:15:00,Mizuho Securities Remains a Buy on Gilead Sciences (GILD),122088077,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6e14aaaa1fda95484977038d86cae5e93f2084aba635f1447b58018751625565
company,2023-08-15 09:19:04,"UPDATE 1-Gilead ties up with Tentarix for cancer, inflammatory disease therapies",122051327,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"Gilead Sciences said on Tuesday it had entered into an agreement with privately held Tentarix Biotherapeutics to develop therapies for cancer and inflammatory diseases.  Tentarix will receive upfront payments and an equity investment totaling $66 million from Gilead, which has the option to buy up to three of the drug developer's units for $80 million each, the companies said.  The deal gives Gilead access to Tentarix's proprietary drug development platform for antibody-based therapies that specifically target immune cells related to the disease without activating other immune cells that may lead to adverse events.",https://finnhub.io/api/news?id=7d558f47f3182f873443ef6c14f94bc6caa742c9b91a061f934576ddb293dc29
company,2023-08-15 08:30:00,Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation,122051328,https://media.zenfs.com/en/business-wire.com/582f73599ccef27eca0bd72d7b3a8624,GILD,Yahoo,"FOSTER CITY, Calif. & SAN DIEGO, August 15, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) and Tentarix Biotherapeutics today announced that the companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. Designed to enhance both therapeutic benefit and safety, these molecules have the potential to conditionally target immune cells related",https://finnhub.io/api/news?id=b4abf684a75f5c59d63b2b533665259ba74938c22152ced54aca5bce398e3782
company,2023-08-15 08:00:29,We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt,122040355,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...",https://finnhub.io/api/news?id=f51f60def18ba48508fe606d23456e38bcdfa437717f88ba5cde662ca1d56752
company,2023-08-15 05:10:00,Gilead and Tentarix partner to develop protein therapeutics,122051316,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4265ad560c5aa98de69653c7c93a1ff07ba8c21717959051c2f37237cf25645b
company,2023-08-15 03:48:00,Gilead sees transaction with Tentarix to reduce EPS by 3c-4c,122051319,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=380ceffab850016201c758b0353a6649c5f992ec3aebb553637e85bdf9d6826d
company,2023-08-15 03:46:00,Gilead has option to acquire up to three Tentarix subs for $80M per subsidiary,122051320,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=08f5e5be82ccc5b0085ae93d3599920329cd02b7c980f5888e8835966e8cb8b2
company,2023-08-15 03:43:00,"Gilead and Tentarix in pact to find therapies for cancer, inflamation",122051321,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e735165f51f21cd1636b4e7ba59305f6267296ab372537994242814d33d9e93c
company,2023-08-14 23:43:00,"Gilead Sciences Inc. stock falls Tuesday, still outperforms market",122097103,,GILD,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5f226490779a547fc203c70de5f39d17319fbdf697b7724676f7f0fe306bd85d
company,2023-08-22 12:42:00,"Gilead Sciences Inc. stock rises Tuesday, outperforms market",122287483,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.54% higher to $76.35 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the...",https://finnhub.io/api/news?id=70709cff95df32cd8f97b2a72839f9e270224fe0b624c517f87b0e39d19bbe3c
company,2023-08-22 11:47:00,Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold,122168118,https://media.zenfs.com/en/zacks.com/b1a88f62c79fa9497813c06567d05a92,GILD,Yahoo,Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.,https://finnhub.io/api/news?id=a450b4ba032eb2c7fbe49d4b4656c501e42be013c51c09d9da2996406e8f7f4e
company,2023-08-22 01:12:00,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Regeneron (REGN) and Syndax Pharmaceuticals (SNDX)",122169241,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f749c82d5699a73ae8c5482099e320054ea4b2e4aa23933474877e1dc9201032
company,2023-08-21 16:10:21,Legend Biotech: Working On Supply Issues,122158675,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215919674/image_1215919674.jpg?io=getty-c-w1536,GILD,SeekingAlpha,Carvykti's successful manufacturing ramp-up and clinical de-risking in earlier lines of multiple myeloma put Legend Biotech in a strong position. Learn more on LEGN stock here.,https://finnhub.io/api/news?id=6c8b9a3f8d6ef35420021aa524bfacc8ae4a29473cf57f6df20acbe85189fd3a
company,2023-08-21 12:42:00,"Gilead Sciences Inc. stock rises Monday, still underperforms market",122287484,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.08% higher to $75.94 Monday, on what proved to be an all-around mixed trading session for the stock market, with the...",https://finnhub.io/api/news?id=b47bb8cffe6e4b85b288aa10f028870d2c4356530854a8fc185b6b6079a9aa9f
company,2023-08-21 08:58:00,Vaccine makers light up as COVID hospitalizations rise,122168813,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9c04bc01b189a5441fca950cbb8cc0ade1f61365d7a1d5b5ce6ec70f352d7ff5
company,2023-08-21 08:55:23,UPDATE 1-US FDA puts Gilead Sciences blood cancer drug studies on hold,122150520,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,GILD,Yahoo,"Gilead Sciences said on Monday the U.S. health regulator placed a clinical hold on studies of its blood cancer drug, just a month after the company scrapped a late-stage trial due to efficacy concerns.  The company gained access to the drug, magrolimab, with its $4.9 billion buyout of Forty Seven Inc in March 2020.  The company said the U.S. Food and Drug Administration (FDA) had paused screening and enrollment of new study participants, while the patients already under the studies may continue to receive treatment.",https://finnhub.io/api/news?id=dd2be4244640ad0f16e353a6da4523e48b0b64abe8596ae517ae3d77f4686967
company,2023-08-21 08:30:00,Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML,122150521,https://media.zenfs.com/en/business-wire.com/c66048a90462137ba7646ed152606392,GILD,Yahoo,"FOSTER CITY, Calif., August 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia (AML).",https://finnhub.io/api/news?id=e875091cf3e3b7732c576bd110feafcc8d8d7235350fd498561b808b008c2628
company,2023-08-21 07:32:00,Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner,122167987,,GILD,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=69cc7b9ae897565daa11296f7604a1c94e5f9d1ead14b73d33cb55044f706e31
company,2023-08-21 06:33:00,5 Safe Stocks Under $40 to Buy Immediately,122168043,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c898b838ad047b0f2c57b5224f30cc5e21ef3c7f3a7050148dcb018dbdef5558
company,2023-08-21 06:00:24,Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative on HIV in the Southern United States,122150653,,GILD,Finnhub,"FOSTER CITY - Gilead Sciences, Inc. and Meharry Medical College, one of the nation's oldest and largest historically Black academic health science centers, today announced the publication of a new...",https://finnhub.io/api/news?id=6080d74414b2f6acc48509c8059327df3e43a203b4830d40df3f01a73869a34a
company,2023-08-21 05:29:00,Gilead Sciences announces another magrolimab setback via US FDA action,122215471,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=91118600452909f3efabd91caf402e8b11d4e12340c2db2fe0074d4898516a15
company,2023-08-21 05:04:03,Gilead Sciences Magrolimab Studies Enrollment Paused by FDA Request,122150443,,GILD,Finnhub,By Adriano Marchese Gilead Sciences will pause the enrollment of new participants for its investigational drug study in treating acute myeloid leukemia. The pharmaceutical company said...,https://finnhub.io/api/news?id=170ba00f66c83fa65d6eb310d36e06c71e94d2fe3647161d0951dfa555d5ef4b
company,2023-08-21 04:47:00,Gilead says FDA hits pause on study of leukemia treatment,122287486,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,GILD,MarketWatch,Gilead Sciences Inc. said Monday that the U.S. Food and Drug Administration has put a partial clinical hold on U.S. studies evaluating a treatment for acute...,https://finnhub.io/api/news?id=aa87753c9b7363a4708f1477582ba0a7bd1269d5f998c5413679ad5183b06dc7
company,2023-08-21 04:37:23,US FDA puts Gilead Sciences blood cancer drug studies on hold,122150272,,GILD,Finnhub,Gilead Sciences said onMonday the U.S. Food and Drug Administration had placed apartial clinical hold on initiating new patients in the U.S.studies for drug to treat a type of blood...,https://finnhub.io/api/news?id=f76f54a58fdaab8c938d38a40f382eed1b15fe4073e3ceaf544ed3803e270f4a
company,2023-08-21 04:00:00,Gilead announces FDA partial hold on leukemia trial,122215473,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2612d453e65c78477b8efbcc2092d1bcf00d0ae35ff711720fbea451635fd5c6
company,2023-08-21 03:37:00,Gilead announces partial clinical hold on magrolimab studies,122215475,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=eb8ab58ab107c3d06caa8d7fa70f366daa4af921f95ea35d16065c2ccfdcb8d0
company,2023-08-21 01:43:00,IN BRIEF: Guild Esports to launch Counter-Strike men's team,122215477,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6ca327dc6c70e842e834cbce81592002363a75bde4a0fdd37e68ff359b59c630
company,2023-08-20 09:00:34,"A Closer Look At Gilead Sciences, Inc.'s (NASDAQ:GILD) Impressive ROE",122144486,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",https://finnhub.io/api/news?id=97b14b2a66eee91a77d31a15dfe66702640947d679fee0bd4f6a76f7f6bebe72
company,2023-08-25 12:42:00,"Gilead Sciences Inc. stock rises Friday, outperforms market",122287478,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.69% higher to $76.86 Friday, on what proved to be an all-around favorable trading session for the stock market, with...",https://finnhub.io/api/news?id=6bdecf670554c0d1f5fba6b57968bb3e7bdc9fcdff62771124e89893537475ea
company,2023-08-25 11:48:00,Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment,122239179,https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7,GILD,Yahoo,"Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.",https://finnhub.io/api/news?id=5a34554dfd5a3dd24c293fba8e3f45d7da7d5596777b969e39488e07fec1079e
company,2023-08-25 09:16:00,"The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics",122239180,https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe,GILD,Yahoo,"Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.",https://finnhub.io/api/news?id=3d889f90ada5d45046212517ad13a0bb941d0724c0bf449622f0de6c15d5c3e4
company,2023-08-25 04:47:08,"Gilead Sciences, Inc. - FDA Approves Veklury to Treat COVID-19 in People with Mild to Severe Hepatic Impairment with no Dose Adjustment",122234683,,GILD,Finnhub,"FOSTER CITY - Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration approved a supplemental new drug application for the use of Veklury with no dose adjustments to...",https://finnhub.io/api/news?id=424224023c5ae05a993169d2d7f38b4737f1e419f22653e9a4eba3caf69993b3
company,2023-08-25 04:30:00,"Galapagos: Good To Have An Approval, Bad To Have No Major Catalysts",122234440,https://media.gettyimages.com/id/1399434551/photo/portrait-of-a-giant-tortoise.jpg?b=1&s=170667a&w=0&k=20&c=WHNzPFzK3Azc73IF1MPKrHy4cJc2gma9sPzSKWpeHoQ=,GILD,SeekingAlpha,"Galapagos has an approved drug, filgotinib, for rheumatoid arthritis and ulcerative colitis. Read more to see why I'm rating GLBG stock as a soft sell.",https://finnhub.io/api/news?id=ec1928557bf79916f44c908784d2fc93e8fe8cb3d5ef10308dbf2aadfda0f4fa
company,2023-08-25 02:59:00,Guild Esports shares jump on launch of new Street Fighter team,122246086,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4fa0cd3cd30eca09497ba46d0fc311b2eec0cc3f241ac04505a0720ca73c18f4
company,2023-08-25 01:46:00,Robert W. Baird Sticks to Their Hold Rating for Gilead Sciences (GILD),122245436,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d0127a68d58a6acd85ffdf34ecc09afed9ee86da3e86c70b9f10e70c00613a34
company,2023-08-24 12:42:00,Gilead Sciences Inc. stock outperforms market despite losses on the day,122287479,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slipped 0.92% to $76.33 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=d5cbe13387219873fb5bec979112bf126c489ffa54bdead31b5eedf1c7902599
company,2023-08-24 08:30:00,FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment,122201042,https://media.zenfs.com/en/business-wire.com/900607447b2e9a5a38f07c3d956f9970,GILD,Yahoo,"FOSTER CITY, Calif., August 24, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) with no dose adjustments to treat COVID-19 in people with mild, moderate and severe hepatic impairment. This approval further supports the safety profile of Veklury as the first and only approved antiviral COVID-19 treatment that can be used across all stages of liver di",https://finnhub.io/api/news?id=f937b7f39617073113fa585f8e523dcbe6449a715a01030e7bd77a45df5002e9
company,2023-08-24 06:40:00,GILD Stock Alert: FDA Approves Gilead Sciences’ Veklury Covid-19 Treatment,122215439,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=89c690a99c910ae90c7c25efb4be0e7ae7a2289e5ae825404314b33457443c95
company,2023-08-24 06:00:00,Galapagos cut to Neutral at Citi on lack of catalysts,122207401,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3146b51bde445e55a68bcff424561012bc2fcb458d82fb57eb21f837671f9a6e
company,2023-08-24 05:22:00,Gilead Sciences' Veklury wins FDA approval as Covid treatment option,122215441,,GILD,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ee88936e21e82b815d24c1ca48c5758c578824dff96ff7d28e9ca9d3828197d7
company,2023-08-24 05:19:02,Gilead Covid-19 Drug Cleared by FDA for Patients with Liver Disease,122200647,,GILD,Finnhub,"By Dean Seal Gilead Sciences said regulators have approved its antiviral remdesivir, sold under the name brand Veklury, for Covid-19 patients with hepatic impairment, or liver failure. The...",https://finnhub.io/api/news?id=5cb6126942d3ad56f3af49ccf21428176560802a42010541b097c3753f22cdb8
company,2023-08-24 04:46:00,Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico,122205516,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=323e62aa4a2526bd984da085607284014db2dbfc15837237f94a2ae0977a2d3c
company,2023-08-24 04:00:00,Gilead wins FDA nod to use Veklury for COVID-19 in liver disease,122215445,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a51bec9b9ebf3143fd832e20840803e55f1193250e436aa446b217d8aef73f0a
company,2023-08-24 03:39:00,FDA approves Gilead's Veklury for COVID-19 in people with hepatic impairment,122215446,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=638cdcc2d71c4de43aeea1836ecd9485fcae8d986e2e4a0a85a62c230cb56ac1
company,2023-08-23 22:23:00,GILD Stock Alert: FDA Expands Indications for Gilead Sciences’ Veklury Covid-19 Treatment,122215450,,GILD,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4d476746e08e3dbe18944462914417691f4927daa51a99bab650e87741323f36
company,2023-08-23 22:20:26,Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition,122195778,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Discover why Bristol-Myers is a strong investment, undervalued with a promising dividend yield. After a slow start, expect a bullish turnaround.",https://finnhub.io/api/news?id=8aadcfcce666098da02f8040842f7d3e8f37654e9d67d2dbd3c0d80938b0f419
company,2023-08-23 16:05:00,Gilead Sciences to Present at Upcoming Investor Conferences,122199975,https://media.zenfs.com/en/business-wire.com/be208f922e1485b46af1da5405141061,GILD,Yahoo,"FOSTER CITY, Calif., August 23, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",https://finnhub.io/api/news?id=f674b980712c1bf6fb18835219a4987ac81cd4f6904c294b0a021b131173eda4
company,2023-08-23 12:42:00,"Gilead Sciences Inc. stock rises Wednesday, still underperforms market",122287481,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.90% higher to $77.04 Wednesday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=4adea3aedc720ee7c3743513076502aad21a3f54322942af2d43f9072a6c4958
company,2023-08-23 08:45:00,How Gilead’s Pharmaceutical Development and Manufacturing Team Delivers Transformative Medicines,122187216,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / August 23, 2023 / Gilead Sciences When Stacey Ma was a little girl, her dream was to work with patients as a doctor. ""As it turns out, I became an engineer who makes medicine to help patients,"" says Stacey, who joined ...",https://finnhub.io/api/news?id=34208e69ec6fd89c1055a28ac5050a11edfc60b5bb4fa950ea79b7e85a0b414a
company,2023-08-23 04:45:00,"Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data",122261773,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,GILD,MarketWatch,"Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. Arcus Biosciences Inc. and iTeos Therapeutics...",https://finnhub.io/api/news?id=84b1129d850b759954fc5d56f75f3f430b8551a9252084e61a70984d9744240c
company,2023-08-23 02:06:00,BMO Capital Remains a Buy on Gilead Sciences (GILD),122213609,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6faf3b6e13ce86be4d98fe39936320a647d8ba392e8327c7332adc03ed557098
company,2023-08-23 01:25:00,"Arcus to 'trade with strength' after leaked Roche data looked 'good,' says BofA",122215266,,GILD,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f5cab9effd8c480c1c79ea9c7d0c40c73ccd00824fc751bfe4fe04dfddfae300
company,2023-08-23 00:01:00,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Zimmer Biomet Holdings (ZBH) and Premier (PINC)",122203283,,GILD,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b6921c005264b06ec4425e337f96f0fbb05c7a4537628a484abe785c00013abd
company,2023-08-30 12:42:00,Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors,122330163,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 0.70% to $77.66 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=f9ee6c0805647bd6a3ada444f3a5c1e9796cae1fe1ccc59b6880fd19ecd24a44
company,2023-08-30 08:45:00,Gilead Sciences: Fifth Anniversary of COMPASS: Helping Address the HIV Epidemic in the U.S. South,122315163,https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613,GILD,Yahoo,"This year marks the fifth anniversary of the Gilead COMPASS Initiative®, a 10-year, more than $100 million commitment to addressing the HIV epidemic in the Southern United States.",https://finnhub.io/api/news?id=6a063a4c15698f647d8841c0d7b5f877b2972e50571ae4bb6b12e81e5d74049c
company,2023-08-30 04:44:00,Upcoming Dividend Run For GILD?,122333694,,GILD,Dividend Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=95503cd82eeae60a22297601160a81d92c4b72cd29e5105f4ea95d6a812cf98a
company,2023-08-29 12:43:00,Gilead Sciences Inc. stock outperforms competitors on strong trading day,122330165,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. rallied 1.52% to $78.21 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=224941316c7ec8087a76c5c91f15e1c6804826034da24167ddefd035688bcfbd
company,2023-08-29 10:40:58,"Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data",122307858,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1390247272/image_1390247272.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. Click here for more on RCUS stock.",https://finnhub.io/api/news?id=cdc522f69f1f431a9e6dfa57a0b0b784cbbdd000f74fc7bb85ab30ea8f164447
company,2023-08-29 09:45:00,Nearing Retirement? These Stocks Will Pay You For Life,122301090,,GILD,Yahoo,"One place to look is the stock market.  Investing in reliable dividend stocks can be a great source of steady passive income, but only if the stocks in question have the tools to distribute growing payouts for a while.  Let's look at two companies that can do that: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD).",https://finnhub.io/api/news?id=36e1c3957a66124a676da7f7a95204c0d3df57af363e226ce6b01c9de0787682
company,2023-08-28 12:42:00,"Gilead Sciences Inc. stock rises Monday, still underperforms market",122287477,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.23% higher to $77.04 Monday, on what proved to be an all-around positive trading session for the stock market, with...",https://finnhub.io/api/news?id=9b3fbab10b8076eb86bf2d5559a85ea1fa480013548b4040840cb4df0bce4088
company,2023-08-28 09:39:25,12 Undervalued Wide Moat Stocks To Invest In,122275885,https://media.zenfs.com/en/insidermonkey.com/7fce214e14d6a0b0a624c5fe20813220,GILD,Yahoo,"In this piece, we will take a look at 12 undervalued wide moat stocks to invest in. If you want to skip our primer on wide moat investing, then check out 5 Undervalued Wide Moat Stocks To Invest In. The strategy of wide moat investing has gained a lot of traction over the past few […]",https://finnhub.io/api/news?id=d541fcf43cce06e52f548e79f261e3a365647a3fa7e98e6cdc2f86daab4fe554
company,2023-08-28 08:37:00,10 Health Care Stocks Whale Activity In Today's Session,122280851,,GILD,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bc98157ba0a031f9475db22e29d976b7af0ba3cdf3201c7a8237980194e418ea
company,2023-08-28 03:00:00,Gilead Sciences: Searching For A Catalyst,122273822,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1254330022/image_1254330022.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Over the long run, Gilead Sciences' pipeline and its oncology segment could lead to higher sales. Click here to read why GILD stock is a Buy.",https://finnhub.io/api/news?id=bfb0a1ce4b5898221208872c11da4bf6e63ee210fb6d0763ce8f563874194bf8
company,2023-08-27 09:00:16,Here's Why We Think Gilead Sciences (NASDAQ:GILD) Is Well Worth Watching,122266477,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,"It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...",https://finnhub.io/api/news?id=f66591d303c135f88f8741f34ce384b7835ca8cac38feabbe93c9ef5928e15b0
company,2023-08-27 08:18:00,AlloVir: An Intriguing $3 Biotech Concern,122266916,,GILD,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0eafeed543d8caae2f2c815ea1b19e0ee7e52cb28e114d19d821982cde2cd69e
company,2023-09-01 17:50:12,Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know,122383927,https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f,GILD,Yahoo,"In the latest trading session, Gilead Sciences (GILD) closed at $76.65, marking a +0.22% move from the previous day.",https://finnhub.io/api/news?id=a8f5b489c78e94b86500415992b88df07bbf2d2c0b55d205584012f4e7a255bc
company,2023-09-01 12:42:00,Gilead Sciences Inc. stock outperforms market on strong trading day,122396721,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. inched 0.22% higher to $76.65 Friday, on what proved to be an all-around favorable trading session for the stock market, with...",https://finnhub.io/api/news?id=36f4371f016c5d32c9d11f305aaea16751802ac46e2118b7405dda35227e0c0e
company,2023-08-31 12:42:00,Gilead Sciences Inc. stock underperforms Thursday when compared to competitors,122396722,https://images.mktw.net/im-220105/social,GILD,MarketWatch,"Shares of Gilead Sciences Inc. slid 1.52% to $76.48 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=3e1b0008dd147eea7c77882a45e7c9761bcbea74821438d22be45f1e7859defc
company,2023-08-31 10:00:19,"With 86% institutional ownership, Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst the big guns",122352054,https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb,GILD,Yahoo,Key Insights Institutions' substantial holdings in Gilead Sciences implies that they have significant influence over...,https://finnhub.io/api/news?id=1f13224113df7a2ebb33c5f73a55c07db239bea330a671422c23746924198605
company,2023-08-31 06:30:00,The Highest Quality Dividend Challenger Summary,122342211,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912726380/image_912726380.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Discover the top 20 highest-quality Dividend Challengers, along with stocks offering favorable valuations and compelling metrics for various investor types.",https://finnhub.io/api/news?id=10cc6ee889baa87dfb31887c86248c2db205f6208bc8939c3b12f09b274912d0
